
IIS-FJD SCIENTIFIC AND FINANCIAL REPORT




2025

Instituto de Investigación Sanitaria
Fundación Jiménez Díaz

UAM
Universidad Autónoma de Madrid

Hospital Universitario Fundación Jiménez Díaz
Grupo quirónsalud


FUNDACION JIMENEZ DIAZ
CLINICA DE LA CONCEPCION


FUNDACION JIMENEZ DIAZ

Table of Contents

1. INTRODUCTION 13

1.1 History of IIS-FJD 13

1.2 Establishment of IIS-FJD 14

1.3 Mission, Vision, Values 15

2. ORGANIZATIONAL STRUCTURE 19

2.1 Governing Board 20

2.2 Scientific Director 21

2.3 External Scientific Advisory Committee 22

2.4 Research Committee 23

2.5 Social Stakeholders Advisory Board 26

2.6 Scientific Integrity Committee 27

2.7. Quality Committee 28

2.8. Innovation Committee 29

2.9 HUFJD Research Ethics Committee 30

2.10 IIS-FJD Animal Ethics and Welfare Committee 33

2.11 Structure of the IIS-FJD Research Areas 34

2.12 IIS-FJD Human Resources and gender perspective 36

2.13 IIS-FJD Stabilization programme 40

3. FINANCIAL REPORT 43

3.1 Funding sources 43

3.2 Statement of Financial Position and Income Statement 46

4. SCIENTIFIC PROGRAMME 49

4.1 Strategic Plan 2024–2028: action plan indicators 50

5. SCIENTIFIC ACTIVITY AND OUTPUT 55

5.1 Human Resources programmes co-funded by official agencies (national and regional) 55

5.2 Scientific activity 58

5.3 Participation in cooperative research structures 62

5.4 Scientific production: 65

Table of Contents

5.5 Innovation and knowledge transfer 67

5.5.1 Knowledge transfer 67

5.5.2 Clinical practice guidelines, recommendations, clinical procedures and publications derived from clinical trials 70

6. RESEARCH AREAS AND GROUPS 73

6.1 Cancer Area 77

6.1.1. ANATOMICAL PATHOLOGY GROUP 81

6.1.2. MEDICAL ONCOLOGY GROUP 84

6.1.3. HAEMATOLOGY GROUP 87

6.1.4. GENETIC SUSCEPTIBILITY TO RARE AND COMPLEX DISEASES GROUP (UAM) 90

6.1.5. GENERAL SURGERY, THORACIC SURGERY, NEUROSURGERY AND OTHER SURGICAL SPECIALTIES ASSOCIATED GROUP 92

6.1.6. RADIATION ONCOLOGY ASSOCIATED GROUP 95

6.2 INFECTIOUS, INFLAMMATORY AND CHRONIC DISEASES AREA 97

6.2.1. ALLERGY AND IMMUNOLOGY GROUP 101

6.2.2. INFECTIOUS DISEASES AND TROPICAL MEDICINE GROUP 103

6.2.3. MICROBIOLOGY GROUP 105

6.2.4. PNEUMOLOGY GROUP 107

6.2.5. RHEUMATOLOGY AND BONE METABOLISM GROUP 109

6.2.6. TRAUMATOLOGY ASSOCIATED GROUP 112

6.3 Neurosciences Area 115

6.3.1. NEUROLOGY GROUP 120

6.3.2. PSYCHIATRY AND MENTAL HEALTH GROUP 123

6.3.3. MITOCHONDRIAL CALCIUM SIGNALLING GROUP (UAM) 125

6.4 CRM AREA (CARDIOVASCULAR, RENAL AND METABOLIC DISEASES) 127

6.4.1. CARDIOLOGY GROUP 131

6.4.2. NEPHROLOGY AND HYPERTENSION, VASCULAR DISEASE AND DIABETES GROUP 134

6.4.3. LIPID DISORDERS: CLINICAL AND EXPERIMENTAL RESEARCH GROUP (ADULTS AND CHILDREN) 137

Table of Contents

6.4.4. CARDIAC AND VASCULAR SURGERY ASSOCIATED GROUP 139

6.4.5. UROLOGY ASSOCIATED GROUP 142

6.5 Genomics and epidemiology area 145

6.5.1. GENETICS AND GENOMICS OF RARE AND COMPLEX DISEASES GROUP 150

6.5.2. PREVENTIVE MEDICINE, PUBLIC HEALTH AND PRIMARY CARE ASSOCIATED GROUP 153

6.6 Healthcare technology and innovation area 155

6.6.1. INNOVATION IN OPHTALMOLOGY GROUP 161

6.6.2. GROUP OF MEDICAL ENGINEERING DEVELOPMENT AND INNOVATION (UAM) 163

6.6.3. NEW THERAPIES RESEARCH GROUP 165

6.6.4. ADVANCED THERAPIES GROUP (CIEMAT) 168

6.6.5. REGENERATIVE MEDICINE AND TISSUE BIOENGINEERING GROUP 171

6.6.6. MEDICAL AND SURGICAL INNOVATION ASSOCIATED GROUP 173

6.6.7. NURSING ASSOCIATED GROUP (UAM): EXTRACORPOREAL CIRCULATION AND PERFUSION 175

7. RESEARCH SUPPORT PLATFORMS AND UNITS 179

7.1 National and international platforms 179

7.2 Experimental surgery and preclinical models service (CEMP) 180

7.3 Biobank 184

7.4 Genomics and Proteomics Units 187

7.5 Cell Biology Unit: confocal microscopy and flow cytometry 189

7.6 Cell Culture Unit 192

7.7 Biostatistics and Epidemiology Unit 192

7.8 Clinical Research and Clinical Trials Unit (UICEC) 195

7.9 Innovation and Technology Transfer Unit 201

7.10 Bioinformatics Unit 201

7.11 Hospital pharmacy service 202

7.12 Imaging Unit 204

7.13 Radioisotope laboratory 206

7.14 Information technology service 211

Table of Contents

7.15 Library 212

7.16 English language translation service 213

7.17 Clinical documentation service 213

8. RESEARCH MANAGEMENT AREA 217

8.1 Administration and Support Services Unit 218

8.1.1. Scientific Activity Unit 218

8.1.2.- Quality Unit 219

8.1.3.- Financial management 220

8.1.4.- Training and Outreach Unit 221

8.1.5.- Clinical Research Management Unit 222

8.1.6.- Research Human Resources Unit (HR) 224

8.2.- Project Management Unit 226

8.3 Legal Department 227

8.4 Marketing and Communications Area 228

8.5 Occupational Health and Safety 229

8.6 Quality Area 229

9. COMMUNICATION STRATEGY 233

10. IIS-FJD TRAINING PLAN 237

10.1 Target audience for research training 237

10.2 Training Structures 238

10.3 Identification of training needs 239

10.3.1 Needs of the Spanish National Health System (SNS) 239

10.3.2 Needs of the R&D&I Environment 240

10.3.3 Research staff training needs 240

10.4 Undergraduate research training 241

10.5 Postgraduate Research Training 254

10.5.1 Doctoral programmes, master's programmes and university-specific degrees in collaboration with UAM and other universities 254

10.5.2 Supervision of Doctoral Theses 264

Table of Contents

10.5.3 Promotion of Research Training: Clinical and Experimental Research Awards. 267

10.6 Human Resources Programmes and Research Fellowships 268

10.7 Training of IIS-FJD research staff. 268

10.7.1 Specific Research Training Courses 2025 268

10.7.2 Other training courses 2025 269

10.7.3 Specific training activities organised by each research area: laboratory and journal club seminars. 270

10.7.4 Training activities in the field in animal experimentation 270

10.7.5 Training activities in scientific integrity. 273

10.8 Specialised healthcare training, primary care training and continuing education 274

10.8.1 Specialised healthcare training (in coordination with the Education Directorate). 274

10.8.2 Primary care professional portal (http://apfjd/default.aspx). 277

10.8.3 Continuing education programme and other training opportunities. 278

10.9 Seminars and Conferences. 278

10.9.1 Regular General Seminars at IIS-FJD 278

10.9.2 10th Margarita Salas Predoctoral Research Seminar Series at IIS-FJD 279

10.9.3. 2nd early career researcher talks series 280

10.9.4 8th Fundación Jiménez Díaz research chair seminar series on regenerative medicine and tissue bioengineering (IIS-FJD-UC3M-CIEMAT). 282

10.9.5 7th annual meeting of IIS-FJD research areas and groups 283

10.9.6 Welcome day for new IIS-FJD researchers 286

10.9.7. Research open days at IIS-FJD affiliated hospitals 286

10.9.8. 1st meeting with primary care researchers 287

10.10 Other outreach activities and scientific meetings. 287

11. CONCHITA RÁBAGO FOUNDATION 301

12. PUBLIC FUNDING BODIES 307


FUNDACION JIMENEZ DIAZ
CLINICA DE LA CONCEPCION



Carmen Ayuso
Scientific Director

Dear colleagues and friends,

It is my pleasure to present the 2025 Annual Report of the Fundación Jiménez Díaz Health Research Institute (IIS-FJD, UAM).

This year has been particularly significant for our institution, as it successfully renewed its accreditation as a Health Research Institute, a distinction that recognizes the quality and excellence of its scientific activity. This achievement was celebrated the 16th of December at the Aula Magna of the Fundación Jiménez Díaz University Hospital (HUFJD), held as part of the celebrations for the 15th anniversary of its first accreditation. During the event, Dr Javier Arcos, Chair of the IIS-FJD Governing Board, and Dr Manuel Cuenca, Deputy Director General for Research Evaluation and Promotion at the Carlos III Health Institute, highlighted the Institute's trajectory, sustained growth, and scientific contributions over the past fifteen years, further consolidating IIS-FJD as a leading institution in health research and innovation.

As an institution committed to promoting citizen participation in research, the IIS-FJD has relied on its Social Stakeholders Advisory Committee (CAAS), which throughout 2025 has been involved in the evaluation of our projects, from their conception and application stage through to their outcomes and performance indicators.

Likewise, the IIS-FJD remains committed to Responsible Research and Innovation (RRI), promoting open science and research integrity, as well as providing training for researchers in these areas. To ensure transparency and quality in management, the Institute is aligned with the European Human Resources Strategy for Researchers (HRS4R). In line with these policies, during 2025 the Innovation Unit continued the preparatory process to obtain certification under the new ISO 56001:2024 standard.

During 2025, the IIS-FJD structure maintained its six thematic areas and 29 research groups (21 established and 8 affiliated).

Scientific activity and intramural collaboration among research groups were fostered through the 7th Annual Meetings of the Research Areas and Groups, held during the year and open to the IIS-FJD community and its affiliated hospitals, as well as members of our External Scientific Advisory Board.

IIS-FJD has sustained a high level of research excellence, as reflected in its key scientific output indicators for 2025:

A total of 964 articles indexed in PubMed were published, of which 937 had an Impact Factor. Notably, 599 publications (63.93%) appeared in first quartile (Q1) journals, while 267 (28.5%) were published in first decile (D1) journals. The cumulative Impact Factor reached 7,311.4, and the average Impact Factor attained a value of 7.8.

A total of 477 research projects were carried out with funding obtained through competitive public and private calls at both the national and international levels.

The number of active clinical trials reached 680, while the number of newly initiated clinical trials increased to 173.

Alongside this growth, the Institute also experienced an increase in the public and private funding secured. These resources were reinvested to support the expansion of the IIS-FJD, including the co-funding of our human resources programme, such as the stabilization and intramural intensification of researchers and the financing of personnel for shared research platforms, as well as investments in common-use equipment and other strategic initiatives.

Regarding research innovation and technology transfer, in 2025 IIS-FJD processed 7 European patent applications and 1 European divisional application. From its patent portfolio, 5 patent families were extended internationally through Patent Cooperation Treaty (PCT) applications, and 9 national phase entries were filed. In addition, 1 European patent was granted, bringing the total number of active granted patent families, including those granted in previous years, to 26.

The successful achievement of all these milestones has relied on the essential support provided by the Research Management Area.

And, of course, none of this scientific activity would have been possible without the contribution of those who have carried it out, promoted it, supported it and funded it. I would therefore like to express my sincere gratitude to all those who have made these achievements possible: to the funding agencies, particularly the Carlos III Health Institute (ISCIII), the Ministry of Science, the Regional Ministries of Health and of Science, Universities and Innovation of the Community of Madrid, the Quirónsalud Group, and the Conchita Rábago Foundation; as well as to our scientific collaborators and advisors, and to the institutions that make up IIS-FJD (the Autonomous University of Madrid, CIEMAT, and the Fundación Jiménez Díaz, Infanta Elena, Rey Juan Carlos, and General de Villalba University Hospitals).

Best regards.





1 Introduction

1 History of IIS-FJD

The history of Fundación Jiménez Díaz University Hospital (HUFJD) dates to 1934, when the Association for the Support of Professor Jiménez Díaz's Chair was established. Chaired by the banker Pablo Garnica, whose name was later given to the Nuclear Medicine Laboratory, this initiative preceded the founding of the ***Institute for Clinical and Medical Research in 1935*** and its official recognition by Order of the Ministry of Education on April 13th, 1939 (Order of the Ministry of National Education, Universities Section, No. 266; C. Jiménez Díaz, *La historia de mi instituto,* p. 53, Paz Montalvo, Madrid, 1965).

The Institute was in the Faculty of Medicine building of the Complutense University of Madrid, in Ciudad Universitaria. The aim of the institution was to integrate clinical practice and research laboratories. These laboratories were organised into different sections, each led by professionals specialised in their respective techniques, all working in close collaboration as part of a unified structure (Horacio Oliva Aldamiz, *Maestros y dómines,* Madrid, 1997, Ibáñez & Plaza).

After the Spanish Civil War, during which these facilities were destroyed and many of their members dispersed, Professor Jiménez Díaz decided to reopen the Institute on February 13th, 1940, in a villa located in the Pacífico district of Madrid, bringing back some of the former collaborators while attracting new ones. Existing equipment was reused, and more modern instruments were gradually incorporated. This Institute, which represented an extraordinary effort under difficult circumstances, became a leading centre for both clinical practice and research.

In 1942, the Spanish National Research Council (CSIC, according to its Spanish acronym of Consejo Superior de Investigaciones Científicas) established the National Institute of Medical Sciences, bringing together several CSIC research centres as well as joint institutes associated with medical institutions. One of these was the Carlos Jiménez Díaz Institute for Medical and Clinical Research (Rafael Huertas García-Alejo, Biomedical Sciences in the CSIC, p. 29, Tiempos de Investigación. JAE-CSIC: One Hundred Years of Science in Spain, CSIC, 2007). This Institute, since 1951, had its own scientific publication edited in English (Bulletin of the Institute of Medical Research of the University of Madrid) (C Jiménez Díaz p. 83; 1965).

By official decree on December 4th, 1953 (Official State Gazette No. 356 of December 22nd, 1953, p. 7525), the Institute for Clinical and Medical Research was reorganised and officially recognised as a charitable and educational institution (C. Jiménez Díaz, p. 90, 1965). Meanwhile, the rebuilt Rubio Institute building was granted to Professor Jiménez Díaz in recognition as a prize and incentive for his pioneering work. This marked the creation of the Clínica de ***Nuestra Señora de la Concepción,*** which was inaugurated on February 13th, 1955, with the aim of bringing together healthcare, teaching and research under one roof (C. Jiménez Díaz, 1965; Horacio Oliva, 1997), at the site currently occupied by the Fundación Jiménez Díaz Health Research Institute (IIS-FJD).

In 1957, new buildings were added to expand the number of hospital beds and to accommodate research laboratories, classrooms, a library and a School of Nursing. The private clinical practice of Institute members was also initiated, and an agreement was established with the National Health Insurance Scheme, providing financial support for two further expansions dedicated to central services and additional research units. Finally, in 1964, the ***Fundación Jiménez Díaz (FJD)*** was formally established through the merger of the Association for the Support of Professor Jiménez Díaz's Chair and the Institute for Clinical and Medical Research (C. Jiménez Díaz, 1965).

Since 1970, **Fundación Jiménez Díaz has been affiliated with the Faculty of Medicine of the Autonomous University of Madrid (UAM),** where it teaches various subjects within the undergraduate medical curriculum.

The HUFJD has a long-standing research tradition, documented in its **scientific reports published since**

the 1970s, which already included information on research activities, teaching activities through its relationship with the Autonomous University of Madrid (UAM), and healthcare provision.

The 1974 annual report refers to the professionals working at HUFJD who had previously been members of Professor Jiménez Díaz's former Institute for Clinical and Medical Research. It also documents the Institute's affiliation with UAM, as well as the scientific and clinical activities carried out by each department, the scientific meetings and conferences held at HUFJD, continuing medical education courses, newly acquired infrastructures and equipment, oversight committees, and the mobility of research staff through fellowships at international research institutions, among other activities (Fundación Jiménez Díaz Activity Report 1974).

1.2 Establishment of IIS-FJD

The process leading to the formal establishment of IIS-FJD began in early 2009 with the preparation of the documentation required to meet the criteria set out in Royal Decree 339/2004. During the same period, the foundations were laid for the collaboration agreement with the Autonomous University of Madrid (UAM), which, together with HUFJD, initially constituted IIS-FJD. The agreement was formally signed on December 22nd, 2009, and the IIS-FJD Governing Board was subsequently established on December 23rd, 2009. On January 11th, 2010, the External Scientific Advisory Committee was constituted and held its first meeting. On December 16th, 2010, the Minister of Science and Innovation, Cristina Garmendia, signed the ministerial order granting IIS-FJD accreditation as a Health Research Institute for a period of five years.

Throughout these years, extramural research groups from the Autonomous University of Madrid (UAM) have gradually been incorporated. From 2013 onwards, a close scientific collaboration was established between IIS-FJD and researchers from hospitals within the Madrid Public Health Network: Infanta Elena University Hospital (HUIE), Rey Juan Carlos University Hospital (HURJC), and General de Villalba University Hospital (HUGV), as well as with two research groups from CIEMAT.

On December 11th, 2014, the deed of incorporation of the Fundación Jiménez Díaz Health Research Institute Foundation was signed. During the same act, the statutes governing its operation were approved, establishing the management of IIS-FJD as its primary purpose.

At the end of December 2015, the Spanish Ministry of Economy and Competitiveness (MINECO), through the Secretariat of State for Research, granted IIS-FJD the renewal of its accreditation as a Health Research Institute for a further five-year period, following a scientific and management evaluation of the 2010-2014 period conducted by the Carlos III Health Institute (ISCIII).

In 2017, the Scientific Integrity Committee (CIC) was established to promote good scientific practices and provide training in research integrity to IIS-FJD professionals.

In January 2018, the Clinical Research Ethics Committee (CEIC) was accredited by the Madrid Regional Health Authority as a Research Ethics Committee with Medicines CEIm, according to its Spanish acronym for Comité de Ética de la Investigación con Medicamentos). This accreditation was renewed in February 2021.

In December 2019, IIS-FJD marked the tenth anniversary of its establishment, consolidating during its first decade a leading position in the promotion of high-quality research and in the translation of advances in medicine into clinical practice as efficiently and rapidly as possible, in pursuit of excellence.

On June 4th, 2020, IIS-FJD submitted its application for renewal of its accreditation as a Health Research Institute, in accordance with the requirements established in Royal Decree 279/2016 of 24th June. This initiated an evaluation process that concluded during the first quarter of 2021 with the renewal of accreditation for a further five-year period.

In accordance with the provisions of Royal Decree 279/2016 of 24th June on the accreditation of biomedical and health research institutes, IIS-FJD submitted a request to ISCIII in 2021 for authorisation of a significant

change to incorporate HURJC, HUIE and HUGV into IIS-FJD. Approval was granted by ISCIII on February 7th, 2022. Likewise, in 2024, authorisation for a further significant change was requested to incorporate the Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), and approval was granted by ISCIII on February 29th, 2024.

On June 13th, 2025, IIS-FJD submitted a new application for renewal of its accreditation as a Health Research Institute, in accordance with the requirements established in Royal Decree decre279/2016 of 24th June. The evaluation process concluded during the fourth quarter of 2025 with the renewal of accreditation for a further five-year period.

1.3 Mission, Vision, Values

The IIS-FJD is a multidisciplinary and translational biomedical research structure dedicated to basic, clinical, epidemiological and health services research.

It brings together the clinical and basic research groups of Fundación Jiménez Díaz University Hospital (HUFJD) and three additional university hospitals within the Madrid Public Health Network: Infanta Elena University Hospital (Valdemoro), Rey Juan Carlos University Hospital (Móstoles), and General de Villalba University Hospital. It also includes teaching and research staff from the Autonomous University of Madrid (UAM) and researchers from the Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT).

MISSION

To develop an environment for scientific management and translational research aimed at addressing healthcare challenges within the National Health System and improving citizens' quality of life, with demonstrated quality and excellence, enabling IIS-FJD to become a national and international reference centre.

To provide the knowledge generated through research to support the training of undergraduate, postgraduate and specialist healthcare professionals, in coordination with the University and the relevant teaching institutions.


VISION

To be recognised as a reference centre and an organisation of excellence by its various stakeholders (researchers, teaching staff, patients, clients, healthcare professionals and society at large), distinguished by scientific leadership, the quality of its services, the efficient use of resources, the development of advanced management systems and organisational flexibility.

VALUES

Our values define the ethical framework and serve as a guiding reference for the Institute's development.

- Patient focus
- Quality
- Transparency
- Humanism
- Knowledge
- Professional excellence
- Innovation



FUTURE CHALLENGES

IIS-FJD has maintained a trajectory of sustained growth, supported by the commitment of the institutions that constitute it to further develop the Institute as a centre of excellence in biomedical research. This commitment will be reflected through several strategic actions:

- Adapting and expanding research facilities and scientific infrastructure.
- Implementing growth programmes to foster the development and transfer of knowledge.
- Promoting clinical research.
- Expanding scientific, technical and research support activities.
- Supporting the transfer of scientific knowledge to industry and its clinical application.
- Fostering an attractive environment for biomedical and biotechnology companies.


FUNDACION JIMENEZ DIAZ
CLINICA DE LA CONCEPCION




2

Organizational **Structure**

Organizational Structure

2

The following figure shows the organizational structure of IIS-FJD in 2025:



2.1 Governing Board

The Governing Board is the governing body responsible for the representation, strategic direction and administration of IIS-FJD. All institutions that form part of the Health Research Institute are represented on the board.

Chair:

- **Mr Javier Arcos Campillo.** Chief Executive Officer of Fundación Jiménez Díaz University Hospital (HUFJD).

Vice-Chairs:

- First Vice-Chair: **Ms Amaya Mendikoetxea Pelayo**. Rector of the Autonomous University of Madrid (UAM).
- Second Vice-Chair: **Mr Víctor Madera Núñez**. Chairman of the Board of Trustees of Fundación Jiménez Díaz (FJD).

Board members:

- **Mr Damián García Olmo,** representative appointed by Autonomous University of Madrid (UAM).
- **Ms Ana María Posada Pérez,** member appointed by Fundación Jiménez Díaz (FJD).
- **Ms Carmen Ayuso García,** member appointed by the Governing Board.
- **Mr Alberto Montero Manso,** member appointed by HURJC (IDCSalud Móstoles). (Until April 2025).
- **Ms Raquel Barba Martín,** member appointed by HURJC (IDCSalud Móstoles)
- **Mr Francisco Javier Ruiz Hornillos,** member appointed by HUIE (IDCSalud Valdemoro).
- **Mr Jesús Fernández Tabera,** member appointed by HUGV (IDCSalud Villalba). **Ms Yolanda Benito Moreno,** member appointed by CIEMAT (since April 2025).

Secretary:

- **Mr Celso González García,** Secretary of the Board of Trustees of the Fundación Jiménez Díaz Health Research Institute Foundation (FIISFJD).

Functions:

- To approve the admission and withdrawal of members of IIS-FJD.
- To appoint and dismiss the Scientific Director of IIS-FJD.
- To appoint and dismiss the members of the External Scientific Advisory Committee and the Research Committee of IIS-FJD.
- To oversee, supervise, monitor and guide the activities of IIS-FJD, establishing its general policies and strategic planning.
- To approve the annual budget, inventory and financial statements of IIS-FJD.

- To approve proposals concerning the allocation of resources obtained by IIS-FJD.
- To approve the annual IIS-FJD Activity Report.
- To approve the IIS-FJD Research Plan and the specific programmes and projects to be implemented under it, subject to prior review by the External Scientific Advisory Committee.
- To approve the IIS-FJD Strategic Plan for five-year periods.
- To approve the IIS-FJD Quality, Ethics and Good Scientific Practice Plan.
- To approve the annual plans for the promotion and support of research, ensuring that they are adequately reflected in the budget.
- To approve the Research Training Plan.
- To approve policies promoting knowledge sharing within IIS-FJD.
- To approve the protocol establishing the requirements and conditions for the incorporation of new researchers and research groups.
- To collaborate in the management of personnel affiliated with IIS-FJD.
- To approve IIS-FJD operational protocols, procedures and internal regulations.

2.2 Scientific Director

The Scientific Director of IIS-FJD is the individual appointed by the Governing Board to be responsible for the scientific leadership of the Institute. The Board of Trustees of the Fundación IIS-FJD, as the managing entity of IIS-FJD, grants the powers necessary for the performance of these duties. To be eligible for appointment as Scientific Director, candidates must belong to the staff of either Fundación Jiménez Díaz (FJD) or IIS-FJD.

The Scientific Director chairs the Research Committee and is also a member of the Institute's governing bodies through the Executive Board.

Dr Carmen Ayuso García currently serves as Scientific Director.

Functions:

- To implement the scientific policy of IIS-FJD, reporting directly to the Chair of the Governing Board.
- To serve as the principal scientific representative and spokesperson of IIS-FJD before external institutions and organisations.
- To implement the decisions adopted by the governing bodies within the scope of his or her responsibilities.
- To direct the research, collaboration and training activities of IIS-FJD.
- To propose research programmes.
- To coordinate relations among the IIS-FJD research units.
- To foster and promote collaboration among research groups.
- To chair the Research Committee.

2.3 External Scientific Advisory Committee

The main purpose of the IIS-FJD External Scientific Advisory Committee (CCE according to its Spanish acronym, Comité Científico Externo) is to ensure the scientific quality of the Institute s activities and to contribute to their continuous improvement.

The IIS-FJD CCE is composed of scientists and research managers of recognised scientific and professional standing in the fields of biomedical and health research, encompassing both basic and clinical research.

The members of the Committee are therefore individuals of outstanding expertise, representing a broad range of disciplines within biomedical research and providing valuable input to the scientific strategy of IIS-FJD. Members are appointed and dismissed by the Governing Board upon proposal of the Scientific Director of IIS-FJD. Appointments are made according to the principles of gender equality, seeking to maintain an appropriate balance between women and men. In addition, it is always ensured that at least one Committee member is based outside Spain.

Its composition in 2025 is as follows:

- **Antonio L. Andreu Périz** (Scientific Director, Coordination and Support Office, EATRIS ERIC, the Netherlands).
- **Joaquín Arenas Barbero** (former Director of the Research Institute of 12 de Octubre University Hospital).
- **Ángel Carracedo Álvarez** (Professor of Forensic Medicine, University of Santiago de Compostela; Director of the Galician Public Foundation of Genomic Medicine; Director of the main node of the National Genotyping Centre).
- **Mónica de la Fuente del Rey** (Professor of Physiology, Faculty of Biological Sciences, Complutense University of Madrid).
- **Ángel Gil de Miguel** (Professor of Preventive Medicine and Public Health, Faculty of Health Sciences, Rey Juan Carlos University; until March 2025).
- **Ana Lluch Hernández** (Professor of Medicine at the University of Valencia and Head of the Haematology and Oncology Department at University Clinical Hospital of Valencia).
- **Federico Mayor Menéndez** (Professor of Biochemistry and Molecular Biology, Severo Ochoa Centre for Molecular Biology, Madrid).
- **Fátima Núñez Mangado** (Deputy Director for Innovation, Research and Knowledge Management, Sant Joan de Déu Hospital, Barcelona).
- **Maria A. Oquendo** (Ruth Meltzer Professor and Chairman of Psychiatry. Perelman School of Medicine, University of Pennsylvania. Philadelphia, Pennsylvania, United States).
- **Flora de Pablo Dávila** (Research Professor, Biological Research Centre (CIB-CSIC), Madrid).

In addition, the Committee is supported by a Committee Secretary (Victoria del Pozo, IIS-FJD) and a Recording Secretary (Ana Rubio Araiz, Deputy Scientific Director), who is responsible for preparing the minutes of the meetings and managing the documentation related to the Committee's activities.

The Committee also has a Standing Committee composed of five members, who are appointed for a three-year term.

Functions:

- To ensure the scientific quality of IIS-FJD activities and contribute to their continuous improvement.
- To act as an advisory body to the Governing Board on matters requiring specialised expertise, including the operation of the Institute, research lines, the incorporation of researchers, the creation of research groups and, more generally, the scientific policy to be pursued according to the Strategic Plan.
- To review the planning of IIS-FJD in its various areas (training plan, quality plan, etc.) to ensure its proper future development.
- To evaluate proposals from the Research Committee regarding the integration of new groups into IIS-FJD, assessing the quality and strategic value of their research lines and issuing recommendations on the suitability of their incorporation into the Institute.

Activity:

During 2025, the External Scientific Advisory Committee held two regular meetings (in March and in October). During these meetings, updates were provided on the implementation of the 2024-2028 Strategic Plan; the 2024 Scientific Report; the 2025 national competitive funding calls and European Union funding opportunities; the evolution of IIS-FJD scientific activity during 2025; IIS-FJD clinical trials, including both newly initiated and ongoing studies; developments in human resources during 2025; the new management facilities within IIS-FJD; the implementation of Fundanet; and preparations for the 2025 reaccreditation process. Furthermore, members of the External Scientific Advisory Committee participated in seven discussion panels held during the Annual Meeting of IIS-FJD Research Areas and Groups (7th Annual Meeting), making an active contribution to the development of research activities carried out within the Institute.

2.4 Research Committee

The purpose of the Research Committee is to promote scientific and technical research, as well as training and education, bringing together the different types and research lines within a common environment that fosters synergies and facilitates collaboration among basic researchers, clinical researchers, and researchers from different specialties and disciplines within the fields of health and life sciences.

Composition of the Research Committee: the Committee is composed of a chair, held by the Scientific Director of IIS-FJD, a secretary, and representatives of the different research groups, seeking, whenever possible, to ensure the participation of the various categories of researchers and compliance with the principles of gender equality. The Committee also includes the individuals responsible for training, innovation and quality at IIS-FJD. In addition, the Research Committee is supported by a recording secretary responsible for preparing the minutes of its meetings.

Chair:

- **Carmen Ayuso García** (Scientific Director of IIS-FJD and Deputy Director for Research at HUFJD).

Secretary:

- **María Victoria del Pozo Abejón** Deputy Scientific Director of IIS-FJD, Allergy and Immunology, HUFJD).

Board members:

- **Nicolás Alejandre Alba** (Research in New Therapies, HUFJD; until August 2025).

- **Gloria Álvarez Llamas** (Allergy and Immunology. HUFJD).
- **Enrique Baca García** (Psychiatry and Mental Health. HUFJD, HURJC, HUIE and HUGV).
- **Juan Antonio Bueren** (Advanced Therapies. CIEMAT; since February 2025).
- **Manuel Dómine Gómez** (Medical Oncology. HUFJD).
- **Jaime Esteban Moreno** (Microbiology. HUFJD).
- **Sergio Fernández Bravo** (Allergy and Immunology. HUFJD).
- **Carmen Garcés Segura** (Lipid Disorders: Clinical and Experimental (Adults and Children). HUFJD).
- **Mariano García Arranz** (Research in New Therapies. HUFJD).
- **Damián García Olmo** (Research in New Therapies. HUFJD, HURJC, HUIE and HUGV).
- **Carmen Gómez Guerrero** (Nephrology and Hypertension, Vascular Disease and Diabetes. UAM).
- **Raquel Largo Carazo** (Rheumatology and Bone Metabolism; Training. HUFJD).
- **Lucía Llanos Jiménez** (Clinical Research and Clinical Trials Unit; Quality. HUFJD).
- **Ignacio Mahíllo Fernández** (Epidemiology and Biostatistics Unit. HUFJD).
- **María Dolores Martín Ríos** (Preventive Medicine, Public Health and Primary Care, HUFJD, HURJC, HUIE and HUGV. Until December 2025).
- **Alberto Ortiz Arduán** (Nephrology and Hypertension, Vascular Disease and Diabetes; Innovation. HUFJD; HURJC; HUIE; HUGV).
- **Federico Gustavo Rojo Todo** (Anatomical Pathology; Biobank. HUFJD).
- **José Antonio Rueda Camino** (Medical and Surgical Innovation. HURJC).
- **Francisco Javier Ruiz Hornillos** (Allergy and Immunology. HUIE).
- **Jessica Mire Santillán Coello** Research in New Therapies. HUGV).
- **José María Serratosa Fernández** (Neurology. HUFJD).
- **Sandra Zazo Hernández** (Pathology; Biobank. HUFJD).

Invited Board Members:

- **Isabel Ferreiro Carrobles** (Manager of Conchita Rábago Foundation).
- **Alberto Montero Manso** (Managing Director of IIS-FJD).

Recording Secretary:

- **Ana Rubio Araiz** (Assistant to the Scientific Director)
- Several members of the Research Committee also serve as Coordinators of the Institute's scientific areas:

Area Coordinators:

- Cancer Area: **Federico Rojo Todo.**
- Infectious, Inflammatory and Chronic Diseases Area: **Victoria del Pozo / Raquel Largo Carazo.**
- Neurosciences Area: **Enrique Baca García / José María Serratosa Fernández.**
- Renal, Metabolic and Cardiovascular Diseases Area: **Alberto Ortiz Arduán / Carmen Gómez-Guerrero / Carmen Garcés Segura.**
- Genetics and Genomics Area: **Carmen Ayuso García.**
- Health Technology and Innovation Area: **Damián García-Olmo.**

Functions:

- To advise the Governing Bodies on all scientific, strategic and organisational matters related to IIS-FJD.
- To analyse and make recommendations regarding all IIS-FJD plans and operational regulations, particularly the Strategic Plan, including the Integration Plan and the Training Plan, and to monitor their implementation.
- To propose annual scientific objectives and the actions required to achieve them to the Governing Bodies.
- To provide the External Scientific Advisory Committee with any information necessary to enable it to carry out its advisory and consultative functions effectively and efficiently, as well as to facilitate the implementation and monitoring of its recommendations once approved by the Governing Bodies.
- To serve as the participation body through which research areas and groups contribute to the scientific governance of IIS-FJD, and to promote the creation of emerging groups of early-career researchers that will bring new research lines to the Institute.
- To coordinate the relationship of its members with the various IIS-FJD committees and bodies, including the HUFJD Deputy Directorate for Education, the Research Ethics Committee with Medicines (CEIm), and the IIS-FJD Research Management Area, as well as with public and private organisations and other research institutions.
- To establish and promote agreements, exchanges and collaborative initiatives with public and private institutions, universities, scientific and professional associations, foundations and other organisations at both national and international levels.
- To promote collaboration with distinguished individuals and organisations in fields related to the objectives of the Research Committee and, more generally, with all professionals and institutions operating within the healthcare sector.
- To organise, sponsor and participate in courses, seminars, lecture series, congresses, symposia and workshops.
- To promote, organise and contribute to international meetings, whether broad or topic-specific, periodic or permanent, on subjects related to basic, clinical, epidemiological or public health research.

- To propose scientific content for the IIS-FJD website, social media channels and other dissemination platforms, as well as to review the Annual Scientific Report.
- To evaluate the quality and relevance of project proposals and establish priorities when necessary.
- With the exclusion of members affiliated with the Biobank, the Research Committee shall act as the Scientific Committee of the HUFJD Biobank, carrying out the functions established in Article 13 of the Biobank Internal Regulations and in Royal Decree 1716/2011 on November 18th, which establishes the basic requirements for the authorisation and operation of biobanks for biomedical research purposes and for the handling of human biological sample:
    - To advise on the scientific direction and objectives of the Biobank and its associated nodes, and to contribute to the development of its operating standards.
    - To advise on research activities of strategic importance for the optimal use and development of the Biobank.
    - To conduct the scientific evaluation of requests for biological samples originating from research projects when the samples are stored in any of the nodes of the HUFJD Biobank.
    - To approve any transfer of biological samples to third parties and advise on the prioritisation of their release, including any associated data where applicable, when the samples are stored in any of the nodes of the HUFJD Biobank.

2.5 Social Stakeholders Advisory Board

The Social Stakeholders Advisory Council (Consejo Asesor de Agentes Sociales, CAAS, in Spanish) is an advisory body to the Internal Scientific Committee (Research Committee). Its purpose is to make recommendations concerning the research carried out at IIS-FJD, with the aim of aligning it with the interests and needs of society.

The creation of the CAAS responds to the growing need to incorporate key non-scientific stakeholders into research institutions, enabling them to participate actively in the research conducted within these organisations. The objective is to involve non-specialist members of the public, together with researchers and professionals, in the prioritisation and design of research projects, as well as in the review of research strategies. This approach helps to maximise the translation of research findings and their impact on both the National Health System and society.

The activities of the Social Stakeholders Advisory Council (CAAS) will provide IIS-FJD with guidance on how to project its research activities towards society, with the aim of maximising their effectiveness and ensuring that society plays a role both in the scientific process and in the application, benefits and impact of research.

In addition, the creation of this Council is aligned with the requirements set out in the ISCIII Guidelines for the Evaluation of Health Research Institute Accreditation, as well as with the growing support from the European Union for citizen science across an increasing number of research areas.

Its composition in 2025 is as follows:

- **Juan Francisco Corona Ramón** Member of the Board of Trustees of Fundación Jiménez Díaz (industry representative).
- **Alberto Durán López:** Executive Vice-Chairof Fundación ONCE.
- **Julio Fernández Llamazares:** General Director of Communications and Marketing, Quirónsalud Group.

- **Julián Isla Gómez:** Data and Artificial Intelligence Consultant, Microsoft Spain.
- **Pilar Martínez Gimeno.** President of the Diabetes Madrid Association.
- **Amelia Martín Uranga:** Associate Director of Clinical and Translational Research, Farmaindustria.
- **Miguel Mir Cordero:** Lay Member of the IIS-FJD Research Ethics Committee.

Functions:

- To advise the Internal Scientific Committee (Research Committee) on non-scientific aspects and other matters complementary to scientific development, helping to ensure that IIS-FJD research outcomes are better aligned with societal needs.
- To provide advice on the prioritisation and design of research projects.
- To contribute to the collection of data and biological samples.
- To actively participate in the analysis and dissemination of research results.
- To contribute to the review of research strategies, particularly regarding the application, benefits and societal impact of research.

Activity:

During the meeting held in February 2025, the members of the CAAS reviewed the lay summaries of the 34 research projects submitted by IIS-FJD researchers to the ISCIII 2025 Strategic Action in Health call. The comments provided through an evaluation form were subsequently forwarded to the researchers.

2.6 Scientific Integrity Committee

Since 2017, IIS-FJD has had a Scientific Integrity Committee whose mission is to support the quality of research, contribute to safeguarding its integrity, and ensure compliance with Good Research Practices, as well as to address enquiries and mediate in conflicts that may arise in this area. The Scientific Integrity Committee is a body established and appointed by the Scientific Director and operates independently.

Its composition in 2025 is as follows:

- The Head of the Technical Secretariat of the Research Ethics Committee with Medicines (CEIm), or a qualified delegate appointed by the Head of the Secretariat: **Lucía Llanos Jiménez**
- A physician actively involved in clinical practice and clinical research (preferably a member of the CEIm): **vacant**
- A researcher from one of the other institutions comprising IIS-FJD (HURJC, HUIE or HUGV): **José Antonio Rueda Camino**
- A basic researcher (preferably a member of the Research Committee): **Victoria del Pozo Abejón**
- A member of the Clinical Ethics Committee: **Francisco Javier Ruiz Hornillos**
- A professor of the Autonomous University of Madrid (UAM): **Damián García-Olmo**
- An external expert in the field who is not affiliated with the institution: **Maria Luisa Salas**

Functions:

- To promote compliance with the principles set out in the IIS-FJD Guide on Quality, Ethics and Good Research Practices.
- To ensure the regular review and updating of the Guide on Quality, Ethics and Good Research Practices.
- To act as an arbitration body in response to enquiries or conflicts related to scientific integrity, whether raised by the parties concerned, referred by the IIS-FJD management, submitted by third parties, or brought before the Committee on the initiative of any of its members.
- To promote training and raise awareness among IIS-FJD staff regarding developments, needs and guidance relating to the ethical and professional standards of biomedical research.

2.7. Quality Committee

IIS-FJD has a Quality Committee responsible for promoting and overseeing all quality-related activities carried out within the framework of the Health Research Institute.

The specific functions assigned to the Quality Committee are as follows:

- To ensure that quality-related activities are aligned with the strategic needs and priorities of IIS-FJD.
- To advise the Scientific Director and IIS-FJD on matters relating to quality.
- To develop and monitor the implementation of the Institute's Quality Plan, defining objectives, methodologies, staff participation mechanisms, indicators and timelines.
- To review and assess the achievement of the objectives set out in the Strategic Plan using performance indicators and to promote actions aligned with the Institute's priorities.
- To analyse and propose specific quality-related initiatives to the Scientific Director and the Managing Director, and to monitor the implementation of improvement actions and proposed measures.
- To define and propose specific objectives for the Quality Committee.
- To propose and coordinate quality-related training activities for IIS-FJD staff.
- To contribute to the oversight and integrated maintenance of all management systems implemented within IIS-FJD.

Composition

The Quality Committee is composed of:

- **Chair:** Victoria del Pozo Abejón – Deputy Scientific Director of IIS-FJD
- **Vice-Chair:** Bibiana Navarro Arqued – Director of the HUFJD Quality Unit
- **Secretary:** Margarita Rodríguez-Osorio Campos – Representative of the HUFJD Quality Unit

- **Member boards:**
  - Ana Rubio Araiz – IIS-FJD Research Management Area, Assistant to the Scientific Director
  - Oliver Ajo Villarraso – IIS-FJD Research Management Area, Project Management Unit
  - María Ester Martín Aparicio – IIS-FJD Research Management Area, Scientific Activity Unit
  - Rafael Ceballos Martín – IIS-FJD Research Management Area, Innovation and Knowledge Transfer Unit
  - Pilar del Peso Hernández – IIS-FJD Research Management Area, Training Unit
  - Ruth Fernández Sánchez – Representative of the IIS-FJD Methodological Platform
  - Alberto Ortiz Arduán – Representative of the Research Committee
  - Cristina Villaverde Montero – Representative of the IIS-FJD Platforms
- **Invited Members**:
- Carmen Ayuso García – Scientific Director of the IIS-FJD
- Alberto Montero Manso – Managing Director of the IIS-FJD

2.8. Innovation Committee

In 2017, as part of the certification of the Institute's R&D&I Management System under the UNE 166002 standard, the Innovation Committee was established to define and oversee the procedures governing ideas, projects and innovation initiatives generated within the Institution and managed through the Innovation Support Unit. The Innovation Unit is currently preparing for certification under the new ISO 56001:2024 Innovation Management System standard, with certification planned for 2026.

Objectives of the Innovation Committee

The specific objectives of the Committee are:

- To review innovation proposals.
- Assessing the portfolio of ongoing projects.
- To decide about the continuation of existing projects and the incorporation of new ones.
- To decide about technology transfer and/or the protection of research results.

Composition

The Innovation Committee is composed of:

- **Chair:** Carmen Ayuso García (Scientific Director of IIS-FJD).
- **Vice-chair:** Alberto Montero Manso (Managing Director of IIS-FJD).
- **Secretary:** Rafael Ceballos Martín (Head of the Innovation and Knowledge Transfer Area).

- **Member boards:**
  - Oliver Ajo Villarraso (Projects Representative)
  - Marta Cremades Sendino (Management Representative)
  - Victoria del Pozo Abejón (Research Committee Representative)
  - Álvaro Moreno Pérez (Quality Unit Officer)
  - Alberto Ortiz Arduan (Research Committee Representative)
  - Margarita Rodriguez-Osorio Campos (Quality Unit Representative)

2.9 HUFJD Research Ethics Committee

The HUFJD Research Ethics Committee (CEIm-HUFJD) is an independent and multidisciplinary body whose primary purpose is to safeguard the rights, the safety and the well-being of individuals participating in biomedical research projects. It provides public assurance in this regard by issuing an opinion on the documentation submitted for each research project, considering, among other perspectives, those of lay members, particularly patients and patient organisations.

The Committee has been accredited as a Research Ethics Committee with Medicines (CEIm) since January 11th, 2018. This accreditation was renewed in February 2021 and again in May 2024. The Committee is authorised to issue opinions on clinical trials involving medicinal products and on clinical investigations involving medical devices.

About its scope of activity, the opinion issued by the CEIm is valid throughout the national territory for clinical trials involving medicinal products, clinical investigations involving medical devices and observational studies with medicinal products. For other research studies and/or projects for which a single CEIm opinion is not applicable, the Committee's area of competence is the Single Health Area, as established in Article 2.2 of Law 6/2009 on November 16th on Freedom of Choice within the Healthcare System of the Community of Madrid.

Composition

The composition of the CEIm-HUFJD complies with current regulations, which require a minimum of ten members and the inclusion of the following profiles:

- A lay member representing the interests of patients, with no involvement in biomedical research or clinical practice, and who must not be employed by a healthcare institution.
- At least three physicians actively involved in clinical practice.
- A specialist in clinical pharmacology.
- A hospital pharmacist and a primary care pharmacist.
- A registered nurse.
- One member of the Clinical Ethics Committee and one member of the Research Committee of the institution in which the Committee is established.

- At least two members who are not healthcare professionals, one of whom must hold a degree in Law and the other must be a Data Protection Officer or, alternatively, an expert with adequate knowledge of Regulation (EU)2016/679.
- At least one member with accredited training in bioethics.

At least two members of the Committee must be independent of the institutions where the research is conducted. The CEIm-HUFJD ensures a renewal system that allows for the regular incorporation of new members, at least every four years, while maintaining the Committee's expertise and experience.

The following members belong to the Committee:

- **Chair:** Dr Javier Bécares Martínez. Pharmacist. Hospital Pharmacy Department, HUFJD.
- **Vice-Chair:** Dr Macarena Bonilla Porras. Pharmacist. Hospital Pharmacy Department, HUFJD.
- **Technical Secretary:** Dr Lucía Llanos Jiménez. Clinical Pharmacologist. Clinical Research Unit, HUFJD. Secretary of the Scientific Integrity Committee and Member of the IIS-FJD Research Committee.
- **Board Members:**
  - Mr Fernando Abellán-García Sánchez. Lawyer.
  - Dr Miriam Blanco Rodríguez Attending Physician. Paediatrics. HUFJD.
  - Dr Irene Carrillo Acosta. Attending Physician. Internal Medicine. HUFJD.
  - Dr Ana Díez Alcántara. Primary Care Pharmacist. Dirección Asistencial Noroeste.
  - Ms Ana García Díaz. Lawyer.
  - Dr Francisco Javier González García. Attending Physician. Ophthalmology. HURJC.
  - Dr Carolina Gotera Rivera. Attending Physician. Pneumology. HUFJD.
  - Dr Montiel Jiménez Fuertes. Attending Physician. General and Digestive Surgery. HUFJD.
  - Dr Ángela Lamarca Lete. Attending Physician. Oncology. HUFJD.
  - Dr Ignacio Mahillo Fernández. Biostatistician and Epidemiologist. HUFJD. Member of the Regional CEIm.
  - Ms Marta Marín Crespo. Data Protection Department. Quirón Group.
  - Dr Roberto Martín Reyes. Attending Physician. Cardiology,HLL.
  - Mr Miguel Mir Cordero. Lay member not affiliated with the institution.
  - Dr Carolina Miranda Castillo. Attending Physician. Haematology HURJC.
  - Dr Nélida Muñoz Sanz. Attending Physician. Ophthalmology, HUFJD.
  - Ms Ana Lorena Pérez Hernández. Registered Burse HUFJD.
  - Dr José Antonio Rueda Camino. Attending Physician. Member of the IIS-FJD Research Committee. Internal Medicine HURJC.

- Dr Francisco Javier Ruiz Hornillos. Attending Physician. Member of the IIS-FJD Research Committee and the Clinical Ethics Committee. Allergy and Immunology HUIE.
- Dr Rosa Sánchez Hernández. Attending Physician. Nephrology HUGV.
- Dr Sandra Zazo Hernández. Biologist. Member of the IIS-FJD Research Committee. Anatomical Pathology HUFJD.

- **Administrative Secretaries:** Nieves Martínez García and Noemí Rodríguez Beas.

Functions and operating procedures

The CEIm-HUFJD, accredited as a Research Ethics Committee with Medicines (CEIm) on January 11th, 2018, and reaccredited on February 18th, 2021, and May 29th, 2024, performs the functions set out in Article 12 of Royal Decree 1090/2015. These functions are related to the evaluation of the ethical, methodological and legal aspects of clinical trials involving medicinal products and other biomedical research studies, to protect the fundamental rights and freedoms of research participants. The Committee is committed to complying with the timelines established in the "Memorandum of Collaboration and Information Exchange between the Spanish Agency of Medicines and Medical Devices (AEMPS, according to its Spanish acronym for Agencia Española de Medicamentos y Productos Sanitarios) and the Research Ethics Committees with Medicines (CEIms)", both for the assessment of new clinical trials and for the evaluation of substantial modifications, regardless of the date on which applications are submitted.

Accordingly, applications for the ethical review of any type of research study may be submitted at any time at the applicant's convenience. The assessment of clinical trials involving medical products is conducted within the timelines established by the Spanish Agency of Medicines and Medical Devices (AEMPS), in accordance with the applicable regulations. For all other studies, documentation must be submitted no later than 12 days before the corresponding Committee meeting, provided that the maximum number of studies established for review at that meeting has not been exceeded.

The CEIm-HUFJD meets twice each month, on the second and fourth Tuesday. Meeting dates and submission deadlines are published on the IIS-FJD website, together with the required documentation and the contact details of the Committee Secretariat.



2.10 IIS-FJD Animal Ethics and Welfare Committee

The IIS-FJD Animal Ethics and Welfare Committee (CEBA, according to its Spanish acronym for Comité Ético de Bienestar Animal) is the body authorised by the Directorate-General for the Environment of the Regional Ministry of Environment and Territorial Planning to evaluate projects involving the use of experimental animals, according to Royal Decree 53/2013 of February 1st, which establishes the basic rules for the protection of animals used for scientific and educational purposes, including teaching activities. The CEBA is subject to periodic inspections and reviews. The most recent on-site inspection took place on June 16th, 2022, and assessed both the composition of the Committee and compliance with its regulations.

Its general objectives are to ensure respect for the dignity and welfare of animals and to promote, whenever possible, the well-being of animals used as experimental models in research and educational activities.

Composition

- **Chair:** Carlos Castilla Reparaz (Experimental Medicine and Surgery).
- **Vice Chair:** Carlos Carnero Guerrero (Experimental Medicine and Surgery).
- **Secretary:** Javier Martínez Useros (Medical Oncology).
- **Members:**
    - Carmen Gómez Guerrero (Nephrology and Hypertension, Vascular Pathology and Diabetes).
    - Luis Blanco Colio (Nephrology and Hypertension, Vascular Pathology and Diabetes).
    - Vanesa Esteban Vázquez (Allergy and Immunology).
    - Mariano García Arranz (Research in New Therapies).
- **Technical Secretary:** Carlos Carnero Guerrero (Area Supervisor).
- **External Advisor:** John Jairo Aguilera Correa (CIBER).

Functions and operating procedures

This body serves as the Animal Welfare Body (AWB: Órgano Encargado del Bienestar Animal, OEBA, in Spanish) and is entrusted with the following functions, in accordance with Article 38 of Royal Decree 53/2013 of 1st of February:

- To advise staff involved in animal care and use on matters related to animal welfare, including animal acquisition, housing, care and use.
- To advise staff on the application of the principles of Replacement, Reduction and Refinement (the 3Rs), and to keep them informed of scientific and technical advances relating to the implementation of these principles.
- To establish and review internal operating procedures concerning the monitoring, reporting and follow-up of information related to animal welfare.
- To provide advice on rehoming or adoption programmes, including the appropriate socialisation of animals intended for rehoming or adoption.

- To prepare the report referred to in Article 33.1 of Royal Decree 53/2013 of February 1st and to monitor research projects, considering their impact on the animals used, as well as to identify and assess measures that best contribute to Replacement, Reduction and Refinement.

As a designated authorised body, it is responsible for the evaluation and retrospective assessment of submitted projects. In this capacity, the authorised body submits an annual report detailing its activities to the competent authority, including, at a minimum, a list of all projects that have undergone evaluation or retrospective assessment. All documentation is retained and made available to the competent authority for a minimum period of three years.

The body is also required to retain, for at least three years, records of its recommendations and the decisions taken in relation to those recommendations. These records are made available to the competent authority upon request.

The Animal Ethics and Welfare Committee (CEBA) / Animal Welfare Body (AWB; OEBA in Spanish) meets as often as necessary, with a minimum frequency of once every three months. Once the documentation has been submitted by the Principal Investigator, the Technical Secretariat has a period of fifteen days to issue a favourable or unfavourable opinion on the project evaluation.

When the opinion is favourable, a formal approval document is issued. In the event of an unfavourable opinion, the Secretariat contacts the Principal Investigator and requests the necessary modifications.

Once the documentation has been submitted to the competent authority (Community of Madrid), the authority has forty days to issue a decision. If no response is received within this period, administrative approval by positive silence shall apply, provided that the opinion of the Authorised Body is favourable.

2.11 Structure of the IIS-FJD Research Areas

The structure of IIS-FJD has been organised around four thematic research areas and two cross-cutting areas, which were prioritised based on the analyses conducted as part of the Strategic Plan. The structure and composition of the six research areas are presented below:

- Cancer (4 groups and 2 associated groups).
- Infectious, Inflammatory and Chronic Diseases (5 groups and 1 associated group).
- Neurosciences (3 groups).
- CRM (Cardiovascular, Renal and Metabolic Diseases) (3 groups and 2 associated groups).
- Genomics and Epidemiology (1 group and 1 associated group).
- Health Technology and Innovation (5 groups and 2 associated groups).

THEMATIC AREAS	RESEARCH GROUPS
Cancer	Anatomical Pathology
	Medical Oncology
	Haematology
	Genetic Susceptibility to Rare and Complex Diseases
	Associated Groups
	General Surgery, Thoracic Surgery, Neurosurgery and Other Surgical Specialties
	Radiation Oncology
Infectious, Inflammatory and Chronic Diseases	Allergy and Immunology
	Infectious Diseases and Tropical Medicine
	Microbiology
	Pneumology
	Rheumatology and Bone Metabolism
	Associated Groups
	Traumatology
Neurosciences	Neurology
	Psychiatry and Mental Health
	Mitochondrial Calcium Signalling
CRM (Cardiovascular, Renal and Metabolic Diseases)	Cardiology
	Nephrology and Hypertension, Vascular Disease and Diabetes
	Lipid Disorders: Clinical and Experimental (Adults and Children)
	Associated Groups
	Cardiac and Vascular Surgery
	Urology
CROSS-SECTIONAL AREAS	**RESEARCH GROUPS**
Genomics and Epidemiology	Genetics and Genomics of Rare and Complex Diseases
	Associated Groups
	Preventive Medicine, Public Health and Primary Care
Health Technology and Innovation	Innovation in Ophthalmology
	Medical Engineering Development and Innovation
	Research in New Therapies
	Advanced Therapies (CIEMAT)
	Regenerative Medicine and Tissue Bioengineering (CIEMAT-UC3M)
	Associated Groups
	Medical and Surgical Innovation
	UAM Nursing: Extracorporeal Circulation and Perfusion

Following approval by the Research Committee and the IIS-FJD External Scientific Advisory Committee, the research areas were restructured. As a result, in 2025 the Preventive Medicine, Public Health and Primary Care Group became part of the Genetics and Genomics Area, which was subsequently renamed the Genomics and Epidemiology Area. In addition, the Genetic Susceptibility to Rare and Complex Diseases Group was incorporated into the Cancer Area.

Furthermore, from 2025 onwards, the Renal, Metabolic and Cardiovascular Diseases Area was renamed the CRM Area (Cardiovascular, Renal and Metabolic Diseases).

2.12 IIS-FJD Human Resources and gender perspective


IIS-FJD is firmly committed to respect, diversity and equality among its members. In this regard, one of its key objectives is to ensure and promote equal opportunities across all activities, regardless of gender, ethnicity, ideology, age, sexual orientation or religion. The Institute seeks to uphold the principles of equal treatment for women and men at all levels and to ensure fairness in the allocation of resources and opportunities.

IIS-FJD is a signatory to the European Charter for Researchers and the Code of Conduct for the Recruitment of Researchers (C&C).


The Institute is composed of **1,347** professionals from a wide range of backgrounds, 61.24% of whom are women. This workforce includes 577 researchers corresponding to the R1, R2, R3 and R4 profiles defined by the European EURAXESS classification, 17 emeritus researchers, **524** clinical researchers, 176 scientific and technical support staff working across the Institute's platforms and units, and 53 professionals working in administration and management (see HR Figure 1).

The following sections present analyses of IIS-FJD staff distribution disaggregated by gender: by professional category (HR Figure 2), by clinical/basic research profile (HR Figure 3), by age group (HR Figure 4), and by scientific areas and research groups (HR Figures 5, 6 and 7).


HR-Figure 1




HR-Figure 2




HR-Figure 3
PI Clinical / Experimental




HR-Figure 4
Sex and age (RI-R4)




HR-Figure 5
Research Profile - Scientific Area



HR-Figure 6
Scientific Area
n=professionals from different disciplines



HR-Figure 7
Research Groups
n = professionals from different staff categories



2.13 IIS-FJD Stabilization programme

By the end of 2025, thanks to the stabilisation programme, 17 researchers had joined the permanent staff of IIS-FJD and a further 7 had joined the permanent staff of HUFJD. All of them had previously been recruited through the human resources programmes of the Carlos III Health Institute (ISCIII) and the Ministry of Economy and Competitiveness (Ministerio de Economía y Competitividad, MINECO), with co-funding provided by these public agencies:

IIS-FJD

- GLORIA ÁLVAREZ LLAMAS
- JOSÉ MIGUEL BENITO HUETE
- LUIS MIGUEL BLANCO COLIO
- BLANCA CÁRDABA OLOMBRADA
- MARTA CORTÓN PÉREZ
- MARÍA VICTORIA DEL POZO ABEJÓN
- VANESA ESTEBAN VÁZQUEZ
- CARMEN GARCÉS SEGURA
- RAQUEL LARGO CARAZO
- JUAN MADOZ GÚRPIDE
- ARANZAZU MEDIERO MUÑOZ
- NEREA MÉNDEZ BARBERO
- PABLO ALBERTO MÍNGUEZ PANIAGUA
- NORMA RALLÓN AFANADOR
- ADRIÁN MARIO RAMOS CORTASSA
- MARINA SÁNCHEZ GARCÍA
- ANA BELÉN SANZ BARTOLOMÉ (R&C)

HUFJD

- BERTA ALMOGUERA CASTILLO
- DIANA BETANCOR PÉREZ
- BEATRIZ FERNÁNDEZ FERNÁNDEZ
- CATALINA MARTÍN CLEARY
- Mª INMACULADA MARTÍN MÉRIDA
- Mª VANESA PÉREZ GÓMEZ
- LAURA RODRÍGUEZ-OSORIO JIMÉNEZ





3


Financial **Report**

3.1 Funding sources

During 2025, the funding available to IIS-FJD amounted to €28,945,520.30.

The table below presents the data for 2025, classified according to funding source. Public funding includes the amounts awarded for the reporting year by the respective funding bodies, whereas for all other funding sources, the figures correspond to the funds received and therefore available for use in research activities.


FUNDING SOURCES		ANNUAL AMOUNT 2025	%
PUBLIC FUNDING	External funding	11,137,703.09 €	38.48%
NON-PUBLIC FUNDING	External funding	15,807,817.21 €	54.61%
	HUFJD Funding	2,000,000.00 €	6.91%
	Total	**28,945,520.30 €**	



Public Funding Sources

During 2025, IIS-FJD was awarded competitive research funding amounting to €11,137,703.09. The breakdown by funding body is presented below.

PUBLIC FUNDING SOURCES	2025 ANNUAL AMOUNT	%
Carlos III Health Institute (ISCIII)	9,933,042.21 €	89.18%
Other Government Ministries	735,524.02 €	6.60%
Community of Madrid	290,784.07 €	2.61%
European Commission and Other International Sources	178,352.79 €	1.60%
Total	**11,137,703.09 €**	




During 2025, IIS-FJD secured €15,807,817.21 in private funding to support its research activities and strategic objectives. The distribution of these funds is detailed in the table below.

Non-Public Funding Sources.

During 2025, IIS-FJD secured private funding totalling €15,807,817.21 to support its research activities and objectives. A breakdown of these funds is provided in the table below.

NON-PUBLIC FUNDING SOURCES	2025 ANNUAL AMOUNT	%
Clinical trials	9,389,699.78 €	59.40%
Observational studies	534,200.68 €	3.38%
Competitive research projects	1,254,392.48 €	7.94%
Non-competitive research projects	3,344,192.97 €	21.16%
Service delivery	897,362.80 €	5.68%
Training and dissemination (courses and conferences)	387,968.50 €	2.45%
Total	**15,807,817.21 €**	



In addition to the funding sources described above, Fundación Jiménez Díaz contributed €2 million to the IIS-FJD budget to support:

- Predoctoral, postdoctoral and senior research staff (29 co-funded positions and 21 fully funded positions), covering the portion of costs not financed through the indirect costs associated with competitive public grants.
- Support staff for the research platforms (Animal Facility, 6; Methodology Platform, 2; Biobank Platform, 2; Other Platforms, 8). Of these, 7 positions were co-funded and 11 were fully funded.
- Technical and management staff (33 positions). Of these, 1 position was co-funded and 32 were fully funded.
- Structural maintenance costs and refurbishment of facilities.
- Intramural and extramural research projects.

3.2 Statement of Financial Position and Income Statement

The annual financial statements of IIS-FJD, comprising the Statement of Financial Position as of 31st December, 2025 and the Income Statement presented below, have been audited:

STATEMENT OF FINANCIAL POSITION AS AT 31 DECEMBER 2025 (THOUSANDS OF EUROS)

ASSETS	31/12/2025	EQUITY AND LIABILITIES	31/12/2025
A) NON-CURRENT ASSETS	**1,427**	**A) EQUITY**	**2,937**
I. Intangible Assets	**54**	**A-1) Equity funds**	**1,895**
1. Development	0	**I. Foundation Endowment**	298
5. Software Applications	54	**II. Reserves**	1,768
III. Property, Plant and Equipment	**1,329**	**III. Retained Earnings from Previous Years**	-1,142
2. Technical Installations and Other Tangible Assets	1,312	**IV. Profit for the Year**	971
3. Assets Under Construction and Advances	17		
VI. Long-term Financial Investments	**44**	**A-3) Grants, Donations and Bequests Received**	**1,042**
5. Other Financial Assets	44	**II. Donations and Bequests**	1,042
B) CURRENT ASSETS	**46,741**	**B) NON-CURRENT LIABILITIES**	**3,636**
II. Inventories	**33**	**I. Long-term Provisions**	**875**
6. Advanced to Suppliers	33	4. Other provisions	875
IV. Trade and Other Receivables	**9,251**	**II. Long-term debt**	**2,761**
1. Trade Receivable	657	5. Other financial liabilities	2,761
2. Receivables from Group and Associated Entities	33		
3. Other Receivables	8,556	**C) CURRENT LIABILITIES**	**41,595**
4. Employees	0	**III. Short-term debt**	**39,503**
6. Other Receivables from Public Authorities	5	5. Other financial liabilities	39,503
V. Short-term Investments in Group and Associated Entities	**0**	**VI. Trade and other payables**	**2,092**
2. Loans to group entities	0	1. Trade payables	876
VI. Short-term Financial Investments	**0**	3. Other payables	666
VII. Prepayments and Accrued Income	**5**	4. Employees (accrued salaries)	52
VIII. Cash and Cash Equivalents	**37,452**	6. Other liabilities to public authorities	343
1. Cash and banks	37,452	7. Customer advances	155
TOTAL ASSETS (A+B)	**48,168**	**TOTAL EQUITY AND LIABILITIES (A+B+C)**	**48,168**

STATEMENT OF PROFIT OR LOSS FOR THE YEAR ENDED 31 DECEMBER 2025 (THOUSANDS OF EUROS)

PROFIT AND LOSS ACCOUNT	FINANCIAL YEAR 2025
A) CONTINUING OPERATIONS	**971**
1. Net turnover (Net revenue)	**-**
a) Sales	-
4. Cost of goods sold / Supplies	**-6,631**
a) Consumption of merchandise	-2,307
b) Work performed by other companies	-4,324
5. Other operating income	**19,468**
a) Ancillary income and other current operating income	19,468
6. Staff costs	**-8,235**
a) Wages and salaries	-6,435
b) Social security contributions	-1,800
7. Other operating expenses	**-3,494**
a) External Services	-3,422
b) Taxes	-
c) Losses, impairment and changes in provisions for trade operations	-72
d) Other current management expenses	-
8. Depreciation and amortization	**-400**
9. Asset Grants Recognized as Income	**335**
A.1) OPERATING PROFIT	**1,043**
13. Finance costs	**-73**
a) Interest on debts with third parties	-73
15. Exchange rate differences	**1**
A.2) FINANCIAL RESULT	**-72**
A.3) PROFIT BEFORE TAX	**971**
A.4) PROFIT FOR THE YEAR FROM CONTINUING OPERATIONS	**971**
A.5) PROFIT FOR THE YEAR	**971**



4

Scientific **Programme**

Scientific Programme 4

The IIS-FJD Strategic Plan serves as the overarching framework through which the Institute's general objectives for the promotion and development of research, development and innovation (R&D&I) activities are defined.

Following the completion of the 2019-2023 Strategic Plan, a comprehensive review of the Institute's activities was undertaken, together with a reformulation of its strategic planning for the new 2024-2028 period. This process took into consideration all the activities and requirements set out in the Technical Guide for Health Research Institute Accreditation.

For the 2024-2028 period, the overall strategy of IIS-FJD has been structured around six major Strategic Lines. These build upon the strategic framework established for the 2019-2023 period, while further strengthening and developing it to address the challenges and opportunities of the new strategic cycle.

4.1 Strategic Plan 2024-2028: action plan indicators

STRATEGIC LINE 1. SCIENTIFIC ACTIVITY	
Strategic Objective 1.1. Scientific Plan	
Operational Objectives	**Outcome**
% Of publications in which an IIS-FJD author is the first or corresponding author >=35% (breakdown by women/men)	38.05% (317/833) (104 Women; 213 Men)
% Of publications derived from publicly funded projects >=20%	19.81% (165/833)
Number of Principal Investigators (PIs) with active regional, national or international competitive projects >=60 (breakdown by women/men)	70 (34 Women / 36 Men)
Field-Weighted Citation Impact (FWCI) during the evaluation period >=1,5	2.00
Strategic Objective 1.2. Human Resources Policy Development Plan	
Operational Objectives	**Outcome**
Increase the number of training activities promoting gender equality >1	0
% Of Principal Investigators (PIs) holding an R2 profile (e.g. Juan Rodés) or an R3 profile (e.g. Miguel Servet, Ramón y Cajal) according to the EURAXESS European classification>= 30% of all IPs	42.86 % (30/70)
Strategic Objective 1.3. Consolidation Plan for High-Potential Research Groups	
Operational Objectives	**Outcome**
Achieve a few IIS-FJD researchers conducting health and care research (breakdown by women/men)	108 (17 Men / 91 Women)
Annual number of new researchers, associate researchers or collaborators >= 10	41
Strategic Objective 1.4. Integration Plan for Research Groups within the IIS-FJD Environment	
Operational Objectives	**Outcome**
Intra-institutional collaboration: percentage of publications co-authored by researchers from different IIS-FJD research groups >=15%	13.93% (116/833)
Intra-institutional collaboration: percentage of publications involving at least two of the institutions comprising IIS-FJD >=15%	18.13 (151/833)
Strategic Objective 1.5. Infrastructure, Facilities and Support Services Plan	
Operational Objectives	**Outcome**
Area exclusively dedicated to research and under the direct management of the IIS-FJD Scientific Director >3,000 m²	3,582.99 m²

STRATEGIC LINE 2. TRANSLATION AND INNOVATION	
Strategic Objective 2.1. Clinical Research Promotion Plan	
Operational Objectives	**Outcome**
Increase the number of non-commercial clinical studies by 15% compared with the previous period	0% [28(2024) - 28(2025)]
Increase the number of clinical studies by >= 10 per year	6 [173(2025) - 167(2024)]
Strategic Objective: 2.2. Research Translation Enhancement Plan	
Operational Objectives	**Outcome**
Research outcomes generated at IIS-FJD and translated into clinical practice across the healthcare institutions that comprise IIS-FJD. Previous 3 years >= 5	15 (5 in 2025)
Increase in the number of licensed industrial property registrations, licensed intellectual property registrations, and/or licensed new medical products or devices >3 over the previous 5 years	12
Strategic Objective: 2.3. Clinical Translation Plan for Academic Research Groups	
Operational Objectives	**Outcome**
% of publications with an experimental author involving collaboration with clinical researchers >= 50%	60.22% (112/186)
% of competitive public research projects involving collaboration with clinical researchers >=60	70.00% (28/40)
Strategic Objective: 2.4. Plan de fomento de la innovación	
Operational Objectives	**Outcome**
Promote collaboration between translational research groups (primarily from UAM and CIEMAT) and clinical research groups	–

STRATEGIC LINE: 3. COLLABORATION AND INTERNATIONALISATION	
Strategic Objective: 3.1. Internationalisation Promotion Plan	
Operational Objectives	**Outcome**
% of publications which involve international collaboration >=35%	51.02% (425/833)
Ratio of publicly funded European competitive projects per Principal Investigator (PI) over the previous 5 years (>=European project per 10 PIs [10%])	36.84% (35 Projects/ 95 PIs)
Strategic Objective: 3.2. Collaboration with Other Organisations and Networks Plan	
Operational Objectives	**Outcome**
Participate in at least 12 national and international networks/platforms	12
Strategic Objective: 3.3. Primary Care Integration Promotion Plan	
Operational Objectives	**Outcome**
Number of IIS-FJD researchers who are Primary Care professionals > 5% or 30 researchers	39

STRATEGIC LINE: 4. SUSTAINABILITY	
Strategic Objective: 4.1 Public Funding Promotion Plan	
Operational Objectives	**Outcome**
11 Projects awarded through national, European or international competitive public funding calls over the previous 5 years (breakdown by women/men) >=70	118 2021: 24 projects (13men/ 11 women) 2022: 25 projects (12 men/ 13 women) 2023: 20 projects (10 men/10 women) 2024: 27 projects (14 men/13 women) 2025: 22 projects (13 men/9 women)
Success rate of proposals submitted to national competitive public funding calls during the previous year >25% (breakdown by women/men)	45% (18/40) (25% men ;20% women)
Strategic Objective: 4.2. Private Funding Promotion Plan	
Operational Objectives	**Outcome**
% of competitive and non-competitive funding derived from public sources <=60%	38.48% (€11,137,703.09 €/28,945,520.30)
Strategic Objective: 4.3. Management Procedures and Support Services Improvement Plan	
Operational Objectives	**Outcome**
Number of procedures/processes managed through the SharePoint/Fundanet platform >4 new procedures every 5 years	1
Income generated by support services and research platforms>= €200,000	€414,395.98

STRATEGIC LINE 5. TRANSPARENCY AND QUALITY	
Strategic Objectives 5.1. Management Process Improvement Plan and 5.2. Quality and Continuous Improvement Plan	
Operational Objectives	**Outcome**
General satisfaction level among IIS-FJD professionals >50% satisfaction (minimum participation rate: 10%)	60% satisfied; 8%
Strategic Objective 5.3. Ethics and Scientific Integrity Plan	
Operational Objectives	**Outcome**
Activities carried out in the field of ethics and scientific integrity ≥3 activities every 2 years	9
Strategic Objective 5.4. Data Management, Omics and Open Science Plan	
Operational Objectives	**Outcome**
% of nationally, European and/or internationally funded competitive public projects with open data deposition >=75%	73.68% (14/19)
% of publications (original articles and reviews) published in Open Access (OA) journals relative to the total number of publications in the year >=100%	84.42% (136/165)

STRATEGIC LINE 6. KNOWLEDGE	
Strategic Objective 6.1. Scientific Training Plan	
Operational Objectives	**Outcome**
Number of training activities: increase of 2 collaborative projects/activities	63
% of researchers in training with an R1 category according to the EURAXESS classification>=20%	24.61 % (142/577)
Objetivo Estratégico: 6.2 Communication Plan	
Operational Objectives	**Outcome**
Number of external scientific communication activities >=3 specific activities	14
Strategic Objective 6.3. Corporate Identity Consolidation Plan	
Operational Objectives	**Outcome**
% of publications authored by IIS-FJD researchers that include IIS-FJD affiliation >=70%	90.52% (754/833)
Strategic Objective 6.4. Plan for the Involvement of Social Stakeholders in IIS-FJD Activities	
Operational Objectives	**Outcome**
% of projects involving the participation of key non-scientific stakeholders in their design and development over the last 2 years >=10%	25.86% (30/116)
More than 20 outreach activities organised by IIS-FJD and targeted at specific citizen groups or communities	37



5

Scientific **Activity and** Output

5.1 Human Resources programmes co-funded by official agencies (national and regional)

During 2025, 31 basic and clinical researchers and 9 research technicians and assistants were recruited. In addition, one Health Research management contract was awarded through official competitive human resources programmes. These positions are detailed below, classified by programme and year of the call for applications:

COMMUNITY OF MADRID

Laboratory Technician Contracts

- ESTEFANIA LONDOÑO LONDOÑO (2025)

Research Assistant Contracts

- CLAUDIA ARGUIÑANO HOLGUIN (2023)
- MARÍA DE SANCHA MALUENDA (2023)
- JIMENA PÉREZ MAROTO (2023)
- ALBERTO IRIGARAY MORENO (2025)
- MAR GONZÁLEZ FERNÁNDEZ (2025)

Predoctoral contracts

- LUCÍA PALACIOS GARCÍA (2022)
- ROCÍO RUIZ JIMÉNEZ (2022)
- ANA GARCÍA BAUTISTA (2023)
- MARIA FRESNADILLO CASTAÑO (2023)
- CAROLINA RUIZ SÁNCHEZ (2023)

MINISTRIES

Laboratory Technician Contracts

- MARÍA BELÉN BENAVIDES MORI (2020)
- SUSANA HIDALGO VICO (2022)

Predoctoral contracts (FPU y BES programmes)

- NATALIA VILLAR GÓMEZ (2022)

Juan de la Cierva Programme

- MARTA CASQUERO VEIGA (2022)

Ramón y Cajal Programme

- JORGE OLLER PEDROSA (2021)

ISCIII

Technical Support Contract

- YOLANDA BENÍTEZ QUESADA (2025)

ISCIII Predoctoral Contracts

- CRISTINA ESPADAS NÍGUEZ (2021)
- ARIADNA MARTÍN BLÁZQUEZ (2021)
- SERGIO FERNÁNDEZ BRAVO (2022)
- MARÍA JOSÉ FERNÁNDEZ GÓMEZ (2022)
- MIRIAM MORALES GALLEGO (2022)
- CRISTINA LENDÍNEZ GONZÁLEZ (2023)
- MIGUEL MARCO BONILLA (2023)
- CARLA MAYA LÓPEZ (2023)
- OLGA POMARES SEMPERE (2023)
- GRACIELA URÍA REGOJO (2023)
- CARIDAD MARIA SERRANO MARTINEZ (2024)
- PABLO ROMERO GONZALEZ (2024)
- CRISTINA ROSALES ARIZA (2024)

Sara Borrell Programme

- ÓSCAR LÓPEZ PÉREZ (2022)
- RUBÉN FERNÁNDEZ SANTAMARÍA (2023)
- FÁTIMA MILHANO DOS SANTOS (2023)

Juan Rodés Programme

- ALEJANDRO PORRAS SEGOVIA (2022)

Miguel Servet Programme


- MERITXELL DE JESÚS GARCÍA QUINTANILLA (2019)
- MARTA MARTÍN LORENZO (2022)
- JOSÉ ANTONIO CAÑAS MAÑAS (2023)
- ANA DEL RÍO MACHÍN (2023)
- SANDRA RAYEGO MATEOS (2023)
- DAVID DA SILVA MOURA (2024)

ISCIII Health Research Management Contract

- ANA RUBIO ARAIZ (2023)

In addition, the Clinical Research Unit employs one pharmacist, one biologist, two clinical trial nurses, one study coordinator and one technician. Three of these positions are co-funded through the Platform for Clinical Research Support, while the remaining three are fully funded through the Clinical Research and Clinical Trials Unit (UICEC).

The Biobank Platform also includes one specialist technician and one PhD-level researcher.



5.2 Scientific activity


During 2025, IIS-FJD participated in 26 cooperative research structures and support platforms, conducted 312 research projects funded through public or private sources, managed 57 research personnel contracts, received 5 awards, and carried out 77 funded observational studies.

	Competitive				Non-competitive		Total	
	Públic		Private					
	Active	New	Active	New	Active	New	Active	New
Research Projects	94	23	46	14	172	84	312	121
Cooperative Research	26	7	0	0	0	0	26	7
Human Resources Contracts	46	7	0	0	11	1	57	8
Awards	0	0	0	0	5	2	5	2
SUBTOTAL	**166**	**37**	**46**	**14**	**188**	**87**	**400**	**138**
Observacional Estudies	0	0	0	0	77	18	77	18
TOTAL	**166**	**37**	**46**	**14**	**265**	**105**	**477**	**156**


During 2025, the 166 competitive publicly funded scientific programmes and activities carried out by IIS-FJD comprised 20 projects funded by the European Union and the NIH, 103 funded by ISCIII, 8 corresponding to CIBER research groups, 19 funded by Spanish Ministries, and 16 funded by the Community of Madrid. 37 were newly awarded during the year.

In addition, 234 privately funded research projects and activities were undertaken, including 46 projects funded through competitive private calls and 188 supported through non-competitive funding sources.


In addition to funded research projects and observational studies, IIS-FJD conducted 116 academic research projects and 334 academic observational studies during 2025. These studies received no external funding and were reviewed and approved by the Research Ethics Committee with Medicines (CEIm).



The figure below shows the funding obtained for scientific activities during the 2021-2025 period:




Particularly noteworthy is the continued growth in clinical trial activity, which reached a total of 680 active clinical trials in 2025, including 173 newly initiated trials.




The clinical development phases and the different types of clinical trials active during 2025 are presented in the following figures:

Clinical Development Phases 2025




Clinical Trials 2025




	MULTICENTRE	INTERNATIONAL
NO	14	107
YES	666	573

Early Phases vs Late Phases



	2021	2022	2023	2024	2025
EARLY PHASES (I, I/II, II)	288	305	370	354	375
LATE PHASES (II/III, III, III/IV O IV/OTHERS)	237	240	280	290	305
TOTAL	525	545	650	644	680

Pre-Registration (Phases I-III) vs Post-Registration (Phase IV/Others)



	2021	2022	2023	2024	2025
PHASES I–III	456	496	590	586	617
IV/OTHERS	69	49	60	58	63

5.3 Participation in cooperative research structures

CIBER

It is also worth highlighting IIS-FJD's active participation and strong commitment to several thematic areas of the CIBER cooperative research structures, in which it contributes through different nodes or units within the Consortium, including:

• 2 units within the CIBER on Cardiovascular Diseases (CIBERCV): Luis Blanco Colio and Borja Ibáñez.	ciber | CV
• 1 unit within the CIBER on Diabetes and Associated Metabolic Diseases (CIBERDEM): Jesús Egido de los Ríos.	ciber | DEM
• 3 units within the CIBER on Rare Diseases (CIBERER): Carmen Ayuso, Juan Antonio Bueren and Marcela del Río.	ciber | ER
• 1 unit within the CIBER on Respiratory Diseases (CIBERES): Victoria del Pozo.	ciber | ES
• 1 unit within the CIBER on Infectious Diseases (CIBERINFEC): Jaime Esteban Moreno.	ciber | INFEC

RICORS

IIS-FJD also provides support and infrastructure to several Cooperative Research Networks Oriented towards Health Outcomes (RICORs), in which its researchers actively participate, including:

- Inflammation and Organ and System Immunopathology Network (RICORS2040-KIDNEY DISEASE). RD21/0005/0001. Principal Investigator: Alberto Ortiz Arduán; and RD21/0005/0002. Principal Investigator: Marta Ruiz Ortega. (RICORS2040-Renal). RD24/0004/0001. Principal Investigator: Alberto Ortiz Arduán; and RD24/0004/0021. Principal Investigator: Marta Ruiz Ortega.

- Advanced Therapies Network (RICORS TERAV). RD21/0017/0003. Principal Investigator: Damián García Olmo. (TERAV+). RD24/0014/0014. Principal Investigator: Damián García Olmo. RD24/0014/0023. Principal Investigator: Paula Río Galdo.

- Inflammatory Diseases Research Network (RICORS REI). RD21/0002/0025 and RD24/0007/0031. Principal Investigator: Miguel Ángel González-Gay Mantecón.

In addition, IIS-FJD researchers participate in other collaborative initiatives, such as:

- National Bioinformatics Network (TRANSBIONET). Expansion of the Spanish National Bioinformatics Institute (INB) to increase its international impact. RED2024-153760-E. Principal Investigator: Pablo Alberto Mínguez Paniagua.

- IMPaCT Programme: Infrastructure for Precision Medicine associated with Science and Technology. Ethics and Scientific Integrity Committee. Carmen Ayuso García.

- IMPaCT Genomics Programme. Genomic Medicine (Ethical and Legal Aspects). Coordinator: Carmen Ayuso García.
- IMPaCT Genomics 2. Genomic Medicine. Infrastructure for Precision Medicine associated with Science and Technology. PMPER24/00002. Principal Investigator: Carmen Ayuso García.

• IMPaCT-Data 2. PMP24/00024 (IMPaCT Digital Platform for the capture, integration and modelling of biomedical data associated with the IMPaCT Cohort and projects). Principal Investigator: Pablo Alberto Mínguez Paniagua.

• State Network Consortium for the Development of Advanced Therapy Medicinal Products (CERTERA). CERT22/00025. Principal Investigator: Damián García Olmo.

• COST Action: Building an Open European Network on Osteoarthritis Research (NetwOArk). CA21110. Principal Investigator: Raquel Largo Carazo.
• COST Action: European Network on Optimising Treatment with Therapeutic Antibodies in Chronic Inflammatory Diseases (ENOTTA). CA21147. Principal Investigator: María José Martínez Becerra.
• COST Action: Personalised Medicine in Chronic Kidney Disease: Improved Outcomes Based on Big Data (PerMediK). CA21165. Principal Investigator: Alejandro Avello Escribano
• COST Action: Precision Medicine in Biliary Tract Cancer (Precision-BTC-Network). CA22125. Principal Investigator: Ángela Lamarca Lete


5.4 Scientific production:

The total of publications indexed in PubMed during 2025 was 964, of which 937 had an impact factor. Among these, 599 (63.93%) were published in first quartile (Q1) journals and 267 (28.5%) in first decile (D1) journals.


The cumulative impact factor reached 7,311.4, while the average impact factor was 7.8.

The figures below show the evolution of scientific publications over the last five years:


- Evolution of the number of publications over the last five years:




- Evolution of the Impact Factor of Publications Over the Last Five Years:



- Percentage of publications in which the leading author (first author, last author or corresponding author) is an IIS-FJD researcher:



- Publications resulting from intramural collaboration between IIS-FJD research groups:



Number of scientific publications by category:

PUBLICATION TYPE	No
Book	1
Case Reports	45
Editorial, Comment	28
Journal Article	560
Journal Article, Comparative Study	11
Journal Article, Multicenter Study	69
Journal Article, Observational Study	18
Journal Article, Validation Study	3
Journal Article; Review	125
Journal Article-Clinical Trial	51
Journal Article-Image	4
Letter	39
Practice Guideline	16
Published Erratum	10
Scientific Letter	4
TOTAL GENERAL	**984**

5.5 Innovation and knowledge transfer

5.5.1 Knowledge transfer

Since October 2013, IIS-FJD has had an Innovation Unit integrated within the ITEMAS Platform of the Carlos III Health Institute (ISCIII). Following its establishment, the Institute implemented a Patent Policy and a Patent Plan (both approved by the Governing Board in July 2013) and adopted an active strategy to promote innovation and protect industrial and intellectual property. This strategy included awareness and dissemination activities for IIS-FJD researchers, as well as the development of standard operating procedures (SOPs) for patent applications.

On May 29th, 2017, the IIS-FJD Innovation Management System was certified under the UNE 166002:2014 Standard. The Innovation Unit is currently working towards certification under the new ISO 56001:2024 Innovation Management System Standard, which is expected to be achieved in 2026.

Throughout 2025, IIS-FJD continued to strengthen the protection of research results generated within the Institution and to promote the transfer of knowledge and innovation to society and the healthcare sector:


- Industrial Property Portfolio: Applications Filed:
  - 7 European patent applications and 1 European divisional patent application were filed.
  - 5 patent families were extended internationally through Patent Cooperation Treaty (PCT) applications.
  - 9 national phase entries were filed.

- Industrial Property Portfolio: Granted Rights
  - 1 European patent was granted, bringing the total of active patent families granted in previous years to 26.
  - In addition, 8 national phase applications were granted: 2 in Brazil, 1 in Mexico, 1 in Australia, 1 in the United States and 3 in Japan.
- Industrial and/or Intellectual Property Licensing Portfolio:
  - The Institution currently holds 11 patent licence agreements and 1 know-how licence agreement.

Patent Applications Filed in 2025


No	PATENT APPLICATION No	PATENT TITLE	RESEARCH AREA	INVENTOR RESEARCH GROUP	IIS-FJD INVENTORS
1	**EP25382367.8**	LAFORA - NUCLEIC ACID VECTOR COMPRISING A CODING SEQUENCE OF THE EPM2B GENE	NEUROSCIENCES	NEUROLOGY	JOSE MARÍA SERRATOSA FERNANDEZ, MARINA SANCHEZ GARCIA, LUIS ZAFRA PUERTA
2	**EP25382040.1**	PREVENTION AND/OR TREATMENT OF ACUTE KIDNEY INJURY	CRM AREA (CARDIOVASCULAR, RENAL AND METABOLIC DISEASES)	NEPHROLOGY AND HYPERTENSION, VASCULAR DISEASES AND DIABETES	ANA BELÉN SANZ BARTOLOMÉ; ALBERTO ORTIZ ARDUAN; JUAN GUERRERO MAUVECIN; NATALIA VILLAR GÓMEZ
3	**EP25382612.7**	EXOSOMES DERIVED FROM PANCREATIC TUMOR CELLS FOR USE AS SELECTIVE DRUG DELIVERY VEHICLES IN THE TREATMENT OF PANCREATIC CANCER	CANCER	MEDICAL ONCOLOGY	MARTÍNEZ USEROS JAVIER, SANZ CRIADO LARA, GARCÍA-FONCILLAS LÓPEZ JESÚS MIGUEL
4	**EP25382690.3**	EFFICIENT PRIME EDITING FOR A PREVALENT COL7A1 MUTATION CAUSING RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA	HEALTH TECHNOLOGY AND INNOVATION	REGENERATIVE MEDICINE AND TISSUE BIOENGINEERING	LAURA UGALDE DÍAZ
5	**EP25382912.1**	SYSTEM FOR CLINICAL MONITORING USING A SENSOR EQUIPPED MOUTHPIECE	INFECTIOUS, INFLAMMATORY AND CHRONIC DISEASES	PNEUMOLOGY	SARA HEILI
6	**EP25383094.7**	IN VITRO BIOMARKERS FOR PREDICTING KIDNEY DONOR GRAFT FUNCTIONALITY	RENAL, METABOLIC AND CARDIOVASCULAR DISEASES	NEPHROLOGY AND HYPERTENSION, VASCULAR DISEASE, AND DIABETES.	GLORIA ALVAREZ LLAMAS, ROCÍO RUÍZ JIMÉNEZ, MARTA MARTÍN LORENZO
7	**EP26382174.6**	SYSTEMS AND METHODS FOR AUTOMATED CLASSIFICATION OF COAGULATION TEST RESULTS	CANCER	HAEMATOLOGY	DIEGO VELASCO

Between 2021 and 2025, 38 patent applications were filed, as illustrated in the following figure:




Since 2010, a total of 355 ideas has been registered with the IIS-FJD Innovation Unit, of which 110 have been protected. During 2025, the active ideas were at different stages of development, as shown in the figure below. The main categories under which these projects are classified include biotechnology and molecular diagnostics, healthcare and organisational innovation, pharmaceuticals and drug development, advanced therapies, and health information and communication technologies (ICTs). The distribution of ideas across these categories from 2021 to 2025 is presented in the following figure:

DEVELOPMENT STAGE OF REGISTERED INNOVATION IDEAS (2021-2025)



Distribution of Ideas by Category



Regarding the public-private partnership projects funded in 2025:

- 2 Two Public-Private Collaboration (CPP) projects, in the areas of Cancer and Infectious, Inflammatory and Chronic Diseases.
- 1 ISCIII Technological Development Project in the Health Technology and Innovation Area.

In addition, several training workshops on technology transfer and industrial property is currently being prepared.

5.5.2 Clinical practice guidelines, recommendations, clinical procedures and publications derived from clinical trials

76 clinical practice guidelines were published in 2025. 75 were published in journals with an impact factor, including 40 in first quartile (Q1) journals and 21 in first decile (D1) journals.

These publications are identified as ⊕ CLINICAL PRACTICE GUIDELINES in the publication lists corresponding to each research group and research area.


Hospital Infanta Elena




6

Research **Areas and Groups**


The structure of IIS-FJD is organised around six research areas, comprising 21 research groups and 8 associated groups, which vary in size and number of researchers. These differences influence the scientific output of each group. Research groups are composed of Group Leaders and Principal Investigators (PIs). For the purposes of IIS-FJD, PIs are defined as researchers leading active projects funded through national, European or international competitive public funding programmes.

The figure below shows the evolution of the publications by research area during the period 2021-2025.


Evolution of the total number of publications by research area




Scientific Publications of IIS-FJD 2025




No of publications / No of principal investigators (PIs) by research area




No of publications / No of research groups by area




No of publications (Q1) / No of principal investigators (PIs) by research area




No of publications Q1 / Nº de research groups by area



Cumulative Impact Factor / No of principal investigators (PIs) by research area



Cumulative impact factor / Nº of groups by research area



Publications Involving IIS-FJD Researchers Published in Journals with an Impact Factor Greater than 10 (ranked by impact factor):

In 2025, a total of 138 publications involving IIS-FJD researchers were published in journals with an impact factor above 10. 135 were published in first decile (D1) journals and 3 in second decile (D2) journals.


FUNDACION JIMENE
CLINICA DE NTRA SRA DE LA CO

6.1 Cancer Area

Research Groups within the Cancer Area

PATHOLOGICAL ANATOMY GROUP

MEDICAL ONCOLOGY GROUP

HAEMATOLOGY GROUP

GENETIC SUSCEPTIBILITY TO RARE AND COMPLEX DISEASES GROUP

GENERAL SURGERY, THORACIC SURGERY, NEUROSURGERY AND OTHER SURGICAL SPECIALTIES ASSOCIATED GROUP

RADIATION ONCOLOGY ASSOCIATED GROUP

Definition of the area and priority objectives

Research within the Cancer Area is conducted across three complementary levels: basic research, translational research and clinical research. The Cancer Area includes the Pathology, Medical Oncology and Haematology Groups, as well as two associated groups.

Its main objectives include:

Cancer Area Objectives	Level of Achievement in 2025
To improve understanding of genetic and protein alterations in solid and haematological malignancies.	
To further investigate the mechanisms underlying resistance to current therapies, with a particular focus on the immune system and the tumour microenvironment, to identify new immunotherapeutic strategies.	
To promote research into the tumour microenvironment through both drug development and clinical trials; to explore new technologies and approaches for its characterisation; and to evaluate strategies aimed at targeting the pro-tumorigenic microenvironment to maximise therapeutic benefit	
To identify, using prospective samples, tumour cell and immune biomarkers that may help distinguish patients most likely to benefit from next-generation therapies.	
Scale:	

NOT ACHIEVED		PARTIALLY ACHIEVED		ACHIEVED	


Following approval by the Research Committee and the IIS-FJD External Scientific Advisory Committee, the research areas were restructured. As a result, in 2025 the Preventive Medicine, Public Health and Primary Care Group became part of the Genetics and Genomics Area, which was subsequently renamed the Genomics and Epidemiology Area. In addition, the Genetic Susceptibility to Rare and Complex Diseases Group was incorporated into the Cancer Area.

Scientific activity of Cancer Area

	2025	Pathological anatomy	Medical Oncology	Haematology	Genetic Susceptibility to Rare and Complex Diseases	General Surgery, Thoracic Surgery, Neurosurgery and Other Surgical Specialties	Radiation Oncology	TOTAL
PROJECTS	→EU/NIH PROJECTS	//	4	1	//	//	//	**5**
	→ISCIII PROJECTS	5	6	1	//	//	//	**12**
	→CIBER PROJECTS	//	//	//	//	//	//	**//**
	→MINISTRY-FUNDED PROJECTS	1	2	//	//	//	//	**3**
	→CAM PROJECTS	2	1	1	//	//	//	**4**
	→AWARD	//	//	1	//	//	//	**1**
	→NON-OFFICIAL PROJECTS	11	33	12	1	1	//	**58**
	→OBSERVATIONAL STUDIES	3	11	17	//	//	//	**31**
	TOTAL	**22**	**57**	**33**	**1**	**1**	**//**	**114**
CLINICAL TRIALS	→EARLY-PHASE TRIALS (I, I/II, II)	1	267	61	//	//	1	**330**
	→LATE-PHASE TRIALS (II/III, III, III/IV O IV/ OTHERS	7	111	49	//	//	2	**169**
	TOTAL	**8**	**378**	**110**	**//**	**//**	**3**	**499**

Publications of Cancer Area

2025	Total of publications	No of publications with an Impact Factor	Cumulative impact factor	Average annual impact factor	No of publications in Q1 journals	% of publications in Q1 journals	No of Open Access Publications	No of Clinical Practice Guidelines
Anatomical Pathology	61	59	361	6.12	35	59.32%	42	0
Medical Oncology	90	87	937	10.77	57	65.52%	74	8
Haematology	74	71	608.8	8.57	47	66.20%	52	3
Genetic Susceptibility to Rare and Complex Diseases	1	1	3.9	3.90	1	100.00%	1	0
General Surgery, Thoracic Surgery, Neurosurgery and Other Surgical Specialties	12	10	31.4	3.14	3	30.00%	8	1
Radiation Oncology	8	8	20.6	2.58	1	12.50%	5	0
CANCER AREA	**246**	**236**	**1962.7**	**8.32**	**144**	**61.02%**	**182**	**12**



Five most relevant publications from the Cancer Area in 2025

Is There a Role for Mifamurtide in Nonmetastatic High-Grade Osteosarcoma? Results From the Italian Sarcoma Group (ISG/OS-2) and Spanish Sarcoma Group (GEIS-33) Trials.

Palmerini E, Meazza C, Tamburini A, Márquez-Vega C, Bisogno G, Fagioli F, Ferraresi V, Milano GM, Coccoli L, Rubio-San-Simón A, Gallego O, Llinares Riestra ME, Manzitti C, Mora J, Vaz-Salgado MÁ, Luksch R, Mata C, Pierini M, Carretta E, Cesari M, Paioli A, Marrari A, Scotlandi K, Serra M, Asaftei SD, Gambarotti M, Picci P, Ferrari S, Valverde C, Ibrahim T, Broto JM.

J Clin Oncol. 2025 Oct.43(28):3113-3122.

PMID: 40825172

IF: 43,4

http://dx.doi.org/10.1200/JCO-25-00210

Early-Stage Mycosis Fungoides: Searching for biomarkers associated with advanced stage progression.

Rebollo-González M, Gargallo-Moneva V, Sánchez-Martínez A, Torre-Castro J, Herencia C, Moreno-Delgado M, Alonso-Alonso R, Manso R, Borregón J, Díaz de la Pinta FJ, Pajares R, Gotor-Rivera A, Torres-Navarro I, Morillo-Giles D, Moreno-Vílchez C, Martín-Torregrosa D, Muniesa C, Servitje O, Climent F, Frutos Díaz-Alejo J, Rivera-Díaz R, Ortiz-Romero PL, Rodríguez-Peralto JL, Rodríguez-Pinilla SM, Rodríguez M.

Br J Dermatol. 2025 May 27.

PMID: 40424592

IF: 10,6

http://dx.doi.org/10.1093/bjd/ljaf204

Inflammatory Fibroid Polyp (Vanek's Tumor): A Retrospective Multicentric Analysis of 67 Cases.

Sánchez MM, Domínguez-Prieto V, Qian Zhang S, Quiceno Arias HD, Álvarez Álvarez MB, Fuertes MJ, Meliga C, Jiménez-Galanes S, Labajo HG, Olmo DG, Campos PV.

Cancers (Basel). 2025 Apr 02.17(7).

PMID: 40227778

IF: 4,4

http://dx.doi.org/10.3390/cancers17071209

Diffuse large B-cell lymphoma presenting as acute adrenal hemorrhage.

Torres F, Suárez U, Pizano P.

Blood Res. 2025 Mar 19.60(1):18.

PMID: 40106058

IF: 2,8

http://dx.doi.org/10.1007/s44313-025-00064-8

Epcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results from the EPCORE NHL-2 trial.

Brody JD, Jørgensen JM, Belada D, Costello R, Trněný M, Vitolo U, Lewis DJ, Karimi YH, Sureda A, Andre M, Wahlin BE, Lugtenburg PJ, Jiang T, Karagoz K, Steele AJ, Abbas A, Wang L, Risum M, Cordoba R.

Blood. 2025 Jan 10.

PMID: 39792928

IF: 23,1

http://dx.doi.org/10.1182/blood.2024026830

Gender Perspective in the Cancer Area

The Cancer Area is composed of a team of professionals committed to respect, diversity and equality among its members. The Area seeks to promote the professional development of all staff, ensuring equal opportunities and preventing discrimination on the grounds of gender or age.




Future challenges for the Cancer Area


Development of alternative research models (humanised mice and organoids) to recreate different human tumour models across a broad spectrum of stages of tumorigenesis.

Development of new high-throughput diagnostic tools (next-generation sequencing and proteomics) and minimally invasive technologies (liquid biopsy and imaging) for cancer, aimed at patient stratification and disease monitoring.

6.1.1. ANATOMICAL PATHOLOGY GROUP







GROUP COMPOSITION

Group leaders

Federico Rojo Todo

María Socorro Rodríguez Pinilla

smrodriguez@quironsalud.es

Research

Basic, translational and clinical research

LOCATION

Department of Pathology
Main Building, 8th and 9th Floors
Fundación Jiménez Díaz University Hospital
Avda. Reyes Católicos, 2. 28040 Madrid (Spain)

Pathology Laboratory
Research Building, 4th Floor
Fundación Jiménez Díaz University Hospital
Avda. Reyes Católicos, 2. 28040 Madrid (Spain)

KEYWORDS

Breast cancer, T-cell lymphomas, molecular pathology, tumour microenvironment, immunotherapy, prognostic and predictive factors in cancer, therapeutic resistance.

SUMMARY OF ACTIVITIES

Advances in breast cancer research, together with increased patient awareness, have significantly improved the diagnosis, treatment and survival rates associated with this disease. However, current therapies remain ineffective for a substantial proportion of patients, highlighting the need for further improvements in both survival and quality of life. Our Molecular Pathology group is dedicated to cancer research, particularly breast cancer, and has made important contributions to understanding the mechanisms underlying resistance to specific anticancer therapies.

The group focuses on two main objectives: identifying robust biomarkers capable of predicting resistance to current treatments and developing new therapeutic strategies to overcome resistance to first-line therapies. In recent years, the group has investigated mechanisms of treatment resistance and identified new therapeutic approaches, with particular emphasis on the role of the tumour microenvironment and specific cellular populations in determining treatment efficacy. In addition, the group collaborates extensively with other research teams to uncover new biological mechanisms and potential therapeutic targets.

The group is also actively involved in clinical trials evaluating new drugs and therapeutic approaches in patients, and its research has been instrumental in the design of innovative clinical studies. Beyond its research activities, the group plays an important role in the management of biological samples and the coordination of research initiatives, always with the aim of improving the care and treatment of patients with breast cancer.

In parallel, the group is actively engaged in the study of lymphoma biology, with a particular focus on T-cell lymphomas. Its research projects are aimed at identifying prognostic biomarkers and novel therapeutic targets that may contribute to improved patient outcomes.

CONTRIBUTIONS TO SOCIETY

In 2025, our group published several scientific articles on the molecular mechanisms underlying tumour resistance and presented its findings at national and international conferences, as well as at educational forums and patient association events. Several doctoral theses are currently being conducted within the laboratory, which also hosts students, medical residents and research fellows.

The group actively participates in patient groups, patient associations and cooperative breast cancer research networks. Clinically relevant findings are disseminated through these channels whenever appropriate. In addition, the group is a member of CIBERONC (Center for Biomedical Network Research on Cancer), which further enhances the visibility and dissemination of its research outcomes.

The investigators leading these projects are strongly committed to communicating research findings to society, with the aim of increasing public awareness of this disease and of advances that may contribute to improving patient outcomes. The Group collaborates closely with patient organisations such as AECC, GEPAC, FECMA and AECMM, and regularly participates in public forums and meetings organised by these associations.

The group also collaborates with the INVI Male Breast Cancer Association, incorporating a gender perspective into its research on a disease that, although predominantly affecting women, can also occur in men.

COLLABORATIONS

During 2025, the group established and maintained collaborations with several national and international research teams through high-impact research projects funded by the Carlos III Health Institute (ISCIII), the Community of Madrid and European programmes. Within the Fundación Jiménez Díaz Health Research Institute (IIS-FJD), the group worked closely with numerous research groups, both within the Cancer Area and

across other research programmes. In addition, the group is a member of CIBERONC (ISCIII's Cancer Research Network Biomedical Research Centre), GEICAM and GEMCAD.

These collaborations have enabled significant scientific advances. The group has identified a new mechanism with potential applications in combating breast cancer and has developed experimental models that improve our understanding of how certain tumours acquire resistance to standard therapies. Furthermore, the group has made important contributions to the coordination of innovative clinical trials, with the goal of improving treatment outcomes and the quality of life of patients.

DOCTORAL THESIS


BACHELOR'S DEGREE FINAL PROJECTS
1


MASTER'S DEGREE FINAL PROJECTS
0

DOCTORAL THESIS	
IN PROGRESS	*DEFENDED*
6	1

6.1.2. MEDICAL ONCOLOGY GROUP







GROUP COMPOSITION

LEADERS

María Arantzazu Cebrián Aranda
arancha.cebrian@iis-fjd.es
Manuel Dómine Gómez
mdomine@fjd.es
Jesús García-Foncillas
jgfoncillas@fjd.es
jesus.garciafoncillas@oncohealth.eu
Javier Zenón Martín Broto
javier.martinb@quironsalud.es

PIs

David Da Silva Moura
Ángela Lamarca Lete
Javier Martínez Useros

Research

Basic and clinical research

LOCATION

Translational Oncology Laboratory
START Phase I Unit
START PDX Unit
Fundación Jiménez Díaz University Hospital
Avda. Reyes Católicos, 2. 28040 Madrid (Spain)

Oncology Laboratory
Fundación Jiménez Díaz University Hospital
Avda. Reyes Católicos, 2. 28040 Madrid (Spain)
General de Villalba University Hospital
Camino de Alpedrete &, M-608, Km 41, 28400 Collado Villalba, Madrid

KEYWORDS

Identification of new molecular targets and signalling pathways in colorectal cancer, small-cell and non-small-cell lung cancer, pancreatic cancer, neuroendocrine tumours and sarcomas, development of patient-derived tumour models, early-phase clinical trials, phase II/III clinical trials.

SUMMARY OF ACTIVITIES

Our research group follows a translational approach that spans from clinical research to basic and translational science.

From a clinical perspective, the group has activated a substantial number of clinical trials, ranging from Phase I studies (more than 100 trials) to Phase II-III studies (more than 150 trials). In addition, group members have published numerous articles in high-impact journals, including The New England Journal of Medicine, The Lancet, The Lancet Oncology, JAMA Oncology, Journal of Clinical Oncology, and Nature Reviews Clinical Oncology, among others.

From a basic research perspective, the group focuses primarily on the identification and characterisation of new molecular targets and signalling pathways involved in cancer development and progression. These studies are conducted using tumour samples obtained from patients, from which experimental models are also generated in immunodeficient animals to facilitate the study of tumour biology and the evaluation of new therapeutic strategies.

CONTRIBUTIONS TO SOCIETY

Our group has identified several prognostic factors that help distinguish patients with lung, colorectal, pancreatic and sarcoma cancers who have differing prognoses and may therefore benefit from alternative therapeutic approaches. In addition, we have characterised the mechanisms underlying resistance to a variety of anticancer treatments and identified therapeutic strategies capable of modulating these processes, which are responsible for markedly reducing the effectiveness of established therapies.

These findings contribute to a more personalised approach to cancer treatment, improving patient stratification, therapeutic decision-making and the development of novel treatment strategies aimed at overcoming drug resistance and enhancing clinical outcomes.

COLLABORATIONS

- Faculty of Medicine, Autonomous University of Madrid (UAM).
- Rey Juan Carlos University.
- Alfonso X el Sabio University.
- Catholic University of Murcia.
- University of Alcalá.
- Carlos III Health Institute (ISCIII).
- European Society for Medical Oncology (ESMO).
- Spanish Lung Cancer Group (GECP, Spanish acronym).
- European Thoracic Oncology Platform (ETOP).
- Karolinska Institute, Stockholm (Sweden).
- START, San Antonio (TX, USA).
- Rey Juan Carlos University Hospital, Móstoles.

- General de Villalba University Hospital.
- Infanta Elena University Hospital, Valdemoro.
- American Society of Clinical Oncology (ASCO).
- ASCO Quality Oncology Practice Initiative (QOPI®).
- OECI-EEIG Organisation of European Cancer Institutes.
- Preclinical and Translational Research Collaborators: Heather Hayenga (University of Texas), Leonidas Bleris (University of Texas), Zuzana Ozaniak (Motol University Hospital, Praga), Paulino Gómez Puertas (Severo Ochoa Centre for Molecular Biology [CBMSO], Madrid, Spain), Val Brunton (Edinburgh University, Edimburgo), Paul Huang (The Institute of Cancer Research (ICR), Londres), Sandro Pasquali (Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milán), Nadia Zaffaroni (Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milán), Alberto Jiménez Shumacher (Health Research Institute of Aragón [IISA], Zaragoza, Spain), Javier Alonso García de la Rosa (Institute for Rare Diseases Research [IIER], Carlos III Health Institute [ISCIII], Majadahonda, Madrid, Spain), Jose Antonio Lopez Guerrero (Health Research Institute Foundation, Valencia, Spain), Mario Perez (University of Seville, Seville), Luis Valencia Cabrera (University of Seville, Seville, Spain), Jesús López Marti (Freelancer, Spain), Victor Villar Cortes (University of St Andrews ,St. Andrews, Scotland), Maria Peña Chilet (La Fe Health Research Institute, Valencia, Spain), María Sonsoles Carlos III Health Institute [ISCIII], Madrid, Spain), Tiago Goss dos Santos (A.C. Camargo Cancer Center, São Paulo, Brazil).

DOCTORAL THESIS


BACHELOR'S DEGREE FINAL PROJECTS
3


MASTER'S DEGREE FINAL PROJECTS
4

DOCTORAL THESIS	
IN PROGRESS	*DEFENDED*
10	1

6.1.3. HAEMATOLOGY GROUP







GROUP COMPOSITION

Leader

Mª Pilar Llamas Sillero

pllamas@fjd.es

PIs

Raúl Córdoba Mascuñano

Ana del Río Machín

Sergio Ramos Cillán

Research

Basic and clinical research

LOCATION

Cancer Area Laboratory
Experimental Haematology
4th Floor, Research Building and Basement Level (-1),
Private Patients Building

IIS-FJD
Fundación Jiménez Díaz University Hospital
Avda. Reyes Católicos, 2. 28040 Madrid (Spain)

KEYWORDS

Immunotherapy, cell therapy, CAR-T cells, NK cells, senescence, immune-senescence, acute myeloid leukaemia (AML), quiescence, germline predisposition, multi-omics studies, personalised medicine, leukemic niche, tumour microenvironment, machine learning, nanocarriers, lymphoma, chronic lymphocytic leukaemia (CLL), cardiotoxicity, cardio-oncology, haemato-geriatrics, frailty, digital health, PROMs/PREMs, COVID-19 in haematology, platelet disorders.

SUMMARY OF ACTIVITIES

I. Improving the efficacy and persistence of CAR-T cell immunotherapy for haematological malignancies.

II. Developing new approaches in Haematology based on 3D culture systems, nanomedicine and artificial intelligence.

III. Elucidating the role of germline variants in patients with hereditary myeloid neoplasms to improve early detection, genetic counselling and clinical management.

IV. Investigating acute myeloid leukaemia from clinical, biological and translational perspectives.

V. Conducting research on thrombotic and bleeding disorders.

VI. Performing translational and clinical research in lymphoid malignancies, including lymphomas and chronic lymphocytic leukaemia (CLL).

VII. Assessing frailty in older patients with haematological malignancies.

VIII. Using digital health tools to personalise the follow-up and monitoring of patients with haemato-oncological diseases.

IX. Characterising COVID-19 disease in haemato-oncological patients.

X. Conducting studies to evaluate cardiotoxicity in lymphoma patients receiving anthracycline-based therapy.

XI. Promoting value-based healthcare through the assessment of health outcomes using PROMs and PREMs in patients with haematological malignancy.

XII. Studying and characterising platelet disorders in both adults and children.

CONTRIBUTIONS TO SOCIETY

- Development of a CAR-T Cell Therapy for multiple myeloma, currently being used in Patient Care.
- Development of new CAR-T cell therapies for patients with non-Hodgkin lymphoma.
- Establishment of a specialised referral committee and clinical pathway for the diagnosis and follow-up of patients with a germline predisposition to haematological malignancies.
- Identification of new therapeutic targets for high-risk subtypes of acute myeloid leukaemia.
- Discovery of a seasonal pattern in the diagnosis of acute myeloid leukaemia.
- Development of fully humanised and more physiologically relevant preclinical models aimed at reducing or replacing the use of animal models and lowering costs for the Spanish public healthcare system.
- Empowering patients and promoting their active involvement in healthcare by collecting patient-reported outcome measures (PROMs) and patient-reported experience measures (PREMs).
- Improving cardiovascular health prevention in patients at high risk of developing cardiotoxicity associated with anticancer treatments.
- Identifying frailty profiles among older patients with haematological malignancies to avoid undertreatment of fit and robust patients and overtreatment of unfit or frail patients.

- Contributing to the development of new drugs for the treatment of lymphomas and chronic lymphocytic leukaemia (CLL).
- Characterising COVID-19 disease in patients with haematological malignancies.
- Promoting the digitalisation of healthcare with new technologies for the follow-up and management of haematology patients.

COLLABORATIONS


National: CIEMAT; IDIBAPS/Hospital Clínic Barcelona; 12 de Octubre University Hospital; La Paz University Hospital; the PETHEMA Acute Myeloid Leukaemia Cooperative Group; the GLAM Regional Acute Leukaemia Cooperative Group; Complutense University of Madrid; University of Alcalá; Ramón y Cajal University Hospital; Reina Sofía University Hospital; GELTAMO (Spanish Lymphoma and Bone Marrow Transplantation Group); GELLC (Spanish Chronic Lymphocytic Leukaemia Group); Niño Jesús Children's University Hospital; Vall d'Hebron University Hospital; and the Murcian Biomedical Research Institute .


International: MD Anderson Cancer Centre (Houston, Texas, USA); Cincinnati Children's Hospital Medical Centre (USA); University of Lausanne (Switzerland); European Haematology Association (EHA); Barts Cancer Institute (London, United Kingdom); National Health Service (United Kingdom); UK Cancer Genetics Group and the CanGene-CanVar Programme (United Kingdom); King's College Hospital (London, United Kingdom); University of Pavia (Italy); University of Helsinki and the Institute for Molecular Medicine Finland (FIMM-HiLIFE) (Finland); St. Anna Children's Cancer Research Institute (Vienna, Austria); University of Birmingham (United Kingdom); Institute for Research in Immunology and Cancer (Montreal, Canada); Semmelweis University (Budapest, Hungary); and the Francis Crick Institute (London, United Kingdom).


DOCTORAL THESIS

BACHELOR'S DEGREE FINAL PROJECTS	MASTER'S DEGREE FINAL PROJECTS	DOCTORAL THESIS	
		IN PROGRESS	*DEFENDED*
2	0	4	1

6.1.4. GENETIC SUSCEPTIBILITY TO RARE AND COMPLEX DISEASES GROUP (UAM)







GROUP COMPOSITION

Leader

Javier Santos Hernández

javier.santos@uam.es

Research

Basic and translational research

LOCATION

Severo Ochoa Centre for Molecular Biology (CBMSO).
Genome Dynamics and Function Programme
Genome Decoding Unit
c/ Nicolás Cabrera, 1
Campus de Cantoblanco.
Autonomous University of Madrid (UAM)
28049 Madrid.

KEYWORDS

Genetics and genomics, T-cell lymphoblastic neoplasms, angioimmunoblastic T-cell lymphomas, identification of biomarkers and development of new therapeutic approaches.

SUMMARY OF ACTIVITIES

T-cell acute lymphoblastic leukaemia (T-ALL) is an aggressive haematological malignancy characterised by the abnormal proliferation of immature thymocytes. During the reporting period, our group provided personalised genomic and molecular profiling for patients treated at HUFJD and investigated the role of circular RNAs in the differentiation of immature T lymphocytes within the thymus. We also initiated the study of long non-coding RNAs (lncRNAs) as master regulators of gene expression and established a new experimental approach for their quantification. Over the course of the year, we identified several lncRNAs, including MALAT1 and TCLlnc1, that are dysregulated in T-cell lymphoblastic neoplasms and in angioimmunoblastic T-cell lymphomas (AITLs). These findings contribute to a better understanding of the molecular mechanisms underlying these malignancies and may lead to the identification of newbiomarkers and therapeutic targets for patients with T-cell neoplasms.

CONTRIBUTIONS TO SOCIETY

We have filed a patent application for a novel in vitro method to quantify specific cellular RNA molecules.

COLLABORATIONS

The results obtained have benefited from our collaboration with the HUFJD Haematology group, led by Dr Pilar Llamas, in the study of T-cell lymphoblastic neoplasms, and with Dr Rodríguez-Pinilla's Group from the HUFJD Department of Pathology, working with samples from patients with angioimmunoblastic T-cell lymphoma (AITL).


DOCTORAL THESIS


BACHELOR'S DEGREE FINAL PROJECTS
0

MASTER'S DEGREE FINAL PROJECTS
0

DOCTORAL THESIS	
IN PROGRESS	*DEFENDED*
0	1

6.1.5. GENERAL SURGERY, THORACIC SURGERY, NEUROSURGERY AND OTHER SURGICAL SPECIALTIES ASSOCIATED GROUP







GROUP COMPOSITION

Leaders

Ricardo Díez Valle

rdiezvalle@quironsalud.es

Ignacio Muguruza Trueba

imuguruza@hospitalreyjuancarlos.es

Research

Clinical research

LOCATION

Department of General and Digestive Surgery. Department of Thoracic Surgery. Department of Neurosurgery. Fundación Jiménez Díaz University Hospital Avda. Reyes Católicos, 2. 28040 Madrid (Spain)

KEYWORDS

Resection of brain tumours, intraoperative imaging in neurosurgery, innovation in neurosurgery. Anterior choroidal artery disorders, intracranial haemorrhage, intracranial aneurysms.

SUMMARY OF ACTIVITIES

The research activity of the General Surgery, Thoracic Surgery, Neurosurgery and Other Surgical Specialties group encompasses several research lines related to different surgical disciplines and is reflected in several publications indexed in the international scientific literature. Among its main objectives are to contribute to a better understanding, diagnosis, treatment and prevention of thoracic neoplasms, as well as to facilitate the translation of these advances into clinical practice. The group is also committed to the development and implementation of innovative surgical techniques aimed at improving treatment strategies and patient outcomes.

CONTRIBUTIONS TO SOCIETY

All scientific activities carried out by the General Surgery, Thoracic Surgery, Neurosurgery and Other Surgical Specialties group are directly focused on benefiting patients and society. The group performs extensive surgical activity using state-of-the-art robotic and minimally invasive surgical techniques, with a particular focus on oncological diseases. In addition, the group actively participates in multidisciplinary research studies, many of which are centred on cancer research, with the aim of improving clinical outcomes and advancing standards of care.

COLLABORATIONS

- Active clinical trials:
  - NEOCOAST-2 Trial (D9077C00001): Phase II, open-label, multicentre, randomized study evaluating neoadjuvant and adjuvant treatment in patients with resectable early-stage (II to IIIB) non-small cell lung cancer (NSCLC). Collaborating Investigator: Ignacio Muguruza Trueba.
  - REGENERON Trial (R6767-ONC-2266): Phase II perioperative trial of fianlimab and cemiplimab in combination with chemotherapy versus cemiplimab plus chemotherapy in patients with resectable early-stage NSCLC (stages II to IIIB [N2]). Collaborating Investigator: Ignacio Muguruza Trueba.
- Clinical trials in the start-up phase:
  - MIGRANT Trial (GECP 24-02): Randomized Phase II clinical trial evaluating the safety and feasibility of faecal microbiota transplantation (FMT) in patients with stage II-III non-small cell lung cancer (NSCLC), using donors who have responded to immune checkpoint inhibitors (ICIs). Collaborating Investigator: Ignacio Muguruza Trueba
  - ATHENEA Trial (GECP 23-02): Phase II clinical trial of chemotherapy plus atezolizumab in patients with stage IIIA-IIIB NSCLC, followed by adjuvant atezolizumab after surgery and maintenance atezolizumab in non-operated patients following chemoradiotherapy. Collaborating Investigator: Ignacio Muguruza Trueba.
- Other projects and studies:
  - Study: "Needle Aspiration versus Digital Aspiration in the Treatment of Primary Spontaneous Pneumothorax." Quality Improvement Project submitted to CAPAC. Principal Investigator: Yuri Bellido Reyes.
  - AEGEAN Phase III Trial. Thoracic Surgery Investigators: Ignacio Muguruza Trueba, José Zapatero Gaviria.Sub-Investigator: Juan Manuel Corral Cano

- NeoADAURA Study. Investigator (Thoracic Surgery): Ignacio Muguruza Trueba.
- CASSANDRA Project. Ignacio Muguruza Trueba.
- CHIRON Study. Collaborating investigator: I. Muguruza Trueba.
- BXU513667A Hemopatch vs Tachosil Study. Collaborating Investigators: Sara Isabel Vicente Antunes, Juan Manuel Corral Cano, Pablo Fernández Gómez Escolar, Lisette Rico Martínez, David Rincón García, Yuri Bellido Reyes.
- Characterization of Recurrences and Second Tumours (RyST) in Lung Cancer... PIs: Felipe Villar Álvarez e Ignacio Muguruza Trueba.
- Lung Cancer: Changes in the metabolomic profile following surgical treatment. PROMOTER Study. PI: Dra Sara Vicente Antunes.
- Spanish multicenter study of Pneumology neuroendocrine tumours (EMETNE-SEPAR). FJD-HURJC Investigators: Dr I. Muguruza Trueba, Dr J. Zapatero Gaviria, Dra Sara Vicente Antunes.
- NADIM: Neo-Adjuvant immunotherapy study... researcher (Thoracic Surgery): I. Muguruza Trueba.
- CIBER respiratory diseases lung biobank platform. Collaborating investigators: Dr I. Muguruza Trueba, Dr J. Zapatero Gaviria.
- Generation of an in vivo human tumour bank from Cancer patients (PDX Models). Principal Investigator. PI Jesús García Foncillas.
- María Salmerón Jiménez, PhD candidate, Faculty of Medical and Surgical Sciences, Complutense University of Madrid. Doctoral Thesis Title: Airway Complications in Lung Transplantation.

DOCTORAL THESIS

BACHELOR'S DEGREE FINAL PROJECTS
0

MASTER'S DEGREE FINAL PROJECTS
0


DOCTORAL THESIS	
IN PROGRESS	*DEFENDED*
0	1


Instituto de Investigación Sanitaria
Fundación Jiménez Díaz

6.1.6. RADIATION ONCOLOGY ASSOCIATED GROUP









GROUP COMPOSITION

Leaders

Francisco Javier Luna Tirado

jluna@fjd.es

Pilar María Samper Ots

pilar.samper@hospitalreyjuancarlos.es

Research

Clinical research

LOCATION

Department of Radiation Oncology
Basement Level (-1)
Fundación Jiménez Díaz University Hospital.
Avda. Reyes Católicos, 2. 28040 Madrid (Spain).

KEYWORDS

Radiation oncology, technological advances in radiation therapy, therapeutic index optimization, radiobiological models, intensity-modulated arc therapy (VMAT), stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), Surface-guided radiation therapy (SGRT), three-dimensional conformal radiation therapy (3D-CRT), image-guided radiation therapy (IGRT), high-dose-rate (HDR) brachytherapy, radiomics, auto-segmentation.

SUMMARY OF ACTIVITIES

Radiation Oncology is a medical specialty that operates within a multidisciplinary clinical setting and is dedicated to the diagnostic, clinical care and, more specifically, therapeutic aspects of cancer patient management. Its primary focus is the use of radiation-based treatments and associated therapeutic modalities. As a branch of clinical medicine, Radiation Oncology employs ionizing radiation, either alone or in combination with other treatment approaches, for the management of cancer and, in selected cases, non-neoplastic diseases. The group's activities are focused on the continuous improvement of radiation therapy techniques, the optimization of treatment efficacy and safety, and the integration of technological innovations that contribute to more precise, personalized and effective patient care.

CONTRIBUTIONS TO SOCIETY

All scientific activities carried out by the Radiation Oncology group are directly aimed at benefiting patients and society. In recent years, advances in information technology have enabled major technological developments that have significantly improved the precision of radiation therapy treatments. These include three-dimensional imaging, automated segmentation of organs at risk, Image-Guided Radiation Therapy (IGRT), and Surface-Guided Radiation Therapy (SGRT), all of which contribute to higher-quality treatment delivery.

These improvements in precision have made it possible to safely deliver higher radiation doses per fraction while accurately conforming the prescribed dose to the target volume and better sparing surrounding healthy tissues, thereby improving patient outcomes and reducing treatment-related toxicity. Furthermore, treatment schedules have been substantially shortened, reducing the number of treatment sessions from 28-30 fractions to as few as 3-10 fractions in selected indications, while simultaneously increasing the biological effectiveness of treatment.

COLLABORATIONS

- Medical oncology
    - Therapeutic combinations involving new drugs, targeted therapies and new radio sensitising agents for the local management of cancer. Current research programmes include next-generation immunotherapeutic agents for the treatment of lung cancer.
    - Combination strategies using chemotherapeutic agents, such as trabectedin together with radiotherapy, within the multidisciplinary management of soft tissue sarcomas.
- Development and evaluation of predictors of treatment response to assess therapeutic efficacy in specific malignancies, including the use of radiomics in rectal and lung cancer.
- Collaborative approaches involving Medical Oncology, Radiology and Digestive Surgery for organ preservation strategies and conservative management of rectal cancer.
- Development and implementation of systems for process automation aimed at improving treatment efficiency, quality and patient safety.

DOCTORAL THESIS

BACHELOR'S DEGREE FINAL PROJECTS
3

MASTER'S DEGREE FINAL PROJECTS
0

DOCTORAL THESIS	
IN PROGRESS	*DEFENDED*
0	0

6.2 INFECTIOUS, INFLAMMATORY AND CHRONIC DISEASES AREA

ALLERGY AND IMMUNOLOGY GROUP

INFECTIOUS DISEASES AND TROPICAL MEDICINE GROUP

MICROBIOLOGY GROUP

PNEUMOLOGY GROUP

RHEUMATOLOGY AND BONE METABOLISM GROUP

TRAUMATOLOGY ASSOCIATED GROUP

Definition of the area and priority objectives

The main characteristic of this area is the broad spectrum of diseases and conditions it addresses, together with its strongly multidisciplinary nature.

Its main objectives include:

Objectives of the Infectious, Inflammatory and Chronic Diseases Area	Level of Achievement in 2025
To investigate the mechanisms of cellular and tissue damage and repair associated with infectious, inflammatory and chronic diseases, including respiratory diseases, allergic and immune-mediated disorders, infectious diseases, and musculoskeletal disorders.	
To study the immunological and pathogenic aspects of HIV infection and viral hepatitis, with the goal of contributing to the development of strategies aimed at improving the control of these infections or achieving their complete eradication.	
To develop new proteomic and metabolomic analytical methodologies based on mass spectrometry for the identification of diagnostic and prognostic biomarkers in different diseases, facilitating their translation into clinical practice.	
To investigate COVID-19 infection from different perspectives, including its clinical impact in hospitalised individuals, disease severity in patients with respiratory disorders, viral and variant characterisation, and the role of different immune cell populations in the course of infection, among other aspects.	
Scale:	


NOT ACHIEVED		PARTIALLY ACHIEVED		ACHIEVED		

Scientific Activity of the Infectious, Inflammatory and Chronic Diseases Area

	2025	Allergy and Immunology group	Infectious diseases and tropical medicine group	Microbiology	Pneumology	Rheumatology and bone metabolism group	Traumatology	TOTAL
PROJECTS	→EU/NIH PROJECTS	1	//	//	1	1	//	**3**
	→ISCIII PROJECTS	13	2	2	1	8	//	**26**
	→CIBER PROJECTS	1	//	1	//	//	//	**2**
	→MINISTRY-FUNDED PROJECTS	2	//	//	1	//	//	**3**
	→CAM PROJECTS	3	//	//	//	2	//	**5**
	→AWARDS	//	//	//	//	//	1	**1**
	→NON-OFFICIAL PROJECTS	11	6	5	14	16	2	**54**
	→OBSERVATIONAL STUDIES	1	//	//	3	2	1	**7**
	TOTAL	**32**	**8**	**8**	**20**	**29**	**4**	**101**
CLINICAL TRIALS	→EARLY-PHASE TRIALS (I, I/II, II)	2	6	//	2	2	//	**12**
	→LATE-PHASE TRIALS (II/III, III, III/IV O IV/ OTHERS)	6	8	//	14	2	9	**39**
	TOTAL	**8**	**14**	**//**	**16**	**4**	**9**	**51**

Publications of the Infectious, Inflammatory and Chronic Diseases Area

2025	Total of publications	No of publications with an Impact Factor	Cumulative impact factor	Average annual impact factor	No of publications in Q1 journals	% of publications in Q1 journals	No of Open Access Publications	No of Clinical Practice Guidelines
Allergy and Immunology	54	53	405.8	7.66	43	81.13%	45	7
Infectious diseases and tropical medicine	48	47	169.1	3.60	19	40.43%	28	3
Microbiology	40	39	235.7	6.04	21	53.85%	28	3
Pneumology	40	31	251.8	8.12	22	70.97%	26	2
Rheumatology and bone metabolism	71	68	302.4	4.45	43	63.24%	55	2
Traumatology	44	38	88.7	2.33	14	36.84%	28	5
INFECTIOUS, INFLAMMATORY AND CHRONIC DISEASES AREA	**297**	**276**	**1453.5**	**5.27**	**162**	**58.70%**	**210**	**22**



Five most relevant publications from the Infectious, Inflammatory and Chronic Diseases Area in 2025

Factors associated with failed conservative treatment in patients with degenerative full-thickness supraspinatus tears : a prospective cohort study.

Martinez-Catalan N, Gabardo-Calvo S, Valencia M, Luengo-Alonso G, Delgado C, Foruria AM, Fernandez-Jara J, Calvo E.

Bone Joint J. 2025 Dec 01.107-B(12):1295-1300.

PMID: 41319708

IF: 4,6

http://dx.doi.org/10.1302/0301-620X.107B12.BJJ-2025-0742.R2

Functional cure of HIV-1 infection in an exceptional elite controller: a case report.

Benito JM, Lopez-Bernaldo JC, Fisher K, Pereyra-Casanova A, Cabello A, Estrada V, Gorgolas M, Buzon MJ, Palmer S, Rallón N.

Lancet HIV. 2025 Dec.12(12):e850-e860.

PMID: 41202829

IF: 13

http://dx.doi.org/10.1016/S2352-3018(25)00233-4

Optimized use and performance of culture for periprosthetic joint infection diagnosis: a comprehensive literature review.

Esteban J, Patel R, Aguilera-Correa J-J, Nelson SB, Culture Working Group of the Unified PJI Definition Task Force.

Clin Microbiol Rev. 2025 Dec 11.38(4):e0005425.

PMID: 40965158

IF: 19,3

http://dx.doi.org/10.1128/cmr.00054-25

Role of Inflammasome in IgE-Mediated Anaphylaxis.

Fernandez-Bravo S, Fernandez-Santamaria R.

Allergy. 2025 Oct 25.

PMID: 41137486

IF: 12

http://dx.doi.org/10.1111/all.70123

Sultiame once per day in obstructive sleep apnoea (FLOW): a multicentre, randomised, double-blind, placebo-controlled, dose-finding, phase 2 trial.

Randerath W, Grote L, Stenlöf K, Fietze I, Chevts J, Buntinx E, Albares J, Kuhn K, Hansen C, Völp A, Hedner J, FLOW study investigators (FLOW study investigators: Troncoso-Acevedo F).

Lancet. 2025 Oct 25.406(10514):1983-1992.


PMID: 41077049

IF: 88,5

http://dx.doi.org/10.1016/S0140-6736(25)01196-1

Gender perspective in the Infectious, Inflammatory and Chronic Diseases Area

The Infectious, Inflammatory and Chronic Diseases Area is composed of a team of professionals committed to respect, diversity and equality among its members. The Area seeks to promote the professional development of all staff, ensuring equal opportunities and preventing discrimination on the grounds of gender or age.





Future challenges for the Infectious, Inflammatory and Chronic Diseases Area

- Identification of the molecular mechanisms, diagnostic and prognostic biomarkers, and new therapeutic targets involved in inflammatory diseases through the application of proteomics, metabolomics and genomics, particularly in anaphylaxis, asthma and respiratory diseases.
- HIV infection research: studies on disease progression, functional cure models and the identification of potential therapeutic targets, as well as the impact of HIV and HCV coinfection on the host immune system.
- Bacterial infections and biomaterial-associated infections: development of new diagnostic and therapeutic approaches, including phage therapy and nanoparticle-based treatments, as well as the development of new vaccines and infection models.
- Synovial biopsy studies in chronic arthritis aimed at identifying tissue biomarkers of prognosis and treatment response. Application of musculoskeletal ultrasound as a diagnostic and prognostic tool in rheumatic diseases. Investigation of comorbidities associated with chronic arthritis and their relationship with inflammatory burden, including adipose tissue alterations, sarcopenia and non-alcoholic fatty liver disease, together with their potential therapeutic implications.
- Clinical studies on the treatment of prevalent osteoporotic fractures and anatomical and embryological studies of shoulder anatomy with applications in surgery.
- Application of telemedicine and digital technologies to support healthcare delivery in low-resource settings.
- Innovation in big data and artificial intelligence for the diagnosis and treatment of infectious, inflammatory and chronic diseases.
- Application of artificial intelligence in infectious, inflammatory and chronic diseases.

6.2.1. ALLERGY AND IMMUNOLOGY GROUP







GROUP COMPOSITION

Leaders

Gloria Álvarez Llamas
GAlvarez@fjd.es
Blanca Cárdaba Olombrada
BCardaba@fjd.es
Javier Cuesta Herranz
JCuesta@fjd.es
Victoria del Pozo Abejón
VPozo@fjd.es
Vanesa Esteban Vázquez
vesteban@fjd.es
Joaquín Sastre Domínguez
JSastre@fjd.es

PIs

José Antonio Cañas Mañas
Marta Martín Lorenzo

Research

Basic and clinical research

LOCATION

Department of Immunology
Fundación Jiménez Díaz University Hospital.
Avda. Reyes Católicos, 2. 28040 Madrid (Spain).
Allergy, Immunology and Proteomics Laboratories
4th Floor, Research Building

IIS-FJD
Fundación Jiménez Díaz University Hospital.
Avda. Reyes Católicos, 2. 28040 Madrid (Spain).

KEYWORDS

Allergy, Asthma, Anaphylaxis, Immunology, Cardiovascular Diseases, Diagnostics, Disease Mechanisms, Metabolomics, Proteomics, Renal Diseases, Therapy, Extracellular Vesicles.

SUMMARY OF ACTIVITIES

The group's clinical and research activities focus on the study of diseases with an immunological basis, primarily allergic and cardiovascular disorders, as well as on the identification of diagnostic and prognostic biomarkers through omics-based approaches, particularly in the cardiorenal field. In both acute inflammatory conditions, such as anaphylaxis, and chronic inflammatory diseases, including asthma and vascular wall remodelling, the group investigates the immunopathogenic mechanisms and signalling pathways underlying disease development and progression. In parallel, efforts are directed towards the development of innovative tools aimed at improving disease diagnosis, prognosis and treatment.

CONTRIBUTIONS TO SOCIETY

Over the last decade, the group has contributed to society with the publication of more than 600 original articles and review papers in high-impact scientific journals, the development of 20 clinical guidelines and management protocols, and the filing of two patents. The group maintains strong engagement with society through close collaboration with patient associations and by carrying out dissemination and outreach activities in school settings. In addition, members of the group have carried out educational videos and actively participated in media outreach initiatives, sharing their expertise and contributing to public awareness and improved understanding of these diseases.

COLLABORATIONS

The group is an active member of several Spanish and European scientific societies in the fields of Allergy, Immunology, Cardiovascular and Kidney disease, and is represented on the Executive Committee of the European Academy of Allergy and Clinical Immunology (EAACI). At the national level, the Group participates in CIBERES and RICORS2040 and maintains numerous collaborative links with leading researchers through both intra and extramural networks and initiatives, including CIBERES, ARADyAL, REI, GEIVEX, PROTEORED and SESMET.

At the international level, the group has established numerous long-standing collaborations with leading research teams and institutions worldwide. In addition, all group leaders serve on the editorial boards of prestigious international journals and actively contribute as editors to leading publications in their respective fields.


DOCTORAL THESIS


BACHELOR'S DEGREE FINAL PROJECTS	MASTER'S DEGREE FINAL PROJECTS	DOCTORAL THESIS	
		IN PROGRESS	*DEFENDED*
5	2	13	1

Instituto de Investigación Sanitaria
Fundación Jiménez Díaz

6.2.2. INFECTIOUS DISEASES AND TROPICAL MEDICINE GROUP







GROUP COMPOSITION

Leaders

José Miguel Benito Huete
jose.benito@fjd.es
Alfonso Cabello Úbeda
acabello@fjd.es
Miguel Górgolas Hernández-Mora
MGorgolas@fjd.es
Norma Rallón Afanador
norma.rallon@fjd.es

Research

Basic and clinical research

LOCATION

Division of Infectious Diseases
Fundación Jiménez Díaz University Hospital.
Avda. Reyes Católicos, 2 - 28040 Madrid (Spain).

HIV and Viral Hepatitis Research Laboratory
Rey Juan Carlos University Hospital.
C/ Gladiolo s/n - 28933 Móstoles (Spain).

KEYWORDS

HIV; Viral Hepatitis; Cellular Immune Response; HIV and Cancer; Inflammation; HIV vaccines; Viral persistence and latency; Sexually Transmitted Infections (STIs); Tropical Diseases; Cardiovascular Infections.

SUMMARY OF ACTIVITIES

The group's main research lines comprise both basic and clinical studies on HIV infection, with a particular focus on investigating the mechanisms underlying viral persistence and latency, the factors associated with viral control, the role of chronic inflammation, and the interactions between HIV infection and cancer. The group is also actively involved in the evaluation of novel antiretroviral therapies and HIV vaccine candidates. In addition, the Group conducts clinical research in other areas of infectious diseases and tropical medicine, contributing to the advancement of knowledge, diagnosis and treatment of a broad range of infectious conditions.

CONTRIBUTIONS TO SOCIETY

The scientific knowledge generated by our group represents a significant contribution to addressing the challenges faced by vulnerable populations affected by HIV infection, other infectious diseases and cancer. Through rigorous research, collaboration with patient associations, and the promotion of preventive education initiatives, we actively contribute to improving public health outcomes and reducing health inequalities from a social justice perspective. Our work supports the development of innovative strategies for the prevention, diagnosis and treatment of infectious diseases, while also enhancing the quality of life of affected individuals. By fostering knowledge transfer and engagement with healthcare professionals, patients and the wider community, the group seeks to maximise the societal impact of its research and contribute to evidence-based healthcare policies and practices.

COLLABORATIONS


The group actively collaborates with both intramural research teams across all institutions comprising IIS-FJD and with external groups at the national and international levels. Notable collaborations include the Centre for Virus Research at the Westmead Institute for Medical Research, Faculty of Medicine and Health, The University of Sydney (Australia); the Faculty of Medicine of the Pedagogical and Technological University of Colombia (UPTC); the Proteomics Unit of the Ramón y Cajal Institute for Health Research (IRYCIS) at Ramón y Cajal University Hospital; the Immunogenetics Unit of the Department of Experimental Biology at the University of Jaén; the Maimónides Health Research Institute of Córdoba (IMIBIC) and Córdoba Science and Technology Park; the National Centre for Microbiology (ISCIII) in Majadahonda, Madrid; the Proteomics Unit of the Spanish National Centre for Cardiovascular Research (CNIC) in Madrid; the Departments of Internal Medicine at Gregorio Marañón University Hospital and Clínico San Carlos University Hospital, both in Madrid; the Alberto Sols Biomedical Research Institute (CSIC-UAM); the Tumour Immunomodulation Group at the Research Institute of 12 de Octubre University Hospital; the Spanish National Cancer Research Centre (CNIO) in Madrid;Vall d'Hebron University Hospital in Barcelona; the National Centre for Electron Microscopy (ICTS) at the Complutense University of Madrid; the Madrid Science Park Foundation (UAM); the Metabolomics and Bioanalysis Centre of CEU San Pablo University in Madrid; and the Bioinformatics Unit of CNIC.


DOCTORAL THESIS

BACHELOR'S DEGREE FINAL PROJECTS	MASTER'S DEGREE FINAL PROJECTS	DOCTORAL THESIS	
		IN PROGRESS	*DEFENDED*
9	10	3	0

6.2.3. MICROBIOLOGY GROUP







GROUP COMPOSITION

Leaders

Jaime Esteban Moreno

JEsteban@fjd.es

Ignacio Gadea Gironés

IGadea@fjd.es

PIs

Meritxell de Jesús García Quintanilla

Research

Basic and clinical research

LOCATION

Clinical Microbiology Department
Basement Level (-1)
Fundación Jiménez Díaz University Hospital.
Avda. Reyes Católicos, 2. 28040 Madrid (Spain).
Experimental Microbiology Laboratory
Basement Level (-1), Private Patients Building

IIS-FJD
Fundación Jiménez Díaz University Hospital.
Avda. Reyes Católicos, 2. 28040 Madrid (Spain).

KEYWORDS

Biomaterials, implants, phage therapy, biofilms, antibiotic resistance, mycobacteria, SARS-CoV-2, next-generation sequencing, vaccines.

SUMMARY OF ACTIVITIES

The Group conducts research on the causes, pathogenesis, diagnosis and treatment of infectious diseases. Major research lines include the study of implant-associated infections and mycobacterial diseases, the development of new therapeutic approaches such as bacteriophage therapy and nanoparticle-based treatments, and the implementation of innovative diagnostic techniques based on molecular biology, as well as preventive strategies including vaccine development.

CONTRIBUTIONS TO SOCIETY

Dr Jaime Esteban: Development of national protocols and consensus documents on osteoarticular infections, mycobacterial diseases and phage therapy. Participation in the Spanish National Tuberculosis Plan. Co-author of the new international unified definition of prosthetic joint infection.

Dr Meritxell García Quintanilla: Participation in the first national protocol for phage therapy and in the first multicentre phage therapy project conducted in Spain.

COLLABORATIONS

The Microbiology group collaborates with numerous national research teams working in the fields of infectious diseases and clinical microbiology through CIBERINFEC, where it participates in a multicentre and multidisciplinary research group involving investigators from IIS-FJD, CENIM-CSIC, Carlos III University of Madrid, La Paz University Hospital, 12 de Octubre University Hospital, Clinic University of Navarra (Madrid), Hospital Santa Creu i Sant Pau, and Bellvitge University Hospital. The group also collaborates with CIBEREHD, as well as with several national groups specialising in osteoarticular infections and mycobacterial diseases through the corresponding working groups of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) and the Spanish Society for Mycobacteriology (SMMC). Additional collaborations are maintained with the Complutense University of Madrid. Research on viral variability is carried out in collaboration with the Severo Ochoa Centre for Molecular Biology (CSIC-UAM), the National Biotechnology Centre (CNB-CSIC) and the Institute for Molecular Biology of Barcelona (IBMB) through the Global Health PTI Platform.

At the international level, the group collaborates with European partners through the ESGMYC, ESGIAI and ESGB study groups of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID). Additional collaborations have been established with the University of Helsinki, Aarhus University, Ghent University, The Ohio State University, and several international reference centres. These collaborations focus on research into biomaterials, innovative therapeutic approaches, implant-associated infections, healthcare-associated infections and mycobacterial diseases.


In the field of phage therapy, key national collaborators include the Biomedical Research Institute of A Coruña (INIBIC) at A Coruña University Hospital, the Centre for Plant Biotechnology and Genomics (CBGP, UPM-INIA) in Madrid, and partners within the FAGOMA Network, including the National Biotechnology Centre (CNB-CSIC) and the Cavanilles Institute of Biodiversity and Evolutionary Biology at the University of Valencia. International phage therapy collaborations include the Croix-Rousse Hospital of the Hospices Civils de Lyon and the Institute for Research in Infectiology of Montpellier (IRIM-CNRS) in France.


DOCTORAL THESIS

BACHELOR'S DEGREE FINAL PROJECTS	MASTER'S DEGREE FINAL PROJECTS	DOCTORAL THESIS	
		IN PROGRESS	*DEFENDED*
1	1	5	2

6.2.4. PNEUMOLOGY GROUP







GROUP COMPOSITION

Leaders

M Jesús Rodríguez Nieto

Mjrodriguezn@fjd.es

PIs

Carolina Gotera Rivera

Felipe Villar Álvarez

Research

Basic and clinical research

LOCATION

Department of Pneumology
1st Floor
Fundación Jiménez Díaz University Hospital.
Avda. Reyes Católicos, 2. 28040 Madrid (Spain).

Experimental Research Laboratory
P1 Floor, Research Institute
IIS-FJD
Clinical Research Unit

KEYWORDS

Chronic Obstructive Pulmonary Disease (COPD), emphysema, lung cancer, asthma, sleep apnoea, pulmonary fibrosis, respiratory failure, hypoxia, interventional bronchoscopy.

SUMMARY OF ACTIVITIES

The group conducts integrated clinical, basic and experimental research as part of the CIBER on Respiratory Diseases (CIBERES), working in multidisciplinary collaboration with other medical specialties and health science disciplines. Research activities are organised around five main areas: COPD, emphysema and lung cancer; sleep apnoea; asthma; respiratory failure and hypoxia (Respiratory Intermediate Care Unit, RICU); and interstitial lung diseases and pulmonary hypertension.

CONTRIBUTIONS TO SOCIETY

The IIS-FJD Pneumology group contributed to the Neumomadrid Position Statement on Immunisation of Adult Patients with Respiratory Diseases. The Group also coordinates the population-based lung cancer screening programme, aimed at improving early detection and reducing mortality associated with lung cancer.

COLLABORATIONS

National collaborations:

- Within Fundación Jiménez Díaz University Hospital (HUFJD): Departments of Cardiology, Rheumatology, Allergy, Otorhinolaryngology (ENT) and Immunology.
- Other centres and networks:
  - CIBIR: basic Research Group on Oncogenes and Mediators in Lung Cancer.
  - Autonomous University of Madrid (UAM): Basic Research Group on Cellular Damage Induced by Hypoxia and Tobacco Smoke Exposure.
  - CIBER: Participation in the Airway Inflammatory Diseases Research Programme.
  - NEREA: Regional research network focused on the characterisation of interstitial lung diseases associated with autoimmune disorders.
  - REVA: Réseau Européen de Ventilation Artificielle.
  - PII of SEPAR (Integrated Research Programme).


DOCTORAL THESIS


BACHELOR'S DEGREE FINAL PROJECTS
1


MASTER'S DEGREE FINAL PROJECTS
0

DOCTORAL THESIS	
IN PROGRESS	*DEFENDED*
3	0

6.2.5. RHEUMATOLOGY AND BONE METABOLISM GROUP







GROUP COMPOSITION

Leaders

Miguel Ángel González-Gay Mantecón
miguel.ggay@quironsalud.es
Raquel Largo Carazo
RLargo@fjd.es
Aránzazu Mediero Muñoz
aranzazu.mediero@iis-fjd.es
Esperanza Naredo Sánchez
esperanza.naredo@quironsalud.es

PIs

Olga Sánchez Pernaute (Until March 2025)

Research

Basic and clinical research

LOCATION

Rheumatology and Bone Metabolism Laboratory
4th Floor, Research Building
IIS-FJD. Fundación Jiménez Díaz University Hospital.
Avda. Reyes Católicos, 2. 28040 Madrid (Spain).

KEYWORDS

Osteoarthritis, rheumatoid arthritis, metabolic syndrome, sarcopenia, psoriatic arthritis, synovial inflammation, synovial biopsy, mechanisms of inflammation, innate immunity, musculoskeletal ultrasound, prognostic and predictive factors of treatment response in chronic arthritis, and systemic autoimmune diseases.

SUMMARY OF ACTIVITIES

- Study of histological alterations and the mechanisms of synovial inflammation and cartilage degeneration in early osteoarthritis.
- Use of synovial biopsy in chronic arthritis to identify tissue biomarkers associated with disease prognosis and treatment response.
- Characterisation of the mechanisms involved in the resolution of joint inflammation in microcrystalline arthritis.
- Investigation of the impact of metabolic syndrome on the clinical presentation and progression of autoimmune diseases and vasculitis.
- Evaluation of purinergic system modulation as a therapeutic target in secondary sarcopenia and osteoporosis.
- Application of artificial intelligence to ultrasound image analysis for the diagnosis of Sjögren's disease in patients with sicca symptoms.
- Investigation of metabolic alterations and cardiovascular risk in rheumatic diseases, particularly rheumatoid arthritis, systemic lupus erythematosus and Sjögren's disease.
- Study of metabolic dysfunction-associated liver disease in patients with rheumatoid arthritis.
- Development and evaluation of biomaterials for bone regeneration.

CONTRIBUTIONS TO SOCIETY

Our group is developing the use of minimally invasive ultrasound-guided synovial biopsy for the study, in collaboration with the Pathology Department of our institution, of diagnostic, prognostic and treatment-response biomarkers in patients with chronic arthritis, including rheumatoid arthritis, psoriatic arthritis and related conditions. This represents an important healthcare innovation that provides new tools for improving patient management and outcomes.

- We are investigating the use of specialised pro-resolving lipid mediators in the treatment of microcrystalline arthritis. This new therapeutic approach aims to activate the body's natural mechanisms for resolving inflammation, rather than relying exclusively on conventional anti-inflammatory drugs.
- We seek to advance precision medicine for patients with autoimmune diseases, with the goal of selecting the most appropriate treatment for each individual patient. Through this strategy, we aim to improve healthcare efficiency, reduce the morbidity and mortality associated with these complex diseases, and generate added value for both patients and society.

COLLABORATIONS

- Dr Víctor Luis Ruíz. Human Genetics and Molecular Pathology. Alberto Sols Biomedical Research Institute (IIBM), CSIC, Madrid, Spain
- Dr Sandra Carolina Cifuentes Cuéllar. Associate Professor, Experimental Sciences and Technology Area, Department of Applied Mathematics, Materials Science and Engineering, and Electronic Technology, Rey Juan Carlos University, Madrid, Spain.

- Dr Joaquín Rams Ramos. Professor, Experimental Sciences and Technology Area, Department of Applied Mathematics, Materials Science and Engineering, and Electronic Technology, Rey Juan Carlos University, Madrid, Spain.
- Dr Enrique Calvo Aranda. Consultant Rheumatologist, Infanta Leonor University Hospital, Madrid, Spain. Professor, Alfonso X el Sabio University, Madrid, Spain.

DOCTORAL THESIS


BACHELOR'S DEGREE FINAL PROJECTS
0


MASTER'S DEGREE FINAL PROJECTS
0

DOCTORAL THESIS	
IN PROGRESS	*DEFENDED*
6	0

6.2.6. TRAUMATOLOGY ASSOCIATED GROUP







GROUP COMPOSITION

Leader

Emilio Calvo Crespo

ECalvo@fjd.es

Research

Basic and Clinical Research

LOCATION

Department of Orthopaedic Surgery and Traumatology. 1st Floor
Fundación Jiménez Díaz University Hospital.
Avda. Reyes Católicos, 2. 28040 Madrid (Spain).

KEYWORDS

Chronic pain, shoulder disorders, instability, rotator cuff, Latarjet procedure, reverse shoulder arthroplasty, arthroplasty, osteoarthritis, meniscus, meniscal root injuries, septic arthritis, osteoarticular infection, orthopaedic implants, thumb carpometacarpal osteoarthritis , distal radioulnar joint instability, proximal humerus fracture, orthopaedic devices, low back pain, osteoporosis, osteoporotic vertebral fractures, cement-augmented screws, pedicle subtraction osteotomy, spinal instability and telemedicine.

SUMMARY OF ACTIVITIES

- The Traumatology groups participate in:
- The study of shoulder instability.
- The study of rotator cuff disorders.
- The study of the treatment of proximal humerus fractures.
- The analysis of glenoid bone defects in revision reverse shoulder arthroplasty.
- The application of artificial intelligence to the management of rotator cuff tear.
- The application of artificial intelligence to the management of meniscal tears.
- The application of artificial intelligence to clinical pathways in musculoskeletal disorders.
- The comparative evaluation of two different elbow prosthesis designs.
- The study of prosthetic joint and osteoarticular infections.
- The study of the treatment of osteoporotic vertebral fractures.
- The study of spinal fixation in patients with osteoporosis.
- The study of the treatment of trapeziometacarpal osteoarthritis.
- The study of the innervation of the distal radioulnar joint.
- The experimental and clinical study of meniscal root injuries.

CONTRIBUTIONS TO SOCIETY

- Telemonitoring of hip fractures.
- Patient-reported experience and satisfaction questionnaires for patients undergoing rotator cuff repair surgery or meniscal injury surgery.

COLLABORATIONS

- Effectiveness of treatment for massive rotator cuff tears assessed using patient-reported outcomes: a mixed-methods study. Quantitative sub-study. Hospital del Mar and Autonomous University of Barcelona.
- Multicentre study on acromioclavicular joint dislocations. ISAKOS Shoulder Committee.
- Diagnosis and treatment of shoulder instability. Anterior Shoulder Instability International Consensus Group.
- Study of prosthetic joint infections. Hospital Clínic Barcelona, University of Barcelona.

DOCTORAL THESIS

BACHELOR'S DEGREE FINAL PROJECTS
0

MASTER'S DEGREE FINAL PROJECTS
0

DOCTORAL THESIS	
IN PROGRESS	*DEFENDED*
4	1

6 Research Areas and Groups



6.3 Neurosciences Area

NEUROLOGY GROUP

PSYCHIATRY AND MENTAL HEALTH GROUP

MITOCHONDRIAL CALCIUM SIGNALLING GROUP

Definition of the area and priority objectives

The research activities of the Neurosciences Area are focused on the genetic and clinical study of a wide range of diseases and disorders affecting the Central Nervous System (CNS), including epilepsies (including rare diseases in which epilepsy is one of the main manifestations), dementias, movement disorders, mental disorders and suicidal behaviour. Additional research lines include pharmacogenetics in psychiatry, psychiatric care, and motion analysis in neurological and psychiatric disorders.

The Neurology group focuses on the study of highly prevalent CNS disorders, such as epilepsies, dementias and movement disorders, as well as rare neurological diseases including Lafora disease, developmental and epileptic encephalopathies, familial dementias and Huntington's disease. These studies make use of molecular genetics techniques and animal models, with the goal of translating research findings into clinical practice through the implementation of novel therapeutic strategies aimed at curing these disorders.

The Psychiatry and Mental Health group investigates the genetic and environmental factors involved in the onset, progression and treatment of mental disorders. To define clinical phenotypes, the group applies ecological momentary assessment (EMA) technologies and machine learning approaches. This objective is complemented by research into factors affecting the delivery of care within public mental health services. Emphasis is placed on schizophrenia, affective disorders and substance use disorders, as these represent some of the most severe and prevalent mental health conditions. An additional area of focus is suicidal behaviour, which remains one of the leading causes of mortality in Western countries.

The Mitochondrial Calcium Signalling and Ageing Group investigates the role of Ca^{2+} signalling in brain metabolism and studies the involvement of Aralar and SCaMC proteins in human disease.

Among its specific objectives for 2025, the following should be highlighted:

Neurosciences Area Objectives:	Level of Achievement in 2025
To develop a gene therapy for Lafora disease. Lafora Epilepsy Cure Initiative (LECI).	
To study the natural history of Lafora disease and translate research findings into clinical practice through controlled clinical trials.	
To establish registries of rare genetic epilepsies to create cohorts of patients with specific mutations who may be eligible for future clinical trials aimed at developing personalised treatments.	
To continue identifying phenotypes associated with genetic epilepsies to improve the clinical care of affected patients.	

Neurosciences Area Objectives:	Level of Achievement in 2025
To develop devices capable of detecting epileptic seizures and monitoring seizure frequency in patients' homes.	
To investigate clinical-genetic correlations and biomarkers in familial dementias and cognitively preserved nonagenarians	
To identify Parkinson's disease subtypes with distinct clinical and phenotypic progression patterns. This includes the study of several aspects of Parkinson's disease, such as the effects of safinamide, hypomimia, remission of parkinsonian tremor, and motor assessment using external monitoring devices.	
To investigate the factors affecting the delivery of care to patients with mental disorders within public healthcare services, particularly in schizophrenia, affective disorders, substance use disorders and suicidal behaviour.	
To study the role of Ca^{2+} signalling in brain metabolism and the contribution of Aralar and SCaMC proteins to human disease.	
Scale:	


NOT ACHIEVED		PARTIALLY ACHIEVED		ACHIEVED		


Scientific activity of Neurosciences Area


	2025	Neurology	Psychiatry and Mental Health	Mitochondrial calcium signalling	TOTAL
PROJECTS	→EU/NIH PROJECTS	1	//	//	**1**
	→ISCIII PROJECTS	//	3	//	**3**
	→CIBER PROJECTS	//	//	//	**//**
	→MINISTRY-FUNDED PROJECTS	//	//	//	**//**
	→CAM PROJECTS	1	2	//	**3**
	→AWARDS	1	//	//	**1**
	→NON-OFFICIAL PROJECTS	15	7	//	**22**
	→OBSERVATIONAL STUDIES	7	10	//	**17**
	TOTAL	**25**	**22**	**//**	**47**
CLINICAL TRIALS	→EARLY-PHASE TRIALS (I, I/II, II)	4	//	//	**4**
	→LATE-PHASE TRIALS (II/III, III, III/IV O IV/OTHERS)	17	8	//	**25**
	TOTAL	**21**	**8**	**//**	**29**

Publications of the Neurosciences Area

2025	Total of publications	No of publications with an Impact Factor	Cumulative impact factor	Average annual impact factor	No of publications in Q1 journals	% of publications in Q1 journals	No of Open Access Publications	No of Clinical Practice Guidelines
Neurology	44	44	183.4	4.17	22	50.00%	29	1
Psychiatry and Mental Health	23	23	76.5	3.33	9	39.13%	17	1
Mitochondrial Calcium Signalling	1	1	3.9	3.90	1	100.00%	1	0
NEUROSCIENCES AREA	**68**	**68**	**263.8**	**3.88**	**32**	**47.06%**	**47**	**2**







Five most relevant publications from the Neurosciences Area in 2025

Impact of Digital Safety Plan Activation on Subsequent Emergency Departments Visits Following an Initial Suicide Attempt: Quasi-Experimental Study.

Barrigón ML, Schmidt C, Elices M, Porras-Segovia A, De Granda-Beltrán AM, Artés-Rodríguez A, Courtet P, Pérez-Sola V, Baca-García E.

JMIR Ment Health. 2025 Jun 17.12:e70253.

PMID: 40526825

IF: 5,8

http://dx.doi.org/10.2196/70253

Advancing Risk Assessment in Myotonic Muscular Dystrophy Through Translational Research and Personalized Medicine.

Amarante-Cuadrado C, Vazirani R.

JACC Clin Electrophysiol. 2025 May.11(5):1039.

PMID: 40436470

IF 7,7

http://dx.doi.org/10.1016/j.jacep.2025.02.045

Prevalence, disability, and economic impact of migraine in Spain: a nationwide population-based study.

Sanchez-Del-Rio M, García-Azorín D, Peral C, Armada B, Irimia-Sieira P, Porta-Etessam J.

J Headache Pain. 2025 May 15.26(1):117.

PMID: 40375151

IF: 7,9

http://dx.doi.org/10.1186/s10194-025-02069-1

Artificial intelligence in healthcare: Revolution or unfulfilled promise?

Anmella G, Baca-García E.

Eur Neuropsychopharmacol. 2025 Feb 15.94:1-3.

PMID: 39956012

IF: 6,7

http://dx.doi.org/10.1016/j.euroneuro.2025.01.006

Decoding the general role of tRNA queuosine modification in eukaryotes.

Díaz-Rullo J, González-Moreno L, Del Arco A, González-Pastor JE.

Sci Rep. 2025 Jan 02.15(1):345.


PMID: 39747999

IF: 3,9

http://dx.doi.org/10.1038/s41598-024-83451-y

Gender Perspective in the Neurosciences Area

The Neurosciences Area is composed of a team of professionals committed to respect, diversity and equality among its members. The area seeks to promote the professional development of all staff, ensuring equal opportunities and preventing discrimination on the grounds of gender or age.





Future Challenges for the Neurosciences Area

- Development, validation and implementation of systems for monitoring motor activity in neurological and psychiatric disorders, enabling the assessment of disease severity.
- Development of diagnostic and therapeutic tools to improve the care of patients affected by brain disorders.
- Identification of genes involved in neurological and psychiatric diseases and their interactions with environmental factors, with the aim of achieving more accurate and personalised genetic diagnoses and more effective treatments.
- Establishment of an animal models unit for neurological diseases to support the development and preclinical testing of therapies prior to their evaluation in humans.
- Development of advanced therapies for brain disorders, including gene therapy, antisense oligonucleotides, antibody-drug/enzyme conjugates, and drug repurposing strategies.
- Investigation of the role of Ca^{2+} signalling in brain metabolism and the generation of tissue-specific ARALAR knockout mouse models to precisely determine its role and evaluate the potential use of ketogenic diets for the treatment of epileptic seizures.
- Neuropharmacology and therapeutic approaches for Parkinson's disease and movement disorders, including deep brain stimulation and novel pharmacological treatments.
- Consolidation of machine learning applications for the analysis of genetic and healthcare databases in Psychiatry.
- Development and validation of diagnostic tools based on next-generation sequencing technologies for the study of both common and rare forms of epilepsy.
- Establishment of reference units dedicated to the study of rare forms of dementia, movement disorders and epilepsy.
- Accurate diagnosis of genetic dementias.
- Neurogenetics of movement disorders, particularly dystonia, ataxia and Parkinson's disease.
- Investigation of the factors influencing the care provided to patients with mental disorders within public healthcare services, particularly those affected by schizophrenia, affective disorders and suicidal behaviour.
- Development of technologies for the identification and assessment of digital phenotypes

6.3.1. NEUROLOGY GROUP







GROUP COMPOSTION

Leaders

Pedro José García-Ruiz Espiga
pgarcia@fjd.es
Estrella Gómez Tortosa
egomezt@fjd.es
Jesús Porta Etessam
jesus.porta@quironsalud.es
José M. Serratosa Fernández
JMSerratosa@fjd.es

PIs

José Carlos Fernández Ferro

Research

Basic and clinical research

LOCATION

Neurology Group
4th Floor, Research Building
IIS-FJD
Fundación Jiménez Díaz University Hospital.
Avda. Reyes Católicos, 2. 28040 Madrid (Spain).

KEYWORDS

Epilepsy, Lafora disease, epileptic seizures, neurological disorders, gene therapy, Alzheimer's disease, frontotemporal dementias, clinical-genetic correlations in dementia, and dementia biomarkers.

SUMMARY OF ACTIVITIES

The Neurology group includes an Epilepsy Unit/Laboratory focused on the clinical and genetic study of rare genetic epilepsies, the characterisation of several mouse models of Lafora disease, and the development of novel therapeutic approaches. To date, the group has contributed to the identification of several genes responsible for different genetic epilepsies, including the discovery of the first gene associated with Lafora disease. Its main objective is the development of personalised therapies targeting specific genetic defects underlying epileptic disorders.

In 2022, the group launched a research line aimed at developing a gene therapy for Lafora disease, leading to the filing of a patent application for an adeno-associated viral (AAV) vector.

The group also includes a Cortical Pathology Unit, dedicated to the comprehensive study of familial neurodegenerative dementias. Its research focuses on the identification of novel genetic causes, the analysis of diagnostic biomarkers in cerebrospinal fluid (CSF) and plasma, and the provision of genetic counselling. In recent years, the Movement Disorders Unit has concentrated its research activities on three main areas: 1) Neuropharmacology and therapeutics of movement disorders, 2) Neurogenetics, 3) Rare diseases.

CONTRIBUTIONS TO SOCIETY

The Epilepsy Unit/Laboratory actively participates in numerous clinical trials aimed at improving and implementing new treatments for epilepsy. The Unit also promotes the enrolment of patients in several international registries, including the Lafora Disease Registry (LD-Registry), Lennox-Gastaut Registry (LG-Registry), KCNA2 Registry, SLK Registry, and the Drug-Resistant Epilepsy Registry. These prospective registries are designed to improve knowledge of these diseases and to identify suitable candidates for future clinical trials. In addition, members of the Unit provide specialised training courses through the Spanish Society of Neurology (SEN) and the Spanish Epilepsy Society (SEEP).

The Cortical Pathology Unit contributes to educational activities and clinical guidelines promoted by the Spanish Society of Neurology and is also involved in outreach and awareness initiatives organised by the Frontotemporal Dementia Association.

COLLABORATIONS

The Neurology group maintains collaborations with a number of national and international research teams and institutions, including: the Institute of Biomedicine of Valencia (CSIC, CIBERER) led by Pascual Sanz; the University of Valencia, CIBERER-UV-INCLIVA (Carlos Romá-Mateo); the Viral Vector Unit of the Autonomous University of Barcelona (Miguel Chillón); the Reina Sofía Foundation and the Institute of Neurosciences of Alicante; the Amyloid Biomarker Study Group; the European Early-Onset Dementia Consortium; Secugen S.L.; and the University of Kentucky, USA (Matthew Gentry).

The Movement Disorders Unit is currently involved in several international multicentre projects, including Deep Brain Stimulation in Genetic Dystonia, in collaboration with Cornell University, the University of Alberta, and the University of California, San Francisco. The Unit was awarded the Quirónsalud Research Activity Intensification Award 2023.

Since 2017, the Group has maintained an active scientific collaboration with the Spanish National Centre for Cardiovascular Research (CNIC), which has enabled the establishment of two research lines. The first is an experimental programme using porcine models to investigate cerebral reperfusion injury following stroke. The second, more recent line of research is conducted in collaboration with the Population Studies Area within the PESA-BRAIN prospective cohort, focusing on the relationship between preclinical markers of vascular damage and Alzheimer's disease.

DOCTORAL THESIS


BACHELOR'S DEGREE FINAL PROJECTS
4


MASTER'S DEGREE FINAL PROJECTS
2

DOCTORAL THESIS	
IN PROGRESS	*DEFENDED*
8	0

6.3.2. PSYCHIATRY AND MENTAL HEALTH GROUP







GROUP COMPOSITION

Leaders

Enrique Baca García

EBaca@quironsalud.es

Research

Clinical research

LOCATION

Department of Psychiatry
Fundación Jiménez Díaz University Hospital.
Avda. Reyes Católicos, 2. 28040 Madrid (Spain).

KEYWORDS

Mental disorders, depression, schizophrenia, behavioural monitoring, ecological momentary assessment (EMA), and suicide.

SUMMARY OF ACTIVITIES

In 2025, the Group published numerous scientific articles in peer-reviewed indexed journals, primarily focused on suicide prevention, depression, schizophrenia, artificial intelligence, and the analysis of complex datasets. In addition, the Group secured several competitive grants and research projects. Among these, particular emphasis should be placed on the project "SMARTomicS: Suicide Prevention through Therapeutic Interventions Guided by Digital Phenotyping and Pharmacogenetics", funded under the Research Projects for the Implementation of Personalised Precision Medicine Programme. This project aims to develop innovative strategies for suicide prevention by integrating digital phenotyping tools and pharmacogenetic approaches to support more personalised and effective clinical interventions.

CONTRIBUTIONS TO SOCIETY

The Group has contributed to the development of clinical guidelines on suicidal behaviour and has actively participated in research project evaluation committees. In addition, Group members have been involved in public outreach and science communication activities aimed at reducing the stigma associated with mental disorders, particularly that surrounding suicide.

Through these initiatives, the Group seeks to promote awareness, improve mental health literacy, support evidence-based clinical practice, and encourage a more informed and compassionate societal response to mental health conditions and suicidal behaviour.

COLLABORATIONS


- Icahn School of Medicine, Mount Sinai Hospital (New York, United States).
- Department of Signal Theory and Communications, Carlos III University of Madrid (Madrid, Spain).
- INSERM, University of Montpellier (Montpellier, France).


DOCTORAL THESIS

BACHELOR'S DEGREE FINAL PROJECTS	MASTER'S DEGREE FINAL PROJECTS	DOCTORAL THESIS	
		IN PROGRESS	*DEFENDED*
2	0	8	2

6.3.3. MITOCHONDRIAL CALCIUM SIGNALLING GROUP (UAM)







GROUP COMPOSITION

Leaders

Araceli Del Arco Martínez

adelarco@cbm.uam.es

Beatriz Pardo Merino

bpardo@cbm.csic.es

Jorgina Satrústegui Gil-Delgado

jsatrustegui@cbm.csic.es

Research

Basic

LOCATION

Laboratory 321
Severo Ochoa Molecular Biology Centre (CBMSO)
Autonomous University of Madrid (UAM).
C/ Nicolás Cabrera nº 1, Cantoblanco,
28049 Madrid (Spain).

KEYWORDS

Calcium signalling, mitochondrial physiology and pathophysiology, neuronal metabolism, hepatic metabolism, and diseases associated with mitochondrial transporters.

SUMMARY OF ACTIVITIES

The research conducted by our group has focused on mitochondrial pathophysiology in the brain and liver, particularly in relation to the activity of mitochondrial aspartate/glutamate carriers (AGCs). In this context, we have demonstrated that, in hepatocytes deficient in SLC25A13/Citrin, the liver-specific isoform responsible for Citrullinemia Type II (CTLN2), exogenous expression of SLC25A12/Aralar, the isoform predominantly expressed in excitable tissues, is functional and partially reverses the pathological phenotype. This finding opens new therapeutic avenues for the treatment of liver diseases associated with SLC25A13/Citrin deficiency, providing a basis for the development of innovative strategies aimed at restoring mitochondrial function and improving disease outcomes.

CONTRIBUTIONS TO SOCIETY

Citrullinemia Type II (CTLN2) and neonatal intrahepatic cholestasis caused by Citrin deficiency, both resulting from SLC25A13/Citrin deficiency, are rare disorders that are particularly prevalent in certain regions of Asia. Effective treatments for these conditions remain limited, highlighting the need to identify and develop novel therapeutic strategies. The group's findings provide new insights into the pathophysiology of these diseases and open promising avenues for the development of innovative therapies aimed at restoring mitochondrial function and improving clinical outcomes for affected patients.

COLLABORATIONS

National Collaborations: J.M. Cuezva (Severo Ochoa Molecular Biology Centre [CBMSO], Autonomous University of Madrid); María José Casarejos (Ramón y Cajal Health Research Institute [IRYCIS]); Gloria González-Aseguinolaza (Centre for Applied Medical Research [CIMA], Pamplona); Alberto Paradela (National Biotechnology Centre [CNB-CSIC]); and María Luz Martínez-Chantar (CIC bioGUNE, Bilbao).

International Collaborations: E.R.S. Kunji (Medical Research Council, University of Cambridge, United Kingdom); and T. Saheki (Kagoshima University, Japan).

DOCTORAL THESIS

BACHELOR'S DEGREE FINAL PROJECTS	MASTER'S DEGREE FINAL PROJECTS	DOCTORAL THESIS	
		IN PROGRESS	*DEFENDED*
1	1	3	1

6.4 CRM Area (Cardiovascular, Renal And Metabolic Diseases)

CARDIOLOGY GROUP

NEPHROLOGY AND HYPERTENSION, VASCULAR DISEASE AND DIABETES GROUP

LIPID DISORDERS: CLINICAL AND EXPERIMENTAL (ADULTS AND CHILDREN) GROUP

CARDIAC AND VASCULAR SURGERY ASSOCIATED GROUP

UROLOGY ASSOCIATED GROUP

Definition of the area and priority objectives

Upon receipt of these surveys, they are reviewed and analysed with the aim of identifying new initiatives that may be incorporated into the Institute's Training Plan in future years. In this way, the participation of all professionals in the development of the IIS-FJD training portfolio is encouraged.

Furthermore, the IIS-FJD promotes the organization of forums and meetings among researchers through research area meetings. At our Institute, an annual meeting of research areas and research groups is held, as will be detailed below, in which all research groups participate and where they also express the training needs of our professionals.

Its main objectives include:

CRM Area (Cardiovascular, Renal and Metabolic Diseases) Objectives	Level of Achievement in 2025
To advance the understanding of the mechanisms of injury and repair in renal, urological, cardiovascular and metabolic diseases, including diabetes, across the lifespan, starting from childhood. Within this common framework, each group and subgroup focuses on specific aspects of these disorders, sharing expertise and technologies to accelerate scientific discovery and facilitate the translation of research findings into clinical practice.	
To investigate the cellular and molecular mechanisms involved in the pathogenesis of selected diseases, including fibrosis, immune-inflammatory responses, apoptosis, intracellular signalling pathways, cytokines and the renin-angiotensin system, among others. These studies encompass conditions such as atherothrombosis, myocardial ischaemia-reperfusion injury, cardiomyopathies, diabetic kidney disease, hypertension, glomerular diseases, acute kidney injury, nephrotoxicity, obesity and diabetes.	
To apply advanced platforms and imaging technologies, including proteomics, genomics, metabolomics, cardiac magnetic resonance imaging and molecular imaging, to identify novel molecules with diagnostic and therapeutic potential in the above-mentioned diseases.	
To discover and undertake preclinical development of novel therapeutic approaches for the prevention and treatment of cardiovascular, renal and metabolic diseases, with the goal of their translation into clinical practice.	
Escala:	

NOT ACHIEVED		PARTIALLY ACHIEVED		ACHIEVED		

In addition, there is substantial clinical research activity, including both observational studies and clinical trials sponsored by industry as well as investigator-initiated studies conducted by researchers from IIS-FJD and other institutions.


The Area maintains a wide network of collaborations with national and international investigators. Within IIS-FJD, close collaborations have been established with the Pathology, Haematology, Medical Oncology, Clinical Biochemistry, Infectious Diseases, Immunology, Microbiology, Rheumatology, Orthopaedic Surgery and Traumatology, Endocrinology, Digestive Surgery and Intensive Care research groups and departments.

Scientific activity of CRM Area (Cardiovascular, Renal and Metabolic Diseases)

	2025	Cardiology	Nefrology and Hypertension, vascular disease and diabetes group	Lipid disorders: clinical and experimental (adults and children)	Cardiac and vascular surgery	Urology	TOTAL
PROJECTS	→EU/NIH PROJECTS	4	6	//	//	//	**10**
	→ISCIII PROJECTS	2	28	2	//	//	**32**
	→CIBER PROJECTS	1	2	//	//	//	**3**
	→MINISTRY-FUNDED PROJECTS	1	6	//	//	1	**8**
	→CAM PROJECTS	//	1	//	//	//	**1**
	→AWARDS	//	//	1	//	//	**1**
	→NON-OFFICIAL PROJECTS	8	24	1	2	5	**40**
	→OBSERVATIONAL STUDIES	3	4	2	1	2	**12**
	TOTAL	**19**	**71**	**6**	**3**	**8**	**107**
CLINICAL TRIALS	→EARLY-PHASE TRIALS (I, I/II, II)	2	10	//	//	5	**17**
	→LATE-PHASE TRIALS (II/III, III, III/IV O IV/ OTHERS)	17	18	3	//	6	**44**
	TOTAL	**19**	**28**	**3**	**//**	**11**	**61**

Publications of CRM Area (Cardiovascular, Renal and Metabolic Diseases)

2025	Total of publications	No of publications with an Impact Factor	Cumulative impact factor	Average annual impact factor	No of publications in Q1 journals	% of publications in Q1 journals	No of Open Access Publications	No of Clinical Practice Guidelines
Cardiology	67	64	892.4	13.94	55	85.94%	43	9
Nephrology and hypertension, vascular disease and diabetes	176	174	2002.8	11.51	131	75.29%	131	14
Lipid disorders: clinical and experimental (adults and children group)	11	11	37.6	3.42	5	45.45%	7	1
Cardiac and vascular surgery group	3	3	40.7	13.57	2	66.67%	2	0
Urology	14	14	35.3	2.52	3	21.43%	6	0
CRM AREA (Cardiovascular, renal and metabolic diseases)	**271**	**266**	**3008.8**	**11.31**	**196**	**73.68%**	**189**	**24**



Five most relevant publications of CRM Area (Cardiovascular, Renal and Metabolic Diseases) in 2025

Excessive glycosylation drives thoracic aortic aneurysm formation through integrated stress response.

Rochano-Ortiz A, San Sebastián-Jaraba I, Zamora C, Simó C, García-Cañas V, Martínez-Albaladejo S, Fernández-Gómez MJ, Marcos-Ríos D, Martínez-Núñez P, Martín-Lorenzo M, Velho TR, Ruíz-Rodríguez MJ, Leal-Zafra A, Gabandé-Rodríguez E, Martínez-Martínez S, Guala A, Lorenzo Ó, Blanco-Colio LM, Martín-Ventura JL, Álvarez-Llamas G, Aldamiz-Echevarría G, Teixidó-Tura G, Forteza A, Nistal JF, Redondo JM, Méndez-Barbero N, Mittelbrunn M, Oller J.

Eur Heart J. 2025 Dec 01.46(45):4988-5005.

PMID: 40720766

IF: 35,7

http://dx.doi.org/10.1093/eurheartj/ehaf556

Beta-Blockers after Myocardial Infarction without Reduced Ejection Fraction.

Ibanez B, Latini R, Rossello X, Dominguez-Rodriguez A, Fernández-Vazquez F, Pelizzoni V, Sánchez PL, Anguita M, Barrabés JA, Raposeiras-Roubín S, Pocock S, Escalera N, Staszewsky L, Pérez-García CN, Díez-Villanueva P, Pérez-Rivera JA, Prada-Delgado O, Owen R, Pizarro G, Caldes O, Gómez-Talavera S, Tuñón J, Bianco M, Zarauza J, Vetrano A, Campos A, Martínez-Huertas S, Bueno H, Puentes M, Grigis G, Bonilla-Palomas JL, Marco E, González-Juanatey JR, Bangueses R, González-Juanatey C, García-Álvarez A, Ruiz-García J, Carrasquer A, García-Rubira JC, Pascual-Figal D, Tomás-Querol C, San Román JA, Baratta P, Agüero J, Martín-Reyes R, Colivicchi F, Ortas-Nadal R, Bazal P, Cordero A, Fernández-Ortiz A, Basso P, González E, Poletti F, Bugani G, Debiasio M, Cosmi D, Navazio A, Bermejo J, Tortorella G, Marini M, Botas J, de la Torre-Hernández JM, Ottani F, Fuster V, REBOOT-CNIC Investigators.

N Engl J Med. 2025 Nov 13.393(19):1889-1900.

PMID: 40888702

IF: 78,5

http://dx.doi.org/10.1056/NEJMoa2504735

Sleep-Wake Cycle and Circadian Misalignment in People With Autism Across the Lifespan With an Emphasis on Living Conditions.

Martínez-Cayuelas E, García-Muñoz AM, de Ocaña-Moreno MLS, Richdale AL, Gisbert-Gustemps L, Lugo-Marín J, Rodríguez-Morillas B, Peiró-Peiró AM, Victoria-Montesinos D, López-Anguas C, Meseguer-Illán MD, Ballester-Navarro P.

Autism Res. 2025 Jun 02.

PMID: 40452585

IF: 5,6

http://dx.doi.org/10.1002/aur.70058

Global, regional, and national prevalence of child and adolescent overweight and obesity, 1990-2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021.


GBD 2021 Adolescent BMI Collaborators (Ortiz A). Lancet. 2025 Mar 08.405(10481):785-812.
PMID: 40049185
IF: 88,5
http://dx.doi.org/10.1016/S0140-6736(25)00397-6

Evaluation and Analysis of Costs Associated with Prophylaxis of Recurrent Urinary Tract Infections (RUTIs) in Women.

Hernández-Sánchez JE, Szczesnieski JJ, Padilla-Fernández BY, González-Enguita C, Flores-Fraile J, Lorenzo-Gómez MF.
Microorganisms. 2025 Feb 11.13(2).
PMID: 40005759
IF: 4,2
http://dx.doi.org/10.3390/microorganisms13020393

Gender Perspective in the CRM Area (Cardiovascular, Renal and Metabolic Diseases)

The CRM Area (Cardiovascular, Renal and Metabolic Diseases) is composed of a team of professionals committed to respect, diversity and equality among its members. The Area seeks to promote the professional development of all staff, ensuring equal opportunities and preventing discrimination on the grounds of gender or age.



Future Challenges for the CRM Area (Cardiovascular, Renal and Metabolic Diseases)

1. To improve outcomes in kidney diseases through the development of novel diagnostic and risk stratification tools, as well as new therapeutic strategies.


2. To improve outcomes in metabolic diseases through the development of novel diagnostic and risk stratification tools, as well as new therapeutic strategies.


3. To improve outcomes in cardiovascular diseases through the development of novel diagnostic and risk stratification tools, as well as new therapeutic strategies.

4. To implement innovative therapeutic strategies and Health Outcomes Assessment approaches in Urological Diseases.

6.4.1. CARDIOLOGY GROUP







GROUP COMPOSITION

Leaders

Borja Ibáñez Cabeza

BIbanez@fjd.es

José Tuñón Fernández

JTunon@quironsalud.es

Research

Basic and clinical research

LOCATION

Department of Cardiology. 3rd Floor.
Fundación Jiménez Díaz University Hospital.
Avda. Reyes Católicos, 2. 28040 Madrid (Spain).

KEYWORDS

Acute myocardial infarction, heart failure, arrhythmias, biomarkers, inflammation, cardio-oncology and cardiotoxicity.

SUMMARY OF ACTIVITIES

The group investigates a wide range of cardiovascular diseases, including coronary artery disease, heart failure, atrial fibrillation, cancer therapy-related cardiotoxicity, and amyloidosis, with the aim of advancing the understanding of their pathophysiology, enabling earlier diagnosis, improving cardiovascular risk prediction, and developing new therapeutic approaches. A major focus of the group's research is the improvement of secondary prevention strategies, particularly the identification of the most effective combinations of pharmacological therapies for patients who have experienced an acute myocardial infarction. Research activities also include the study of biomarkers capable of predicting future cardiovascular events, with particular emphasis on inflammation and mineral metabolism. In this context, the group investigates the effects of vitamin D on cardiovascular health and examines the real-world impact of PCSK9 inhibitors on the incidence of cardiovascular events. The group is also highly active in the field of primary prevention of atherosclerotic cardiovascular disease, with a particular focus on the role of cardiovascular imaging in the early detection of subclinical disease. Within this area, the Group has developed a pioneering research line aimed at improving understanding of the vascular component of Alzheimer's disease and its relationship with atherosclerosis during asymptomatic stage.

CONTRIBUTIONS TO SOCIETY

Our group places a strong emphasis on dissemination and outreach activities aimed at communicating research findings to both the public and patients. Borja Ibáñez is the inventor of four patents related to the treatment of cardiovascular diseases and their diagnosis using magnetic resonance imaging. Dr Borja Ibáñez and Dr José Tuñón have also contributed to several clinical practice guidelines of the European Society of Cardiology (ESC). Dr Ibáñez has played a leading role as Chair of the ESC Guidelines for the management of acute coronary syndromes. Through these scientific, clinical and educational activities, the Group actively contributes to the translation of research findings into clinical practice and to improving cardiovascular health outcomes.

COLLABORATIONS

Our department participates in numerous national and international research projects. The large clinical trials led by the Group are primarily investigator-driven and scientifically oriented, although the Group also participates in studies sponsored by the pharmaceutical industry.

The Group coordinates several major European consortia funded by the European Commission through the Horizon Europe and Horizon 2020 programmes. Notable examples include the Horizon Europe ERA4Health projects STREAMLINE and HF4HF, as well as the Horizon 2020 health project RESILIENCE. The latter is coordinated by our Group, in collaboration with other hospital departments, including Haematology, and involves institutions from six European countries, together with the European Society of Cardiology (ESC), Philips, and a patient association. The Group also plays a prominent role as a key partner in the Horizon 2020 health project RITA-MI2, as well as in several Horizon Europe projects, including SGLT2HYPE, GRACE, COMPASS, and CHAIN. In addition, the Group leads the "LURK" project, funded by la Caixa Foundation, in the field of cardio-oncology. The Group coordinated the largest clinical trial ever conducted worldwide to evaluate the benefits of beta-blocker therapy in patients with myocardial infarction and preserved cardiac function (REBOOT trial, involving 8,500 patients in Spain and Italy). The findings of this study have influenced treatment recommendations for post-myocardial infarction patients worldwide. Borja Ibáñez serves as an editorial board member and editor for several leading cardiovascular journals, including the high-impact journals European Heart Journal and JAMA Cardiology. He also leads a research group within the CIBER on Cardiovascular Diseases (CIBERCV).


DOCTORAL THESIS


BACHELOR'S DEGREE FINAL PROJECTS
5


MASTER'S DEGREE FINAL PROJECTS
1

DOCTORAL THESIS	
IN PROGRESS	*DEFENDED*
9	2

6.4.2. NEPHROLOGY AND HYPERTENSION, VASCULAR DISEASE AND DIABETES GROUP







GROUP COMPOSITION

Leaders

Luis Miguel Blanco Colio
lblanco@fjd.es
Jesús Egido de los Ríos
JEgido@quironsalud.es
Beatriz Fernández Fernández
BFernandez@fjd.es
Carmen Gómez-Guerrero
Cgomez@fjd.es
Emilio González-Parra
EGParra@quironsalud.es
Óscar Lorenzo González
OLorenzo@fjd.es
José Luis Martín Ventura
JLMartin@fjd.es
Nerea Méndez Barbero
nerea.mendez@iis-fjd.es
Alberto Ortiz Arduán
AOrtiz@fjd.es
Adrián Mario Ramos Cortassa
AMRamos@fjd.es
Marta Ruiz Ortega
mruizo@quironsalud.es
María Dolores Sánchez Niño
mdsanchez@fjd.es
Ana Belén Sanz Bartolomé
asanzb@fjd.es
Clotilde Vázquez Martínez
clotilde.vazquez@quironsalud.es

PIs

Sebastián Mas Fontao (Co-IP)
Jorge Oller Pedrosa
María Vanessa Pérez Gómez
Sandra Rayego Mateos

Research

Basic and clinical research

LOCATION

Department of Nephrology and Hypertension.
3rd Floor Fundación Jiménez Díaz University Hospital.
Avda. Reyes Católicos, 2. 28040 Madrid (Spain).

Nephrology and Hypertension, Vascular Disease and Diabetes Laboratory
4th Floor, Research Building and Basement Level (-1), Building 6
IIS-FJD. Fundación Jiménez Díaz University Hospital.
Avda. Reyes Católicos, 2. 28040 Madrid (Spain).

KEYWORDS

Kidney disease, hypertension, atherosclerosis, chronic kidney disease, acute kidney injury, diabetes, and diabetic kidney disease.

SUMMARY OF ACTIVITIES

The group carries out multidisciplinary research focused on the mechanisms, diagnosis and treatment of renal, cardiovascular and metabolic diseases. Its main strategic research lines include:

- Chronic kidney disease (CKD): identification of biomarkers of disease progression, inflammation, fibrosis and tubular injury.
- Hypertension, atherosclerosis and vascular damage: investigation of pathophysiological mechanisms, vascular remodelling, arterial stiffness and endothelial dysfunction.
- Diabetes mellitus, obesity and vascular complications: research into diabetic kidney disease, microvascular injury and associated cardiovascular risk.
- Kidney-heart-metabolism interactions: study of the integrative mechanisms linking CKD, hypertension, diabetes and cardiovascular disease.
- Precision medicine: risk stratification, genetics, proteomics and the identification of new therapeutic targets.

CONTRIBUTIONS TO SOCIETY

The Group collaborates with national patient associations, including ALCER, and international organisations such as the European Kidney Patients' Federation (EKPF), to improve the prevention, diagnosis and treatment of diabetes and renal and cardiovascular diseases.

Its contribution to society is reflected in its extensive scientific output, including more than 1,000 publications cited over 200,000 times, the development of more than 10 clinical practice guidelines, and the generation of more than 10 patents. The group is also actively involved in scientific societies and congresses and contributes to educational initiatives, including the development of the Renal MOOC and other training activities aimed at healthcare professionals, patients and the general public: https://www.edx.org/course/rinones-conoce-sus-funciones-para-mejorar-tu-salud).

COLLABORATIONS

The group maintains numerous national and international collaborations within the framework of projects funded by the Spanish National R&D Plan, the European Union, and working groups belonging to national and international scientific societies. Among its main national collaborations are:

- Spanish Renal Research Network (REDINREN): participation in multicentre projects focused on chronic kidney disease, biomarkers and renal protective therapies.
- CIBERDEM and CIBERCV: collaborations on studies addressing diabetes, obesity, cardiovascular risk and inflammatory mechanisms.

- University Hospitals in the Madrid Region (La Paz University Hospital, 12 de Octubre University Hospital, Ramón and Cajal University Hospital and Clínico San Carlos University Hospital): shared patient cohorts, clinical trials and translational research projects.
- Autonomous University of Madrid (UAM): teaching activities, supervision of doctoral theses and joint biomedical research projects.
- Biomedical Research Centres (CNIC, CNIO and IMDEA): mechanistic studies on inflammation, metabolism and vascular injury.

DOCTORAL THESIS


BACHELOR'S DEGREE FINAL PROJECTS
2


MASTER'S DEGREE FINAL PROJECTS
4

DOCTORAL THESIS	
IN PROGRESS	*DEFENDED*
23	6

6.4.3. LIPID DISORDERS: CLINICAL AND EXPERIMENTAL RESEARCH GROUP (ADULTS AND CHILDREN)







GROUP COMPOSITION

Leaders

Carmen Garcés Segura

CGarces@fjd.es

Leandro Soriano Guillén

LSoriano@fjd.es

Research

Basic and clinical research

LOCATION

Lipid Laboratory.
4th Floor, Research Building
IIS-FJD.
Fundación Jiménez Díaz University Hospital.
Avda. Reyes Católicos, 2. 28040 Madrid (Spain).

KEYWORDS

Lipids, cardiovascular risk, obesity, diabetes, pubertal disorders, and infants born small or large for gestational age.

SUMMARY OF ACTIVITIES

1. Investigation of the potential causes involved in the development of obesity during childhood.
2. Analysis of factors associated with the emergence of metabolic complications and increased cardiovascular risk in children and adolescents with obesity.
3. Research into the influence of nutritional status on pubertal development.
4. Evaluation of cardiovascular risk and excess weight in infants born small or large for gestational age.

CONTRIBUTIONS TO SOCIETY

1. Establishment of a specialised Paediatric Obesity Unit at Children's Hospital Fundación Jiménez Díaz, providing comprehensive care for children and adolescents with complex obesity.
2. Design and implementation of the INFASEN ("Childhood with Meaning") Project aimed at the prevention of childhood and adolescent obesity.
3. Delivery of educational talks on nutrition and healthy lifestyle habits in schools within the hospital's catchment area.
4. Development of clinical guidelines for the diagnosis and treatment of pubertal disorders as part of the Puberty Working group of the Spanish Society of Paediatric Endocrinology.

COLLABORATIONS

1. Puberty Working Group of the Spanish Society of Paediatric Endocrinology.
2. Nutrition Working Group of the Spanish Atherosclerosis Society.
3. Spanish Society of Adolescent Medicine.
4. Prof. Ana Claudia Latronico, University of São Paulo, Brazil. Pioneer research group in the study of the molecular basis of precocious puberty.
5. Prof. Alejandro Lomniczi, Division of Neuroscience, Oregon National Primate Research Centerer/OHSU, USA. This group is internationally recognised for its pioneering work on the epigenetic regulation of nutrition and puberty in experimental animal models.

DOCTORAL THESIS


BACHELOR'S DEGREE FINAL PROJECTS
0


MASTER'S DEGREE FINAL PROJECTS
0

DOCTORAL THESIS	
IN PROGRESS	*DEFENDED*
1	0

6.4.4. CARDIAC AND VASCULAR SURGERY ASSOCIATED GROUP







GROUP COMPOSITION

Leaders

Gonzalo Aldámiz-Echevarría Castillo

galdamiz@quironsalud.es

César Aparicio Martínez

CAparicio@quironsalud.es

Research

Clinical research

LOCATION

Department of Cardiac Surgery, Unit 66.
Department of Vascular Surgery, Unit 33, 3rd Floor.
Fundación Jiménez Díaz University Hospital.
Avda. Reyes Católicos, 2. 28040 Madrid (Spain).

KEYWORDS

Atherosclerosis, aortic aneurysms, lower limb ischaemia, endovascular treatment, carotid artery disease, and diabetic foot.

SUMMARY OF ACTIVITIES

The Group focuses on the prevention, investigation, diagnosis and treatment of diseases affecting the heart, pericardium, great vessels and peripheral vascular system, as well as on the development of new techniques, procedures and medical devices for their management.

More specifically, its activities encompass the study and surgical treatment of disorders affecting the heart, pericardium and thoracic great vessels; acquired and congenital heart diseases manifesting in adulthood; coronary artery disease, valvular heart disease and thoracic aortic disorders. The group is also actively involved in the development and application of endovascular therapies for the treatment of thoracic and abdominal aortic aneurysms, lower and upper limb ischaemia, carotid artery disease and other vascular conditions, with the aim of improving patient outcomes through innovative and minimally invasive approaches.

CONTRIBUTIONS TO SOCIETY

Through the development of new techniques and treatments, the group aims to improve the quality of life of patients with cardiovascular diseases by implementing surgical procedures that are safer, more effective and less invasive.

INTERNATIONAL COOPERATION:

- Dr Gonzalo Aldámiz-Echevarría has coordinated the cardiovascular cooperation programme in Africa of the NGO Recover Foundation - Hospitals for Africa (Burkina Faso and Cameroon) since 2008. This initiative includes on-site collaboration in patient diagnosis and follow-up, as well as the surgical treatment of selected patients in Spain.

In addition, continuous training and specialization in the field of cardiac and vascular surgery are provided, contributing to improved patient care overall. In this regard, the following educational activities were carried out in 2025.

COURSE ORGANISATION AND TEACHING ACTIVITIES:

- Conformability and Control in the Treatment of the Thoracic and Abdominal Aorta. Fundación Jiménez Díaz University Hospital (HUFJD). Organised by Gore. 21-22 October 2025. Faculty: Dr César Aparicio Martínez and Dr Alejandro González García.
- 5th Workshop on Retrograde Ultrasound-Guided Puncture in Thiel Cadavers. March 2025. Autonomous University of Madrid (UAM), Madrid, Spain. Co-Director and Faculty Member: Dr Arribas. Faculty of Medicine. Vascular Diagnostics Chapter (CDV), Spanish Society of Angiology and Vascular Surgery (SEACV).
- Hands-on Workshop in Vascular Ultrasound (Knobology, Arterial Physiology and Haemodynamics, Hands-on Buttons, Knobs, Transducer and Settings, Hands-on Venous Ultrasound, Hands-on Arterial Ultrasound). ESVS Academy. Bellvitge University Hospital, Barcelona, Spain. 2025. Faculty Member: Dr Arribas.
- 1st Diabetic Foot Disease Patient Workshop: "Are You Diabetic? Learn About Diabetic Foot Disease and How to Take Care of Your Feet". Fundación Jiménez Díaz University Hospital, Madrid, Spain. On February 20th, 2025. Faculty Member: Dr Arribas.
- TxThiel Course 2025, 12th Edition: "Renal Transplantation: Techniques and Fundamentals. Kidney Procurement Surgery, Bench Surgery and Renal Transplantation in Human Cadavers Preserved Using W. Thiel Embalming Technique and Simulators". In April 2025. Autonomous University of Madrid, Madrid, Spain. Co-Director and Faculty Member: Dr Arribas. Faculty Members: Dr González and Dr Díaz.

- 70th National Congress of the Spanish Society of Angiology and Vascular Surgery. 22nd Preparatory Course for the Vascular Diagnostics Chapter (CDV-SEACV) Personal Certification Examination. Madrid, Spain. 2025. Faculty Member and Examiner: Dr Arribas.
- 70th National Congress of the Spanish Society of Angiology and Vascular Surgery. Simuvasc LeMaitre Practical Workshop: "Abdominal Aortic Surgery". SEACV. Madrid, Spain. In May 2025. Faculty Member: Dr Arribas.
- Masterclass in Open Thoracoabdominal Surgery. National Symposium on Angiology and Vascular Surgery (SNACV). Autonomous University of Madrid, Madrid, Spain. In November 2025. Co-Director and Faculty Member: Dr Arriba.
- Masterclass in Open Thoracoabdominal Surgery. National Symposium on Angiology and Vascular Surgery (SNACV). Autonomous University of Madrid, Madrid, Spain. In November 2025. Faculty Member: Dr Aparicio.
- Simuvasc Course, held during the 70th SEACV Congress. In May 2025. Faculty Member: Dr Díaz.
- Infrapopliteal Vascular Dissection Course. Fundación Jiménez Díaz University Hospital. In June 2025. Organised by Dr Baeza.

COLLABORATIONS

The group's activities require close collaboration among surgeons, cardiologists, biomedical engineers and other healthcare professionals to improve the effectiveness and safety of surgical interventions in the cardiovascular field.

ONGOING PROJECTS:

- Collaborators in the PLIANT II Registry, focused on the outcomes of iliac branch devices: César Aparicio Martínez, Alejandro González García and Ana Arribas Díaz.


In addition, the group collaborates with professionals from other healthcare institutions and academic centres to share knowledge and resources, thereby contributing to the advancement of vascular surgery. César Aparicio Martínez is Associate Professor of Surgery at the Faculty of Medicine of the Autonomous University of Madrid. Ana Arribas Díaz is Associate Professor of Surgery at the Faculty of Medicine of Alfonso X el Sabio University. Ciro Baeza Bermejillo is Professor of Anatomy at the Fundación Jiménez Díaz School of Nursing (Autonomous University of Madrid). Gala Fernández Martín Forero is Associate Professor of Surgery at the Faculty of Medicine of Alfonso X el Sabio University. Tomás Bolívar Gómez is Associate Professor of Surgery at the Faculty of Medicine of Rey Juan Carlos University. Alejandro González García is Teaching Collaborator in Surgery at the Faculty of Medicine of the Complutense University of Madrid. Ciro Baeza Bermejillo is also a Teaching Collaborator in Surgery at the Faculty of Medicine of the Complutense University of Madrid. Jennifer Díaz Cruz teaches the theoretical and practical sessions of the Specialist Programme in Vascular Access Nursing (2024-2025 academic year).


DOCTORAL THESIS

BACHELOR'S DEGREE FINAL PROJECTS	MASTER'S DEGREE FINAL PROJECTS	DOCTORAL THESIS	
		IN PROGRESS	*DEFENDED*
0	0	0	0

6.4.5. UROLOGY ASSOCIATED GROUP







GROUP COMPOSITON

Leader

Carmen González Enguita

CGEnguita@fjd.es

Research

Clinical

LOCATION

Department of Urology, 1st floor.
Fundación Jiménez Díaz University Hospital.
Avda. Reyes Católicos, 2. 28040 Madrid (Spain).

KEYWORDS

Urology, urological oncology, translational research, clinical trials, personalised medicine, urological surgery, biomarkers, and quality of life.

SUMMARY OF ACTIVITIES

The Department of Urology conducts research aimed at improving the diagnosis, treatment and follow-up of both oncological and benign urological diseases. Its research activities integrate clinical trials, translational studies and innovation projects in surgery, pharmacology, medical devices and regenerative medicine. The group actively participates in studies designed to evaluate new therapeutic approaches, assess the efficacy and safety of surgical techniques, and explore tools that support the transition towards more precise, personalised and patient-centred medicine. In this context, the group is promoting several projects based on artificial intelligence to enhance clinical data analysis, optimise diagnostic processes, support therapeutic decision-making, and develop predictive models capable of anticipating the course of specific urological diseases. These activities facilitate the translation of scientific knowledge into clinical practice and contribute to the development of innovative solutions for highly prevalent and impactful urogenital disorders.

CONTRIBUTIONS TO SOCIETY

Our research activity aims to translate scientific innovation into improved healthcare. Through clinical and translational research projects, we contribute to the development of new treatments, drugs, surgical techniques, diagnostic strategies and artificial intelligence-based digital tools, supporting a safer, more precise, more efficient and more personalised approach to medicine.

Moreover, part of our work is focused on improving the patient experience throughout the entire care pathway. We are involved in initiatives aimed at enhancing patient well-being, quality of life and support for individuals with urological diseases, incorporating technologies that facilitate follow-up, outcome prediction and shared decision-making.

The Department of Urology also participates in national and international collaborative networks, promoting knowledge exchange, the generation of scientific evidence and technology transfer for the benefit of patients and society.

COLLABORATIONS

The Department of Urology maintains an active network of collaborations with scientific societies, cooperative groups, foundations, hospital departments and academic institutions. These partnerships enable the development of multicentre studies, the promotion of new research lines and the advancement of knowledge in the field of genitourinary disorders.

The Department currently collaborates with a range of organisations and institutions, including:

Spanish Association of Urology
Our research group is aligned with the objectives of the Spanish Association of Urology, which promotes multicentre research through its Multicentre Research Studies Platform. We participate in collaborative studies aimed at consolidating clinical data, evaluating treatments, developing national registries and improving patients' quality of life.

Advanced Therapies Group of IIS-FJD
We collaborate in the development of innovative therapies for urinary incontinence through a regenerative medicine project based on mesenchymal stem cells.

Foundation for research in Urology
We participate in a clinical study evaluating the treatment of high-risk non-muscle-invasive bladder tumours with IMUNO BCG Moreau RJ.

European Uro-Oncology Group
We collaborate in a Phase II clinical trial on upper urinary tract urothelial carcinoma.

UNICANCER, Health Cooperative Group
We participate in the ALBAN clinical trial, which evaluates the efficacy of atezolizumab in combination with BCG in patients with high-risk non-muscle-invasive bladder cancer.

In addition, the Department of Urology collaborates closely with the Departments of Oncology and Nephrology at Fundación Jiménez Díaz University Hospital (HUFJD) through the donation of biological samples for strategic research projects, including the TITANIA Study, focused on cancer diagnosis and therapies using multi-omics analysis, and the FJD-ENBIBA (European Nephrectomy Biobank) project.

DOCTORAL THESIS

BACHELOR'S DEGREE FINAL PROJECTS	MASTER'S DEGREE FINAL PROJECTS	DOCTORAL THESIS	
		IN PROGRESS	*DEFENDED*
0	0	5	0

6.5 Genomics and epidemiology area

GENETICS AND GENOMICS OF RARE AND COMPLEX DISEASES GROUP
PREVENTIVE MEDICINE, PUBLIC HEALTH AND PRIMARY CARE ASSOCIATED GROUP

Following approval by the IIS-FJD Research Committee and External Scientific Advisory Committee, the research areas were restructured. As a result, in 2025 the Genetics and Genomics Area wasas renamed the Genomics and Epidemiology Area. In addition, the Genetic Susceptibility to Rare and Complex Diseases Group ceased to be part of this Area and was incorporated into the Cancer Area. In its place, the Preventive Medicine, Public Health and Primary Care Group joined the Area.

Definition of the area and priority objectives

The Genomics and Epidemiology Area conduct its scientific activities through a range of research projects focused on rare and common genetic diseases. These projects address their pathophysiological, cellular and molecular characterisation, the development and validation of diagnostic techniques and algorithms, and epidemiological analyses in patient cohorts. The goal is to design clinically useful tools with clear applications in patient care, while facilitating the development of new therapeutic strategies.

Its objectives include both area-specific goals and cross-cutting objectives aimed at providing methodological support and specialised expertise to the other research groups and areas of IIS-FJD:

Genomics and Epidemiology Area Objectives	Level of Achievement in 2025
SPECIFIC OBJECTIVES	
Understanding the molecular basis of rare and complex diseases.	IN PROGRESS
Development of algorithms for the analysis and interpretation of omics data through the application of Bioinformatics and Systems Biology.	IN PROGRESS
Translation of biotechnology into postnatal diagnosis and the prevention of genetic disorders through prenatal and reproductive diagnosis in different clinical fields, including ophthalmology, paediatrics, neurology, hereditary cancer, cardiology, nephrology and others.	IN PROGRESS
Development of therapeutic approaches based on pharmacogenetics (PGx), cell and gene therapies, and molecular targets.	IN PROGRESS
New experimental approaches and innovation. Single-cell and mosaicism studies; long-read whole-genome sequencing (WGS) and optical genome mapping. Validation of diagnostic kits for repeat expansion disorders and new developments in NIPT and PGT-M/PGT-A.	IN PROGRESS
Preventive Medicine, Public Health and Primary Care Group: development of epidemiological studies, both independently and in collaboration with other groups, on chronic and communicable diseases; assessment of the impact of vaccination on communicable diseases; implementation of training and dissemination activities; and promotion of Good Research Practice principles through educational and outreach initiatives.	IN PROGRESS
CROSS-CUTTING OBJECTIVES	
To apply a genomic approach to the study of common diseases, opening new research lines in neurological, psychiatric, oncological and cardiovascular disorders.	
To identify genetic determinants and pharmacogenetic (PGx) factors that contribute to the progression of rare and complex diseases, enabling the selection of more individualised therapies and advancing genomic and personalised medicine.	
To analyse and implement organisational, ethical and regulatory aspects related to Genomics, Big Data and Artificial Intelligence.	
Scale:	
NOT ACHIEVED	PARTIALLY ACHIEVED	ACHIEVED	

The research lines of the Genetics and Genomics of Rare and Complex Diseases Group are focused on the genetic, clinical and epidemiological study of a wide range of hereditary and chromosomal disorders, with a strong translational component. Strategically, the validation and implementation of next-generation sequencing (NGS) technologies constitute a priority objective because of their direct application to clinical diagnosis and their potential as experimental tools for the molecular characterisation of numerous physiological and pathological processes. These technologies enable genetic diagnosis and counselling in congenital malformations and monogenic and complex diseases throughout all stages of life, from the preconceptional, embryonic and foetal periods (particularly through non-invasive prenatal testing), to postnatal and predictive genetic testing.

A key aspect of the group's activity is the analysis, harmonisation and implementation of emerging technologies, including NGS and Artificial Intelligence (AI), within an appropriate ethical and regulatory framework. This approach aims to facilitate both the primary and secondary use of omics information and health data for the generation of new knowledge through research and for the improvement of healthcare processes and patient outcomes.


The Preventive Medicine, Public Health and Primary Care group aims to contribute to the delivery of personalised healthcare through the application of epidemiological and public health strategies. Its activities focus on Epidemiology, Health Protection and Health Promotion, Disease Prevention, the improvement of individual and population health, Patient Safety, and the enhancement of Healthcare Quality. The group also promotes activities related to research methodology and ethics, scientific integrity principles, and good research practices. In addition, its members are actively involved in undergraduate and postgraduate teaching activities.


Scientific Activity of the Genomics and Epidemiology area


	2025	Genetics and Genomics of Rare and Complex Diseases	Preventive Medicine, Public Health and Primary Care Associated Group	TOTAL
PROJECTS	→EU/NIH PROJECTS	//	//	**//**
	→ISCIII PROJECTS	11	1	**12**
	→CIBER PROJECTS	1	//	**1**
	→MINISTRY-FUNDED PROJECTS	5	//	**5**
	→CAM PROJECTS	2	//	**2**
	→AWARDS	//	1	**1**
	→NON-OFFICIAL PROJECTS	5	3	**8**
	→OBSERVATIONAL STUDIES	//	1	**1**
	TOTAL	**24**	**6**	**30**
CLINICAL TRIALS	→EARLY-PHASE TRIALS (I, I/II, II)	//	//	**//**
	→LATE-PHASE TRIALS (II/III, III, III/IV O IV/OTHERS)	//	3	**3**
	TOTAL	**//**	**3**	**3**

Publications of the Genomics and Epidemiology area

2025	Total of publications	No of publications with an Impact Factor	Cumulative impact factor	Average annual impact factor	No of publications in Q1 journals	% of publications in Q1 journals	No of Open Access Publications	No of Clinical Practice Guidelines
Genetics and Genomics of Rare and Complex Diseases	28	27	133	4,93	19	70,37%	24	1
Preventive Medicine, Public Health and Primary Care Associated Group	43	43	161,7	3,76	25	58,14%	26	6
GENOMICS AND EPIDEMIOLOGY RESEARCH AREA	**71**	**70**	**294,7**	**4,21**	**44**	**62,86%**	**50**	**7**







Five most relevant publications from the Genomics and Epidemiology area in 2025

CCL18: a potential immunosuppressive biomarker for prognosis in ABC diffuse large B-cell lymphoma.

Rodríguez M, Rojas-Vega F, Díaz-Alejo JF, Mahillo-Fernández I, Serrano C, López A, Morales-Ruiz T, Roldan-Arjona T, Sánchez-García J, Río-Machín A, Morillo D, Pérez MA, Córdoba R, Llamas-Sillero P, Rodríguez-Pinilla SM, Serrano-López J.

Front Immunol. 2025.16:1693730.

PMID: 41472741

IF: 5,9

http://dx.doi.org/10.3389/fimmu.2025.1693730

Dual Action of Dipyridamole in Experimental Rheumatoid Arthritis: Suppression of Joint Inflammation and Upregulation of Muscle Anabolism via Adenosine and AMPK pathways.

Marco-Bonilla M, Fresnadillo M, Sanchez-Platero I, de la Riva-Bueno M, Huete-Toral F, Carracedo G, Conde C, Benitez Y, Minguez P, Cifuentes SC, Rams J, Herrero-Beaumont G, Largo R, Mediero A.

Arthritis Rheumatol. 2025 Dec 29.

PMID: 41466573

IF: 10,9

http://dx.doi.org/10.1002/art.70047

SARS-CoV-2 mutant spectrum complexity is an epidemiologically evolvable trait.

Martínez-González B, Soria ME, de Ávila AI, Somovilla P, Aguilar-Sabido C, Mínguez P, Ferrer-Orta C, Salar-Vidal L, Lorenzo-Redondo R, Delgado S, Morán F, Verdaguer N, Gadea I, Domingo E, Perales C.

Proc Natl Acad Sci U S A. 2025 Sep 30.122(39):e2515706122.

PMID: 40991435

IF: 9,1

http://dx.doi.org/10.1073/pnas.2515706122

Long-Read Whole-Genome Sequencing as a Tool for Variant Detection in Inherited Retinal Dystrophies.

Rodilla C, Núñez-Moreno G, Benitez Y, Rodríguez de Alba M, Blanco-Kelly F, López-Alcojor A, Fernández-Caballero L, Perea-Romero I, Del Pozo-Valero M, García-García G, Balanzá M, Villaverde C, Zurita O, Jubin C, Fund C, Delepine M, Leduc A, Deleuze JF, Millán JM, Minguez P, Corton M, Ayuso C.

Int J Mol Sci. 2025 Apr 18.26(8).

PMID: 40332496

IF: 4,9

http://dx.doi.org/10.3390/ijms26083825

Bi-allelic variants in three genes encoding distinct subunits of the vesicular AP-5 complex cause hereditary macular dystrophy.

Kaminska K, Cancellieri F, Quinodoz M, Moye AR, Bauwens M, Lin S, Janeschitz-Kriegl L, Hayman T, Barberán-Martínez P, Schlaeger R, Van den Broeck F, Ávila Fernández A, Fernández-Caballero L, Perea-Romero I, García-García G, Salom D, Mazzola P, Zuleger T, Poths K, Haack TB, Jacob J, Vermeer S, Terbeek F, Feltgen N, Moulin AP, Koutroumanou L, Papadakis G, Browning AC, Madhusudhan S, Gränse L, Banin E, Sousa AB, Coutinho Santos L, Kuehlewein L, De Angeli P, Leroy BP, Mahroo OA, Sedgwick F, Eden J, Pfau M, Andréasson S, Scholl HPN, Ayuso C, Millán JM, Sharon D, Tsilimbaris MK, Vaclavik V, Tran HV, Ben-Yosef T, De Baere E, Webster AR, Arno G, Sergouniotis PI, Kohl S, Santos C, Rivolta C.

Am J Hum Genet. 2025 Apr 03.112(4):808-828.


PMID: 40081374

IF: 8,1

http://dx.doi.org/10.1016/j.ajhg.2025.02.015

Gender Perspective in the Genomics and Epidemiology Area

The Genomics and Epidemiology Area is composed of a team of professionals committed to respect, diversity and equality among its members. The Area seeks to promote the professional development of all staff, ensuring equal opportunities and preventing discrimination on the grounds of gender or age.





Future challenges for the Genomics and Epidemiology Area

- **Epidemiology and molecular basis of rare and complex diseases:** identification of new genes, loci and variants involved in human diseases with a genomic basis. Hidden genetic causes of cancer, cardiovascular disease and neurodegeneration; inherited retinal dystrophies; intellectual disability and neurodevelopmental disorders; and ocular malformations.
- **Integration of basic (functional genomics and proteomics) and translational research:** development, validation and harmonisation of diagnostic techniques and identification of novel therapeutic target.
- **Research into therapies applicable to genetic diseases:** pharmacogenetics (PGx), pharmacological therapies and advanced therapies, including gene therapy, gene editing (CRISPR/Cas9) and cell reprogramming using induced pluripotent stem cells (iPSCs), encompassing cell culture, cell line characterisation and genetic monitoring.
- **Translation:** to clinical practice through the development of diagnostic algorithms, the application of artificial intelligence tools, and the implementation of protocols and clinical guidelines for rare and complex diseases:
    - New experimental approaches and innovation, including single-cell and mosaicism studies; long-read whole-genome sequencing (WGS) and optical genome mapping; genome-wide methylation studies using arrays and long-read sequencing; transcriptomic analyses using RNA-seq; multi-omics integration; validation of diagnostic kits for repeat expansion disorders; and new developments in non-invasive prenatal testing (NIPT) and preimplantation genetic testing for monogenic disorders and aneuploidies (PGT-M/PGT-A).
    - Development and validation of bioinformatics tools and algorithms for the reanalysis of undiagnosed cases, the processing of data generated by emerging technologies, and their translation into clinical practice.
    - Validation of NGS procedures and cross-cutting processes in clinical genetic diagnosis, including informed consent, report formats, panel and algorithm design, implementation of whole-exome sequencing (WES), and ORPHA coding.
- **Assessment of the scientific** and societal impact of our research activities.
- **Harmonisation of regulatory** and ethical aspects related to the use of genomics and health data within the Institute and at national and international levels.
    - Consolidation of participation in epidemiological studies, both observational and interventional, on communicable diseases such as respiratory syncytial virus (RSV), COVID-19 and others.
    - Promotion of related educational activities, including the Immunisation Workshop, the Scientific Integrity Workshop, and the Research Workshop for secondary school and high school students.
    - Consolidation of national and international collaborations.

6.5.1. GENETICS AND GENOMICS OF RARE AND COMPLEX DISEASES GROUP







GROUP COMPOSITION

Leaders

Carmen Ayuso García

CAyuso@fjd.es

Marta Cortón Pérez

mcorton@quironsalud.es

Pablo Alberto Mínguez Paniagua

pablo.minguez@iis-fjd.es

PIs

Berta Almoguera Castillo

Almudena Ávila Fernández

Ana Laura Osorio Cabrero

Research

Basic and clinical research

LOCATION

Department of Genetics. 2nd and 4th floors
Fundación Jiménez Díaz University Hospital
Avda. Reyes Católicos, 2. 28040 Madrid (Spain).

KEYWORDS

Rare diseases, genetic diseases, neurodevelopmental disorders, intellectual disability, inherited retinal dystrophies, ocular malformations, cardiovascular diseases, hereditary kidney diseases, neurogenetic disorders, complex genetic diseases, hereditary cancer, pharmacogenetics and gene therapy; Translational research: genetic diagnosis, non-invasive prenatal diagnosis, reproductive and fetal health; Methodological approaches: genome and exome next-generation sequencing, bioinformatics; Ethical aspects of genetic studies.

SUMMARY OF ACTIVITIES

The group is multidisciplinary, highly translational in nature and it plays a key role in clinical activities, particularly in the diagnosis and prevention of genetic diseases, as well as in the development of research lines across a wide range of rare diseases. Through close collaboration with other IIS-FJD research groups, it contributes to the translation of advances in both rare and common genetic disorders into clinical practice. In addition, the group is engaged in the development and validation of diagnostic techniques and algorithms, as well as new therapeutic and preventive strategies aimed at providing comprehensive care for patients with genetic diseases.

CONTRIBUTIONS TO SOCIETY

Guidelines/Recommendations:

- Rivolta C, Celik E, Kamdar D, Cancellieri F, Kaminska K, Ullah M, Barberán-Martínez P, Bouckaert M, Cortón M, Delanote E, Fernández-Caballero L, García García G, Holtes LK, Karali M, Lopez I, Peter VG, Schneider N, Vincke L, Ayuso C, Banfi S, Bocquet B, Coppieters F, Cremers FPM, Inglehearn CF, Iwata T, Kalatzis V, Koenekoop RK, Millán JM, Sharon D, Toomes C, Quinodoz M. RetiGene, a comprehensive gene atlas for inherited retinal diseases. Am J Hum Genet. 2025 Oct 2; 112(10):2253-2265. doi: 10.1016/j.ajhg.2025.08.017. Epub 2025 Sep 16. PMCID: PMC12696501.PMID: 40961941.

- Lazcoz Moratinos G, Nicolás Jiménez P, Ayuso C. Regulación de los hallazgos secundarios e incidentales derivados del análisis genético: desde el ámbito clínico hasta el Espacio Europeo de Datos de Salud. Rev Bio y Der UB. 2025, 63:88-106, DOI 10.1344/rbd2025.63.47664.

Activities for patient associations, secondary school students and the general public:

- Building DNA. International Day of Women and Girls in Science (Fundación Jiménez Díaz University Hospital).
- Decoding the Code. International Day of Women and Girls in Science (Fundación Jiménez Díaz University Hospital).
- Variability in KBG Syndrome Regarding Clinical Presentation and Severity of Manifestations. KBG Spain Congress.
- Podcast "The Science of the Singular". Patient Participation in Research. Sant Joan de Déu Research Foundation.
- Round Table: ONCE Foundation for Low Vision. ONCE.
- Extended Mind: To Infinity and Beyond? Philosophy and Health.
- Preimplantation Genetic Diagnosis of Genetic Diseases. Fanconi Anaemia Foundation Congress.
- Is Personalised Medicine Personal? Scientific Outreach Series "Science with Chocolate".
- Approaches to the Genetic Diagnosis of Rare Neurological Diseases. Families Meeting, Purple Warriors Association 2025.
- Integration of Clinical and Genomic Data for the Study and Management of Patients with Rare Diseases. Families Meeting, Purple Warriors Association 2025.
- What Is Bioinformatics? Discover How Programming Helps Us Study Diseases! Science and Innovation Week.
- Podcast "Retina: Present and Future". Retina Podcast Channel, Retina Murcia Association.
- Advances in Assisted Reproduction: PGT. Charcot-Marie-Tooth Conference. ONCE Foundation.
- Research in the 21st Century: Personalised Medicine in Hereditary Cancer. Coffee, Pastries and Science Meetings.
- Bringing Science Closer to Schools. Research and Drug Development in Rare Diseases (Fundación Jiménez Díaz University Hospital).

Scientific Committees: FARPE Scientific Committee; Retina International Scientific Committee; FEDER Good Governance Committee; Purple Warriors Scientific Committee.

Advisory Boards: Choroideremia Research Foundation, DGenes, Incontinentia Pigmenti and Aniridia-Europe Association, Spanish Aniridia Association, AccesAccess de Luz Association, and FEDER.

Carmen Ayuso is member of the Spanish Ministry of Health Committee for the Genetics and Genomics Services Portfolio of the National Health System.

Almudena Ávila-Fernández is member of the Spanish Ministry of Health Committee for the Nephrology Services Portfolio.

Isabel Lorda, Ana Bustamante and Carmen Ayuso are members of the National Commission on Assisted Human Reproduction (CNRHA) of the Spanish Ministry of Health.

COLLABORATIONS

INTERNATIONAL CONSORTIA AND PROJECTS: Beyond 1 Million Genomes (ELSI, WP7), ERDC, Aniridia-Net Cost Action, Optic Atrophy-OPA8, GoOD.2) CIMBA (Consortium of Investigators of Modifiers of BRCA1/2), MERGE (Male Breast Cancer Genetics Consortium). Proyectos Internacionales: NEXOME (Rivolta Lausanne University). WGS Easigenomics. Otras: UCL, Oxford-University, INSERM, Semmelweis University, Hungary, EMQN (European Molecular Quality Network). ProgRet (Nº Proyecto: 101120562), Aristos.

NATIONAL CONSORTIA: IMPaCT-Genómica 2 (Co-Coordinator; Project No. PMPER24/00002), IMPaCT-Data, IMPaCT Vuscan, TransBioNet, GEICAM (Spanish Breast Cancer Research Group), CLASSIFI_ER, and CIBERER Working Groups: Bioinformatics (P. Mínguez), RNA Therapies (C. Ayuso), RNA-Seq (C. Ayuso), Secondary Genomic Findings (C. Ayuso), Epi-ENOD, Epigenomics (B. Almoguera), and Newborn Screening. SpadaHC (Spanish Variant Database for Hereditary Cancer).

COLLABORATIONS WITH OTHER IIS-FJD GROUPS: Nephrology and Hypertension, Vascular Disease and Diabetes; Medical and Surgical Innovation; Advanced Therapies; Preventive Medicine, Public Health and Primary Care; Epidemiology and Biostatistics Unit; Pathology; Rheumatology and Bone Metabolism; Innovation in Ophthalmology; Medical Oncology; Research in New Therapies; Haematology; Infectious Diseases and Tropical Medicine; Information Systems; Allergy and Immunology; Microbiology; Mitochondrial Calcium Signalling; Neurology; and Lipid Disorders: Clinical and Experimental Research (Adults and Children).

DOCTORAL THESIS

BACHELOR'S DEGREE FINAL PROJECTS
4


MASTER'S DEGREE FINAL PROJECTS
4


DOCTORAL THESIS	
IN PROGRESS	*DEFENDED*
10	1

Instituto de Investigación Sanitaria
Fundación Jiménez Díaz

6.5.2. PREVENTIVE MEDICINE, PUBLIC HEALTH AND PRIMARY CARE ASSOCIATED GROUP







GROUP COMPOSITION

Leaders

Lucía Llanos Jiménez

lucia.llanos@quironsalud.es

María Dolores Martín Ríos

maria.mrios@hospitalreyjuancarlos.es

Research

Epidemiological research

LOCATION

Department of Preventive Medicine
Clinical Research Unit
Fundación Jiménez Díaz University Hospital.
Avda. Reyes Católicos no. 2, 28040, Madrid.

KEYWORDS

Healthcare-associated infections, viral infection, bacterial infection, pandemic, COVID-19, vaccination, influenza, bronchiolitis, epidemiology, diagnosis, hospitalisations, pharmacovigilance, Good Research Practices, scientific integrity, research ethics, and clinical trials.

SUMMARY OF ACTIVITIES

The group aims to contribute to the delivery of personalised healthcare through the application of epidemiological and public health strategies. Its activities focus on Epidemiology, Health Protection and Health Promotion, Disease Prevention, the improvement of individual and population health, Patient Safety, and the enhancement of Healthcare Quality. Group members participate in a range of teaching activities at both undergraduate and postgraduate levels. The group also promotes activities related to research ethics, scientific integrity principles and Good Research Practices. In addition, its members actively participate in undergraduate and postgraduate teaching activities.

CONTRIBUTIONS TO SOCIETY

The Preventive Medicine, Public Health and Primary Care Group is strongly oriented towards improving healthcare delivery and public health through the reduction of risks associated with medical care, the optimisation of healthcare resource utilisation, and the promotion of evidence-based practice. The goal of these activities is to provide better care for patients and to improve the health of the community. In addition, the group develops educational and outreach activities related to research ethics, scientific integrity and Good Research Practices. These initiatives aim to ensure that scientific research is conducted to the highest standards of quality and reproducibility, while safeguarding the rights of research participants and maintaining public trust in science and healthcare research.

COLLABORATIONS

NA

DOCTORAL THESIS

BACHELOR'S DEGREE FINAL PROJECTS
4

MASTER'S DEGREE FINAL PROJECTS
2

DOCTORAL THESIS	
IN PROGRESS	*DEFENDED*
3	0

6.6 Healthcare technology and innovation area

INNOVATION IN OPHTHALMOLOGY GROUP

MEDICAL ENGINEERING DEVELOPMENT AND INNOVATION GROUP

RESEARCH IN NEW THERAPIES GROUP

ADVANCED THERAPIES GROUP (CIEMAT)

REGENERATIVE MEDICINE AND TISSUE BIOENGINEERING GROUP (CIEMAT-UC3M)

MEDICAL AND SURGICAL INNOVATION ASSOCIATED GROUP

NURSING ASSOCIATED GROUP (UAM): EXTRACORPOREAL CIRCULATION AND PERFUSION

Definition of the area and priority objectives

Following approval by the IIS-FJD Research Committee and External Scientific Advisory Committee, the research areas were restructured. As a result, in 2025 the Preventive Medicine, Public Health and Primary Care Group became part of the Genetics and Genomics Area, which was subsequently renamed the Genomics and Epidemiology Area.

This cross-cutting strategic area is composed of five consolidated research groups and two associated groups, primarily focused on the application of novel healthcare technologies for diagnosis and the implementation of innovative therapeutic approaches.

Its main objectives include:

Objectives of the Healthcare Technology and Innovation Area	Level of Achievement in 2025
Innovation in Ophthalmology Group: To establish the utility of adipose tissue-derived mesenchymal stem cells in an in vitro model of conjunctivochalasis and Meibomian gland dysfunction. To validate a patented algorithm for intraocular lens power calculation in patients with irregular corneas. To participate in Phase II and Phase III clinical trials evaluating investigational drugs for inherited retinal diseases, macular degeneration and uveitis. To collaborate with the Spanish National Research Council.	
Medical Engineering Research and Development Group: We will continue to advance the European EIC Pathfinder project "MOSAIC" (GAP-101186537). Significant progress has been made in the design of an optoacoustic sensor that enables non-invasive blood pressure measurement, and the first pilot clinical trial is scheduled to be conducted. In parallel, we are carrying out a comprehensive clinical evaluation of a new dermatological imaging device in the field of aesthetic dermatology. We also continue our research lines in optometry and ophthalmology, with new developments focused on paediatric screening, the detection and grading of keratoconus, and the incorporation of adaptive optics into our refractive error measurement systems.	

Objectives of the Healthcare Technology and Innovation Area	Level of Achievement in 2025
New Therapies Research Group: Study of the ADSC secretome in wound healing and submission of a clinical trial application to the Spanish Agency of Medicines and Medical Devices (AEMPS). Investigation of methylated SEPTIN9 (mSEPTIN9) in rectal cancer. Development of a clinical trial on cell therapy for urinary incontinence. Development of a system for the treatment of intraluminal tumours. Preclinical toxicity studies of peritoneal collagenase and submission of a clinical trial application to the AEMPS. Specifically, the Otorhinolaryngology team will conduct the following studies: - A randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of dupilumab in patients with uncontrolled chronic rhinosinusitis without nasal polyps (CRSsNP). - A Phase III, randomised, double-blind, parallel-group study to evaluate the efficacy and safety of 100 mg subcutaneous depemokimab in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) (GSK). - A Phase IV, randomised, double-blind, head-to-head study comparing dupilumab versus omalizumab in patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP) and concomitant asthma. - An international, Phase III, randomised, double-blind, placebo-controlled trial to evaluate the efficacy and safety of tezepelumab in patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP) (AstraZeneca).	
Advanced Therapies Group: The group plans to apply to the Spanish Agency of Medicines and Medical Devices (AEMPS) for authorisation of a gene therapy clinical trial for patients with Diamond-Blackfan anaemia. An additional clinical trial will be submitted for the treatment of graft-versus-host disease using genetically modified mesenchymal stromal cells. The group will also continue the development of transposon-generated CAR-T cells for the treatment of lymphomas and will initiate work aimed at extending the use of these CAR-T cells to the treatment of patients with lupus, in a programme coordinated by Fundación Jiménez Díaz. In parallel, preclinical studies on gene therapy and gene editing for the treatment of haematopoietic disorders will continue. In collaboration with Rocket Pharma, the group will maintain the follow-up of three pivotal gene therapy clinical trials, and marketing authorisation applications will be submitted for two of these therapies.	
Regenerative Medicine and Tissue Bioengineering Group: In vivo gene correction using viral vector-mediated gene editing for Recessive Dystrophic Epidermolysis Bullosa and Pachyonychia Congenita. Clinical trial: Mesenchymal Stromal Cells (MSCs) for the treatment of chronic wounds (EudraCT 2019-004637-16). Correction of disease-causing mutations in Epidermolysis Bullosa through base editing and prime editing technologies. MSC-based cell therapy for Epidermolysis Bullosa. Development of aptamer-based therapies for chronic wound healing, inflammation, fibrosis and hair follicle disorders. Preclinical studies of MSC-based cell therapy in an animal model of Epidermolysis Bullosa. Characterisation of new fibrosis modulators and therapeutic approaches for Recessive Dystrophic Epidermolysis Bullosa. Development of a microfluidic system for Skin-on-a-Chip applications. Clinical development of a gene-editing Advanced Therapy Medicinal Product (ATMP) for Epidermolysis Bullosa.	
Medical and Surgical Innovation Associated Group: Evaluation of the effects of metoprolol in patients with community-acquired pneumonia. Development of tools based on the analysis of physiological monitoring signals to support the management of critically ill patients. Multicentre study of the use of continuous haemodynamic monitoring worldwide. Evaluation of the impact of the duration and depth of hypotension in patients with septic shock.	
UAM Nursing Associated Group: ***Extracorporeal Circulation and Perfusion.*** The group is committed to providing students with comprehensive training and equipping them with the competencies required for advanced clinical practice and research in extracorporeal circulation and perfusion across all areas of application. Through this advanced training, the group aims to improve the quality of care and patient safety for individuals requiring these specialised techniques.	
Scale:	


NOT ACHIEVED		PARTIALLY ACHIEVED		ACHIEVED		

Scientific Activity of the Healthcare Technology and Innovation Area

	2025	Innovation in Ophtalmology	Medical Engineering Development and Innovation	Research in New Therapies	Advanced Therapies	Regenerative Medicine and Tissue Bioengineering	Medical and Surgical Innovation	Nursing UAM: Extracorporeal Circulation and Perfusion	TOTAL
PROJECTS	→EU/NIH PROJECTS	//	//	1	//	//	//	//	**1**
	→ISCIII PROJECTS	2	//	7	5	2	1	//	**17**
	→CIBER PROJECTS	//	//	//	1	1	//	//	**2**
	→MINISTRY-FUNDED PROJECTS	//	//	//	//	//	//	//	**//**
	→CAM PROJECTS	//	//	//	1	//	//	//	**1**
	→AWARDS	//	//	//	//	//	//	//	**//**
	→NON-OFFICIAL PROJECTS	4	//	16	12	3	10	1	**46**
	→OBSERVATIONAL STUDIES	1	//	3	//	//	5	//	**9**
	TOTAL	**7**	**//**	**27**	**19**	**6**	**16**	**1**	**76**
CLINICAL TRIALS	→EARLY-PHASE TRIALS (I, I/II, II)	4	//	5	//	//	3	//	**12**
	→LATE-PHASE TRIALS (II/III, III, III/IV O IV/ OTHERS)	5	//	11	//	//	9	//	**25**
	TOTAL	**9**	**//**	**16**	**//**	**//**	**12**	**//**	**37**

Publications of the Healthcare Technology and Innovation Area

2025	Total of publications	No of publications with an Impact Factor	Cumulative impact factor	Average annual impact factor	No of publications in Q1 journals	% of publications in Q1 journals	No of Open Access Publications	No of Clinical Practice Guidelines
Innovation in Ophtalmology	29	26	96,4	3.71	18	69.23%	21	1
Medical Engineering Development and Innovation	2	2	16	8.00	2	100.00%	1	0
Research in New Therapies	92	86	311,8	3.63	41	47.67%	65	8
Advanced Therapies	41	41	521,6	12.72	31	75.61%	33	1
Regenerative Medicine and Tissue Bioengineering	11	11	66,3	6.03	8	72.73%	10	0
Medical and Surgical Innovation	48	46	209,5	4.55	31	67.39%	31	5
Nursing UAM: Extracorporeal Circulation and Perfusion	//	//	//	//	//	//	//	//
HEALTHCARE TECHNOLOGY AND INNOVATION AREA	**223**	**212**	**1.221,6**	**5.76**	**131**	**61.79%**	**161**	**15**



Five most relevant publications from the Healthcare Technology and Innovation Area in 2025

Base edited skin equivalents with clinical potential for ex vivo correction of recessive dystrophic epidermolysis bullosa.

Bassons-Bascuñana A, Duarte B, Méndez-Jiménez E, Ugalde L, Sanabria-Betrián P, Aussel C, Peña-Gutiérrez I, Olalla-Sastre B, Ammann S, Cathomen T, Del Rio M, Río P, Larcher F, López-Manzaneda S.

Mol Ther. 2025 Nov 17.

PMID: 41254941

IF: 12

http://dx.doi.org/10.1016/j.ymthe.2025.11.023

Lentiviral Gene Therapy for Severe Leukocyte Adhesion Deficiency Type 1.

Booth C, Sevilla J, Almarza E, Kuo CY, Zubicaray J, Terrazas D, O'Toole G, Chitty-Lopez M, Choi G, Nicoletti E, Long-Boyle J, Fernandes A, Chetty K, De Oliveira S, Banuelos C, Xu-Bayford J, Bastone AL, John-Neek P, Jackson C, Moore TB, Gilmour K, Schambach A, Rothe M, Kasbekar S, Rao GR, Patel K, Shah G, Thrasher AJ, Bueren JA, Schwartz JD, Kohn DB.

N Engl J Med. 2025 May 01.392(17):1698-1709.

PMID: 40305711

IF: 78,5

http://dx.doi.org/10.1056/NEJMoa2407376

Depigmentation of RPE Hypertrophy in Vogt-Koyanagi-Harada Syndrome.

González-Coín EJ, Carreño E.

JAMA Ophthalmol. 2025 Mar 01.143(3):e246230.

PMID: 40111315

IF: 9,2

http://dx.doi.org/10.1001/jamaophthalmol.2024.6230

GUÍA PRÁCTICA CLÍNICA ***Implementing a closed loop clinical decision support system for sustainable preoperative care.***

Gracia Martínez JL, Pfang B, Morales Coca MÁ, Caramés Sánchez C, Del Olmo Rodríguez M, Villegas García MA, Short Apellaniz J, Arcos Campillo J, Álvaro de la Parra JA, Manzano Lorefice F, Muñoz Alameda LE.

NPJ Digit Med. 2025 Jan 03.8(1):6.

PMID: 39753745

IF: 15,1

http://dx.doi.org/10.1038/s41746-024-01371-7

All-in-one gene therapy alternative for DBAS.

Navarro S, Río P.

Cell Stem Cell. 2025 Jan 02.32(1):4-6.


PMID: 39753111

IF: 20,4

http://dx.doi.org/10.1016/j.stem.2024.12.003

Gender perspective in the Healthcare Technology and Innovation Area

The Health Technology and Innovation Area is composed of a team of professionals committed to respect, diversity and equality among its members. The Area seeks to promote the professional development of all staff, ensuring equal opportunities and preventing discrimination on the grounds of gender or age.




Future challenges the Healthcare Technology and Innovation Area


- To develop cloud-based tools for the personalised calculation of intraocular lens power based on corneal tomography.
- To design a new multicentre study on the use of stem cells for the treatment of autoimmune diseases of the conjunctiva.
- To analyse the outcomes of our corneal cross-linking protocol according to patient age.
- To assess the utility of high definition aberrometry in predicting quality of life in patients with endothelial dystrophy.
- To participate in the national prospective registry of patients with endophthalmitis.
- To develop a porcine model of perianal fistula and evaluate treatment with frozen and lyophilised ADSC secretome.
- To submit documentation on ADSC-derived exosomes to the Spanish Agency of Medicines and Medical Devices (AEMPS) for the development of a clinical trial in complex perianal fistula.
- To validate methylated SEPTIN9 (mSEPTIN9) as a biomarker in gastrointestinal tumours.
- To conduct a clinical trial using ADSCs for the treatment of wound dehiscence through modulation of the microbiome.
- To perform preclinical studies to validate a GMP-manufactured collagenase and submit a clinical trial application for its use as an adjuvant to HIPE.

- To conduct a clinical trial evaluating butyrate for the treatment of diverticulitis.
- To develop CAR-NK therapies targeting gastrointestinal tumours in the preclinical setting.
- To apply to the AEMPS for a gene therapy clinical trial in patients with Diamond-Blackfan anaemia.
- To apply to the AEMPS for a clinical trial using genetically modified mesenchymal stromal cells for the treatment of graft-versus-host disease.
- To continue the follow-up of patients enrolled in the Phase I/II pivotal gene therapy clinical trial for Fanconi anaemia type A.
- In collaboration with Rocket Pharma, to seek marketing authorisation for gene therapy for Leukocyte Adhesion Deficiency Type I.
- To initiate a Hospital Exemption programme for the gene therapy treatment of Fanconi anaemia type A.
- To consolidate the use of the porcine model for training in cervical surgical techniques and the development of head and neck surgical skill.
- To implement a cadaveric model for training in sialendoscopy technique.
- To improve the surgical skills of ENT residents in head and neck surgery using live-animal (porcine) surgical simulation models.
- To develop new aptamer-based therapies for impaired wound healing, inflammation and alopecia.
- To evaluate the effects of metoprolol in patients with ARDS and investigate the long-term cardiovascular consequences of ARDS.
- To develop tools based on physiological monitoring signal analysis to support the management of critically ill patients.
- To advance the regulatory and clinical phases of an ex vivo gene-editing clinical trial for Epidermolysis Bullosa.
- To develop gene-editing therapies for rare inherited skin disorders with both recessive and dominant inheritance patterns.
- To investigate mechanisms of fibrosis and cancer and develop novel therapeutic approaches for Epidermolysis Bullosa.
- To consolidate participation in epidemiological studies, both observational and interventional, on communicable diseases such as RSV and COVID-19.
- To promote related educational activities, including Immunisation Workshops, the Scientific Integrity Workshop, and the Research Workshop for secondary school students.
- To consolidate national and international collaborations.

6.6.1. INNOVATION IN OPHTALMOLOGY GROUP







GROUP COMPOSITION

Leader

Ignacio Jiménez-Alfaro Morote

IJimenez@quironsalud.es

PIs

Nicolás Alejandre Alba

Research

Basic and clinical research

LOCATION

Department of Ophthalmology. 1st Floor
Fundación Jiménez Díaz University Hospital.
Avda. Reyes Católicos, 2. 28040 Madrid (Spain).

KEYWORDS

Stem cells, keratoconus, cataract surgery, inherited diseases of the cornea, retina and choroid, ocular genetics, ocular electrophysiology, gene therapy, uveitis, ocular inflammation and clinical trials.

SUMMARY OF ACTIVITIES

Over the past year, the Department of Ophthalmology has led two National Research Plan projects focused on the use of mesenchymal stem cells for the treatment of ocular surface and corneal diseases. In addition, the Department has advanced the clinical application of high-resolution aberrometry for the assessment of optical quality in patients with Fuchs endothelial dystrophy and keratoconus. Within the field of visual optics, the impact of intraocular lens tilt and decentration on patients' vision and refractive outcomes has been investigated through two studies involving more than 100 patients. One of these studies was conducted in collaboration with the Spanish National Research Council (CSIC), leading to the establishment of a long-term partnership in this research area and participation in an additional National Research Plan project. This experience has enabled our optics subgroup to file a patent for a method to determine the optimal focal point in patients with irregular corneas. The project was selected to participate in the HealthStart Programme of the Community of Madrid, where it received an award in recognition of its innovative potential.

On the other hand, the Department has been actively involved in clinical studies on diseases such as Age-Related Macular Degeneration (AMD), uveitis, retinitis pigmentosa and inherited retinal disorders. The multidisciplinary team has employed advanced diagnostic technologies and focused on late-phase clinical trials aimed at developing new therapeutic options. Notable studies include the PARASOL trial for AMD, the NOPROD registry for inherited retinal diseases, and the RPGR 021 and 022 gene therapy trials for retinitis pigmentosa. Additional studies have been conducted on uveitis and uveitis macular oedema. Furthermore, the department has provided continuous professional development and training for its staff to ensure the highest standards of patient care. Overall, the department remains a leading centre in ophthalmic research, advancing innovative therapies to improve patients' quality of life.

CONTRIBUTIONS TO SOCIETY

The group has actively collaborated with several patient associations, including AUEVEA, Retimur, ONCE and Retina Madrid, participating in patient education events and contributing to the development of educational and outreach materials.

COLLABORATIONS

The group maintains formal collaborations with the Daza de Valdés Institute of Optics (CSIC) and the Autonomous University of Madrid (UAM).

DOCTORAL THESIS

BACHELOR'S DEGREE FINAL PROJECTS
1


MASTER'S DEGREE FINAL PROJECTS
0


DOCTORAL THESIS	
IN PROGRESS	*DEFENDED*
3	0

Instituto de Investigación Sanitaria
Fundación Jiménez Díaz

6.6.2. GROUP OF MEDICAL ENGINEERING DEVELOPMENT AND INNOVATION (UAM)







GROUP COMPOSITION

Leader

Eduardo Lage Negro

eduardo.lage@uam.es

PI

Juan Aguirre Bueno

Research

Applied research

LOCATION

MEDIC: Medical Engineering Development & Innovation Centre.
Francisco Tomas y Valiente Street, 11,
28049 Madrid, Spain.

Autonomous University of Madrid.
School of Engineering. Department of Electronic Engineering and Communications Technology.
Edificio Joseph Fourier, C101.

KEYWORDS

Medical devices, sensors, medical imaging, biomedical engineering.

SUMMARY OF ACTIVITIES

MEDIC is a research group focused on addressing clinical needs through science and technology. Our developments are always aimed at creating products that can be directly used in patients and/or transferred to industry with minimal modifications for commercialisation. The group also contributes to teaching activities in several courses within the bachelor's degree in biomedical engineering and the bachelor's degree in Telecommunications Engineering and Services at the School of Engineering of the Autonomous University of Madrid.

CONTRIBUTIONS TO SOCIETY

More than two billion people worldwide do not have access to the spectacles they need. At MEDIC, we have developed low-cost technologies for eyeglass prescription, which are currently being commercialised by PlenOptika Inc. (USA and Spain) and Aurolab (India). We also work on the development of optoacoustic imaging technologies to address unmet clinical needs. Our systems can quantify the severity of different inflammatory dermatological diseases with a level of accuracy and reliability that exceeds that of traditional subjective clinical scoring systems.

COLLABORATIONS

- PlenOptika Inc (USA and Spain) à Joint technology development.
- Aurolab (Tamil Nadu, India) à Development of technologies for low- and middle-income countries.
- Aravind EyeCare Hospital (Tamil Nadu, India) à Clinical research.
- John Hopkins University, Department of Biomedical Engineering, Professor Nicholas Durr à Applied research.
- 2eyes Vision SL (Madrid, Spain) à Joint technology development.
- Department of Ophthalmology HUFJD à Clinical research.
- Institute of Biological and Medical Imaging. Technical University of Munich and Helmholtz Munich à Technology development through European research projects.
- Aristotle University of Thessaloniki.
- Universität Graz.
- Universitá degli Studi di Bari.


DOCTORAL THESIS


BACHELOR'S DEGREE FINAL PROJECTS
6


MASTER'S DEGREE FINAL PROJECTS
0

DOCTORAL THESIS	
IN PROGRESS	*DEFENDED*
2	0

6.6.3. NEW THERAPIES RESEARCH GROUP







GROUP COMPOSITION

Leaders

Carlos Cenjor Español

CCenjor@fjd.es

Mariano García Arranz

mariano.garcia@quironsalud.es

Damián García Olmo

damian.garcia@quironsalud.es

PIs

María Luisa de Molina Rampérez

Héctor Guadalajara Labajo

Pedro Villarejo Campos

Research

Basic and clinical research

LOCALIZACIÓN

Departments of General Surgery and Otorhinolaryngology
Fundación Jiménez Díaz University Hospital. Avda. Reyes Católicos, 2 28040 Madrid (Spain).
New Therapies Laboratory

4th Floor, Research Building. IIS-FJD
Fundación Jiménez Díaz University Hospital.
Avda. Reyes Católicos, 2. 28040 Madrid (Spain).

KEYWORDS

Hearing rehabilitation, Ménière's disease, salivary gland disorders, liquid biopsy in gastrointestinal cancer, CAR-NK therapies for gastrointestinal tumours, collagenase, cell therapy, mesenchymal stromal cells, liquid biopsy, experimental surgery, animal models, clinical trials in cell therapy, and the effects of butyrate in gastrointestinal diseases.

SUMMARY OF ACTIVITIES

- Development of semi-implantable cochlear implants without tinnitus for patients with asymmetric hearing loss.
- Surgical training course in cervical surgery.
- Preclinical and clinical development of enzymatic treatments for peritoneal carcinomatosis.
- Detection and predictive value of SEPTIN9 gene methylation using liquid biopsy in gastrointestinal tumours.
- Development of a preclinical model and submission of a clinical trial application evaluating the use of butyrate in diverticulitis.
- Development of clinical trials in cell therapy, gene therapy and enzymatic therapy.
- Design and development of a fluidic scalpel and cell therapy delivery device.
- Investigation of the effects of the microbiota and antibiotic therapy on wound healing, including the submission of a clinical trial application.

CONTRIBUTIONS TO SOCIETY

- Patents developed: Chemical scalpel. Novel treatment for adhesions.
- Clinical guidelines: Continued inclusion of cell therapy as a second-line treatment for perianal fistulas in patients with Crohn's disease.
- Clinical trials: Cell therapy for the treatment of perianal fistulas. Treatment of anal incontinence using myocytes combined with nanoparticles. Treatment of perianal fistulas using exosomes derived from mesenchymal stromal cells. Treatment of diverticulitis with butyrate. Microbiome conditioning to prevent anastomotic leakage following colorectal surgery.
- Development of training programmes through the OPEREMOS initiative.
- International training courses in Otorhinolaryngology.

COLABORACIONES

- TIGENIX: Study of the effects of cell therapy on the microenvironment of perianal fistulas.
- EVOMED: Development of an enzymatic treatment as an adjuvant to HIPEC for peritoneal carcinomatosis. Clinical trial.
- Microviable: Development and analysis of gut microbiota-based products.
- Horizon 2020 project focused on the optimisation and development of a clinical trial using exosomes for the treatment of perianal fistulas.
- ISCIII RICORS Project. National Network for Advanced Therapies (TERAV).
- PEACHES: Development of mesenchymal cell-derived secretome under GMP conditions and its future clinical application.

DOCTORAL THESIS


BACHELOR'S DEGREE FINAL PROJECTS
90


MASTER'S DEGREE FINAL PROJECTS
15

DOCTORAL THESIS	
IN PROGRESS	*DEFENDED*
9	1

6.6.4. ADVANCED THERAPIES GROUP (CIEMAT)







GROUP COMPOSITION

Leaders

Juan Antonio Bueren Roncero (CIEMAT)
juan.bueren@ciemat.es
Paula Río Galdo
paula.rio@ciemat.es

PIs

Marina Inmaculada Garín Ferreira
Jordi Minguillón Pedreño
Susana Navarro Ordóñez
José Carlos Segovia Sanz
Raúl Torres Ruiz

Research

Basic and clinical research

LOCATION

Biomedical Innovation Unit
CIEMAT, Building 70.
Avda Complutense 40. 28040 Madrid (Spain).

KEYWORDS

Advanced therapies, gene therapy, gene editing, haematopoietic stem cells, monogenic diseases, rare diseases, bone marrow failure, inflammatory diseases, autoimmune diseases, CAR-T cells, mesenchymal stromal cells (MSCs), and cancer immunotherapy.

SUMMARY OF ACTIVITIES

The Joint Unit for Advanced Therapies conducts translational research aimed at developing novel gene and cell therapies for congenital and acquired diseases with poor prognoses. These include Fanconi anaemia, paediatric cancers, and pyruvate kinase deficiency, which are currently at advanced stages of clinical development using lentiviral vectors developed within the laboratory, as well as Leukocyte Adhesion Deficiency Type I, for which a gene therapy has recently received FDA approval. Additional gene therapies based on lentiviral vectors and gene-editing technologies for the treatment of haematological and liver diseases are currently being developed at the preclinical stage. Among the cell therapy approaches under investigation, particular emphasis is placed on therapies based on genetically modified mesenchymal stromal cells (MSCs), regulatory T cells (Tregs) and CAR-T cells for the treatment of inflammatory and autoimmune disorders.

The unit is also developing novel combined immunotherapy strategies for the treatment of head and neck squamous cell carcinoma, brain tumours, and other malignancies characterised by specific genetic rearrangements.

CONTRIBUTIONS TO SOCIETY

In addition to the development of clinical trials, the results of which have been highly encouraging, the Unit conducts preclinical studies focused on novel therapeutic approaches that have led to the designation of orphan medicinal products and the filing of international patent applications. The Unit also collaborates actively with patient organisations, including the Fanconi Anaemia Foundation, the Fanconi Cancer Foundation, FA Europe, and patient associations for Diamond-Blackfan anaemia and pyruvate kinase deficiency in Spain, France, Germany and the United States, as well as the CRIS Cancer Foundation, among others.

COLLABORATIONS

In addition to its participation in the Centre for Biomedical Network Research on Rare Diseases (CIBERER) and the National Network for Advanced Therapies (TERAVplus), the Unit maintains numerous outstanding national and international collaborations with leading academic institution:

Collaborations with National Hospitals for the development of clinical trials: Fundación Jiménez Díaz University Hospital (Dr José Luis López-Lorenzo); Niño Jesús Children's University Hospital, Madrid (Dr J. Sevilla); Vall d'Hebron University Hospital, Barcelona (Dr C. Díaz de Heredia); Sant Joan de Déu Hospital, Barcelona (Dr A. Catalá); Gregorio Marañón University Hospital, Madrid (Dr C. Beléndez); Clinic University of Navarra (Dr F. Prosper); Virgen de la Arrixaca University Hospital, Murcia (Dr José M. Moraleda, Dr José Rivera); University Hospital of Salamanca Dr Sánchez-Guijo, Dr Muntion); Fundación Jiménez Díaz University Hospital (Dr Pilar Llamas, Dr García-Olmo); Virgen del Rocío University Hospital, Seville (Dr Salvador Payan); and La Paz University Hospital, Madrid (Dr Antonio Pérez Martínez).

Collaborations with International Hospitals for the development of clinical trials: Great Ormond Street Hospital and University College London (UCL), United Kingdom (Dr A. Thrasher); Children's Hospital Los Angeles, USA (Dr D. Cohn); Stanford University School of Medicine and Lucile Packard Children's Hospital Stanford, USA (Dr M.G. Roncarolo); and Ann & Robert H. Lurie Children's Hospital of Chicago, USA (Dr Xiao-Nan Li).

National collaborations for Preclinical Research: Autonomous University of Barcelona and Sant Pau Hospital, Barcelona (Dr J. Surrallés); Centre for Applied Medical Research (CIMA), Pamplona (Dr F. Prosper, Dr Purificación Fortes, Dr Marta Alonso); Alberto Sols Biomedical Research Institute (CSIC-UAM), Madrid (Dr R. Perona and Dr Leandro Sastre); Complutense University of Madrid (Dr Juarranz, Dr A. Vicente); Gregorio Marañón University Hospital, Madrid (Dr R. Correa-Rocha and Dr M. Pion); 12 de Octubre University Hospital, Madrid (Dr Joaquín Martínez-López, Dr Gargini, Dr Luis Álvarez-Vallina); BloodGenetics (Dr Mayka Sánchez); ViveBiotech (Dr Marie Fertin); Pompeu Fabra University (Dr Marc Güell); University Hospital of the Canary

Islands, University of La Laguna (Dr Eduardo Salido); University Hospital of Salamanca (Dr Sánchez-Guijo, Dr Muntion); Niño Jesús Children's University Hospital (Dr Manuel Ramírez, Dr África González); IdiPAZ/CNIO Joint Unit of Paediatric Haemato-Oncology (Dr Antonio Pérez Martínez); Carlos III Health Institute (ISCIII), Majadahonda (Dr Javier García Castro, Dr Beatriz Martín-Antonio); University of the Basque Country (Dr J.L. Pedráz); and the University of Murcia/Murcian Institute for Biomedical Research Pascual Parrilla (Dr Javier Corral, Dr María Eugenia de la Morena).


International collaborations for Preclinical Research: Rocket Pharma, USA (Dr Gaurav Shah); Kiji Therapeutics, France-Spain (Dr Miguel Forte); DanausGT Biotechnology (Dr Michael Wang); ETH Zurich (Dr Jacob Corn); Fanconi Cancer Foundation (FCF, USA); H. San Louis (Dr Jean Soulier); Hospital Robert-Debre (Dr Thierry Leblanc); University Medical Centre Freiburg (Dr Charlotte Niemeyer); SR-TIGET de Milán (Dr Luigi Naldini; University of Freiburg, Institute for Transfusion Medicine and Gene Therapy (Dr Toni Cathomen); Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlínico (Dr Paola Bianchi); Harvard University (Dr David R. Liu); University of Minnesota (Dr Branden Moriarity); Fred Hutch Cancer Centre (Hans-Peter Kiem); St. Vincent's Institute Fitzroy (Dr Andrew Deans); Stanford University (Dr Matthew Porteus); Utrecht University Hospital (Dr Richard van Wijk); Revertium Therapeutics (Dr Nidhi Jyotsana and Vishal Suri), Vagelos College – Columbia (Maksim Mamonkin).


DOCTORAL THESIS

BACHELOR'S DEGREE FINAL PROJECTS	MASTER'S DEGREE FINAL PROJECTS	DOCTORAL THESIS	
		IN PROGRESS	*DEFENDED*
0	6	14	1

6.6.5. REGENERATIVE MEDICINE AND TISSUE BIOENGINEERING GROUP







GROUP COMPOSITION

Leaders

Marcela del Río

marcela.delrio@ciemat.es

Fernando Larcher Laguzzi

Fernando.Larcher@ciemat.es

PIs

Marta Carretero Trillo

Rodolfo Murillas Angoiti

Research

Basic and clinical research

LOCATION

Joint Unit of Universidad Carlos III de Madrid-CIEMAT. Regenerative Medicine and Tissue Bioengineering. Avda de la Universidad, 30. 28911 Leganés. Madrid.

KEYWORDS

Skin bioengineering, adult stem cells, epithelial stem cells, mesenchymal stem cells, genome editing, genodermatoses, chronic wounds, drug repurposing, nanomedicine, and aptamers.

SUMMARY OF ACTIVITIES

Among our main research activities are:

- Clinical, pathophysiological, cellular and genetic characterisation of genodermatoses and other skin disorders.
- Tissue bioengineering approaches based on Adult Stem Cells, including Mesenchymal Stem Cells and Epithelial Stem Cells, for skin regeneration.
- Development of cellular and gene therapy strategies, including gene-editing approaches, for the treatment of genodermatoses.
- Development of cellular and gene therapy strategies, including gene-editing approaches, for the treatment of genodermatoses.

CONTRIBUCIONES A LA SOCIEDAD

Over the last four years, the group has disseminated its scientific activity through numerous publications, invited lectures and science outreach events. The group participates in multiple research projects funded through competitive calls, R&D contracts with the pharmaceutical industry, collaborations with patient associations and partnerships with private institutions. During this period, three new patents have been obtained, and the group has participated in two clinical trials in the field of regenerative skin medicine. Particular recognition should be given to the involvement of Group members as advisors to DEBRA Spain (Epidermolysis Bullosa) and the Spanish Association of Patients with Ichthyosis, as well as their participation in EB-Clinet, the international network of Epidermolysis Bullosa centres, the Medical and Scientific Advisory Panel (MSAP) of DEBRA International, and the Executive Committee of the European Society for Dermatological Research (ESDR).

COLLABORATIONS

The Group maintains close collaborations through joint research projects and scientific publications with:


- MEDICAL CENTER- UNIVERSITY OF FREIBURG University Hospital of Freiburg (Freiburg, Germany).
- Leitung Molekulare Dermatologie Leitung Genodermatosen-Sprechstunde UNIVERSITÄTSKLINIKUM FREIBURG. (Germany).
- St John's Institute of Dermatology, King's College London (London, UK).
- IHU IMAGINE –Institut des maladies génétiques. Paris (France).
- Laboratorio di Biologia Molecolare e Cellulare Istituto Dermopatico dell'Immacolata - IRCCS. Rome (Italy).


DOCTORAL THESIS

BACHELOR'S DEGREE FINAL PROJECTS	MASTER'S DEGREE FINAL PROJECTS	DOCTORAL THESIS	
		IN PROGRESS	*DEFENDED*
19	6	6	2

6.6.6. MEDICAL AND SURGICAL INNOVATION ASSOCIATED GROUP







GROUP COMPOSITION

Leaders

Orencio Francisco Bosch Esteva

OBosch@quironsalud.es

Dolores Martínez Pérez

DMartinez@fjd.es

Luis Enrique Muñoz Alameda

LEMunoz@quironsalud.es

Manuel Pérez Márquez

MPerezM@fjd.es

Benjamín Arturo Polo Lorduy

BPolo@fjd.es

Claudio José Rodríguez Fernández

claudio.rodriguez@quironsalud.es

PI

Arnoldo de Jesús Santos Oviedo

Research

Basic and clinical research

LOCATION

Department of Anaesthesiology, Critical Care and Pain Medicine, 3rd floor
Fundación Jiménez Díaz University Hospital.
Avda. Reyes Católicos, 2. 28040 Madrid (Spain).

KEYWORDS

Technology, organisational innovation, automation, surgical management, complexity, efficiency, surgical scheduling, and organisational models.

SUMMARY OF ACTIVITIES

The group focuses on the application of technology to the study of advanced life support in patients with severe multiorgan diseases and on the development of new mechanical ventilation strategies. Research activities also include the analysis of acute haemorrhage using thromboelastographyy, to reduce bleeding and to minimise the use of blood product transfusions. In addition, the group has incorporated ultrasound into both intraoperative and immediate postoperative patient care to assess haemodynamic instability and facilitate prompt diagnosis, enabling the rapid implementation of appropriate therapeutic interventions.

CONTRIBUTIONS TO SOCIETY

All scientific activities conducted by the Medical and Surgical Innovation group are directly aimed at improving patient outcomes and generating benefits for society.

COLLABORATIONS

The Medical and Surgical Innovation group collaborates closely with the New Therapies Research group through the incorporation of computer-assisted analysis for the treatment of facial deformities and for the diagnosis and management of dysphagia. The group also contributes to the development of prognostic tools for chronic hepatitis, acute lung injury and acute kidney injury associated with sepsis.

DOCTORAL THESIS


BACHELOR'S DEGREE FINAL PROJECTS
0

MASTER'S DEGREE FINAL PROJECTS
1

DOCTORAL THESIS	
IN PROGRESS	*DEFENDED*
5	2

6.6.7. NURSING ASSOCIATED GROUP (UAM): EXTRACORPOREAL CIRCULATION AND PERFUSION







GROUP COMPOSITION

Leader

María Eva García Perea

eva.garcia@uam.es

Research

Clinical research

LOCATION:

C/ Arzobispo Morcillo 4, Madrid 28029. Faculty of Medicine UAM

KEYWORDS

Perfusion, advanced practice, extracorporeal membrane oxygenation (ECMO), and ventricular assist devices (VADs).

SUMMARY OF ACTIVITIES

Academic Year 2023-2025 Edition:

Delivered by the Department of Nursing of the Autonomous University of Madrid (UAM) and the Fundación Jiménez Díaz University Hospital Sponsored Chair, the Group has conducted the master's degree in advanced Practice in Extracorporeal Circulation and Perfusion (120 ECTS credits) and the Specialisation Diploma in Advanced Clinical Practice for the Comprehensive Care of Patients on ECMO and/or Ventricular Assist Devices (51 ECTS credits).

These are professional qualifications developed in response to the growing need in Spain for Advanced Practice Nurses specifically trained in Extracorporeal Circulation and Perfusion, as well as in the management of ECMO and ventricular assist devices. In addition to training highly qualified professionals capable of working in Critical Care Units and Cardiac Surgery Operating Theatres, our objective is to promote research in the fields of Perfusion and Extracorporeal Circulation through the Bachelor's and Master's final projects generated within these programmes, fostering the development of new research lines and doctoral theses. We have recently renewed the extension of the collaboration agreement originally signed in 2021 with the Regional Ministry of Health of the Community of Madrid

Comunidad de Madrid · Servicio Madrileño de Salud · UAM Universidad Autónoma de Madrid

ADENDA DE PRÓRROGA AL CONVENIO DE COOPERACIÓN EDUCATIVA ENTRE LA COMUNIDAD DE MADRID, A TRAVÉS DE LA CONSEJERÍA DE SANIDAD, EL SERVICIO MADRILEÑO DE SALUD Y LA UNIVERSIDAD AUTÓNOMA DE MADRID, PARA LA REALIZACIÓN DE PRÁCTICAS DE LOS ALUMNOS DE LA FACULTAD DE MEDICINA DEL "MÁSTER PROPIO DE PRÁCTICA CLÍNICA AVANZADA EN CIRCULACIÓN EXTRACORPÓREA Y PERFUSIÓN" Y DEL "DIPLOMA DE ESPECIALIZACIÓN EN PRÁCTICA AVANZADA EN ATENCIÓN INTEGRAL AL PACIENTE EN ECMO Y/O PORTADOR DE DISPOSITIVOS DE ASISTENCIA VENTRICULAR".

Teaching Venue: The theoretical and practical classes, as well as the clinical seminars, were delivered at the Faculty of Medicine of the Autonomous University of Madrid (UAM).

All preclinical, technical and experimental teaching activities were conducted at the Advanced Clinical Simulation and Training Centre (CEASEC), located within the Experimental Surgery Service of La Paz University Hospital /IdiPAZ. Clinical placements were carried out in the Clinical Teaching Units of the Intensive Care, Postoperative Critical Care and Cardiovascular/Thoracic Surgery Operating Theatre Departments at La Paz University Hospital, La Princesa University Hospital, Puerta de Hierro Majadahonda, Fundación Jiménez Díaz, 12 de Octubre University Hospital, Clínico San Carlos University Hospital, the Central University Hospital of Asturias (HUCA), Leiden University Medical Center (LUMC) in the Netherlands, the Regional Hospital of Northern Honduras, and Germans Trias i Pujol University Hospital (Can Ruti) in Badalona.

To facilitate academic teaching, students from other Spanish autonomous communities are given the opportunity to attend classes remotely via Microsoft Teams. All teaching materials and course documentation are available through the UAM Moodle platform. However, examinations, simulation activities and experimental training are conducted exclusively in person.

To obtain either qualification, students must successfully complete all theoretical modules, the final Objective Structured Clinical Examination (OSCE), the required clinical placements in participating healthcare institutions, and the final Master's or Diploma project.

Results of the 2nd Edition:
In this second edition, 18 students graduated from the master's programme and 12 students completed the Specialist Diploma programme. The maximum number of available scholarships (2.5 scholarships) was awarded.

Among the 18 master's students, five came from different Spanish regions (Seville, Murcia, Valencia, Asturias and Salamanca) and one student came from Honduras. Among the Diploma students, three were from Asturias.

Of the 18 master's students, 40% are already working in hospitals across the Community of Madrid, despite not completing their training until the 31st of October 2025. Among the students enrolled in the Specialist Diploma, 90% are currently working in critical care units.

Graduation Ceremony:
The graduation ceremony was held on October 31st, 2025.

COLLABORATIONS

This programme is endorsed by the Regional Ministry of Health of the Community of Madrid, the Official College of Nursing of Madrid, the Spanish General Council of Nursing, ANDE (Spanish Association of Nursing Directors), CNDE (National Conference of Nursing Deans), and the SCELE (Scientific Society of Nursing).

DOCTORAL THESIS

BACHELOR'S DEGREE FINAL PROJECTS
0

MASTER'S DEGREE FINAL PROJECTS
0

DOCTORAL THESIS	
IN PROGRESS	*DEFENDED*
0	0



7

Research Support **Platforms and Units**

7.1 National and international platforms

RESEARCH SUPPORT PLATFORMS IN HEALTH SCIENCE AND TECHNOLOGY (ISCIII)

Biobanks. Biobanks Network within the Spanish National Health System (PT23/00114). PI: Dr Federico Rojo Todo

Clinical Research Units and Clinical Trials PT23/00119 PI: Lucía Llanos Jiménez SCReN (Spanish Clinical Research Network)

INTERNATIONAL CONSORTIA AND PLATFORMS

In addition, IIS-FJD participates in the following international platforms EATRIS and ECRIN.

7.2 Experimental surgery and preclinical models service (CEMP)

• Staff

HEAD OF UNNIT

Carlos Castilla Reparaz (Categories, A, B, C, D y F; Veterinarian)

SUPERVISOR

Carlos Carnero Guerrero (Categories A, B, C, veterinary Technical Assistant, Supervisor and Biosafety Officer)

SPECIALIST TECHNICIANS

Jessica Baltanás Vargas (Categories A, B and C)

Jennifer Ibáñez Julián (Categories A, B and C)

Rubén Mariscal Ruiz (Categories A, B and C)

Tomás San Narciso García (Categories A, B and C)

Nerea Martínez Herranz (Categories A, B and C)

ACCREDITATION LEVEL

All staff members hold the accreditations required to perform the different functions associated with animal experimentation, recognised at both national and European levels. In addition, they hold the certifications issued by the Spanish Nuclear Safety Council (CSN) for the operation of diagnostic imaging equipment using ionising radiation.

• Functions

This service is divided into two units: the Animal Facility and the Experimental Operating Theatre. Both units provide support services to IIS-FJD.

ANIMAL FACILITY

The Animal Facility is primarily responsible for the housing, breeding and maintenance of the different laboratory animal colonies, as well as for providing researchers with the animals required to carry out their research activities. These animals must be housed under the conditions established by current legislation for each species, using appropriate cages and housing systems maintained under optimal hygienic, sanitary and environmental conditions. The facility has the infrastructure and authorisations required to accommodate rodents (of different strains), lagomorphs, pigs and Danio rerio (zebrafish). Laboratory animals are considered biological reagents and, as such, require appropriate housing and care conditions. This is essential to ensure animal welfare, prevent undesirable biological responses, and avoid obtaining anomalous or unreliable experimental results.

EXPERIMENTAL OPERATING ROOM

The Experimental Operating Theatre works primarily with the Research Division in the development and implementation of the experimental models required for different research lines, as well as in the monitoring of these models and the collection of biological samples.

It also supports training within the surgical departments in:

- New surgical techniques (Departments of Digestive Surgery, Thoracic Surgery, Urology, Orthopaedic Surgery and Traumatology, among others).
- Training and validation in the use of new surgical equipment and devices by medical staff.

In addition, the unit is involved in the design and preparation of a wide range of advanced clinical simulation cases and activities, covering both medical and surgical scenarios.

• Clinical Support Activities

The Animal Facility collaborates in the collection of biological samples from different animal species when required by clinical departments on an occasional basis (for example, Allergy, Microbiology and others).

The Animal Facility and Experimental Operating Room facilities have the infrastructure required for the housing, breeding and maintenance of laboratory animals, fully complying with current legislative requirements. They also provide the necessary resources and facilities to minimise animal suffering and pain during experimental procedures.

The number of animals used, and the species involved depend on the specific requirements of the different research lines being conducted.

ACTIVITY IN THE EXPERIMENTAL OPERATING ROOM (ANNUAL OCCUPANCY)	
Bronchoscopy	Days: 0
General Training	Days: 83
Haematology	Days: 4
Preclinical imaging	Days: 35
Immunology	Days: 63
Lipid laboratory	Days: 12
Microbiology	Days: 7
Nephrology	Days: 156
Pneumology	Days: 0
Neurology	Days: 176
Neuroradiology	Days: 0
Oncology	Days: 7
Otorhinolaryngology	Days: 3
Renal Pathology	Days: 161
Rheumatology	Days: 37
Cell Therapies	Days: 151
Orthopaedic surgery and traumatology	Days: 1
Urology	Days: 3
ICU (Intensive Care Unit)	Days: 1

ANIMAL SPECIES	
MICE (DIFFERENT STRAINS) *	
Anatomical Pathology	Total 30 mice
Companies	Total 0 mice
Haematology	Total 23 mice
Immunology	Total 235 mice
Microbiology	Total 90 mice
Nephrology	Total 900 mice
Pneumology	Total 0 mice
Neurology	Total 481 mice
New Therapies	Total 48 mice
Oncology	Total 500 mice
Vascular Pathology	Total 651 mice
Rheumatology	Total 78 mice
*These figures do not include the breeding of the different rodent colonies	
RATS (DIFFERENT STRAINS)	
Nephrology	Total 0 rats
Neurosurgery	Total 0 rats
New Therapies	Total 0 rats
RABBITS (NEW ZEALAND WHITE RABBITS)	
Immunology	Total 0 rabbits
Microbiology	Total 0 rabbits
Rheumatology	Total 0 rabbits
Traumatology	Total 6 rabbits
PIGS*	
Teaching Activities	Total 5 pigs
Interventional Pneumology	Total 0 pigs
Interventional Neuroradiology	Total 0 pigs
New Therapies	Total 4 pigs
Otorhinolaryngology	Total 3 pigs
Urology	Total 3 pigs
ICU	Total 0 pigs
*For Experimental Surgery programmes. Housing time is kept as short as possible and does not exceed 48 hours.	

• Planned teaching activities (in the HUFJD or the faculty of medicine of the UAM)

Internal Training Programmes

- Course on surgical principles and introduction to microsurgery.
- Course on refinement in anaesthesia and monitoring equipment.
- 2nd laparoscopic surgery course.
- Cervical neck dissection course using a porcine model in otorhinolaryngology.
- Laparoscopic surgery course for urology residents.
- Introduction to research using aquatic models.
- Organisation of continuing education courses for nursing staff.

UAM Training Programme

- Introductory courses in laparoscopic surgery.
- Basic suturing course.
- Vascular anastomosis simulation course.
- Resident physician integration course.
- IPQ course.

External Training Programmes

- Training and specialisation programme for residents in otorhinolaryngology and urology.
- Courses leading to accreditation for Functions A, B and C in animal experimentation for IIS-FJD research personnel and external participants (CEB).
- Fundamentals of cardiovascular and renal research: hospital-based translational research.
- Biomedical sciences degree programme at Alfonso X el Sabio University, within the practical courses of immunopathology (coordinated by Dr Vanesa Esteban) and molecular bases of cardiology (directed by Dr Nerea Méndez-Barbero).
- Advanced mechanical ventilation simulation course (RICU).
- 1st ambulatory surgery course for family physicians.
- 1st ambulatory Surgery course for primary care nursing professionals.

In all teaching activities, the service acts either as co-director or as coordinator of the practical workshop component.

• Biomedical Research (Ongoing and Supported Projects)

Projects supported

During 2025, the following animal experimentation projects were carried out.

DEPARTMENT / RESEARCH GROUP	NUMBER OF AUTHORISED PROCEDURES
ALLERGY AND IMMUNOLOGY	2
ANATOMICAL PATHOLOGY	1
INDUSTRY SPONSORED-RESEARCH	1
HAEMATOLOGY	1
NEW THERAPIES RESEARCH	4
MICROBIOLOGY	2
NEPHROLOGY AND HYPERTENSION, VASCULAR DISEASE AND DIABETES	9
NEUROLOGY	1
MEDICAL ONCOLOGY	3
RHEUMATOLOGY AND BONE METABOLISM	3
TRAUMATOLOGY	1
INTENSIVE CARE UNIT (ICU)	1
TOTAL	**29**

Honours and distinctions

- Authorised Body designated by the Spanish Ministry of Agriculture, Fisheries and Food (MAPA) for the evaluation of research projects.
- Member organisation of COSCE (Confederation of Scientific Societies of Spain).

7.3 Biobank

The Biobank of the Fundación Jiménez Díaz (B-FJD), registered under number B.0000647, is a strategic research support platform within IIS-FJD. Its primary mission is to generate and manage high-value biological sample collections, integrating associated clinical and genomic information to promote translational medicine and facilitate the development of new diagnostic and therapeutic tools.

The B-FJD is characterised by its decentralised and multicentre structure, integrating specialised nodes in Pathology, Genetics, Nephrology, Microbiology, Haematology, Cardiology, Immunology, Rheumatology and Assisted Reproduction, as well as collaborations with other hospitals within the Quirónsalud Group. This organisation enables the optimisation of resources and the provision of highly specialised services to both internal researchers and external institutions and companies.

Since 2009, the Biobank has been part of the ISCIII Biomodels and Biobanks Platform, consolidating its position as one of the leading national reference units in the fields of Precision Medicine and Regenerative Medicine. In the 2023 call for grants supporting R&D&I platforms in Biomedicine, the B-FJD received the highest evaluation among all participating units and was awarded the largest amount of funding, thereby ensuring the sustainability of its activities and the strengthening of its infrastructure.

During 2025, the Biobank's activities focused primarily on three major strategic areas: the development of advanced models in Precision Medicine, research in Regenerative Medicine, and the integration of intelligent analytical tools for the exploitation of clinical and genomic data.

Scientific activity and sample collection

One of the main objectives of the Biobank of the Fundación Jiménez Díaz (B-FJD) during 2025 was to strengthen its strategic value through the collection and release of biological simples, primarily aimed at research in oncology, rare diseases, inflammatory disorders and kidney diseases.

The Biobank currently hosts 20 specialised collections, covering oncological diseases, rare diseases, respiratory disorders, metabolic diseases, and autoimmune and rheumatic conditions. The Pathology and Genetics nodes are particularly noteworthy, as they maintain extensive historical archives of samples linked to routine clinical activity, constituting an essential resource for numerous national and international research projects.

During 2025, nine sample transfers corresponding to eight biomedical research projects were formalised, all of which received approval from the appropriate external ethics and scientific committees. Among the most relevant projects were studies on metastatic colorectal cancer, breast cancer, colon cancer, solid tumours and transplant-associated kidney disease.

A total of 312 samples related to cancer and kidney diseases were released, together with 1,254 samples for research on rare and complex diseases. These transfers supported research lines focused on molecular biomarkers, liquid biopsy, personalised treatment response and mechanisms of therapeutic resistance.

In parallel, the B-FJD continued its efforts to integrate clinical and genomic information associated with biological samples. To this end, algorithms were developed to analyse unstructured clinical information extracted from electronic health records, facilitating the identification of patients with specific characteristics required for complex research projects.

In this context, one of the most significant developments of 2025 was the initiation of the implementation of the "Atlas Biobanco" software platform, developed by DBsoft. This system will substantially improve the management and traceability of biological samples by automating processes related to informed consent management, sample storage, advanced sample searching and access control. Deployment began in October 2025, and the platform is expected to become fully operational in 2026.

Innovation, Knowledge Transfer and Service Provision

The Biobank of the Fundación Jiménez Díaz maintains an extensive collaborative network with biotechnology companies and innovation groups, promoting the transfer of knowledge into both clinical practice and the commercial sector.

During 2025, biological samples were provided to companies such as Sysmex Corporation Inc., Vitro S.A., Inbiomotion S.L., and HAWK Biosystems, strengthening public-private partnerships in projects related to personalised medicine, biomarkers and novel diagnostic technologies.

In addition, IIS-FJD currently maintains 51 active patents across different areas of biomedical research, including nephrology, immunology, microbiology, advanced therapies, regenerative medicine and rare disease genetics. These patents cover a broad range of innovations, from diagnostic biomarkers to gene therapies and new medical devices.

Another key component of the B-FJD's activity is the provision of specialised services to researchers and clinical trials. During 2025, the Biobank participated as a central laboratory in several national and international multicentre clinical trials and research projects, including:

- The MATRIX trial, focused on anthracycline-related cardiotoxicity.
- The MADRID-COVID study, addressing respiratory distress associated with COVID-19.

- he Co-THEIA trial on non-infectious uveitis.
- The international MSK-ACCESS project, focused on liquid biopsy and genomic cancer analysis.
- The incorporation of B-FJD into the European BileBank project for the development of a functional bile repository.

In addition to sample management and storage, the Biobank provided advanced services including automated immunohistochemistry, fluorescence in situ hybridisation (FISH), next-generation sequencing (NGS), digital pathology imaging and the generation of tissue microarrays.

Sample storage activity also remained highly significant, including the preservation of more than 3,300 aliquots of plasma, serum and whole blood from oncology patients, as well as breast cancer samples with ESR1 gene determination.

The B-FJD also continues to serve as the headquarters of the GEICAM Biobank, specialised in breast cancer research, providing molecular analysis, sequencing and histopathological assessment services for numerous cooperative research projects.

Development of biomodels and regenerative medicine

One of the areas which shows the greatest growth during 2025 was the development of new tools for Precision Medicine, particularly patient-derived xenograft (PDX) models and tumour organoids.

During the year, 108 PDX models were established from different tumour types, including colon, breast, lung, bladder, liver, prostate and brain cancers, as well as sarcomas. These models enable the study of treatment resistance mechanisms and the evaluation of new antitumour therapies in experimental settings that closely recapitulate human disease.

In parallel, the B-FJD promoted the generation of patient-derived colorectal cancer organoids. Among the 12 patients recruited, organoids were successfully generated in 11 cases, together with tumour-associated fibroblasts and normal fibroblasts. These models represent valuable tools for translational research and the development of personalised therapeutic approaches.

In the field of Regenerative Medicine, the Biobank continued to expand its repository of human adipose tissue-derived mesenchymal stromal cells (MSCs). The repository currently contains 12 stable cell lines, and additional human and porcine cell lines were developed during 2025.

Furthermore, progress was made in the cryopreservation of stem cell-derived secretomes and in the generation of hepatocellular carcinoma cell lines. The development of murine avatar models derived from pancreatic, colorectal and liver tumours was also initiated, with the aim of improving preclinical studies and enabling more personalised treatment evaluation.

Dissemination, Quality and Institutional Outreach

The Biobank of the Fundación Jiménez Díaz (B-FJD) maintains a strong commitment to scientific outreach and public engagement, targeting researchers, patients and the wider community.

In February 2025, the B-FJD organised the first Outreach Workshop on the Role of Biobanks in Cancer Research at Fundación Jiménez Díaz University Hospital. The event was aimed at patients and their relatives and sought to raise awareness of the Biobank's activities and the process of biological sample donation, with particular emphasis on regulatory and ethical aspects. The workshop featured oncologists, molecular biologists and Biobank staff, who provided a comprehensive overview of the importance of biological samples in biomedical research. The event concluded with a round-table discussion in which participants were

able to address questions and concerns raised by attendees. Held in the Aula Magna of Fundación Jiménez Díaz, the event attracted approximately 50 participants, both in person and online. As a result of this initiative, new collaborations were established with several patient associations, particularly through participation in AMOHapp, organised by the Hereditary Breast and Ovarian Cancer Association.

The B-FJD also participates annually in the meetings organised by the ISCIII Platform, contributing actively through oral presentations and scientific posters. At the end of the year, the Platform coordination team requested activity data from all participating biobanks for 2025, and the B-FJD provided the requested information. In addition, the Biobank submits annual surveys and activity reports, thereby contributing to the development and updating of scientific and technical information within the Platform and disseminating this information among IIS-FJD researchers.

During 2025, the B-FJD participated in the third ISCIII Platforms Conference, held in Salamanca, contributing two poster presentations that were selected for exhibition and dissemination:

1. The 1st outreach workshop on the role of biobanks in cancer research at Fundación Jiménez Díaz University Hospital: A pioneering meeting point for patients, families, researchers and healthcare professionals.
2. PDX Models in Translational Oncology: The contribution of the Biobank of the Fundación Jiménez Díaz.

In terms of scientific output, 22 publications arising from B-FJD activities were produced during 2025, of which 11 explicitly acknowledged the Biobank, with an average impact factor of 6.36.

From an organisational perspective, the B-FJD has maintained ISO 9001:2015 certification since 2022 and, during 2025, continued preparations towards achieving ISO 20387 accreditation, the international standard specifically designed for biobanks. The Biobank also continued advancing the integration of information management and traceability systems with the hospital's corporate platforms.

Finally, the B-FJD participated in inter-laboratory comparison exercises organised by the Spanish National DNA Bank to assess the quality of procedures related to DNA and RNA processing. The Biobank achieved satisfactory results, confirming the high technical quality and reliability of its procedures.

Overall, the 2025 Annual Report reflects the continued consolidation of the Biobank of the Fundación Jiménez Díaz as a leading biomedical research infrastructure, distinguished by its advanced technological capabilities, commitment to innovation, and significant contribution to the development of Precision Medicine and Regenerative Medicine.

7.4 Genomics and Proteomics Units

Genomics Unit

The Genomics Unit currently comprises five technology platforms equipped with the following instrumentation:

Nucleic Acid Extraction and Quality Control Platform:

- 2 DNA extraction systems (Qiagen Bio-Robot EZ-1), located in the Neurology Laboratory and the shared Immunology Laboratory, 4th Floor.
- 1 automated electrophoresis system (TapeStation 4200, Agilent), located in the Genetics Laboratory, 4th Floor.

Real-Time PCR and Sanger Sequencing Platform:

- 2 rapid quantitative PCR systems (7500 and 7500 Fast Real-Time PCR, Applied Biosystems), located in the shared laboratory facility, 4th Floor.
- 1 LightCycler 96 (Roche) located in the shared laboratory facility, 4th Floor.
- 2 automated sequencers with 16 and 48 capillaries (3130xl Genetic Analyzer and 3730 Genetic Analyzer, Applied Biosystems), located in the Genetics Laboratory, 2nd Floor.

Next-Generation Sequencing (NGS) Platform:

- 1 high-throughput sequencer (Illumina NextSeq 500), located in the Genetics Laboratory, 4th Floor
- 1 high-throughput sequencer (Illumina NextSeq 2000), located in the Genetics Laboratory, 4th Floor.

Array CGH Platform:

- 1 hybridisation oven and one Agilent SureScan Array CGH scanner, located in the Genetics Laboratory, 4th Floor.

Digital PCR Platform:

- 1 digital PCR system (Bio-Rad QX200), located in the Genetics Laboratory, 4th Floor.

The Genomics Area currently includes two research support technicians and one senior technical specialist responsible for certification and quality management processes.

The unit contributes to:

- Integrating basic research, particularly functional genomics, with translational applications through the development, validation and harmonisation of diagnostic techniques and the identification of new therapeutic targets.
- Identifying genes involved in disease processes and their interactions with environmental factors to achieve more accurate and personalised genetic diagnoses and more effective treatments.
- Implementing monitoring systems capable of assessing disease severity.
- Identifying new genes and loci involved in hereditary human diseases, enabling the development of more sensitive and efficient diagnostic algorithms for genetic characterisation and genetic counselling.
- Improving knowledge of the epidemiology, causes and mechanisms involved in the development of rare and common diseases of genetic origin.
- Implementing next-generation sequencing (NGS) technologies, carrying out their analytical and clinical validation, and developing new diagnostic algorithms applicable to genetically heterogeneous and complex disorders.

Summary of unit activity:

Genomics Platform	No. of requests
Use of equipment	918

Use of equipment by Research Group:

	Lipid Disorders: Clinical and Experimental (Adults and Children)	Haematology	Anatomical Pathology	Genetics and Genomics of Rare and Complex Diseases	Allergy and Immunology	New Therapies	Others (Microbiology, Nephrology, Oncology, etc.)
1. NextSeq500	2	119	29	11	3	0	0
2. NextSeq2000	0	0	0	52	0	0	0
3. Secuenciador Abi3130	0	141	77	245	0	0	0
4. TapeStation 4200	0	98	0	78	6	0	5
5. PCRdd	0	0	0	5	0	47	0

Proteomics Unit

The IIS-FJD Proteomics Unit is equipped with an integrated nano/micro HPLC system (1200 Series) for proteomic and metabolomic analyses. It includes multidimensional liquid chromatography capabilities for the separation of complex biological samples containing peptides, proteins and/or metabolites. The platform consists of a modular system incorporating an autosampler for automated sample analysis and mass spectrometry detection using a triple quadrupole mass spectrometer (MS-QQQ) equipped with ChipCube and JetStream interfaces. The MS-QQQ instrumentation is designed for targeted analysis using Selected Reaction Monitoring (SRM), enabling differential quantification and analysis of proteins and metabolites of interest.

The Unit contributes to:

- Establishing new research lines focused on biomarkers and metabolic pathways associated with disease development.
- Functional analysis and validation of diagnostic, prognostic and predictive biomarkers.
- Advancing the study of molecular alterations.
- Developing analytical methodologies for quantitative targeted mass spectrometry.

7.5 Cell Biology Unit: confocal microscopy and flow cytometry

The applications of flow cytometry, cell sorting and confocal microscopy are highly diverse and encompass fields ranging from biomedical research to food science and materials research. Thanks to the continuous development of new fluorescent probes and detection systems, the range of applications and areas of study continues to expand. At IIS-FJD, within the field of biomedicine, these technologies enable three-dimensional studies of tissue sections and whole-mount preparations, co-localisation analyses using fluorescent

probes, tracking of molecules and ions in living or fixed cells, as well as measurements of cells, organelles and volumetric parameter.

The functions carried out by the unit include:

- Maintenance and calibration of the unit's equipment.
- Management of equipment usage, accounting and billing procedures.
- Training courses and supervision in the use of analytical flow cytometry equipment.
- Maintenance and distribution of commonly used reagents for flow cytometry and cell sorting applications.
- Sample acquisition using FACScalibur, FACSCanto and FACSMelody instruments.
- Analysis of results using specialised software packages.
- Technical advice on complex methodologies and protocols, including the selection of appropriate fluorochromes for different assays and suitable culture substrates for specific cell types.
- Guidance in the design and optimisation of templates for flow cytometers and cell sorters.
- Reconstruction and analysis of multicolour and three-dimensional images using specialised software.
- Liaison between researchers and the application support services provided by equipment manufacturers.

The IIS-FJD is equipped with a flow cytometer, a cell sorter and a Leica confocal microscope, which currently represent some of the most important and widely used institutional research infrastructures available at the Institute.

Cytometers: The Unit operates a FACSCanto II digital flow cytometer (Becton Dickinson) equipped with two lasers and four fluorescence detectors. It is a multicolour analysis system with fully digital data acquisition and processing capabilities, designed for both clinical and research applications. The instrument is equipped with updated acquisition and analysis software, as well as a module that allows the incorporation of automated sample acquisition systems from either tubes or microplates, significantly reducing hands-on time and increasing efficiency for researchers.

Common applications of flow cytometry:

- Immunophenotyping.
- Cell cycle analysis.
- Reporter gene assays.
- Measurement of cell proliferation.
- Apoptosis analysis.
- Calcium flux assays.
- Intracellular signalling studies, including single-cell phosphoprotein detection.
- Multiplex assays for the detection of soluble molecules.

Cell Sorters: The Unit operates a FACSMelody cell sorter (Becton Dickinson), equipped with three lasers (blue, red and violet) and eight fluorescence detectors. This instrument enables the physical separation of particles and cell populations based on the differential expression of one or more parameters measurable by analytical flow cytometry. The sorter is equipped with updated acquisition and analysis software that supports automated sample processing from both tubes and microplates.

Common applications of the cell sorter:

- Isolation of specific cell populations.
- Sorting of viable cells for subsequent cell culture.
- Sorting of fixed cells for downstream genetic analyses.
- Cell cloning applications.

Confocal Microscopes: Confocal microscopy is a branch of optical microscopy, specifically fluorescence microscopy. The development of new fluorescent probes, together with the increased resolution provided by confocal microscopy, has made fluorescence one of the most widely used techniques in biomedical research. The combination of image acquisition in the focal plane and specialised software allows the confocal microscope to function as an optical microtome, enabling the acquisition of optical sections of samples and forming the basis for three-dimensional image reconstruction.

Of the two confocal microscopes available, the most frequently used, owing to its more advanced capabilities, is the Leica TCS SP5 confocal microscope, which meets most confocal microscopy requirements and provides optimal results across a wide range of applications. The system offers a full range of scanning speeds while maintaining high-resolution image acquisition. It is equipped with spectral detectors (SP; up to five simultaneous channels), a tandem scanning system (conventional and resonant scanning for high-speed image acquisition), and an AOBS (Acousto-Optical Beam Splitter) system for dynamic light separation. The TCS SP5 generates bright, low-noise images while minimising sample damage. The microscope is equipped with the following excitation laser lines: 405 nm, 458 nm, 476 nm, 488 nm, 496 nm, 514 nm, 561 nm, 594 nm and 633 nm.

The microscope is based on a Leica DMI6000 inverted platform, fully automated and equipped with a motorised stage, temperature-controlled incubation chamber and CO supply system, allowing live-cell imaging under controlled environmental conditions. For illumination, the system incorporates a Leica EL6000 fluorescence light source for fluorescence imaging, as well as transmitted light illumination for bright-field and differential interference contrast (DIC) microscopy.

To visualise the sample, the system is equipped with the following filter sets:

- A (UV excitation BP 340-380; emission LP 425) for Alexa 405, DAPI and related fluorochromes.
- I3 (blue excitation BP 450-490; emission LP 515) for FITC, Cy2 and related fluorochromes.
- N2.1 (green excitation BP 515-560; emission LP 590) for TRITC, Cy3 and related fluorochromes.
- L5 (excitation 480/40; emission 527/30), a more restrictive filter than the I3 filter.

The objectives available on this system are:

- HC PL APO CS 10X/0.4 DRY.
- HCX PL APO 20X/0.7 IMM (water or oil immersion).
- HCX PL APO CS 40X/1.25 OIL.
- HCX PL APO lambda blue 63X/ 1.4 OIL (with enhanced chromatic correction in the blue wavelength range).
- HCX PL APO CS 100X/1.4 OIL.
- HCX PL APO CS 63X/1.3 GLYC 21 °C (working distance of 280 µm for thick samples at 21°C).

Applications:

- Acquisition of serial image stacks.
- Three-dimensional reconstruction of the structures under study, including skin and other tissues.
- Co-localisation analysis of molecular markers.
- Lateral and orthogonal views of specimens.
- Endocytosis studies.
- Superimposition of images acquired using different techniques.
- Time-lapse microscopy. The observation of living cells by confocal fluorescence microscopy enables the intracellular tracking of fluorescent molecules over time.

7.6 Cell Culture Unit

This is an external service established under the agreement signed in December 2013 between CIEMAT, through the Division of Innovative Therapies in the Haematopoietic System (DTISH), and IIS-FJD for the creation of a Joint Advanced Therapies Unit.

- **General Objective of the Unit:** To promote high-impact research activities between the DTISH at CIEMAT and IIS-FJD, focused on the development and application of advanced therapies for diseases that are difficult to treat using currently available therapeutic approaches.
- **Activities:** These activities are carried out through the combined involvement of CIEMAT research personnel and IIS-FJD contributions, together with the use of the facilities available within the DTISH building at CIEMAT. These facilities include a cell culture area comprising a Biosafety Level 2 laboratory, a high-containment laboratory to produce viral vectors, and a GMP facility accredited by the Spanish Agency of Medicines and Medical Devices (AEMPS) for the manufacture of Advanced Therapy Medicinal Products (ATMPs). The cell culture area is equipped with 12 biological safety cabinets, 12 incubators, microscopes, centrifuges, cell counters, electroporators, and other specialised laboratory equipment.
- **Staff:** The person responsible for this Unit on behalf of IIS-FJD is Juan Antonio Bueren Roncero.

7.7 Biostatistics and Epidemiology Unit

Functions and Objectives

The Biostatistics and Epidemiology Unit provides methodological and statistical support to healthcare professionals and researchers from IIS-FJD and affiliated hospitals, collaborating across all stages of the research process, including study design, methodological planning, data analysis, interpretation of results, scientific dissemination and training.

Service Portfolio

Study design and planning

- Advice on the selection of the most appropriate study design.
- Sample size and/or statistical power calculations.

- Preparation of statistical analysis plans.
- Definition of variables and strategies for data collection and data preparation.
- Generation of randomisation lists.

Statistical Analysis and Research Dissemination

- Data cleaning and statistical analysis.
- Interpretation of results.
- Preparation of tables, figures and summary reports.
- Support in drafting the statistical methods section of scientific publications and research reports.

Teaching

- Courses on research methodology and statistical analysis aimed at healthcare professionals and researchers.
- Participation in postgraduate teaching programmes
- Methodological support for bachelor's degree Final Projects (TFG), master's degree Final Projects (TFM) and doctoral theses.

Staff

Head of Unit: Ignacio Mahíllo Fernández, MSc, PhD

Collaborator: Rafael Dal-Ré, MD, PhD, MPH

Researcher consultations supported by the Unit

Department	Fundación Jiménez Díaz University Hospital	Infanta Elena University Hospital	Rey Juan Carlos University Hospital	General de Villalba University Hospital	Total
Allergy	4				4
Clinical analysis	1				1
Anaesthesiology	1				1
Cardiology	13				13
General and Digestive Surgery	14				14
Vascular Surgery	1				1
Palliative Care	3				3
Dermatology	2				2
Infectious Diseases	2				2
School of Nursing	1				1
Pharmacy	6				6
Genetics	6				6
Geriatrics	1				1

Department	Fundación Jiménez Díaz University Hospital	Infanta Elena University Hospital	Rey Juan Carlos University Hospital	General de Villalba University Hospital	Total
Gynaecology	7				7
Haematology	27				27
Immunology	12				12
Lipid Laboratory	2				2
New Therapies Laboratory	1				1
Family Medicine	2				2
Internal Medicine	5		1		6
Nephrology	4				4
Pneumology	3				3
Neurology	5				5
Ophthalmology	8		1		9
Oncology	4				4
Orthodontics	1				1
Otorhinolaryngology	1				1
Paediatrics	2			5	7
Rehabilitation	5	1			6
Occupational Health	1				1
Traumatology	10			1	11
Emergency Medicine	1				1
Urology	10				9
TOTAL	**166**	**1**	**2**	**6**	**175**

Planned teaching activities (in the HUFJD or in the Faculty of Medicine of the UAM)

MASTER'S DEGREE IN ADVANCED CARE OF PATIENTS IN ANAESTHESIA, CRITICAL CARE AND PAIN MANAGEMENT			
Course Module	**Venue**	**Month**	**Teaching Hours**
Quantitative Research Methodology	HUFJD	January-February	21

BIOSTATISTICS COURSES DELIVERED			
Course Module	**Venue**	**Month**	**Teaching Hours**
Fundamentals of Biostatistics	HUFJD	May	12
Biostatistics I	HUFJD	June	6
Biostatistics II	HUFJD	November-December	6

CO-SUPERVISION OF DOCTORAL THESES		
PhD Candidate	**Thesis Title**	**Status**
Pamela Turrillas Villagra	External Validation of the NECPAL 4.0 Prognostic Model in the Home Care Programme for People with Severe Dependency within the Primary Healthcare Network in Chile: A Mixed-Methods Study	Third Year

Scientific Output

Publication Summary 2025

Total	D1	Q1	Q2	NO IF	Mean IF	Cumulative
27	1	16	8	0	3.54	95.6

7.8 Clinical Research and Clinical Trials Unit (UICEC)

Staff: UICEC Group

Head of unit: Lucía Llanos Jiménez

Project management and monitoring: Mireia Arcas Tomeo (Coordinadora)

Isabel Villalba Juárez

Eva Cerezo Martín

Study Coordinators / Data Entry: Rocío Cortés García

Sara Hernández Recio

Andrea Martínez Ramas (outgoing member)

Clinical Research Nurses: Iris Moreno Viera

Angelina Mercedes Shmyhelska Shmyhelskyy

Sarai Urbiola Sarasola (outgoing member)

The UICEC-FJD is integrated within the ISCIII Platform for Clinical Research Support, funded by the Carlos III Institute of Health (ISCIII) through successive calls of the Strategic Action in Health programme. The Unit was initially funded under the State Programme for Research Oriented towards Societal Challenges within the National Plan for Scientific and Technical Research and Innovation 2013-2016 (PT13/0002/0019), renewed in 2017 (PT17/0017/0022), subsequently supported through the ISCIII Platforms for R&D&I Support in Biomedicine and Health Sciences (PT20/00142), and most recently funded under grant PT23/00119 for the 2024-2026 period. Consequently, the UICEC-FJD will continue to be part of the ISCIII Platform for Clinical Research Support.

GOBIERNO DE ESPAÑA
MINISTERIO DE CIENCIA, INNOVACIÓN Y UNIVERSIDADES
Instituto de Salud Carlos III
Unión Europea
Fondo Europeo de Desarrollo Regional
"Una manera de hacer Europa"


The Clinical Research and Clinical Trials Unit (UICEC-FJD) has the following main functions:

- To collaborate with any Institute researcher who requests support for the development of independent research projects or non-commercial sponsor studies. To this end, the unit provides scientific, methodological, ethical and legal, clinical (medical and nursing), and logistical support services, tailored to the specific needs and available resources of each project.
- To support commercial research, primarily clinical trials but also studies using other research designs to streamline and facilitate their implementation within our Institution. This support helps ensure that research projects are conducted efficiently and that their results are generated to the highest quality standards and within the shortest possible timeframe.

SUMMARY OF ACTIVITITIES

During 2025, the Unit maintained the high level of activity achieved in recent years. A total of 163 studies received support, including 33 newly initiated studies:

- 129 industry-sponsored studies, supported according to their specific needs in activities such as study start-up, study coordination, data entry, nursing procedures and biological sample management.
- 34 investigator-initiated studies, supported according to project requirements through scientific advice, project management and development, and/or monitoring activities.



Of the 163 studies supported by the Unit, more than 50% were conducted by the Departments of Haematology and Nephrology, although the Unit collaborates with a total of 16 hospital departments. A detailed breakdown of activity by department is provided in the summary activity table below.

The unit also provided more limited methodological support to approximately 30 independent research projects through consultation and advisory activities related to study conception and design, protocol de-

velopment, submission to Ethics Committees, responses to requests for clarification, and the preparation of research proposals for submission to public and private funding calls.

The UICEC also actively participates in other IIS-FJD research activities, including:

- Scientific advisory support for IIS-FJD-associated research groups.
- Membership of the IIS-FJD Research Committee.
- Head of the Technical Secretariat of the FJD Research Ethics Committee (CEIm/CEI-FJD).
- Secretariat of the IIS-FJD Scientific Integrity Committee.
- Management of user registration for study registration on www.clinicaltrials.gov
- Biennial organisation of, and participation as faculty in, the IIS-FJD Good Research Practice Course
- During 2025, the Unit participated in the organisation and teaching of the following activities:
    - In May 2025: Good clinical practice course for IIS-FJD investigators, delivered in a blended-learning format. A total of 76 participants attended, and 26 completed the satisfaction survey, with 25 of the 26 respondents awarding the maximum overall rating of 4/4.
    - On December 10th, 2025: tenth edition of the workshop "Bringing Science Closer to Schools: Clinical Research in Rare Diseases", aimed at upper secondary school students, with the participation of approximately 250 students from six secondary schools. The 2025 edition marked the 10th anniversary of this initiative, organised in collaboration with Farmaindustria-I.
    - Clinical teaching collaborator in the fifth year of the medical degree programme at the Autonomous University of Madrid (UAM) during the 2024-2025 academic year. Appointed Associate Professor in Health Sciences affiliated with Fundación Jiménez Díaz from the 2025-2026 academic year onwards, delivering theoretical and practical teaching in clinical and experimental research (first semester) and clinical pharmacology (second semester).
    - Faculty member in the master's degree in clinical trial monitoring and coordination, organised by the Teófilo Hernando Foundation (UAM own degree programme). 3 teaching hours.
    - Faculty member in the master's degree in advanced care of the patient in anaesthesia, critical care and pain management, Fundación Jiménez Díaz-UAM School of Nursing. 1 teaching hour.

SCIENTIFIC OUTPUT

PRESENTATIONS AND COMMUNICATIONS AT CONGRESSES AND OTHER SCIENTIFIC MEETINGS

International Congresses

Phase 2A Multicenter Clinical Trial To Determine The Feasibility And Safety Of The Use Of Adipose-Derived Mesenchymal Stem Cells (Asc) In The Treatment Of Patients With Cicatricial Conjunctivitis (ESCRS25-FP-2911). Nicolas Alejandre, Mariano García Arranz, Lucía LLanos, Eva Cerezo, Ignacio Mahillo, and David Galarreta on behalf of CELOPHIN. 43rd Congress of the ESCRS. Copenhagen, September 2025.

National Congresses and Invited Lectures

Phase IIa multicenter clinical trial to determine the feasibility and safety of the use of adipose-derived mesenchymal stem cells (ASC) in patients with cicatricial conjunctivitis. Nicolás Alejandre, Mariano

Garcia-Arranz, Lucía Llanos, Mª Eugenia Fernández, Ignacio Jiménez Alfaro, Damián García Olmo. Poster presentation at the Annual Meeting of the Spanish Network for Advanced Therapies (RICORS/TERAV), Alicante, Spain, 20-21 November 2025.

Principles of Mesenchymal stromal cell (MSC) therapy. Applications in Critical Limb Ischemia. Invited lecture delivered by Dr Mariano García Arranz, presenting the results of the NOMA and CELOPHIN clinical trials, coordinated by UICEC within SCReN. 19th Summer Course "Advanced Therapies: Scientific Basis and Clinical Applications", Murcia, Spain, From 2nd to 4th of July 2025.

PUBLICATIONS

The total of publications generated during 2025 was 2, including 1 publication indexed in PubMed and a cumulative impact factor of 6.

PROJECTS

Among the 34 investigator-initiated projects supported during 2025, the following 21 projects received competitive public funding at either national or international level. The list includes projects where IIS-FJD acts as sponsor as well as collaborative studies in which IIS-FJD participates, indicating the corresponding Principal Investigator at our institution:

1. No-More-Amputations Carlos III Health Institute (ISCIII; PIC18/00010), Independent Clinical Trials in Advanced Therapies Programme. Sponsor: IIS-FJD. Principal Investigator: Damián García Olmo.

2. Phase 2a multicentre clinical trial to assess the feasibility and safety of adipose tissue-derived mesenchymal stem cells (ASCs) for the treatment of cicatricial conjunctivitis associated with Lyell syndrome, Stevens-Johnson syndrome and ocular mucous membrane pemphigoid. CELOPHIN Study. Funded by the Carlos III Health Institute (ICI21/00060). Sponsor: IIS-FJD. Principal Investigator: Nicolás Alejandre Alba.

3. Phase IIa clinical trial to evaluate the safety and efficacy of treatment with allogeneic adipose-derived mesenchymal stem cells in patients with a single inflammatory stricture associated with Crohn's disease. FJD-MEIC-21-01. Funded by the Carlos III Health Institute (ICI21/00038). Sponsor: IIS-FJD. Principal Investigator: María Dolores Herreros Marcos.

4. ARTROCELL. Phase III, multicentre, randomised, open-label clinical trial comparing treatment with allogeneic mesenchymal stem cells, autologous mesenchymal stem cells, and an active control with hyaluronic acid in patients with knee osteoarthritis. Funded by the Carlos III Health Institute (PIC18/00001). Sponsor: Foundation Institute of Health Sciences Studies of Castilla y León (IECSCYL) - Salamanca Biomedical Research Institute (IBSAL). Principal Investigator at IIS-FJD: Emilio Calvo Crespo.

5. Tradol-PriME. Randomised clinical trial evaluating the utility of CYP2D6 genotyping to improve the efficacy and safety of tramadol in the treatment of acute postoperative pain. Funded by the Carlos III Health Institute (ICI20/00131). Sponsor: Biomedical Research Foundation of La Princesa University Hospital. Principal Investigators at IIS-FJD: Dolores Martínez Pérez and Lucía Llanos Jiménez.

6. FOVOCIP: A multicentre, randomised clinical trial comparing fosfomycin versus ciprofloxacin for the treatment of febrile neutropenia in haematological patients: efficacy and microbiological safety. Sponsor: Foundation for Biomedical Research and Innovation of the Principality of Asturias (FINBA). Funded by the Carlos III Health Institute (ISCIII, ICI Programme). Principal Investigator at IIS-FJD: Laura Solán Blanco.

7. Longitudinal study of the evolution and factors associated with Vision-Related and Health-Related Quality of Life in subjects with non-infectious uveitis. Sponsor: Biomedical Research Foundation of Hospital Clínico San Carlos. Funded by the Carlos III Health Institute (PI20/01221). Principal Investigator at IIS-FJD: Inés Hernanz Rodríguez.

8. SPAREKID: Multi-markers Risk Assessment

of Kidney Sensitivity to Injury to Personalise Prevention of Acute Kidney Injury. Principal Investigator: Alberto Ortiz. European funding programme: ERAPerMed. ISCIII call: AES 2022 International Collaboration Projects. ISCIII Reference: AC22/00027. Duration: 3 years (01/01/2023-31/12/2025).

9. SIGNAL: Body fluid proteome SIGnatures for persoNALised intervention to prevent cardiovascular and renal complications in diabetes. Investigator at IIS-FJD: Beatriz Fernández. European funding programme: ERAPerMed. ISCIII call: AES 2022 International Collaboration Projects. ISCIII Reference: AC22/00028. Duration: 3 years (01/05/2023-30/04/2026).

10. ALOFEC-2019. Phase IIb multicentre, randomised, double-blind clinical trial to evaluate the safety and efficacy of intralesional administration of two doses of expanded allogeneic adipose tissue-derived mesenchymal stem cells (AD-MSCs), embedded in a hyaluronic acid hydrogel, for the treatment of patients with faecal incontinence. Funded by the Carlos III Health Institute (ICI19/00027). Sponsor: Andalusian Public Foundation for Biomedical Research in Málaga (FIMABIS). Principal Investigator at IIS-FJD: Dolores Herreros Marcos.

11. EARLY-GENE: Early treatment with candesartan versus placebo in asymptomatic carriers of genetic variants associated with dilated cardiomyopathy (DCM) (EARLY-GENE trial). Sponsor: Biomedical Research Foundation of Puerta de Hierro Majadahonda University Hospital. Funded by the Carlos III Health Institute (ISCIII; ICI21/00044). 2022-2025. Principal Investigator at IIS-FJD: José Manuel Rubio Campal.

12. DURATIOM: Phase III, multicentre, randomised, open-label, pragmatic clinical trial evaluating the efficacy and safety of different durations of antimicrobial treatment for fracture-related orthopaedic implant-associated infections following long-bone fractures. Funded by the Carlos III Health Institute (ISCIII; ICI21/00014). 2022-2025. Sponsor: Foundation for Health Research Management of Seville (FISEVI). Principal Investigator at IIS-FJD: Antonio Blanco.

13. COLCHIREN Study: Efficacy of colchicine in the secondary prevention of vascular events and renal disease progression in patients with moderate chronic kidney disease. Funded by the Carlos III Health Institute (ISCIII). Sponsor: Biomedical Research Foundation of Gregorio Marañón University Hospital I (FIBHGM).

14. DiagnoLung Dx: Development and validation of a predictive model for the early diagnosis of lung cancer based on molecular biomarkers, imaging and risk factors using Big Data tools through a multicentre observational study. RETOS Programme (RETOS C005_00152799). Sponsor: AMADIX. Principal Investigator at IIS-FJD: María Jesús Rodríguez Nieto.

15. National multicentre Phase I-IIa clinical trial to evaluate the safety and preliminary efficacy of CD19 CAR-T cell therapy in patients with refractory lupus nephritis. Funded by the Carlos III Health Institute (ISCIII; ICI24/00034). 2025-2028. Sponsor: IIS-FJD. Principal Investigator: Alberto Ortiz.

16. SHORTEN-2: Efficacy and safety of 7 versus 14 days of antibiotic therapy for Pseudomonas aeruginosa bacteraemia: a multicentre, randomised clinical trial with a DOOR/RADAR analysis. Funded by the Carlos III Health Institute (ISCIII; ICI21/00075). Sponsor: Foundation for Health Research Management of Seville (FISEVI). Principal Investigator at IIS-FJD: Elizabet Petkova.

17. GENERA: Developing an Accessible Gene-Editing Treatment for Hereditary Anaemias. RETOS Programme (PID2023-152564OB-I00). Sponsor: CIEMAT. Principal Investigator at IIS-FJD: José Luis López Lorenzo.

18. ranspoCART19 Study: Multicentre Phase I/IIa study of the infusion of genetically modified autologous peripheral blood T lymphocytes expanded ex vivo using Sleeping Beauty transposon technology to express an anti-CD19 chimeric antigen receptor (CAR) incorporating the 4-1BB co-stimulatory domain, CD3 signalling domain and huEGFRt. The study is being conducted in patients with relapsed or refractory B-cell lymphoma. Sponsor: IDISNA (ICI19/00069). Principal Investigator at IIS-FJD: Dr Javier Cornago.

19. SIGNAL Study: Feasibility of using urinary proteomic profiles to personalise treatment strategies aimed at preventing cardiovascular and

renal complications in individuals with type 2 diabetes. This study is part of the European SIGNAL project (ISCIII Reference: AC22/00028). Sponsor: Steno Diabetes Center. Principal Investigator at IIS-FJD: Dr Beatriz Fernández. UICEC-FJD is responsible for project management and monitoring activities at our institution.

20. 2G-MSC-GVHD Study: Phase I/II clinical trial for the treatment of graft-versus-host disease using a new generation of mesenchymal stromal cells engineered to ectopically express CXCR4 and IL10. Funded by the Carlos III Health Institute (ISCIII; ICI22/00067). Sponsor: IDISNA. Principal Investigator at IIS-FJD: Dr Javier Cornago. UICEC-FJD is responsible for regulatory activities and shares project management responsibilities with the Sponsor.

21. STREAMLINE Study: Strategies for antiplatelet therapy following acute coronary syndrome. International multicentre clinical trial funded through the ERA4Health 2025 call. Sponsor: IIS-FJD. Coordinating Investigator: Dr Borja Ibáñez.

UICEC ACTIVITY 2025

The attached table provides a summary of the 163 studies that received some form of support during 2025, ordered by decreasing volume of activity and classified by Department/Research Group and sponsor type.

DEPARTMENT	COMMERCIAL		TOTAL	
	COMERCIAL	INVESTIGATOR INITIATED	N	%
HAEMATOLOGY	57	8	65	39.9
NEPHROLOGY	25	8	33	20.2
OFTALMOLOGY	8	3	11	6.7
RHEUMATOLOGY	10	1	11	6.7
PNEUMOLOGY	8	1	9	5.5
DERMATOLOGY	6	2	8	4.9
GASTROENTEROLOGY	5	0	5	3.1
ENDOCRINOLOGY	4	0	4	2.5
ALLERGY	3	0	3	1.8
GENERAL AND DIGESTIVE SURGERY	0	3	3	1.8
PAEDIATRICS	3	0	3	1.8
CARDIOLOGY	0	2	2	1.2
INTERNAL MEDICINE	0	2	2	1.2
TRAUMATOLOGY	0	2	2	1.2
GYNECOLOGY	0	1	1	0.6
ORAL AND MAXILLOFACIAL SURGERY	0	1	1	0.6
TOTAL OF ACTIVE STUDIES	**129**	**34**	**163**	

7.9 Innovation and Technology Transfer Unit

The innovation and technology transfer unit has the primary objectives of facilitating the transfer of research results to society and to healthcare practice, thereby contributing to continuous improvements in patient care quality while also promoting their commercial exploitation. The unit seeks to foster an innovation-driven culture within the IIS-FJD healthcare environment, to provide training to staff in innovation-related matters, to identify innovative ideas with the potential to be developed into products or services, and to support the advancement of innovation projects. Its activities include project support services, intellectual and industrial property management, technology transfer, and assistance with the protection of innovations through appropriate intellectual property strategies. In addition, the unit promotes collaborative agreements for R&D&I projects with stakeholders from the scientific and technological ecosystem, including universities, research institutions and companies at both national and international level.

Functions

The main functions of the Unit are:

- Identification of innovative ideas.
- Evaluation and valorisation of innovative concepts.
- Support for the implementation and development of innovative ideas.
- Protection of research and innovation outcome.
- Transfer of results and technologies to the market.

Since 2017, IIS-FJD has had an Innovation Committee whose objective is to establish guidelines for the evaluation and management of ideas, projects and innovation activities developed within the Institution and identified through the Innovation Unit.

Staff

Head of Unit: Isabel Orbis Ramírez (Until 06/05/2025)
Rafael Ceballos Martín (rafael.cmartin@iis-fjd.es; Ext2958)
(Since 10/06/2025)

Contact: innovacion.invest@iis-fjd.es

7.10 Bioinformatics Unit

The Bioinformatics Unit provides collaborative support to both IIS-FJD research groups and external investigators in the analysis of data generated by omics technologies and their integration with clinical Big Data. The unit's expertise focuses on the bioinformatic processing of genomic, transcriptomic and other large-scale molecular datasets, as well as on the functional characterisation and interpretation of the resulting dat.

Staff

Head of Unit: Pablo Mínguez Paniagua (scientific coordinator)
Yolanda Benítez Quesada (Bioinformatician)

Support activities

- It provides technical, scientific and consultancy support in:
- Experimental design for studies involving subsequent bioinformatic analyses.
- Bioinformatic, statistical and functional analyses of large-scale experiments, including transcriptomic (RNA-Seq), genomic (short- and long-read DNA sequencing), proteomic and other omics studies.
- Development of ad hoc bioinformatic methods and analytical pipelines.
- Preparation of methods and results sections, as well as interpretation of bioinformatic analyses for scientific publications.
- Advice and support in scientific grant applications and in the preparation of omics data management and data-sharing plans.
- Training activities.
- Scientific outreach and dissemination activities.

The Bioinformatics Unit develops and maintains: 1) bioinformatic analysis pipelines (https://github.com/TBLabFJD) for short-read DNA sequencing (https://github.com/TBLabFJD/PARROT-FJD; https://github.com/CIBERER/nf-CBRA-snvs), long-read DNA sequencing (https://github.com/TBLabFJD/WHALE), RNA sequencing, including differential expression and isoform quantification (https://github.com/TBLabFJD/VIsoQLR), as well as pipelines for other omics technologies; 2) a genomic database of patients with genetic diseases; and 3) software tools for genomic variant filtering and prioritisation, and for gene-disease association prediction (www.glowgenes.org). The Unit is involved in initiatives aimed at establishing standards and best-practice guidelines for bioinformatic analyses in clinical settings (CIBERER, TransBioNet) and for the evaluation of projects involving Artificial Intelligence (ANCEI). It is a member of the TransBioNet network (https://inb-elixir.es/transbionet), a joint initiative of the Carlos III Health Institute and the Spanish National Institute of Bioinformatics designed to facilitate the integration of Bioinformatics into healthcare. The unit also participates in the IMPaCT-Data and IMPaCT-Genómica projects, as well as in the mirror group (NMG5) of the Beyond 1 Million Genomes (B1MG) initiative. In addition, it contributed to the design of the IIS-FJD Omics Data Management Plan (https://bit.ly/IIS-FJD_RRI2200005) and actively participates in training and scientific outreach activities.

Summary Publications in 2025

Total	D1	Q1	Q2	No IF	Mean IF	Cumulative IF
11	1	9	2	0	5.85	64.3

7.11 Hospital pharmacy service

Head of Unit: Javier Bécares Martínez (Head of the Hospital Pharmacy Department)
Macarena Bonilla Porras (Consultant in Hospital Pharmacy)
Laura García Jiménez (Consultant in Hospital Pharmacy)
Natalia Barreras Ruiz (Consultant in Hospital Pharmacy)
Mónica González Pulido (Pharmacy Technician)
Mirentxu Olatz Jimeno Hierro (Pharmacy Technician)

Research: Clinical

Research Ethics Committees

Javier Bécares Martínez: Chair of the CEIM of the IIS-FJD.

Macarena Bonilla Porras: Vice-Chair of the CEIM of the IIS-FJD.

Management of Clinical Research Samples

- Investigational medicinal products must be distributed through the Hospital Pharmacy Departments.
- The service is responsible for the custody, storage and dispensing of the clinical investigation medicinal products.
- The Pharmacy Service has the necessary resources to ensure compliance with Good Clinical Practice (GCP) standards regarding the storage, handling, dispensing and returning records of clinical investigation samples, which are kept separate from other pharmaceutical products. The Clinical Trial area has restricted access.
- In addition to storage and dispensing services, the unit performs the following activities:
    - Management of investigational product inventories and databases, including IVRS, IWRS, ClinPhone, ALMAC, ICON, PPD, Perceptive...
    - Participation in monitoring visits.
    - Preparation and handling of investigational products.
    - Management of accountability and dispensing records.
    - Clinical Trials Pharmacist available Monday to Friday, from 08:00 to 15:00.
    - Pharmacist on duty available Monday to Friday from 8 a.m. to 10 p.m., and Saturdays from 9 a.m. to 3 p.m.
    - Relabelling.
    - Expiry date management.
    - Destruction of investigational products.
- The Hospital Pharmacy Department has the following facilities available for the storage of investigational medicinal products and clinical research materials:
    - Restricted-access storage cabinets for investigational products maintained at room temperature.
    - 7 restricted-access refrigerators.
    - 2 freezers:
        - Freezer operating within a temperature range of −20°C to −25°C.
        - Freezer operating within a temperature range of −75°C to −80°C.

Environmental temperature, refrigerator and freezer temperatures are continuously monitored and recorded using an automated monitoring system. Temperature deviation alarm systems are in place, and back-up thermometers are available in the event of incidents affecting the primary monitoring devices.

Standard Operating Procedures (SOPs) are available for all stages of investigational product management and clinical trial monitoring activities.

During 2025:

- CEIC-FJD meetings: **22**
- Number of clinical trials managed: **558**
- Investigational medicinal product shipments received: **1,420**
- Dispensations and returns: **6,467**
- Dispensations and RETURNS: **618**

Projects, contracts and observational studies

REFERENCE	PROJECT TITLE	PRINCIPAL INVESTIGATOR	GROUP/PLATFORM	PROJECT TYPE
2024.112	Analysis of the profile of patients diagnosed with primary immune thrombocytopenia at the hospital	BECARES MARTÍNEZ, JAVIER	HOSPITAL PHARMACY PLATFORM	NON-COMPETITIVE PRIVATE PROJECT
2025.018	AFAPEAH AstraZeneca ProjecT	BECARES MARTÍNEZ, JAVIER	HOSPITAL PHARMACY PLATFORM	NON-COMPETITIVE PRIVATE PROJECT
4749/017	Pharmaceutical Care in Outpatients: Adherence to Biological Therapies	BECARES MARTÍNEZ, JAVIER	HOSPITAL PHARMACY PLATFORM	NON-COMPETITIVE PRIVATE PROJECT
EOH008-23_FJD	Observational study evaluating adherence to TREMFYA® (guselkumab) in routine clinical practice among patients with moderate-to-severe psoriasis	BECARES MARTÍNEZ, JAVIER	HOSPITAL PHARMACY PLATFORM	OBSERVATIONAL STUDIES

7.12 Imaging Unit

The Medical Imaging Department of Fundación Jiménez Díaz University Hospital (HUFJD) collaborates closely with IIS-FJD by facilitating all activities that contribute to the development of research projects carried out by the Institute's different research groups. The department integrates the Diagnostic Imaging and Nuclear Medicine Services.

Functions and Objectives

The primary objective of the HUFJD Medical Imaging Department is to meet the demand for imaging examinations within the Hospital, both for diagnostic and therapeutic purposes, in the most efficient manner and with the highest possible standards of quality and patient safety.

Human Resources

The Department is composed of 2 Heads of Department, 4 Associate Heads, 33 Consultant Specialists, including 5 Section Coordinators, and 11 Medical Residents.

The sections are organised according to an organ-system structure.

- General
- Vascular and Interventional Radiology
- Interventional Neuroradiology
- Diagnostic Neuroradiology
- Diagnostic Neuroradiology
- Musculoskeletal Imaging
- Breast and Female Pelvic Imaging
- Thoracic and Abdominal Imaging
- Cardiac Imaging
- Paediatric Imaging
- Nuclear Medicine

Technological Resources

The Department is equipped with the following technological resources:

General equipment: 9 direct digital radiography rooms (including 2 located in the Emergency Department), 1 direct digital chest radiography room, 1 direct digital remote-controlled fluoroscopy unit, 15 high-performance ultrasound systems, 1 point-of-care portable ultrasound system, 1 portable ultrasound scanner, 3 surgical C-arms, and 2 mobile radiography units.

Advanced imaging equipment: 7 1.5-Tesla magnetic resonance imaging (MRI) scanners (including 1 intraoperative MRI), 2 3-Tesla MRI scanners, one of which is equipped with High-Intensity Focused Ultrasound (HIFU), 4 multidetector CT scanners (3 of them Spectral CT systems), 2 high-performance interventional radiology suites (including 1 biplane system), 2 hybrid operating theatres equipped with interventional radiology C-arms, 4 direct digital mammography units (3 with 3D tomosynthesis), and 1 direct digital 3D mammography system with a prone biopsy table.

Nuclear medicine equipment: 1 digital PET-CT scanner, 1 SPECT-CT system, and 1 portable gamma camera.

Other facilities and resources: Electronic Health Record (EHR) system, RIS-Casiopea, Carestream PACS, ACI (Interesting Case Archive), reporting rooms, 2 outpatient consultation rooms, and advanced centralised imaging workstations with dedicated post-processing software (Syngo and IntelliSpace Portal).

Location and Contact Information

Ground Floor, Main Building, IIS-FJD.
Telephone: 915504800/Extension 3560

7.13 Radioisotope laboratory

The Radioisotope Laboratory is a Category II licensed radioactive facility, authorised for common use by all IIS-FJD research groups. The facility supports the performance of all techniques involving the use of authorised unsealed radioactive isotopes within approved research projects, as well as X-ray densitometry studies in small animal models.

Staff

Head of Radiation Protection Service: Julio Valverde. Radiation physicist.

Radioactive Facility Supervisor: Mar González García-Parreño.

Location and contact information

Basement Level -1, Private Patients Building.

Telephone: 915504800/Extension 3866

Email: mmgonzalez@fjd.es

Functions and objectives

The radioisotope laboratory is a Category II radioactive facility, authorised by the Directorate-General for Industry, Energy and Mines through the licence granting operation of the Research Laboratory of the Fundación Jiménez Díaz radioactive installation (IR/M-83/74-B).

The facility operates under the Radiation Protection Service of the Fundación Jiménez Díaz (SPR/M-0007/96), which is authorised by the Spanish Nuclear Safety Council (CSN).

The activities authorised within the facility include the use of unsealed radioactive materials for research purposes.

Its principal function is to ensure that all activities involving ionising radiation carried out within IIS-FJD are performed under appropriate radiological control and in compliance with current regulations.

Its main objective is to plan and supervise these activities in accordance with the ALARA (As Low As Reasonably Achievable) principle, optimising procedures to minimise radiation exposure while ensuring full compliance with the applicable regulatory framework.

At present, the Radioisotope Laboratory collaborates, or is expected to collaborate subject to the corresponding approvals, in the following clinical trials:

- CAAA603C12101, Phase IbDose Finding Study Assessing Safety and Activity of [177Lu]Lu-NeoBin Combination with Radiotherapy and Temozolomide in Subjects with Newly Diagnosed Glioblastoma with MGMT methylated or unmethylated promoter status, midiendo muestras de sangre para establecer la farmacocinética de Lu177-NeoB.
- CAAA614A12101 (LuMIERE)
- CFXX489A12101
- Lu-177_DOTA-TATE_NETTER3__CAAA601A62301
- Lu-177_Lu177NeoB_CAAA603B12101

Evaluations and reports

- Planning of authorised activities.
- Advice on the design, construction and modification of radioactive facilities.
- Assessment of radiological consequences under normal operating conditions and in accident scenarios.
- Evaluation of radiological risks associated with the operation of the facility.
- Preparation and maintenance of all mandatory documentation.
- Daily completion of the operations logbook.
- Development of radiation protection procedures and guidelines for the handling and use of ionising radiation-emitting equipment and radioactive materials.
- Operation of X-ray-emitting equipment for research purposes.
- Preparation of the mandatory annual report following inspection by the Spanish Nuclear Safety Council (CSN).
- Management and control of radioactive materials, including ordering, receipt, procedures and compliance with regulatory requirements.
- Leak testing of sealed radioactive sources used at Fundación Jiménez Díaz.
- Verification of radiation detection and measurement systems for contamination and irradiation monitoring.

Radioactive material

A specific procedure has been established for the request, receipt and control of radioactive materials. Acquisition of radioactive materials is controlled by the Radiation Protection Service, in accordance with the corresponding Standard Operating Procedure (SOP 02).

Authorised radionuclides and maximum authorised activities:

- Hydrogen-3: 555MBq (15mci)
- Carbon-14: 370 MBq (10mCi)
- Phosphorus-32: 740 MBq (20mCi)
- Phosphorus--33: 740 MBq (20mCi)
- Sulfur-35: 370 MBq (10mCi)
- Calcium-45: 74MBq (2mCi)
- Chromium51: 185 MBq (85 mCi)
- Iodine-125: 555 MBq (15mCi)

Comprehensive management of the radioactive waste generated through these activities is carried out according to SOP 08.

The laboratory also provides technical support for auxiliary equipment required for procedures involving radioactive materials, including counters, refrigerators, incubators, safety cabinets, protective shields and personal protective equipment, as well as guidance on their correct use.

Ionising Radiation-Emitting Equipment: The Unit provides advice on the safe operation and use of equipment emitting ionising radiation, ensuring compliance with applicable radiation protection requirements.

Operational Radiation Monitoring (SOP 07)

- Daily monitoring of contamination and radiation levels is carried out in all working areas through:
- Verification of the absence of contamination and/or irradiation following each authorised procedure.
- DosimetricDosimetry monitoring of occupationally exposed workers.
- Area dosimetry monitoring.
- Classification and appropriate signage of controlled and supervised areas.

In the event of incidents:

- Implementation of the procedures and corrective actions established in the Radiation Protection Service (RPS) Procedures Manual.
- Activation of the emergency plans described in the RPS Procedures Manual.
- Decontamination procedures performed in accordance with the guidelines established in the RPS Procedures Manual.

Radiation protection training

The Radiation Protection Service organises training courses at a frequency adapted to the needs of the research community, typically one course per year.

Participants: Attendance is mandatory for all personnel joining research laboratories who cannot provide evidence of previous radiation protection training from another institution (e.g. a certified course for operators of radioactive facilities).

Course structure: The programme consists of at least six hours of theoretical training and four hours of practical sessions. Participants receive a certificate of attendance upon successful completion of the course.

Ongoing support: Continuous advice and guidance on radiation protection practices are provided by the Radioactive Facility Supervisor, who is available from 08:00 to 15:00.

Equipment

Radioisotope Laboratory

The Radioisotope Laboratory comprises the following facilities:

- Cold room 4ºC: used for the storage of radioactive materials under appropriate safety and security conditions.

Gamma Emitter Handling Laboratory

Equipped with:

- HPLC system.
- Electrophoresis equipment.
- Protective shielding screens specifically designed for Iodine-125 applications.
- Extraction pumps connected to appropriate radioactive waste storage systems.

Beta Emitter Handling Laboratory. Instrumentation Room

- Equipped with:
- Four radiation shielding screens designed for Phosphorus-32 handling.
- Two hybridisation ovens.
- Five electrophoresis tanks with electrodes and power supplies for procedures involving P-32 (EMSA, Southern blot).
- Shaking platforms.
- Thermoblock.
- Water baths.
- Appropriate containers for the disposal of liquid and solid radioactive waste.

Low-energy Beta emitter and metabolic studies room:

This area is equipped with all the necessary resources for working with low-energy beta emitters and radionuclides with long half-lives, such as Hydrogen-3 (^{3}H) and Carbon-14 (^{14}C). The laboratory features work surfaces specifically designed to facilitate decontamination procedures.

This area is equipped with all the resources required to perform metabolic studies in cell cultures using radioisotopes. Available equipment includes:

- Biological safety cabinet.
- Incubator.
- Centrifuge.
- Shaking water baths.
- Suction pumps.
- Beta container.
- Fume hood equipped with filtration system.
- Two semi-automatic cell harvesters with their corresponding vacuum systems.
- Appropriate containers for the collection and disposal of liquid and solid radioactive waste.

Thermocycler area:

Four thermocyclers are available for studies of PCR.

Counting Room. The following equipment is in this room:

- Gamma counter (newly incorporated in 2023).
- Small-animal densitometer (for mice).
- Gel dryer with vacuum pump.
- Hybridisation ovens.

Radioactive waste storage area

Access to this area is restricted to the Facility Supervisor, who is responsible for the complete management of radioactive waste storage, record keeping and disposal, according to the schedules and procedures established by current regulations.

Access rules

The laboratory remains open and under the supervision of the Facility Supervisor from Monday to Friday, 08:00 to 15:00.

To access the laboratory outside these hours, users must request the key from the Security Service of the Fundación Jiménez Díaz, which will record the name and national identification number (ID) of the person requesting access and subsequently communicate this information to the Radiation Protection Service (RPS).

Safety regulations

To work with radioactive isotopes in this facility, personnel must:

- Have successfully completed the training course provided by the Radiation Protection Service (RPS) or hold a valid Radioactive Facilities Operator Licence.

This implies knowledge of, and compliance with, the fundamental radiation safety rules required when working with radioactive isotopes:

- Use the minimum level of radioactivity compatible with the experimental requirements.
- Maintain the greatest possible distance from the radiation source.
- Minimise exposure time.
- Use automatic pipettes.
- Do not smoke, eat or drink.
- Wear appropriate protective clothing.
- Use suitable shielding system.
- Monitor the work area before and after each procedure.
- Consult the Facility Supervisor before starting any experiment and whenever any doubt arises regarding the procedure or safety requirements.

In case of incidents and emergencies

From 08:00 to 15:00:

- Contact the Facility Supervisor.
- Contact the Radiation Protection Service (RPS).

From 15:00 to 08:00, and on public holidays:

- Contact the Security Service of the Fundación Jiménez Díaz.

7.14 Information technology service

The activity of the Information Systems and Information Technology Department is focused on providing solutions that meet the research and healthcare needs of IIS-FJD and its affiliated hospitals, in line with the strategic objectives of Patient Health, Patient Experience and Efficiency, which have been the main priorities throughout 2025. The Information Technology Department has the following main functions and objectives:

- Provide user support.
- Maintain and continuously improve the technological infrastructure and information systems.
- Manage the Electronic Health Record (EHR) system.
- Maintain and develop the different software applications in use across the Institution.
- Manage integration with Primary Care services.
- Carry out strategic planning and project governance activities.
- Maintain project documentation and generate key project management metrics.

The Information Technology Department is currently composed of:

Head of unit: Alberto Pinto Romero – Director of Information Systems HUFJD

Staff:

Director of information systems
Alberto Pinto Romero

Deputy director of information systems
Nazaret Aurora Hernández Muñoz

Integration and departmental applications coordinator
Álvaro Pascual Rodríguez

Clinical objects and Casiopea coordinator
Juan Carlos Jiménez Ibáñez

Business intelligence (BI) coordinator
Juan José Serrano García-Ortega

Support services coordinator
Luis Alberto Blázquez Cañas

Functional team coordinator
Elena Martín Rodrigo

Project management office (PMO)
Sonia Gámez Gámez

Information security manager
Cesar Sendarrubias García

Infrastructure manager
Consuelo Sánchez Gil

Clinical support Team
Isabel Clara Izquierdo Delgado

Data analysts/BI
Ana Isabel Cortés Martínez
Beatriz Chocano Peña
Raúl Ceballos Sánchez
Aitziber García Alonso

Functional team and Project management
Julián Checa Aceituno
Javier Arbex de Miguel
Mariola Seoane Gigirey
Paula Orayen Russo
Ana María Díaz García
Óscar Calvo Escobar
Rocío López García
Adriana Fernández Soleto
David Pérez Huergo

Infraestructure team
Guillermo García Martín-Camuñas
Alfonso Díaz Marcos
Aaron Rodrigo Díaz

Clinical objects and Casiopea team
Juan Carlos Adrian Pradillo
Miguel Angel Morales Coca
Saul Bravo Villamudria
Roberto Carrasco Fernández

Integration and departmental applications team
Alberto González Aranda
Alba Villafranca Martínez
Fernando Zapatero Díaz
Mario Martínez Garrido

Support team
Diego Domínguez Pérez
Juan Ruiz Prieto
Mario Navazo Ariza
Shukria Saud Kokab
Eduardo Rodríguez Prieto
Josué Ugarte Mérida
Marcos Garrido Pastor
Namir Kubba Consuegra
Victor García de Llano
Juan Poderoso Reynaldo
Raúl Marín Vives

Location: The Information Technology Department is located at 55 Hilarión Eslava Street, in the building adjacent to Fundación Jiménez Díaz University Hospital.

7.15 Library

The library is staffed by two librarians who provide services to healthcare professionals at Fundación Jiménez Díaz University Hospital (HUFJD), Rey Juan Carlos University Hospital (HURJC), Infanta Elena University Hospital (HUIE) and General de Villalba University Hospital (HUGV). The total number of subscriptions includes both those acquired directly by the hospitals and those provided through the Virtual Health Library of the Regional Ministry of Health of the Community of Madrid. Individual access is granted to all users through personalised credentials.

All resources can be accessed remotely, and users may request resources or documents that are not available through existing subscriptions via the library's document supply and interlibrary loan services.

EXECUTIVE SUMMARY

During 2025, a total of 10,340 article requests were processed, representing a 3.82% decrease compared with the previous year.

A total of 88.54% of user requests were fulfilled within 24 hours. During 2025, 372 new users were registered with the library, and 1,167 users made use of the article request service.

The library provides access to 4,271 full-text journal titles, including subscriptions directly maintained by the hospitals through the library (14 titles) and resources available through the Virtual Health Library of the Regional Ministry of Health of the Community of Madrid (4,257 titles).

A total of 13 training sessions were delivered to healthcare professionals across the four hospitals within the network, organised through the Teaching Department of the Fundación Jiménez Díaz. These activities achieved an average satisfaction rating of 9.09/10.

User queries were addressed through multiple channels, including email, telephone, social media, messaging services and face-to-face support.

Key Services: The library provides 24-hour access, 365 days a year, through its virtual platform. The library team is available Monday to Friday, from 08:00 to 17:00, to process requests and provide personalised support services.

Throughout 2025, the interlibrary collaboration network played a crucial role in providing access to articles from non-subscribed journals, enabling most requests to be fulfilled free of charge for users.

LIBRARY

https://m-fjd.c17.net

biblioteca@quironsalud.es

CONTACT

María García-Puente

Alter Biblio

info@alterbiblio.com

(+34) 675143538

7.16 English language translation service

The IIS-FJD has access to the services of AdHoc, a professional translation agency specialising in the translation and revision of scientific texts in a variety of formats. Access to the service is available through the following link: https://www.fjd.es/iis-fjd/es/unidades-apoyo/unidades-apoyo-investigacion/servicio-traduccion-lengua-inglesa

This service is available to all clinical and basic researchers affiliated with IIS-FJD and is intended to support and promote the production of scientific articles, book chapters, conference presentations, lectures and other scientific communications, thereby enhancing the international visibility and impact of the Institute's research activities.

7.17 Clinical documentation service

The Clinical Documentation Service of the Fundación Jiménez Díaz University Hospital (HUFJD) collaborates with IIS-FJD by facilitating all activities that support the development of research projects conducted by the Institute's research groups, particularly in clinical research support. Its activities include the development, maintenance and review of the HUFJD clinical database, as well as the preparation of reports for scientific publications, conferences, scientific meetings, doctoral these and other research activities.

Staff

Heads of department: Catalina Martin Cleary

Blanca Rodríguez Alonso

Associate head: Milagros Polo Ordoqui (until May 2025)

Consultant physicians: Lidia Cuevas de Campo (since November 2025)
Esther Lueje Alonso (since September2025)
Pilar Mielgo Bellver

Head of section: Mónica Díaz Herrero

Other staff: Registered Nurses (10)
Clinical documentation technicians (24)
Administrative staff (3)

Clinical Documentation Activities

- Maintenance of the master patient index.
- Management and maintenance of the electronic health record (including digitisation of clinical documentation).
- Preparation of clinical documentation for the Legal Affairs Department.
- Provision of clinical documentation to patients.
- Management of clinical documentation from other hospitals.
- Quality control of clinical records.

Clinical Coding Activities

- Clinical coding using ICD-10-ES.
- APR-DRG grouping and classification.
- Review of clinical databases for Inpatient Admissions, Ambulatory Major Surgery (AMS) and Day Hospital activity.
- Clinical coding quality control.

Clinical Documentation Audit Activities

- Review of admission criteria.
- Review of procedures not performed.
- Review of trials.
- Review of patient transfers.
- Review of accident-related cases.
- Review of episodes lacking a discharge or clinical report.
- Quality review of clinical reports (inpatient, surgical and emergency care reports).
- Review and management of appeals related to activity audits.

Clinical Information Activities

- Review of the Minimum Basic Data Set (MBDS).
- Submission of MBDS data to the Community of Madrid and the Spanish National Statistics Institute (INE).

- Support for Clinical Committees, including the Mortality Committee, Complications and Readmissions Committee, Healthcare Risk Management Functional Unit, and Clinical Documentation Committee.
- Review of clinical information relating to Inpatient Admissions, Ambulatory Major Surgery (AMS) and Day Hospital activity.
- Analysis of indicators related to case complexity, inpatient management, mortality, complications and readmissions.
- Support for the clinical management of medical departments through the preparation of clinical management reports and the evaluation of healthcare quality.
- Support for hospital management through the preparation of clinical management and healthcare quality reports.
- Support for clinical research activities and the provision of data for scientific publications.
- Preparation of healthcare quality and patient safety reports.
- Review of quality indicators from the Healthcare Quality Observatory and AHRQ (Agency for Healthcare Research and Quality).
- Conduct of pre-audits of healthcare activity.

Medical Audit Activities

- Re-audit of the Cardiac Arrest Alert System.

Certifications/ Projects / Studies

- Achievement and maintenance of ISO 9001:2008 Quality Certification for the Clinical Documentation Service.
- Standardisation of clinical documentation as the basis for a multicentre clinical information system to support healthcare management.
- Evaluation of the APR-DRG system as a tool for managing and contracting inpatient hospital activity at HUFJD.
- Assessment of capitation-based healthcare funding models using diagnosis-based risk adjustment methodologies.
- Design of methodological tools aimed at improving healthcare quality.
- Evaluation of Natural Language Processing (NLP) tools as support for ICD-10-ES clinical coding.
- Development of predictive models for healthcare complications.
- Provision of clinical information to support accreditation processes and awards applications by medical departments.
- Training programmes for clinical services aimed at improving the quality of clinical documentation.

Scientific output

The Service also contributes to scientific publications in collaboration with the different medical departments by providing clinical databases generated from the coding of diagnoses and procedures recorded in the HUFJD electronic health record system from 1991 to the present day.



8

Research **Management Area**

Research Management Area 8

The IIS-FJD Research Management Area has its own dedicated management structure and is responsible for providing administrative support to the Institute. Its functions include the management of institutional services and resources, financial and economic administration, and management control activities. The Area is headed by the Managing Director, **Alberto Montero Manso.**

The Area acts as a liaison between funding bodies and researchers, including medical staff, contracted research personnel and IIS-FJD fellows, providing advice, information and management support for the various activities carried out within the Institute.

In addition, the Area provides technical and administrative support to the Research Committee, the Quality and Innovation Committee, the External Scientific Advisory Committee, and the Social Stakeholders Advisory Board.

The Research Management Area also includes a Deputy Coordinator to the Scientific Director, whose role is to strengthen coordination among the different units and ensure alignment between the Institute's scientific strategy and its operational management. Among its responsibilities are:

- Direct support to the Scientific Directorate in the planning, coordination and monitoring of the Institute's scientific activities.
- Acting as a cross-functional coordinator between the Scientific Directorate and the IIS-FJD Management Office, facilitating alignment between the scientific strategy and the Institute's administrative and financial management.
- Promotion and coordination of strategic initiatives, including scientific plans, talent attraction programmes and institutional positioning activities.
- Support in the preparation of strategic documentation, including reports for accreditation processes and evaluations by national and international agencies.
- Coordination of support activities for the Institute's governing and advisory bodies, including the Research Committee, External Scientific Advisory Committee, Management Committee, Social Stakeholders Advisory Board and Quality Committee.
- Identification of opportunities for improvement in research management processes and promotion of initiatives aimed at their optimisation.
- Support in institutional relations and participation in national and international strategic networks and collaborative projects.
- Organisation of, and institutional support for, IIS-FJD scientific meetings, conferences and awards.

Staff

Ana Rubio Araiz (ana.rubioa@iis-fjd.es; Ext 3455, +34 638782706)

In addition, the Research Management Area is structured into two dedicated IIS-FJD units and four units shared with Fundación Jiménez Díaz University Hospital (HUFJD):

IIS-FJD dedicated units:

- 8.1.- Administration and support services unit
  - 8.1.1.- Scientific activity
  - 8.1.2.- Quality
  - 8.1.3.- Financial management

- 8.1.4.- Training and outreach
- 8.1.5.- Clinical research management
- 8.1.6.- Research Human Resources (HR)

- 8.2.- Project management unit

Units shared with HUFJD:

- 8.3.- Legal department
- 8.4.- Marketing and communications department
- 8.5.- Occupational Health and Safety Department
- 8.6.- Quality Department

Head of IIS-FJD dedicated units: Alberto Montero Manso (alberto.mmanso@iis-fjd.es; Ext 2840)

Contact: investigacion@quironsalud.es

Location: C/Maestro Ángel Llorca 6. Ground Floor B. Edificio Alto. 28003 Madrid.

8.1 Administration and Support Services Unit

8.1.1. Scientific Activity Unit

The Scientific Activity Unit is responsible for the evaluation and monitoring of the scientific output generated by IIS-FJD. Its primary objective is to ensure the accurate collection, analysis and dissemination of the research activity carried out across the Institute.

Its scope of activity includes both the management of scientific productivity data and the preparation of strategic reports for different organisational levels and external bodies. The data analysed include indicators related to human resources, research projects, clinical trials, observational studies, patents, licences and scientific publications.

In addition, the unit plays a key role in the preparation of major institutional documentation, including scientific reports, technical and financial reports, as well as the generation of monitoring indicators linked to the Strategic Plan and accreditation and reaccreditation processes. The unit also acts as a liaison between different internal departments and external regulatory and funding bodies, ensuring the quality, consistency and traceability of the information generated.

Functions

The main functions are:

- Supervision and review of data related to IIS-FJD personnel, research projects, clinical trials and observational studies, acting as a liaison with the Human Resources, Research Projects (competitive and non-competitive) and Clinical Trials departments.
- Collection, review and validation of data relating to the Institute's scientific publications.
- Development of indicators for monitoring compliance with the reaccreditation requirements for Health Research Institutes.

- Collaborative development of indicators linked to the IIS-FJD Strategic Plan.
- Preparation of the Annual Report of the Fundación Jiménez Díaz, specifically the research section.
- Preparation of the IIS-FJD Scientific and Financial Annual Report, as well as the R&D&I activity reports for the affiliated hospitals of the Madrid Health Service (HUFJD, HURJC, HUIE and HUGV).
- Dissemination of the Institute's Scientific and Financial Annual Report, both internally and to official organisations.
- Collaborative preparation of indicators for the Madrid Regional Observatory.
- Development of indicators for self-assessment questionnaires related to the Patient Care Quality Index (Best in Class Awards, BIC).
- Preparation of surveys for the Spanish National Statistics Institute (INE) on R&D and innovation activities, covering both IIS-FJD and its affiliated hospitals.
- Preparation of Action Plans of the IIS-FJD and of the Fundación Jiménez Díaz.
- Design, updating and publication of content on the IIS-FJD website.
- Advice on research data management, publication affiliations, Creative Commons licences and deposition of publications in institutional repositories.
- Evaluation and personalised advice regarding researchers' scientific productivity, particularly in relation to official funding calls, in coordination with the Competitive Research Projects Department.
- Management of user registrations and coordination of the professional English translation service (AdHoc), in collaboration with the Procurement Department.
- Management of licences and use of plagiarism detection tools (Turnitin and iThenticate).
- Management of the SCOPUS database.
- Management, validation and submission of bulk publication uploads to the institutional scientific output repository RIMASalud, as well as validation of researcher self-archiving activities, ensuring the integrity and quality of the information.
- Supervision and monitoring of software developments aimed at the collection and management of scientific publication data.
- General support for scientific productivity dissemination activities, including the review of information and preparation of presentations for meetings and institutional events.

Staff

María Ester Martín Aparicio (ester.martin@fjd.es; Ext 3137)

8.1.2.- Quality Unit

The Quality Unit, established within IIS-FJD in 2025, works in close interaction and collaboration with the Quality Department (Section 8.6) of Fundación Jiménez Díaz University Hospital (HUFJD), to ensure effective alignment of quality processes and standards.

The unit's main objective is to ensure the proper implementation, maintenance and continuous improvement of the Institute's quality management system to guarantee compliance with internal and external quality standards and requirements.

Its activities are focused on strengthening process efficiency, which promotes a culture of continuous improvement, and contributing to excellence in research management. To achieve this, the unit develops tools and procedures that enable organisational performance assessment, identification of improvement opportunities and optimisation of the operation of the Institute's different units.

The quality unit also plays a key role in the preparation and monitoring of certification and audit processes, acting as a coordinating body among the Institute's different areas to ensure compliance with regulatory and quality requirements.

Functions

The main functions are:

- Development and implementation of the Institute's Quality Management System.
- Preparation, review and updating of procedures, protocols and internal documentation.
- Monitoring of quality indicators and implementation of actions aimed at the continuous improvement of processes.
- Support for certification processes, internal and external audits, and evaluations conducted by accreditation bodies.
- Coordination with the Institute's different units to improve and optimise internal processes.
- Monitoring of the Strategic Plan.

Staff

Lucía Jiménez Rodríguez (since 19/11/2025). (lucia.jrodriguez@quironsalud.es; Ext 2958)

8.1.3.- Financial management

The Financial Management unit plays a fundamental role in the planning, control and monitoring of the financial resources required to support the Institute's research activities. Its primary mission is to ensure efficient, transparent and fully compliant financial management, thereby supporting the sustainability of both research projects and the Institute's core operational activities.

The unit is responsible for coordinating budgeting activities, accounting management and financial control, providing support to both researchers and administrative units. It also acts as a key liaison with public and private funding bodies, ensuring compliance with financial reporting requirements and contributing to the proper execution of research projects.

Its work is essential for optimising the use of available resources, identifying potential deviations and facilitating strategic decision-making based on reliable and up-to-date financial information.

Functions

The main functions are:

- Planning, execution and monitoring of the Institute's budget, ensuring the efficient allocation of available resources.
- Accounting management of income and expenditure associated with both research projects and the Institute's core operational activities.
- Processing of payments, management of advance payments, and preparation of financial reports

and justifications for public and private funding bodies.

- Continuous financial monitoring of research projects, identifying budget deviations and proposing corrective measures where necessary.
- Support for internal and external audit processes, while ensuring compliance with current financial and economic regulations.
- Management of procurement requests and monitoring of expenditures charged to the budget lines associated with the different research project.

Staff

Diego Villa Niella (diego.villa@iis-fjd.es; Ext 4493)

Cristina Álvarez Burbano (cristina.alvarezb@iis-fjd.es; Ext 4897)

María García Girona (maria.ggirona@iis-fjd.es; Ext 3668)

Beata Ludmila Bem Czyzowska (beata.ben@iis-fjd.es; Ext 3161)

Victor Manuel Mateos Blázquez (victor.mateos@iis-fjd.es; Ext 3668)

Olga Leidy Torrez Álvarez (olga.torrez@iis-fjd.es; Ext 3161)

Contact: pedidosiis@quironsalud.es; Ext 3161

8.1.4.- Training and Outreach Unit

The primary mission of the Training and Outreach Unit is to promote the professional development and continuous training of the Institute's research staff, contributing to the strengthening of the competencies required for the successful conduct of scientific activities.

Through the design and implementation of training programmes, the unit promotes the updating of knowledge, the exchange of experiences and the acquisition of key skills in research and management. It also plays a proactive role in identifying training needs, ensuring that the educational portfolio is aligned with the Institute's strategic objectives.

Training activities are designed both to address internal needs and to facilitate access to external opportunities, ensuring effective dissemination, participation and continuous evaluation of the quality and impact of the activities delivered. In addition, the Unit promotes scientific outreach activities aimed at the public through the organisation and coordination of initiatives such as patient engagement events, the Science Week, the International Day of Women and Girls in Science, and the 4th ESO + Company Programme, among others.

Functions

The main functions are:

- Design, planning and implementation of the Institute's training plan.
- Organisation of courses, workshops and seminars for research and management staff.
- Organisation of training and scientific outreach activities aimed at both internal personnel and the wider community.
- Management of training activities, including registration, attendance monitoring, certification issuance, and evaluation of participant satisfaction and programme impact.
- Identification of training needs and promotion of the continuous professional development of In-

stitute staff.

- Dissemination of training programmes and external professional development opportunities relevant to IIS-FJD staff.
- Dissemination of training programmes and external professional development opportunities relevant to IIS-FJD personnel.
- Administrative management of courses and workshops, including logistical coordination and the management of sponsorships and external collaborations.
- Definition, monitoring and evaluation of training activity indicators to ensure continuous improvement and alignment with the Institute's strategic objectives.
- Recording and monitoring of scientific outreach activities, including those organised by IIS-FJD and those in which its researchers participate.

Staff

María del Pilar del Peso Hernández (pilar.peso@iis-fjd.es; Ext 2115)

8.1.5.- Clinical Research Management Unit

The Clinical Research Management Unit plays an essential role in the proper conduct, oversight and regulatory compliance of clinical studies carried out within the Institute. Its activities focus on ensuring efficient, coordinated and regulation-compliant management, facilitating both the initiation and follow-up of research studies.

The Unit also ensures the effective operation of the Research Ethics Committee with Medicines (CEIm) by providing the administrative support required for the ethical review of research projects and acting as a liaison between investigators, sponsors and assessment bodies.

Through these activities, the unit contributes to ensuring the quality, safety and scientific rigor of clinical research, while promoting compliance with applicable regulations and the protection of study participants.

The Clinical Research Management unit is structured around three main areas of activity: Clinical research technical and administrative management, financial management of clinical research activities and Administrative Secretariat of the Research Ethics Committee with Medicines (CEIm).

• Clinical Research Technical and Administrative Management

Functions

The main functions are:

- Administrative and operational management of clinical trials and observational studies.
- Ongoing coordination with investigators, sponsors and hospital departments involved in the studies.
- Preparation, review and submission of regulatory documentation required for study start-up.
- Feasibility assessment of study budgets, including evaluation of costs, resource requirements and overall study sustainability.
- Management, negotiation and review of clinical study agreements, ensuring their appropriate execution and formalisation.

- Comprehensive follow-up of ongoing studies, ensuring compliance with regulatory and administrative requirements.

Staff

Nieves Martínez García (nmartinez@iis-fjd.es; Ext 4492).

Cristina Blázquez Gómez (cristina.blazquezgom@iis-fjd.es; Ext 3194)

Ana Isabel Lopesino Badorrey (ana.lopesino@iis-fjd.es; Ext 3194)

María Florencia Spirito (florencia.spirito@iis-fjd.es; Ext 3194)

• Clinical research financial management

This area plays an essential role in the financial management of activities related to clinical trials and other research projects. Its primary objective is to ensure accurate invoicing, income monitoring and efficient management of payments arising from research activities, while guaranteeing compliance with the contractual agreements established with sponsors and funding organisations.

Functions

The main functions are:

- Issuance and management of invoices related to clinical research activities in accordance with the terms established in the corresponding agreements and contracts.
- Verification of billable milestones and activities in accordance with the contractual arrangements agreed with study sponsors.
- Administrative registration and control of invoicing processes.
- Coordination with the financial management unit to ensure appropriate accounting integration and financial oversight.
- Monitoring and control of income generated through clinical trials and other research activities.
- Management of payments received, reconciliation of accounts, and resolution of financial discrepancies or issues.
- Coordination with sponsors and internal departments to ensure the timely and accurate receipt of research-related income.

Staff

Gema Navarrete Segade (gnavarrete@quironsalud.es; Ext 4707)

Sheila Belinchon Fernández: sheila.belinchon@iis-fjd.es; Ext 4707). (Until 01/10/2025)

Narcisa de Jesús Crofford Torres narcisa.crofford@iis-fjd.es; Ext 4707)

Carlos García González: carlos.garciagonza@iis-fjd.es; Ext 4708). (Until 22/09/2025)

David Martínez Cuenca: david.mcuenca@iis-fjd.es; Ext 4708)

Leonor Ramos Terreros: leonor.ramos@iis-fjd.es; Ext 4708)

José Carlos Sánchez Rodríguez: JCSanchezR@fjd.es; Ext 4708)

• Administrative Secretariat of the CEIm

Functions

The main functions are:

- Administrative management of the Research Ethics Committee with Medicines (CEIm).
- Receipt, validation and processing of the documentation required for the ethical review of research studies.
- Organisation of CEIm meetings, including the preparation of meeting agendas, minutes and associated reports.
- Communication with investigators and sponsors regarding committee decisions, requests for additional information, and the follow-up of ethical aspects related to research studies.

Staff

Nieves Martínez García (nmartinez@iis-fjd.es; Ext 4492).

Tamara Oria Valero (tamara.oria@iis-fjd.es; Ext 4492)

Noemi Rodríguez Beas: (noemi.rodriguezbeas@iis-fjd.es; Ext 4492)

Contact: ceic@fjd.es; Ext 4492

8.1.6.- Research Human Resources Unit (HR)

The Research Human Resources Unit plays a key role in the comprehensive management of personnel involved in the Institute's research activities, ensuring compliance with current regulations and facilitating the implementation of R&D&I projects from an administrative and employment perspective.

Its activities are focused on providing specialised support to both researchers and the different management areas of the Institute, ensuring the appropriate planning, recruitment and monitoring of research personnel. The unit also acts as a link between scientific needs and administrative requirements, contributing to the successful execution of research projects and the optimisation of available human resources.

In addition, the unit ensures proper document management and traceability of personnel records, promoting process efficiency and compliance with the funding requirements established by the different grant programmes and funding calls.

The Research Human Resources Unit is organised into two distinct areas: the research human resources management area, focused on the employment administration of research staff, and the IIS-FJD Personnel Registry Area, responsible for the management, monitoring and analysis of personnel information and data.

• Human Resources Management

Functions

The functions are:

- Publication and management of job vacancies.
- Comprehensive management of research personnel, including recruitment, onboarding and offboarding processes, contract amendments, and resolution of employment-related issues.
- Administrative management of human resources calls linked to R&D&I projects.
- Provision of guidance to researchers on employment regulations and applicable contractual arrangements.
- Monitoring of personnel allocation to research projects and coordination with the Financial Management Unit.

- Management and maintenance of documentation and records relating to research personnel.
- Issuance of certificates and other administrative documentation.

Staff

Yolanda Calvo Yelmo (yolanda.calvo@iis-fjd.es; Ext 3161)

Iris Cañamares Fernández (iris.canamares@iis-fjd.es; Ext 1994)

Contact: rrhh.investigacion@quironsalud.es

• IIS-FJD Research staff registry

Functions

The main functions associated with the management of the IIS-FJD Research Personnel Registry are as follows:

- Management of the personnel database (IIS-Manager):

  Development, maintenance and continuous updating of the corporate database for research, scientific and technical support, and administrative and management staff, including the registration of appointments, departures and amendments, as well as personnel classification in accordance with the current descriptive framework:

- Registration and monitoring of research trainees and doctoral theses:

  Management and updating of information relating to research trainees, including external training placements and predoctoral researchers, as well as the registration and monitoring of doctoral theses linked to IIS-FJD, ensuring the traceability, integrity and consistency of the data.

- Personnel data analysis and reporting:

  Analysis and exploitation of information contained in the database for the preparation of human resources indicators used in annual reports, ISCIII monitoring reports, the Madrid Health Service Outcomes Observatory, and reporting requirements for bodies such as the External Scientific Committee (CCE) and the Social Stakeholders Advisory Board (CAAS), among others.

- Management of personnel affiliation within PEASIIS:

  Updating and maintenance of information relating to appointments, departures and modifications of staff affiliated with IIS-FJD within the PEASIIS application (Programme for the Evaluation, Accreditation and Monitoring of Health Research Institutes), ensuring the traceability, consistency and reliability of personnel records.

- Issuance of certificates:

  Preparation and issuance of official affiliation certificates for IIS-FJD research personnel, based on the information recorded in the Institute's corporate systems.

- Data quality control, auditing and regulatory compliance:

  Regular verification of the quality, integrity and consistency of registered information, ensuring compliance with ISCIII accreditation and monitoring requirements, as well as with applicable regulations governing data management and human resources administration.

Staff

María del Pilar del Peso Hernández (pilar.peso@iis-fjd.es; Ext 2115)

8.2.- Project Management Unit

The primary function of the Project Management Unit is to support the Institution's researchers in their participation in research projects and other R&D&I initiatives. The unit is responsible for managing activities submitted to public and private competitive funding calls, where funding is awarded through evaluation and selection processes in competition with other proposals, typically at regional, national or international level. The unit also promotes participation in these funding opportunities and encourages collaboration among research groups, both within the Institution and with external organisations and research centres, providing support in the management of joint R&D&I activities. In addition, the unit manages non-competitive funding initiatives, such as agreements, contracts and collaborations with external entities, including their administrative processing and the monitoring of contractual commitments, ensuring the proper implementation and justification of the corresponding activities.

The overarching objective of the unit is to increase participation in research projects and enhance the Institute's capacity to attract research funding and resources.

Functions

In collaboration with the other units, the project management unit is responsible for the following key functions:

- Dissemination and promotion among researchers of available public and private funding opportunities for R&D&I activities.
- Advising researchers on the preparation of grant applications submitted to funding calls from public and private organisations.
- Submission of project activity reports to the Research Committee and the relevant Ethics Committees, and preparation of the corresponding approval reports.
- Review and submission of applications to the relevant funding bodies.
- Guidance on internal project procedures and requirements.
- Administrative management, formalisation, review and validation of agreements, contracts and other collaborative arrangements, as well as monitoring compliance with contractual commitments and the justification of funded activities.

In addition, the Project Management Unit monitors project activities, outcomes and available resources, and prepares follow-up reports to support the Scientific Directorate and Research Groups in identifying areas for improvement and implementing appropriate corrective or strategic actions.

Staff

Oliver Ajo Villarraso (oliver.ajo@iis-fjd.es; Ext3296)

Tatiana Bortolato (Until 14/02/2025)

Jesús García Blas (jesus.garciab@iis-fjd.es; Ext 2961)

Beatriz Garrido Barranco: (beatriz.gbarranco@iis-fjd.es; Ext 2960)

Alexander Mayordomo Cervigón (alexandr.mayordomo@quironsalud.es; Ext 2961). (Since 08/07/2025)

María del Pilar del Peso Hernández (pilar.peso@iis-fjd.es; Ext 2115)

Carlos Repullo Matamala (carlos.repullo@iis-fjd.es; Ext 2960)

Jose Ignacio Sanz Recio (Until 08/05/2025)

Victoria Shapkarina Rachiba (victoria.shapkarina@quironsalud.es; Ext 2959). (Since 25/06/2025)

8.3 Legal Department

The Legal Department is responsible for providing legal advice and support for all activities carried out within IIS-FJD that require legal assessment or intervention.

It has the following personnel for its operation:

Director: Esperanza Hernando Calvo

Legal Advisory Team: David Uría González

Jaime Alonso Alfaro

Fernando Vadillo Domínguez

Administrative Assistant: Olga Mendizábal Martínez

Location: The legal department is in the Hospital Management Corridor of Fundación Jiménez Díaz University Hospital.

During 2025, the legal advice and support provided to IIS-FJD professionals focused primarily on the following areas:

- Resolution, by telephone and email, of 67 legal consultations relating to a wide range of matters, including powers of attorney, insurance, investigators, monitors, agreements associated with IIS-FJD activities, and other legal issues.
- Drafting of 73 legal documents, certificates, accession agreements, meeting minutes and other documentation, together with the corresponding filing and processing when required.
- Monitoring and follow-up of judicial proceedings and litigation.
- Management and processing of the incorporation of new members into IIS-FJD.
- Review and drafting of a total of 304 contracts of various types, including clinical trial agreements, observational study agreements, research project agreements, material transfer agreements, consultancy agreements, teaching agreements, donation agreements, licence agreements, Data Transfer Agreements (DTAs), sponsorship agreements and others.
- Participation in the negotiation and monitoring of all documentation required for the management of relationships with START, AETHER TECH, and the Ramón Areces Foundation.
- Participation in the implementation of the internal whistleblowing system and in the development of the FIIS-FJD Code of Ethics. The Department also participated in the establishment of the Compliance Committee, of which the Director of the Legal Department is a member.
- Legal advice and support in obtaining the licence required for the manufacture of software as a medical device, including the corresponding adaptation of the FIIS-FJD articles of association.

8.4 Marketing and Communications Area

MARKETING

The main functions are:

- Managing the Quirónsalud brand and its corporate communications.
- Developing a consistent internal and external communication style across all Quirónsalud centres in Spain through integrated messaging.
- Contributing to the definition and implementation of the Company's strategic vision.
- Promoting and disseminating the Company's values and philosophy.
- Defining communication strategies aimed at enhancing brand recognition and strengthening the position of Quirónsalud as a leading healthcare provider in Spain and Europe.
- Identifying and segmenting target audiences.
- Defining communication channels and communication tools.
- Developing hospital-specific strategic marketing plans.
- Providing support to the general management and executive management committee.

Target audiences are:

- Patients and their families.
- Employees.
- Healthcare professionals and stakeholders in the sector.
- Potential audiences.

Currently, the area is composed of:

Head of unit: María Cruz García Rueda – Corporate Director of Marketing and Communications. Brenda Barbero, Corporate Marketing Coordinator y Marta Maldonado - Marketing Specialist

Location: Corporate headquarters offices.

COMMUNICATION

The main functions and objectives are:

- Managing IIS-FJD communications.
- Defining a communication strategy to achieve appropriate external recognition, visibility and positioning for IIS-FJD.
- Defining external communication channels and tools.

Target audiences are:

- Mass media

Head of Unit: Eva Sacristán Romero (Director of the Communications Department of HUFJD and IIS-FJD).

Marta Lafora Rodríguez (Deputy Director of the Communications Department of HUFJD and IIS-FJD).

Karen Sánchez Pedrero (Communications Officer, HUFJD and IIS-FJD Communications Department).

Location: HUFJD and the group's central services.

8.5 Occupational Health and Safety

The Occupational Health and Safety Service (OHSS) of HUFJD provides coverage for IIS-FJD employees working within the hospital facilities. Among the services provided are risk assessments of job positions and work areas, health surveillance, health promotion activities, and occupational health and safety training, among others.

8.6 Quality Area

Within the area of Quality and Excellence, Fundación Jiménez Díaz has consolidated its position as one of Spain's leading hospitals, having been recognised as the top hospital in Spain for ten consecutive years according to the Hospital Excellence Index (IEH). The institution continues to stand out in specialties such as Microbiology and Endocrinology and, during 2025, celebrated its 90th anniversary, reinforcing its commitment to innovation and excellence in healthcare since its foundation.

Our objectives are to improve the patient experience and patient safety, humanising care and placing patients at the centre of all activities. We place equal importance on the prevention, promotion and improvement of population health as on the treatment and management of disease, making use of technological innovation and digital transformation, with the support of all healthcare professionals, to ensure the responsible and efficient use of resources.

Building on these established strengths and guided by a continuous improvement strategy focused on patient benefit, and supported by numerous recognitions for excellence, effectiveness and quality of care, Fundación Jiménez Díaz (FJD) closes 2025 having further strengthened its leadership within the Spanish healthcare system. Distinctive features such as its network-based healthcare model, strong commitment to technological innovation, a highly experienced medical staff, and a comprehensive and complex portfolio of services continue to differentiate the institution. These are complemented by the three pillars that underpin its activity: **healthcare, teaching and research.**

Driven by this vision, effort and commitment, the Foundation continues to work towards maintaining the highest standards of excellence, supported by numerous accreditations and certifications. Among these, recognition is given to the **JOINT COMMISSION INTERNATIONAL (JCI) GOLD SEAL OF APPROVAL**, which helps ensure the promotion of a culture and working model focused on healthcare quality, patient safety and organisational efficiency.

The Fundación Jiménez Díaz Comprehensive Cancer Centerr (the new name of the hospital's oncology division), recognised as a "Reference Technological Centre" in the 2025 ConSalud Awards, adopts a comprehensive, multidisciplinary and integrated approach to cancer care. Bringing together specialised professionals and state-of-the-art technology, it is designed to provide the highest standard of personalised cancer diagnosis and treatment.

Fundación Jiménez Díaz University Hospital was also recognised in the sixth Best Spanish Hospitals Awards (BSH) as the Best Hospital in the "Medical Processes" category within the group of High-Technology Public Hospitals. This marks the second consecutive year in which the hospital has received this distinction, ranking among the top three institutions in its hospital group and clinical category.

The hospital has also maintained its leadership position as the Best Hospital in Spain for the ninth consecutive year in both the Forbes 2025 ranking (ranking Forbes) and the Hospital Excellence Index (IEH) published by the Institute for Governance and Applied Economics (Instituto Coordenadas). This achievement reflects a management model based on excellence, innovation and patient-centred care. Its leadership is supported by an exceptional ability to combine cutting-edge technology, highly efficient processes and a strong commitment to the humanisation of healthcare, all within a framework of excellence in management. These strengths, together with outstanding results in waiting times, patient satisfaction and the ability to attract top healthcare professionals, consolidate Fundación Jiménez Díaz as a leading reference centre in Europe.

Fundación Jiménez Díaz has once again been awarded the Top 20 Prize in the category of "Overall Hospital Management" after eight consecutive years, within the group of "Regional and National Referral Hospitals". In addition, the hospital received five Top 20 Awards, standing out among the 190 participating public and private hospitals from different Spanish regions. These awards recognise the most advanced and efficient healthcare institutions, according to their size and management model, across 11 areas. These include "Digestive Diseases", "Musculoskeletal Disorders", "Kidney and Urinary Tract Diseases", and "Cardiology", together with "Respiratory Medicine", "Women's Health", "Paediatrics", "Critical Care", "Hospital Costs", "Nervous System Disorders", and "Emergency Medicine".

Likewise, Fundación Jiménez Díaz was recognised in the 2025 Best in Class Awards as the Best Hospital in "Microbiology", "Endocrinology and Nutrition" and "Obesity" in the 20th edition of the BiC Awards, organised by Gaceta Médica and the Chair of Innovation and Healthcare Management of Rey Juan Carlos University. In addition, the hospital was selected as a finalist in seven other categories: "Best High-Complexity Hospital", "Infectious Diseases", "Preventive Medicine and Public Health", "Pneumology", "Neurology", "Digestive Diseases" and "HIV/AIDS".

Dr Jesús Porta, Head of the Neurology Department of Fundación Jiménez Díaz University Hospital, received the "Clinical Healthcare Leadership Award 2025" in the category of "Neurology" for the third consecutive year. The award was presented by the Health Observatory and Communication Studio.

Fundación Jiménez Díaz (FJD) was also recognised in rankings such as Newsweek's "World's Best Hospitals 2025".

The "Decide Salud" project, developed by the Quirónsalud hospitals integrated within the Madrid Health Service (SERMAS), received the Poco Frecuentes Award in the category of "Technological Innovation in Healthcare", granted by the Institute for Research and Social Development in Rare Diseases. This award recognises the work carried out by Fundación Jiménez Díaz University Hospital. The award-winning project is a value-based medicine initiative focused on what truly matters to patients: their health and personal experience. It provides comprehensive, clear and reliable information to support shared decision-making with healthcare professionals and encourages maximum patient participation in the selection, design and planning of their healthcare process.

Fundación Jiménez Díaz University Hospital was recognised with the "A tu Salud Special Award" on its 90th anniversary. The award acknowledges the impact the institution has had on the healthcare sector over nine decades, its commitment to patients and science, and its capacity for innovation and adaptation to change. These qualities have enabled the hospital to lead the transformation of the Spanish healthcare system since its foundation and to evolve into more than just a hospital: the Fundación Jiménez Díaz Hospital Campus, an ecosystem that integrates healthcare, research and education.

Research Management Area 8

MiQuirónsalud, the digital patient portal of Spain s leading healthcare group, has surpassed 8 million users, consolidating its position as a key tool that allows patients to manage their healthcare services through a computer, mobile phone or tablet.

Fundación Jiménez Díaz is leading international training in neurointerventional treatment of complex vascular malformations through a series of courses aimed at specialists from around the world. The Madrid-based hospital is at the forefront of the application of pioneering techniques for the management of these conditions in both adult and paediatric populations.

The Community of Madrid has recognised Fundación Jiménez Díaz for a project that automates the calculation of optical prescriptions and improves the management of complex ocular diseases. The project received the Ophthalmic Innovation Award from the HealthStart madri+d programme of the Foundation for Knowledge madri+d. The award recognises a pioneering system that reduces consultation times by using an aberrometer to capture the light passing through the eye and an algorithm that eliminates subjectivity from the refraction process and calculates optical prescriptions with high precision. The patent is owned by the Fundación Jiménez Díaz Health Research Institute (IIS-FJD) and is the result of collaboration between Spanish and Portuguese professionals.

Fundación Jiménez Díaz University Hospital has been awarded the "Top Value Global Award" for the fourth time in recognition of its value-based healthcare model. The award, granted by IQVIA, forms part of a benchmarking programme designed to measure and compare organisations according to their orientation towards value-based outcomes, while recognising those institutions that have made the greatest progress in implementing this healthcare philosophy and placing value for patients at the centre of their activities.

Regarding research activity, the following achievements are particularly noteworthy:

- Dr Carmen Ayuso was recognised as an "Outstanding Personality in Healthcare" at the seventh Medical and Patient Awards organised by the Spanish Medical Association (OMC).
- Dr Marta Ruiz-Ortega received the "Excellence in Research Award in Experimental Sciences" granted by the University of Alcalá as part of the 2025 "Doctora de Alcalá" Research Excellence Awards.
- As part of the celebration of the fifteenth anniversary of its accreditation as a Health Research Institute, IIS-FJD successfully renewed its accreditation during the fourth quarter of 2025 for a further five-year period.

Staff: Bibiana Navarro Arqued (Quality Director of HUFJD).
IIS-FJD Quality and Innovation Committee.

Location: HUFJD. Avda. Reyes Católicos, 2, 28040 Madrid.

Instituto de Investigación Sanitaria
Fundación Jiménez Díaz



9

Communication **Strategy**

Communication Strategy 9

The Health Research Institute has a communication strategy whose functions include promoting the dissemination of the cultural, scientific and technical knowledge generated within IIS-FJD. Its ultimate objective is to strengthen the Institute's image within society, thereby enhancing its ability to attract resources and opportunities.

During 2025, IIS-FJD carried out the following activities in the field of Communication:

Number of communication sessions/events held

One of the IIS-FJD's priority objectives is to promote the involvement of the different social stakeholders that form part of the Institute's environment, thereby contributing to the development of research focused on the needs of society.

During 2025, IIS-FJD organised a range of activities within the framework of its Corporate Social Responsibility (CSR) policy, aimed at patient associations and audiences in primary education, secondary education and upper secondary education, among others. These activities are summarised in the following table:

Date	Activity Title
07/02/2025	Research, discover, inspire: The future of science involves everyone
10/02/2025	What does it mean to be a scientist? Bringing science into schools. Outreach talks for primary school students
11/02/2025	II Open Day: What does it mean to be a scientist? Bringing science into schools
12/02/2025	They made science: We do science and you will do science
12/02/2025	Discussion forum between researchers and patients (AEPNAA). Online meeting held in the framework of the International Day of Women and Girls in Science 2025
13/02/2025	What does it mean to be a scientist? Bringing science into schools. Outreach talks for primary school students.
13/02/2025	What Does It Mean to be a Scientist? Bringing science into schools. Outreach talks for primary school students.
13/02/2025	Women in Science. STEM Professions. Outreach talks and workshops for secondary school and upper secondary school students.
13/02/2025	Outreach Workshop: What Is Bioinformatics? Discover how programming helps us study and diagnose diseases.
14/02/2025	The cancer detectives: meet them (ASEICA).
14/02/2025	What does it mean to be a scientist? Bringing science into Schools. Outreach talks for secondary school and upper secondary school students.
14/02/2025	What does it mean to be a scientist? Bringing science into Schools. Outreach talks for primary school students.
27/02/2025	1st Outreach Conference on Biobanks in cancer research.
07/03/2025	Patient Meeting: 2nd asthma and women conference.
24/04/2025	Pancreatic cancer conference for patients.

Date	Activity Title
14/05/2025	Discussion forum: diabetes, nephropathy and research. 2025 update.
26/06/2025	Inherited retinal diseases: understanding them, living with them and facing them.
19/09/2025	National sarcoma day. Open day for patients.
03/10/2025	2nd conference for patients with congenital platelet disorders.
15/10/2025	End of life: changing the perspective
24/10/2025	Madrid Headache Forum
14/11/2025	Science and Innovation Week 2025. Workshop: What Is Bioinformatics? Discover how programming helps us study and diagnose diseases.
17/11/2025	1st Conference for patients with multiple sclerosis.
18/11/2025	Movember FJD: Awareness day on prostate cancer.
10/12/2025	Bringing science to schools: Biomedical research. Research and development of Medicines for rare diseases.

During 2025, IIS-FJD researchers participated in a wide range of activities organised by and for patient associations, neighbourhood associations, regional governments, local authorities and other organisations, contributing to scientific outreach and the promotion of scientific literacy and awareness within society. These activities are summarised in the table below:

Date	Activity Title	Research Group
28/01/2025	European Kidney Forum 2025. Early Detection, Better Outcomes: Advancing Kidney Disease Screening in the EU	Nephrology and Hypertension; Vascular Pathology and Diabetes
11/02/2025	Researcher for a Day at Madres Mercedarias School	New Therapies Research (Nursing)
14/03/2025	UniStem Day 2025: The Endless Journey of Stem Cell Research	New Therapies Research; Advanced Therapies (CIEMAT)
07/04/2025	Talk within the "CIEMAT in Your School" Programme	Advanced Therapies (CIEMAT)
21/05/2025	10th Edition of Pint of Science Madrid	Alberto Ortiz
27/05/2025	Seminar: "Extended Mind: To Infinity and Beyond?". 12th Seminar Series 2025: Philosophy, Evolution and Health	Genetics and Genomics of Rare and Complex Diseases
24/07/2025	Upper secondary school student internship Programme: bioprinting hearts. Advances, challenges and the future of regenerative medicine	Advanced Therapies (CIEMAT)
09/10/2025	Scientific Outreach Lecture: Bioengineering for the humanity of the future. Advances in molecular and cellular biology	IIS-FJD Regenerative Medicine and Tissue Engineering Group
09/10/2025	Scientific Outreach Lecture: Bioengineering for the humanity of the future. Advances in molecular and cellular biology	IIS-FJD Regenerative Medicine and Tissue Engineering Group

Furthermore, the Institute participated in the 4 ESO + Company Programme, promoting students' exposure to the field of biomedical research through 22 observational placements, providing secondary school students with the opportunity to gain first-hand insight into research activities and careers in biomedical science.

Total of press releases issued

During 2025, a greater number of stories relating to IIS-FJD were published, and several highly relevant events associated with the Institute attracted significant media attention. A total of 17 press releases were issued. These were also promoted through posts on the HUFJD X (formerly Twitter) account, linking to the full content available on the website. These press releases generated 1,844 media mentions, including numerous references to IIS-FJD in broader hospital-related coverage.

In addition to these impacts, many others resulted from research- and IIS-FJD-related news disseminated through channels other than press releases, such as interviews, feature articles and other media formats.

Total of articles published in the printed press

The total of print media mentions derived from press releases related to research activities or IIS-FJD during 2025 was 139.

News in other media (radio and television)

During 2025, press releases relating to research activities or IIS-FJD also generated coverage in other media channels, including audiovisual, digital, radio and news agency outlets. These activities are summarised below:

Media type	Number of items
Press	139
Radio	4
Television	2
Online Media	1,676
Agencies	23

Total of visits to the website

The number of visits to the IIS-FJD website during 2025 was 107,260.

Instituto de Investigación Sanitaria
Fundación Jiménez Díaz



10

IIS-FJD Training **Plan**

OBJECTIVES

The **overall objective of the IIS-FJD Training Plan** is to enhance and deepen both general scientific knowledge and expertise in the Institute's priority research areas addressing **clinical problems.** The Plan is aimed at all members of the Health Research Institute and forms part of the actions defined in the IIS-FJD Strategic Plan 2024-2028, under the strategic objective "KNOWLEDGE", which seeks to foster an R&D&I culture through dissemination activities directed at both the scientific community and society, as stakeholders and beneficiaries of research outcome.

This overall objective is pursued through the following specific objectives:

- Continuous acquisition of scientific knowledge, attitudes, competencies and skills by all professionals of the Institution, both healthcare and non-healthcare staff, according to their role and level of responsibility, to enhance the quality of the priority research lines and areas defined in the Scientific Plan.
- Provision of theoretical, practical and methodological training to ensure the appropriate use of biotechnological and bioinformatic resources, as well as mastery of the techniques required for the development of research activities.
- Training in research ethics and professional conduct to ensure that scientific practice is carried out in accordance with Good Research Practices.
- Promotion of interaction between clinical and basic scientists through the creation of a scientific cultural community as a foundation for translational research.

This training plan aims to strengthen the Institute's critical mass of researchers, enabling the generation of a greater volume of high-quality knowledge across the biomedical areas identified as priorities by IIS-FJD.

The Research Training Plan implemented by IIS-FJD in 2025 was structured around several programmes:

- Undergraduate and graduate research training programme.
- Postgraduate research training programme.
- Training programme for IIS-FJD research staff.
- Research training programme for specialist healthcare professionals and Primary Care professionals.
- Seminars, conferences and scientific meetings.

10.1 Target audience for research training

Research training at IIS-FJD encompasses educational activities aimed at all professionals within the organisation, as well as researchers and students from different educational levels interested in participating in the training opportunities offered by the Institute.

In this regard, the courses and activities included in the IIS-FJD Training Plan are intended for the following groups:

- Research trainees of the Institute, including undergraduate and postgraduate university students, primarily from UAM, but also from other universities.

- Students enrolled in Higher Vocational Training Programmes and students from secondary schools within the Community of Madrid who are interested in the research activities carried out at the Institute.
- Specialised Healthcare Training students (residents) undertaking their training at HUFJD and other affiliated hospitals, who are interested in developing a scientific research career.
- Primary Care specialist physicians
- Laboratory technicians, professionals working in institutional support services, and other research support personnel.
- Early-career researchers in the process of consolidating their scientific careers.
- Healthcare professionals with an interest in research activities.
- Established researchers of the Institute seeking to update their knowledge and further develop their competencies.
- Members of the IIS-FJD management structure.
- Other external professionals with scientific interests.

Some of the dissemination and training activities included in the Training Plan are open to researchers and professionals from other research institutions. In addition, the programme includes activities specifically aimed at patient groups and the public.

10.2 Training Structures

The Scientific Directorate of IIS-FJD is responsible for planning the Institute's training activities and is supported in this task by the Training Subcommittee, which forms part of the Research Committee. The training plans developed are submitted to the Research Committee for review, and any recommendations for improvement issued by this body are considered and incorporated into the training planning process. The final training programme is approved by the Institute's Governing Bodies.

To promote synergies with the institutions that make up IIS-FJD as part of the integration process and to increase the efficiency of resources allocated to training, the Institute has incorporated the following training-related roles within its organisational structure:

Training Area	Leader	Institution	Committees/ Bodies
Undergraduate Medical Education	Prof. Damián García Olmo (Professor of Surgery, group leader) Prof. Jesus Garcia Foncillas (Professor of Medicine, group leader)	HUFJD / UAM HUFJD / UAM	IIS-FJD Research Committee IIS-FJD Training Subcommittee Member of the Scientific Integrity Committee UAM Teaching Committee IIS-FJD Training Subcommittee

Training Area	Leader	Institution	Committees/ Bodies
Non-Medical Undergraduate Education	Prof. Raquel Largo Carazo (Group leader)	IIS-FJD	IIS-FJD Research Committee IIS-FJD Training Subcommittee IIS-FJD Training Coordinator
	Prof. Carmen Gómez Guerrero (Associate Professor, Faculty of Medicine; group leader)	UAM	IIS-FJD Research Committee IIS-FJD Training Subcommittee Member of the CEBA
Postgraduate Education	Prof. Raquel Largo Carazo (Group leader)	IIS-FJD	IIS-FJD Research Committee IIS-FJD Training Subcommittee IIS-FJD Training Coordinator
	Prof. Carmen Gómez Guerrero (Associate Professor, Faculty of Medicine; Group Leader)	UAM	IIS-FJD Research Committee IIS-FJD Training Subcommittee Member of the CEBA
Specialised Healthcare Training	Prof. Leandro Soriano Guillén Chair of the HUFJD Teaching Committee; Head of Studies)	HUFJD	Specialised Healthcare Training (FSE) Teaching Committee IIS-FJD Training Subcommittee
Researcher Training	Prof. Raquel Largo Carazo (Group leader)	IIS-FJD	IIS-FJD Research Committee IIS-FJD Training Subcommittee IIS-FJD Training Coordinator
	Dra. Lucía Llanos Jiménez (Secretary of the CEIm; Head of the UICEC)	HUFJD	IIS-FJD Research Committee IIS-FJD Training Subcommittee Technical Secretary of the HUFJD Research Ethics Committee with Medicines (CEIm) Member of the Scientific Integrity Committee
	Prof. Victoria del Pozo Abejón (Deputy Scientific Director; group leader)	IIS-FJD	Secretary of the IIS-FJD Research Committee IIS-FJD Training Subcommittee Quality and Innovation Committee

10.3 Identification of training needs

The three main sources for identifying training needs within IIS-FJD are the needs of the Spanish National Health System (SNS), the needs arising from the R&D&I environment, and the specific needs of the professionals targeted by the Training Plan.

10.3.1 Needs of the Spanish National Health System (SNS)

The needs of the Spanish National Health System (SNS) have been considered in defining the strategic areas that constitute the scientific structure of IIS-FJD. Training activities have been prioritised and oriented towards addressing health problems through basic, clinical and epidemiological research, with the aim of translating this knowledge into clinical practice.

The Training Subcommittee, composed of researchers from our institution, maintains continuous contact with professionals from all areas of IIS-FJD. These professionals directly communicate the different training needs and opportunities identified in their respective environments, which are subsequently incorporated into the IIS-FJD training portfolio from a scientific perspective, strengthening professionals' knowledge and competencies in this field.

10.3.2 Needs of the R&D&I Environment

One of the major priorities of the Spanish State Plan for Scientific, Technical and Innovation Research 2024-2027 is the promotion of R&D&I, renewing and accelerating Spain's commitment to positioning itself among the world's leading countries in science and technology. The State Plan includes a cross-cutting programme aimed at strengthening human resources, in which IIS-FJD already participates. Among its objectives is ensuring the adaptation and development of research trainees through specialised training and active involvement in research activities.

IIS-FJD prepares applications and submits candidates to participate in these programmes, which are linked to the early stages of the research career pathway, including programmes funded by the Carlos III Health Institute (ISCIII), the Ministry of Science and Innovation, the Ministry of Universities, and the Regional Government of Madrid. Through these initiatives, predoctoral and postdoctoral researchers are incorporated into the Institute's research groups.

Universities also play a major role in promoting research training through master's degree programmes and undergraduate final-year research projects. In this context, IIS-FJD hosts students enrolled in official master's programmes offered by the Autonomous University of Madrid (UAM) and other universities to undertake their Master's Final Projects (TFM). Similarly, undergraduate studentsstudents finish curricular and extracurricular placements, as well as Bachelor's Final Projects (TFG), within the Institute.

In addition, IIS-FJD continuously monitors emerging technologies, techniques and methodologies that may contribute to improving the quality of scientific activities. Accordingly, the Institute evaluates the appropriateness of incorporating innovative and relevant topics into its annual training programme, ensuring that researchers and professionals have access to the latest advances applicable to their fields of work.

10.3.3 Research staff training needs

The training programme must address educational needs related to new techniques and technologies to maintain and enhance researchers' competencies, improve the scientific level of IIS-FJD, and facilitate the translation of research findings into clinical practice. Training needs are primarily associated with the Institute's strategic research areas, the application of new technologies and techniques, and their translational potential.

In addition to the courses and seminars delivered within IIS-FJD, other training needs are addressed through mobility programmes involving placements at national and international institutions. In this regard, accreditation as a Health Research Institute has enabled IIS-FJD to establish collaborative frameworks with other accredited institutions, facilitating the exchange of knowledge throughout the national research network.

The Institute's main tool for identifying the training needs of its professionals is the training needs assessment survey. This survey, which is addressed to all IIS-FJD professionals, collects information from researchers regarding:

- Sex.
- Unit or department of affiliation.
- Professional category.
- Areas of interest (with a dedicated section for additional comments and suggestions).
- Preferred type of training.
- Preferred training modality.

- Suggestion for the training activity to be carried out, including (space is provided to add any general comments deemed appropriate):
    - Course title or topic.
    - Reason for the training need (e.g. refresher training, new legislation, new technologies, etc.).
    - Professional categories for which the activity is intended.
    - Estimated number of professionals who would benefit from the activity.
    - Additional observations and/or suggestions.

Upon receipt of these surveys, they are reviewed and analysed with the aim of identifying new initiatives that may be incorporated into the Institute's Training Plan in future years. In this way, the participation of all professionals in the development of the IIS-FJD training portfolio is encouraged.

Furthermore, the IIS-FJD promotes the organization of forums and meetings among researchers through research area meetings. At our Institute, an annual meeting of research areas and research groups is held, as will be detailed below, in which all research groups participate and where they also express the training needs of our professionals.

10.4 Undergraduate research training

The training plan for undergraduate students aims to introduce a research culture to students pursuing studies in the various Health Sciences faculties of the institutions that form part of the IIS-FJD: HUFJD, affiliated hospitals, and UAM, as well as other universities that have signed collaboration agreements with our Institute.

The IIS-FJD is the institution where students of the UAM Faculty of Medicine who undertake their studies at HUFJD complete the courses included in the new curriculum on Introduction to Research. This curriculum (adapted to the so-called "Bologna Process") began to be implemented at UAM during the 2010-2011 academic year and was fully completed with the sixth year of the degree programme in the 2015-2016 academic year. This curriculum reform strongly encourages students to enhance their training in the scientific method and includes research-related training activities specifically designed for medical students.

In addition, the IIS-FJD develops training programmes for undergraduate students from the Faculties of Biology, Chemistry, Pharmacy, and other disciplines at UAM and other universities, who choose our institution to gain exposure to research for a defined period as part of their academic training.

Undergraduate Training for UAM Medical Students:

The Clinical Teaching Unit (CTU) of HUFJD, affiliated with the Faculty of Medicine of the Autonomous University of Madrid (UAM), is coordinated by Prof. Jesús García-Foncillas, the Dean's Delegate at HUFJD. It provides the theoretical and practical training of 25% of the students enrolled in the Faculty of Medicine during the 3rd to 6th years of the Medicine degree programme. The number of medical undergraduate students assigned to the Hospital was 291 in the 2024-2025 academic year and 283 in 2025-2026.

These students include both those enrolled at UAM and those received through other university programmes (ERASMUS, SICUE, Cajal Programme, etc.). Their training is delivered by 119 faculty members (full professors, associate professors, adjunct professors, honorary professors, and emeritus professors), together with the entire hospital medical staff.

Since the 2023-2024 academic year, students enrolled in the Biomedical Engineering Degree programme at the UAM School of Engineering have also begun undertaking clinical placements at the Hospital. Approximately 10 students rotate each semester. During the first semester of the 2025-2026 academic year, no Biomedical Engineering students rotated at the Hospital.

The graduation ceremony for the 6th year of the Medicine degree programme was held on **25 April 2025**, at 4:00 p.m. in the Main Auditorium (Aula Magna) of HUFJD.

The curriculum (adapted to the Bologna Process) began to be implemented at UAM during the 2010-2011 academic year and culminated with the first cohort reaching the sixth year of the degree programme in the 2015-2016 academic year. The most relevant research training activities included in this new curriculum are:

- In the third year of the Medicine Degree programme:
  - A compulsory 6-credit course: "Introduction to Biomedical Research.".
  - Two compulsory 3-credit courses: "Epidemiological Research" and "Clinical Bioethics.".

In addition, within the third-year course Introduction to Surgical Practice (ISP), the following workshops were conducted during the 2025-2026 academic year:

  - Practical Session 1. Asepsis and Antisepsis. 13 February 2026, at 3:00 p.m.
  - Practical Session 2. Suturing Techniques. 20 March 2026, at 3:00 p.m.

- In the fifth year of the Medicine Degree programme:
  - A compulsory 3-credit course: "Experimental Clinical Research."
- In the sixth year of the Medicine Degree programme:
  - A 6-credit course entitled "Bachelor's Final Project" (Final Degree Project), which is a mandatory requirement for obtaining the Degree in Medicine.

Therefore, this training programme comprises a total of 18 ECTS credits (450 hours of student workload) of direct research training for our undergraduate students.

In the 2024-2025 academic year, 291 UAM medical students were assigned to HUFJD. In addition, we hosted 74 students participating in ERASMUS and other mobility programmes. The number of UAM medical students enrolled in research initiation courses at our hospital during the 2024-2025 academic year is detailed below:

- **Third-year medicine degree students:**
  a. INTRODUCTION TO BIOMEDICAL RESEARCH: 57 students
  b. EPIDEMIOLOGICAL RESEARCH: 56 students
- **Fifth-year medicine degree students:**
  c. EXPERIMENTAL CLINICAL RESEARCH: 35 students.
- S**ixth-year medicine degree students:**
  d. BACHELOR'S FINAL PROJECT: 50 students.

Undergraduate training for UAM nursing students:

At the Autonomous University of Madrid (UAM) School of Nursing (Escuela Universitaria de Enfermería, EUE), the total of students enrolled in the Nursing Degree programme was 590 in the 2024-2025 academic year and 657 in the 2025-2026 academic year.

Undergraduate training for students in other health sciences degree programmes:

Regarding the training of undergraduate students from other Health Sciences faculties, each year the Institute welcomes students from UAM and other universities who choose our centre to undertake a period of research training through curricular internships, extracurricular internships, or final degree projects. The IIS-FJD has signed agreements with various universities, including the University of Alcalá, Carlos III University of Madrid, Complutense University of Madrid, Technical University of Madrid, Rey Juan Carlos University, Autonomous University of Barcelona, among others, thereby providing a regulatory framework for these placements.

The training of these undergraduate students is carried out within the different IIS-FJD research groups to which they are assigned. Through their integration into these groups, students gain access both to the training activities organised by the host research group and to the various activities conducted by the IIS-FJD during their placement period.

The undergraduate Medicine students and students from other Health Sciences degree programmes who undertook curricular placements, extracurricular placements, and/or final degree projects within the research groups of our Institute during 2025 are detailed below.

Student	Tutor/s	Research Group	Degree Programme	University
José Carlos Hernández Hernández	Blanca Cárdaba	Allergy and Immunology	Biomedicine	European University of Madrid
Álvaro Arranz Fragua	Victoria del Pozo	Allergy and Immunology	Biochemistry	Autonomous University of Madrid
Patricia Noguera	Vanesa Esteban Vázquez	Allergy and Immunology	Biomedicine	Alfonso X el Sabio University
Andrea Salvador	Vanesa Esteban	Allergy and Immunology	Biomedicine	Alfonso X el Sabio University
Vania Méndez	Vanesa Esteban	Allergy and Immunology	Biomedicine	Alfonso X el Sabio University
Natalia Antón Sánchez	Juan Madoz Gúrpide	Anatomical Pathology	Biological Sciences	Autonomous University of Madrid
Pablo Lozano Moreno	Álvaro Aceña	Cardiology	Medicine	Autonomous University of Madrid
Mireya Blasco Cañas	José Manuel Rubio	Cardiology	Medicine	Autonomous University of Madrid
Ricardo Aguado Gutiérrez	José Manuel Rubio	Cardiology	Medicine	Autonomous University of Madrid
Cleidy de Assis Gallardo	Andrea Kallmeyer, José Tuñón	Cardiology	Medicine	Autonomous University of Madrid
Lucía Ruiz Ferriz	Miguel Orejas, Marcelino Cortés	Cardiology	Medicine	Autonomous University of Madrid
Sara Reumiñan	Eduardo Lage	Development and Innovation in Medical Engineering	Biomedical Engineering	Autonomous University of Madrid
Emanuela Nicoleta Cot	Eduardo Lage	Development and Innovation in Medical Engineering	Biomedical Engineering	Autonomous University of Madrid
Juan José Rodríguez	Juan Aguirre	Development and Innovation in Medical Engineering	Telecommunications Engineering	Autonomous University of Madrid
Jorge Muñoz García	Juan Aguirre	Development and Innovation in Medical Engineering	Biomedical Engineering	Autonomous University of Madrid

10 IIS-FJD Training Plan

Instituto de Investigación Sanitaria
Fundación Jiménez Díaz

Student	Tutor/s	Research Group	Degree Programme	University
Alicia Alonso Dubost	Juan Aguirre	Development and Innovation in Medical Engineering	Biomedical Engineering	Autonomous University of Madrid
Alicia Alonso Dubost	Juan Aguirre	Development and Innovation in Medical Engineering	Biomedical Engineering	Autonomous University of Madrid
Miguel Santiago Paiba Montaña	Norma Rallón	Infectious Diseases and Tropical Medicine	Medicine	Pedagogical and Technological University of Colombia (UPTC)
Paula Bernal	Norma Rallón	Infectious Diseases and Tropical Medicine	Medicine	Pedagogical and Technological University of Colombia (UPTC)
Antonio Ignacio Insúa Rodríguez	Alfonso Cabello Úbeda	Infectious Diseases and Tropical Medicine	Medicine	Autonomous University of Madrid
Miguel Centeno Martínez	Alfonso Cabello Úbeda	Infectious Diseases and Tropical Medicine	Medicine	Autonomous University of Madrid
Ana Barcenilla Martín	Miguel Górgolas Hernández-Mora.	Infectious Diseases and Tropical Medicine	Medicine	Autonomous University of Madrid
Belén Pardo Molina	Alfonso Cabello Úbeda	Infectious Diseases and Tropical Medicine	Medicine	Autonomous University of Madrid
Lucía Vera Rodríguez	Laura Prieto Pérez	Infectious Diseases and Tropical Medicine	Medicine	Autonomous University of Madrid
Lucas Pomeda	Laura Prieto Pérez	Infectious Diseases and Tropical Medicine	Medicine	Autonomous University of Madrid
Celia García Llerenas	Alfonso Cabello Úbeda	Infectious Diseases and Tropical Medicine	Medicine	Autonomous University of Madrid
Isabel Boy González	Saoud Tahsin Swafiri	Genetics and Genomics of Rare and Complex Diseases	Medicine	Francisco de Vitoria University
Izare López Asensio	Saoud Tahsin Swafiri	Genetics and Genomics of Rare and Complex Diseases	Medicine	Francisco de Vitoria University
Maha Aran Malik	Saoud Tahsin Swafiri	Genetics and Genomics of Rare and Complex Diseases	Medicine	Francisco de Vitoria University
Lucía García Delgado	Pablo Mínguez, Arancha Cebrián	Genetics and Genomics of Rare and Complex Diseases / Bioinformatics Unit	Biotechnology	Technical University of Madrid
María Arribas	Daniel Lainez/Juana Serrano López	Haematology	Biomedicine	Francisco de Vitoria University
María del Moral Medina	Pilar Llamas, Ana del Río, Juana Serrano	Haematology	Medicine	Francisco de Vitoria University
Paula Díez Garrido	Alejandro Cencerrado	Haematology	Nursing	FJD School of Nursing, Autonomous University of Madrid
Andrea Carmona Pérez	June Artaechevarria Artieda, Ignacio Jiménez-Alfaro Morote	Innovation in Ophthalmology	Medicine	Autonomous University of Madrid
Diego Yvorra Cerdán	Mariano García Arranz	Research in New Therapies	Biomedical Engineering	Autonomous University of Madrid
Irene Bretón Ortiz	Rocio Olivera	Research in New Therapies	Biomedicine	Alfonso X el Sabio University
Silvia Gutiérrez Menéndez	Rocio Olivera	Research in New Therapies	Biomedicine	Alfonso X el Sabio University

IIS-FJD Training Plan 10

Student	Tutor/s	Research Group	Degree Programme	University
Michelle Brenner Anidjar	María Luisa Sánchez de Molina Rampérez	Research in New Therapies	Medicine	Autonomous University of Madrid
Beatriz López Morato	Pedro Villarejo Campos	Research in New Therapies	Medicine	Autonomous University of Madrid
Rubén Díaz Susmozas	Beatriz González	Research in New Therapies	Nursing	FJD School of Nursing, Autonomous University of Madrid
Claudia Fernández Rodríguez	Beatriz González	Research in New Therapies	Nursing	FJD School of Nursing, Autonomous University of Madrid
Cristina López-Oliva Aldomar	Beatriz González	Research in New Therapies	Nursing	FJD School of Nursing, Autonomous University of Madrid
Irene Montero Barahona	Beatriz González	Research in New Therapies	Nursing	FJD School of Nursing, Autonomous University of Madrid
Lucía Ruiz Aparicio	Beatriz González	Research in New Therapies	Nursing	FJD School of Nursing, Autonomous University of Madrid
María Cabrera Clavel	Belén González	Research in New Therapies	Nursing	FJD School of Nursing, Autonomous University of Madrid
Nabil Boutalib García	Belén González	Research in New Therapies	Nursing	FJD School of Nursing, Autonomous University of Madrid
María González Martín	Belén González	Research in New Therapies	Nursing	FJD School of Nursing, Autonomous University of Madrid
Álvaro Pérez Basas	Belén González	Research in New Therapies	Nursing	FJD School of Nursing, Autonomous University of Madrid
Paloma Mulas Cámara	Belén González	Research in New Therapies	Nursing	FJD School of Nursing, Autonomous University of Madrid
Patricia Rodríguez Rojas	Belén González	Research in New Therapies	Nursing	FJD School of Nursing, Autonomous University of Madrid
Clara Herdin Muñoz	Cristina Barneto	Research in New Therapies	Nursing	FJD School of Nursing, Autonomous University of Madrid
Silvia Gómez Llop	Cristina Gómez	Research in New Therapies	Nursing	FJD School of Nursing, Autonomous University of Madrid
Lucía Ausocua de Sola	Elena Arroyo	Research in New Therapies	Nursing	FJD School of Nursing, Autonomous University of Madrid
Sara García Pastor	Elena Arroyo	Research in New Therapies	Nursing	FJD School of Nursing, Autonomous University of Madrid
Alexia Gómez Fernández	Elena Arroyo	Research in New Therapies	Nursing	FJD School of Nursing, Autonomous University of Madrid

Student	Tutor/s	Research Group	Degree Programme	University
Mª Pilar González Lozoya	Elena Arroyo	Research in New Therapies	Nursing	FJD School of Nursing, Autonomous University of Madrid
Naomi Moyano Bouzada	Elena Arroyo	Research in New Therapies	Nursing	FJD School of Nursing, Autonomous University of Madrid
Amaia Moscat Goñi	Elena Arroyo	Research in New Therapies	Nursing	FJD School of Nursing, Autonomous University of Madrid
Paula Otero Magán	Elena Arroyo	Research in New Therapies	Nursing	FJD School of Nursing, Autonomous University of Madrid
Celia Romero Díaz	Elena Arroyo	Research in New Therapies	Nursing	FJD School of Nursing, Autonomous University of Madrid
Ángela Vázquez Marugán	Elena Arroyo	Research in New Therapies	Nursing	FJD School of Nursing, Autonomous University of Madrid
Ángela Sánchez Luengo	Esther Rodríguez	Research in New Therapies	Nursing	FJD School of Nursing, Autonomous University of Madrid
Sara Gómez Mancebo	Esther Rodríguez	Research in New Therapies	Nursing	FJD School of Nursing, Autonomous University of Madrid
Loreto Ledesma Saldias	Esther Rodríguez	Research in New Therapies	Nursing	FJD School of Nursing, Autonomous University of Madrid
Elena Vilaplana Colorado	Esther Rodríguez	Research in New Therapies	Nursing	FJD School of Nursing, Autonomous University of Madrid
Andrea Xuan Minayo	Esther Rodríguez	Research in New Therapies	Nursing	FJD School of Nursing, Autonomous University of Madrid
Adriana Pacios Relaño	Esther Rodríguez	Research in New Therapies	Nursing	FJD School of Nursing, Autonomous University of Madrid
Sofía Rodríguez Pereira	Esther Rodríguez	Research in New Therapies	Nursing	FJD School of Nursing, Autonomous University of Madrid
Elena Rodríguez Marcén	Esther Rodríguez	Research in New Therapies	Nursing	FJD School of Nursing, Autonomous University of Madrid
Ana Moreno Moral	Isabel Aragón	Research in New Therapies	Nursing	FJD School of Nursing, Autonomous University of Madrid
Laura Carrasco Vigil	Isabel Aragón	Research in New Therapies	Nursing	FJD School of Nursing, Autonomous University of Madrid
María Jiménez García	Isabel Aragón	Research in New Therapies	Nursing	FJD School of Nursing, Autonomous University of Madrid
Paula Peñarando Márquez	Isabel Aragón	Research in New Therapies	Nursing	FJD School of Nursing, Autonomous University of Madrid

Student	Tutor/s	Research Group	Degree Programme	University
Luna Arolas Clemente	José Abad	Research in New Therapies	Nursing	FJD School of Nursing, Autonomous University of Madrid
Lucía Álvaro Martínez	José Abad	Research in New Therapies	Nursing	FJD School of Nursing, Autonomous University of Madrid
Claudia López Nadal	José Abad	Research in New Therapies	Nursing	FJD School of Nursing, Autonomous University of Madrid
Ángel Guillén	José Abad	Research in New Therapies	Nursing	FJD School of Nursing, Autonomous University of Madrid
Pablo Martín Plaza	José Abad	Research in New Therapies	Nursing	FJD School of Nursing, Autonomous University of Madrid
María Gómez Fernández	María Béjar	Research in New Therapies	Nursing	FJD School of Nursing, Autonomous University of Madrid
Eva Arias Comendador	Marta Garrigues	Research in New Therapies	Nursing	FJD School of Nursing, Autonomous University of Madrid
Natalia Alonso Endriss	Marta Garrigues	Research in New Therapies	Nursing	FJD School of Nursing, Autonomous University of Madrid
Dalia Soto García	Marta Garrigues	Research in New Therapies	Nursing	FJD School of Nursing, Autonomous University of Madrid
Adriana San José Medina	Marta Garrigues	Research in New Therapies	Nursing	FJD School of Nursing, Autonomous University of Madrid
Blanca Fraile Lanzarot	Patricia Torres	Research in New Therapies	Nursing	FJD School of Nursing, Autonomous University of Madrid
Marta Corral Santos	Patricia Torres	Research in New Therapies	Nursing	FJD School of Nursing, Autonomous University of Madrid
Hugo Medina Velasco	Patricia Torres	Research in New Therapies	Nursing	FJD School of Nursing, Autonomous University of Madrid
Carlota Aguado Poo	Patricia Torres	Research in New Therapies	Nursing	FJD School of Nursing, Autonomous University of Madrid
Raquel Martín-Benito	Patricia Torres	Research in New Therapies	Nursing	FJD School of Nursing, Autonomous University of Madrid
Alberto Rodríguez Privado	Patricia Torres	Research in New Therapies	Nursing	FJD School of Nursing, Autonomous University of Madrid
Jorge Iborra de la Iglesia	Patricia Torres	Research in New Therapies	Nursing	FJD School of Nursing, Autonomous University of Madrid
Gabriela Andrea Hernández Hernández	Javier Gutiérrez Adame	Research in New Therapies	Nursing	FJD School of Nursing, Autonomous University of Madrid

10 IIS-FJD Training Plan

Instituto de Investigación Sanitaria
Fundación Jiménez Díaz

Student	Tutor/s	Research Group	Degree Programme	University
Ana Arroyo Fernández-Capalleja	Miriam Somolinos Yagüe	Research in New Therapies	Nursing	FJD School of Nursing, Autonomous University of Madrid
Amanda García García	Patricia María Rolle Fernández	Research in New Therapies	Nursing	FJD School of Nursing, Autonomous University of Madrid
Gabriela de Francisco Serrano	Javier Gutiérrez Adame	Research in New Therapies	Nursing	FJD School of Nursing, Autonomous University of Madrid
Raquel Castelao Castañeda	Estela Álvarez Gómez	Research in New Therapies	Nursing	FJD School of Nursing, Autonomous University of Madrid
Alba Hava Rodríguez	Mª Carmen Hernández Cediel	Research in New Therapies	Nursing	FJD School of Nursing, Autonomous University of Madrid
Ignacio Alda Checa	Estela Álvarez Gómez	Research in New Therapies	Nursing	FJD School of Nursing, Autonomous University of Madrid
Jorge Ortiz Serrano	Estela Álvarez Gómez	Research in New Therapies	Nursing	FJD School of Nursing, Autonomous University of Madrid
Elena Romero Hidalgo	Estela Álvarez Gómez	Research in New Therapies	Nursing	FJD School of Nursing, Autonomous University of Madrid
Carla Marín Inocencio	Estela Álvarez Gómez	Research in New Therapies	Nursing	FJD School of Nursing, Autonomous University of Madrid
Vanesa Peña Vigara	Estela Álvarez Gómez	Research in New Therapies	Nursing	FJD School of Nursing, Autonomous University of Madrid
Andrea Rodríguez Fernández	Javier Gutiérrez Adame	Research in New Therapies	Nursing	FJD School of Nursing, Autonomous University of Madrid
Ruth Tovar Senesén	Patricia Rolle Fernández	Research in New Therapies	Nursing	FJD School of Nursing, Autonomous University of Madrid
Carlota Valencia Herrera	Mª Carmen Hernández Cediel	Research in New Therapies	Nursing	FJD School of Nursing, Autonomous University of Madrid
Alba Penas Fernández	Elisa Cortés Zamora	Research in New Therapies	Nursing	FJD School of Nursing, Autonomous University of Madrid
Yadira Pérez Suárez	Javier Gutiérrez Adame	Research in New Therapies	Nursing	FJD School of Nursing, Autonomous University of Madrid
Amanda Seguers García	Patricia Rolle Fernández	Research in New Therapies	Nursing	FJD School of Nursing, Autonomous University of Madrid
Elena Iglesias Ibáñez	Elisa Cortés Zamora	Research in New Therapies	Nursing	FJD School of Nursing, Autonomous University of Madrid
Silvia Adrián Díaz	Estela Álvarez Gómez	Research in New Therapies	Nursing	FJD School of Nursing, Autonomous University of Madrid

Student	Tutor/s	Research Group	Degree Programme	University
Jennifer Gorski Pérez de Bustos	Estela Álvarez Gómez	Research in New Therapies	Nursing	FJD School of Nursing, Autonomous University of Madrid
Celia Jurado Rincón	Mª Carmen Hernández Cediel	Research in New Therapies	Nursing	FJD School of Nursing, Autonomous University of Madrid
Lucía Valenciano Romero	Estela Álvarez Gómez	Research in New Therapies	Nursing	FJD School of Nursing, Autonomous University of Madrid
Luz González García	Elisa Cortés Zamora	Research in New Therapies	Nursing	FJD School of Nursing, Autonomous University of Madrid
Mª Carmen Aparicio Arroyo	Mª Carmen Hernández Cediel	Research in New Therapies	Nursing	FJD School of Nursing, Autonomous University of Madrid
Sara Quilis Larios	Mª Carmen Hernández Cediel	Research in New Therapies	Nursing	FJD School of Nursing, Autonomous University of Madrid
Judit Aguejas Villanueva	Estela Álvarez Gómez	Research in New Therapies	Nursing	FJD School of Nursing, Autonomous University of Madrid
Marta García Aguilar	Patricia Rolle Fernández	Research in New Therapies	Nursing	FJD School of Nursing, Autonomous University of Madrid
Lucía Quirós Gil	Javier Gutiérrez Adame	Research in New Therapies	Nursing	FJD School of Nursing, Autonomous University of Madrid
Víctor Esteban García	Javier Gutiérrez Adame	Research in New Therapies	Nursing	FJD School of Nursing, Autonomous University of Madrid
Ana Carranza Pérez	Javier Gutiérrez Adame	Research in New Therapies	Nursing	FJD School of Nursing, Autonomous University of Madrid
Jorge Vivar Gómez	Miriam Somolinos Yagüe	Research in New Therapies	Nursing	FJD School of Nursing, Autonomous University of Madrid
Paola Álvarez Moratilla	Miriam Somolinos Yagüe	Research in New Therapies	Nursing	FJD School of Nursing, Autonomous University of Madrid
Pablo Cachón Salgado	Javier Gutiérrez Adame	Research in New Therapies	Nursing	FJD School of Nursing, Autonomous University of Madrid
Laura Madariaga Sánchez	Patricia Rolle Fernández	Research in New Therapies	Nursing	FJD School of Nursing, Autonomous University of Madrid
Elena Hernández Sánchez	Carlos León Canseco	Regenerative Medicine and Tissue Bioengineering (CIEMAT-UC3M)	Biomedical Engineering	Carlos III University of Madrid
Celia Gómez Campo	Carlos León Canseco	Regenerative Medicine and Tissue Bioengineering (CIEMAT-UC3M)	Biomedical Engineering	Carlos III University of Madrid
Marina Burgos Martín	Carlos León Canseco, Sara Herráiz Gil	Regenerative Medicine and Tissue Bioengineering (CIEMAT-UC3M)	Biomedical Engineering	Carlos III University of Madrid

10 IIS-FJD Training Plan

Student	Tutor/s	Research Group	Degree Programme	University
Carmen Alonso Casero	Carlos León Canseco	Regenerative Medicine and Tissue Bioengineering (CIEMAT-UC3M)	Biomedical Engineering	Carlos III University of Madrid
Miguel Velarde Olaizola	Sara Guerrero Aspizua	Regenerative Medicine and Tissue Bioengineering (CIEMAT-UC3M)	Biomedical Engineering	Carlos III University of Madrid
Lucía Ruiz Manzano	Sara Guerrero Aspizua	Regenerative Medicine and Tissue Bioengineering (CIEMAT-UC3M)	Biomedical Engineering	Carlos III University of Madrid
Sofía Moreno Zarza	Sara Guerrero Aspizua	Regenerative Medicine and Tissue Bioengineering (CIEMAT-UC3M)	Biomedical Engineering	Carlos III University of Madrid
Juan Pablo Ponce Peceño	Sara Guerrero Aspizua	Regenerative Medicine and Tissue Bioengineering (CIEMAT-UC3M)	Biomedical Engineering	Carlos III University of Madrid
Juan Berzosa Meseguer	Cristina Quílez López	Regenerative Medicine and Tissue Bioengineering (CIEMAT-UC3M)	Biomedical Engineering	Carlos III University of Madrid
Carla López de Zamora Pagán	Cristina Quílez López	Regenerative Medicine and Tissue Bioengineering (CIEMAT-UC3M)	Biomedical Engineering	Carlos III University of Madrid
Laura del Carmen Madrigal Martín	Cristina Quílez López	Regenerative Medicine and Tissue Bioengineering (CIEMAT-UC3M)	Biomedical Engineering	Carlos III University of Madrid
Rodrigo Chinarro Vos	Cristina Quílez López, Leticia Valencia Blanco	Regenerative Medicine and Tissue Bioengineering (CIEMAT-UC3M)	Sciences	Carlos III University of Madrid
Pablo Barquín Soria	Diego Velasco Bayón	Regenerative Medicine and Tissue Bioengineering (CIEMAT-UC3M)	Engineering Physics	Carlos III University of Madrid
Maria Caballero Chacon	Diego Velasco Bayón	Regenerative Medicine and Tissue Bioengineering (CIEMAT-UC3M)	Biomedical Engineering	Carlos III University of Madrid
Fiona Ye Rojo Acero	Diego Velasco Bayón	Regenerative Medicine and Tissue Bioengineering (CIEMAT-UC3M)	Biomedical Engineering	Carlos III University of Madrid
Maria Vizcaya Garrido	Diego Velasco Bayón	Regenerative Medicine and Tissue Bioengineering (CIEMAT-UC3M)	Biomedical Engineering	Carlos III University of Madrid
Laura García Romero	Leticia Valencia Blanco	Regenerative Medicine and Tissue Bioengineering (CIEMAT-UC3M)	Biomedical Engineering	Carlos III University of Madrid
Gonzalo Jorquera Sánchez	Leticia Valencia Blanco	Regenerative Medicine and Tissue Bioengineering (CIEMAT-UC3M)	Energy Engineering	Carlos III University of Madrid
Silvia Pacheco Lozano	Leticia Valencia Blanco	Regenerative Medicine and Tissue Bioengineering (CIEMAT-UC3M)	Biomedical Engineering	Carlos III University of Madrid
Juan Eguizábal Mateos	Ana Blanco Collado	Preventive Medicine	Medicine	Alfonso X el Sabio University
Lucía Ferreño Martín	Ana Blanco Collado	Preventive Medicine	Medicine	Alfonso X el Sabio University

Student	Tutor/s	Research Group	Degree Programme	University
Vega Pescador Gutiérrez	Ana Blanco Collado	Preventive Medicine	Medicine	Alfonso X el Sabio University
Marisol Vivienne López Golay	Ana Blanco Collado	Preventive Medicine	Medicine	Alfonso X el Sabio University
Irene González González	John Jairo Aguilera Correa	Microbiology	Biomedicine	Universidad Europea de Madrid
Pablo Benito Luengo	Adrián Ramos	Nephrology, Vascular Pathology and Diabetes	Health Biology	University of Alcalá
Inés Díaz	Ana B. Sanz	Nephrology, Vascular Pathology and Diabetes	Health Biology	University of Alcalá
Eva Arroyo Casado	José Luis Martín Ventura	Nephrology, Vascular Pathology and Diabetes	Biology	Autonomous University of Madrid
Lucía Muñoz Blanco	Jorge Oller	Nephrology, Vascular Pathology and Diabetes	Biochemistry	University of Castilla La Mancha
Cristina Velez	Nerea Méndez Barbero	Nephrology, Vascular Pathology and Diabetes	Biomedicine	Universidad Alfonso X el Sabio
Daysi Nicole Pineda Morales	Carmen Gómez Guerrero	Nephrology, Vascular Pathology and Diabetes	Human Nutrition and Dietetics	Autonomous University of Madrid
Elena Irurueta.	Carolina Gotera	Neumology	Biomedical Engineering	Technical University of Madrid
Beatriz Panaite	Marina García Sánchez	Neurology	Biomedicine	Alfonso X el Sabio University
David Martínez Ciria	Carlos Ordás Bandera, Héctor Canfield Medina	Neurology	Medicine	Rey Juan Carlos University
Katia Pastor	Jesús Porta	Neurology	Medicine	Autonomous University of Madrid
Eva Setién Rivvera	Agustín Querejeta Coma	Neurology	Biomedical Engineering	Rey Juan Carlos University
Silvia Pérez Rodríguez	Celeste Rodríguez	Medical Oncology	Biology	Autonomous University of Madrid
María Pérez Malheiro	Arancha Cebrián Aranda.	Medical Oncology	Biology	Autonomous University of Madrid
Lucía Cortés	Arancha Cebrián Aranda.	Medical Oncology	Biomedicine	Alfonso X el Sabio University
Daniel Tapia	Arancha Cebrián	Medical Oncology	Biomedicine Entrepreneurship and Project Management	Francisco de Vitoria University
Pablo Sendra	Víctor Moreno	Medical Oncology	Biology	Rey Juan Carlos University
Minerva de Miguel Alonso	Celeste Rodríguez	Medical Oncology	Biotechnology	Alfonso X el Sabio University
Indira Arguello Pérez	Maria A. Carrera-Haro	Medical Oncology	Biomedicine	Alfonso X el Sabio University
Iva Benesova	Maria A. Carrera-Haro	Medical Oncology	Immunology	Charles University, Prague
Sara Lombán Fernández de Murias	Javier Martínez Useros	Medical Oncology	Biomedical Engineering	Rey Juan Carlos University

Student	Tutor/s	Research Group	Degree Programme	University
Carolina Cantemir	Laura Guzmán	Radiation Oncology	Medicine	Autonomous University of Madrid
Pablo Herrero Cerezo	Javier Luna	Radiation Oncology	Medicine	Autonomous University of Madrid
Reyes Maldonado Santaolalla	Javier Luna	Radiation Oncology	Medicine	Autonomous University of Madrid
Roberto López Quintana	Enrique Baca García	Psychiatry and Mental Health	Medicine	Autonomous University of Madrid
Eva Márquez Gálvez	Enrique Baca García	Psychiatry and Mental Health	Medicine	Autonomous University of Madrid
Samuel Esteban Prieto	Araceli del Arco, Luis González Moreno	Mitochondrial Calcium Signalling	Biochemistry	Universidad de Castilla-La Mancha
Nazaret Palencia del Prado	Jordi Minguillón Pedreño	Advanced Therapies (CIEMAT)	Biotechnology	Technical University of Madrid
Beatriz Madroñal Bautista	Jordi Minguillón Pedreño	Advanced Therapies (CIEMAT)	Genetics	CEU San Pablo University

In addition, during 2025, the IIS-FJD hosted 17 students from Vocational Education and Training (VET) institutions in the Community of Madrid who were enrolled in advanced vocational training programmes and carried out their corresponding practical placements within the IIS-FJD research groups.

Student	Supervisor/s	Research Group/ Support Unit	Programme	Educational Institution
Abraham Gil Vidal	Miriam Ortiz Criado	FJD HR	Higher Vocational Training Diploma in Administration and Finance	Juan XXIII
Adrián Álvaro Arranz	Óscar Lorenzo	Nephrology and Hypertension, Vascular Pathology and Diabetes	Higher Vocational Training Diploma in Pathological Anatomy and Cytodiagnosis	ETEE
Adrián Lobato Calle	Lucía Gallego	FJD Finance	Higher Vocational Training Diploma in Administration and Finance	Juan XXIII
Alba Turrado	Javier Martín Broto / David da Silva	Medical Oncology	Higher Vocational Training Diploma in Clinical and Biomedical Laboratory Sciences	EPSUM
Ana Revilla	Javier Martín Broto / David da Silva	Medical Oncology	Higher Vocational Training Diploma in Clinical and Biomedical Laboratory Sciences	Metrodora (Opesa)
Andriu Díaz	María A. Carrera-Haro	Medical Oncology	Higher Vocational Training Diploma in Clinical and Biomedical Laboratory Sciences	EPSUM

IIS-FJD Training Plan 10

Student	Supervisor/s	Research Group/ Support Unit	Programme	Educational Institution
Clarisia Bianca Ganzer Duminica	Juliana García Calvo	Nephrology, Hypertension, Vascular Pathology and Diabetes	Intermediate Vocational Training Programme in Laboratory Operations	IES Luis Buñuel (Alcorcón)
Dámaris Morales Picado	Alberto Montero	Research Management	Higher Vocational Training Diploma in Administration and Finance	Juan XXIII
Elien Selena Garnica Torres	Norma Rallón	Infectious Diseases and Tropical Medicine	Higher Vocational Training Diploma in Clinical and Biomedical Laboratory Sciences	Colegio Valle El Miro
Irene Rueda Campos	Socorro María Rodríguez Pinilla	Anatomical Pathology	Higher Vocational Training Diploma in Pathological Anatomy and Cytodiagnosis	Metrodora (Opesa)
Laura Arolo Recio	Alberto Montero	Research Management	Higher Vocational Training Diploma in Administration and Finance	Juan XXIII
Laura Merino	Javier M. Broto / David da Silva	Medical Oncology	Higher Vocational Training Diploma in Clinical and Biomedical Laboratory Sciences	EPSUM
Lorenzo Villón Zukelly Britt	Norma Rallón	Infectious Diseases and Tropical Medicine	Higher Vocational Training Diploma in Clinical and Biomedical Laboratory Sciences	Medac Albalá
Marta Brasero Moreno	Susana Carrasco y Arancha Pintor	Nephrology, Hypertension, Vascular Pathology and Diabetes	Diploma in Anatomical Pathology and Cytodiagnosis	Medac Albalá
Maruxa Ramírez García	Raquel Largo	Rheumatology and Bone Metabolism	Diploma in Anatomical Pathology and Cytodiagnosis	IES San Juan de la Cruz
Miguel Fuentes Arriaza	Juliana García Calvo	Nephrology and Hypertension, Vascular Pathology and Diabetes	Intermediate Vocational Qualification in Laboratory Operations.	IES Luis Buñuel (Alcorcón)
Valentina de Jesús Franco Gómez	Luis Blanco	Nephrology and Hypertension, Vascular Pathology and Diabetes	Diploma in Anatomical Pathology and Cytodiagnosis	European University of Madrid Professional Training Centre

10.5 Postgraduate Research Training

10.5.1 Doctoral programmes, master's programmes and university-specific degrees in collaboration with UAM and other universities

Researchers at the IIS-FJD have participated as lecturers in various master's programmes and institution-specific postgraduate programmes offered by Spanish and international universities. The master's programmes in which our researchers teach are detailed below:

TEACHER	MASTER'S DEGREE PROGRAMME	UNIVERSITY / INSTITUTION
Laura Prieto Pérez	Second Edition Expert Diploma in Emerging Viruses, High-Risk Viruses and Management in High-Level Isolation Units	Autonomous University of Madrid
Alfonso Cabello Úbeda, Miguel Górgolas Hernández-Mora, Helena Moza Moriñigo, Laura Prieto Pérez	Institution-Specific Master's Degree in Tropical Medicine and International Health	Autonomous University of Madrid
María Dolores Martín Ríos	Master's degree in public health	National School of Public Health
Helena Moza Moríñigo	Master's degree in microbiology	National Centre for Microbiology, Carlos III Health Institute
Carmen Ayuso, Fiona Blanco-Kelly, Ana Bustamante, Blanca Cárdaba, Jesús Martínez Palacio, Ana L. Osorio, Javier Santos Hernández, María Villa Morales	University master's degree in molecular Biomedicine	Autonomous University of Madrid
Estela Álvarez Gómez, Elena Arroyo Bello, Belén González Tejerina, Beatriz María González Toledo, Ignacio Mahíllo Fernández, Alejandro Martínez Arce, Ramón Maruri, Paloma Rodríguez Gómez	Lifelong Learning master's degree in clinical simulation, Debriefing and Patient Safety	Autonomous University of Madrid, FJD School of Nursing
Javier Santos Hernández, María Villa Morales	University Master's Degree in Genetics and Cell Biology	Autonomous University of Madrid / Complutense University of Madrid / University of Alcalá
José Abad Valle, Estela Álvarez Gómez, Elena Arroyo Bello, María del Barrio Velilla, Rubén Casans Francés, Sara Colás Carpallo, Elisa Belén Cortés Zamora, Nieves Domínguez Garrido, José María Fraile Vicente, Cristina Gómez Moreno, Belén González Tejerina, Beatriz María González Toledo, Javier Gutiérrez Adame, Emilia Victoria Guasch Arévalo, Victoriano Leal Caramazana, Ignacio Mahíllo Fernández, María Dolores Martín Ríos, Luis Enrique Muñoz Alameda, Cristina Pérez Aparicio, Vanessa Intriago García-Consuegra, Borja Ibáñez Cabeza, Lucía Llanos Jiménez, Óscar Lorenzo González, Ascensión Revilla Aragón	University master's degree in advanced Patient Care in Anaesthesia, Resuscitation and Pain Management	Autonomous University of Madrid, FJD School of Nursing
Lorena Carballo Rodriguez, Eva García Perea	Lifelong Learning master's degree in advanced clinical Practice in Extracorporeal Circulation and Perfusion	Autonomous University of Madrid
Lucía Llanos Jiménez	Lifelong Learning master's degree in clinical Trial Monitoring and Coordination	Autonomous University of Madrid
Sara Vicente Antunes, Pedro Villarejo Campos	Specialisation Diploma in Interventional Oncology	Autonomous University of Madrid
Elizabet Petkova	Institution-Specific Master's Degree at UAM in the Management and Care of Patients with Vascular Access Devices	Autonomous University of Madrid

TEACHER	MASTER'S DEGREE PROGRAMME	UNIVERSITY / INSTITUTION
Ana del Río Machín	MSc Genomic Medicine. Cancer Pharmacogenomics	Queen Mary University of London (QMUL)
Ana L. Osorio Cabrero	Institution-Specific master's degree in digital health Innovation	Complutense University of Madrid
Arancha Mediero	University master's degree in research and Rational Use of Medicines	University of Valencia
Berta Almoguera Castillo	University master's degree in health Analysis	Complutense University of Madrid
Berta Almoguera, Marta Cortón, Fiona Blanco-Kelly, Saoud T. Swafiri	Lifelong Learning master's degree in clinical Genetics	TECH University
Carlos León Canseco, Cristina Quílez López, Leticia Valencia Blanco	University Master's Degree in Analytical and Bioanalytical Sciences and Technologies	UC3M/UAH/UAM/UCM/URJC/USP-CEU
Carmen Ayuso	Expert Diploma in Personalised and Precision Medicine	International University of Andalusia / PANMEP
Carmen Ayuso	Lifelong Learning Master's Degree in Inherited Metabolic Diseases	University of Santiago de Compostela
Carmen Ayuso	Master's degree in biomedical research and advanced therapies	University of Valladolid / IBGM / CSIC
Carmen Ayuso	15th Specialisation Diploma in Bioethics	University of Granada / Andalusian School of Public Health
Carmen González Enguita; Raquel González López; Luis Miguel Quintana Franco; Héctor Garde	Master's degree in advanced surgery for Urinary Incontinence and Pelvic Floor Disorders	Complutense University of Madrid
Diego Velasco Bayón	University Master's Degree in Biomaterials	Complutense University of Madrid
Susana Amodeo Escribano, Rodrigo Carmona Camacho, Mónica Jiménez Giménez, Laura Muñoz Lorenzo, Sergio Sánchez Alonso	University master's degree in general health psychology	Complutense University of Madrid
Gloria Álvarez Llamas, Mariano García Arranz, Lucía Martínez Santamaría, José Carlos Segovia	University Master's Degree in Regenerative Medicine and Advanced Therapies	CEU San Pablo University
Ignacio Muguruza Trueba	Master's Degree in Oncological Surgery	European University of Madrid / SEOQ-CIMO Chair
Javier Martínez Poles	University Expert Diploma in Epilepsy for Nursing Professionals	Francisco de Vitoria University
Javier Martínez Useros, Ana L. Osorio Cabrero	Online master's degree in molecular Oncology	Francisco de Vitoria University / CEB
Jesús Porta	Specialisation Diploma in Temporomandibular Disorders, Orofacial Pain and Dental Sleep Medicine | Facial Pain in Dentistry	Complutense University of Madrid
Jordi Minguillón Pedreño	University master's degree in advanced Immunology | Tumour Immunology and Cancer Immunotherapy	Autonomous University of Barcelona

10 IIS-FJD Training Plan

TEACHER	MASTER'S DEGREE PROGRAMME	UNIVERSITY / INSTITUTION
Jordi Minguillón Pedreño	Master's in advanced Genetics	Autonomous University of Barcelona
José Antonio Casado Olea	University master's degree in clinical biotechnology	European University of Madrid
Jose Carlos Fernández Ferro	Master's Degree in Neurosonology	University of Almería
José Carlos Segovia, Begoña Díez Cabezas, María Fernández García, Mercedes López Santalla, Raúl Torres Ruiz	University master's degree in advanced therapies in Biomedicine	Francisco de Vitoria University
José Carlos Segovia	University master's degree in molecular Approaches in Health Sciences	University of Valencia
Luis Felipe Navarro del Amo	Master's Degree in Structural Endovascular Interventions	Rey Juan Carlos University / Spanish Society of Cardiology
Magnolia Rincón	International master's degree in advanced Radiation Oncology, Interventional Oncology Track	Francisco de Vitoria University / Spanish Society of Radiation Oncology
María del Carmen de Arriba, Álex Bassons Bascuñana, Esteban Chacón Solano, Mariano García Arranz, Marta García Díez, Inés Idoia Hidalgo Erice, Carlos León Canseco, Estela Méndez Jiménez, Néstor W. Meza, Cristina Quílez López, Leticia Suárez Cabrera, Leticia Valencia Blanco, Diego Velasco Bayón	University master's degree in management and development of biomedical technologies	Carlos III University of Madrid
Mariano García Arranz	Master's Degree in the Pharmaceutical and Biotechnology Industry: Advanced Therapies, Biological Products and Medical Devices	European University of Madrid
Mariano García Arranz	University Master's Degree in Aesthetic, Regenerative and Anti-Ageing Medicine	Complutense University of Madrid
Mariano García Arranz, Marta Rodríguez de Alba	University Master's Degree in Genetics and Cell Biology	Complutense University of Madrid
Marina I. Garín Ferreira	University Master's Degree in Therapeutic Targets in Cell Signalling: Research and Development	University of Alcalá
Marta Garcia Diez	University Master's Degree in Materials Science and Engineering	Carlos III University of Madrid
Marta Martín Lorenzo	University Master's Degree in Biochemistry, Molecular Biology and Biomedicine	Complutense University of Madrid
Néstor W. Meza	University Master's Degree in Virology	Complutense University of Madrid
Óscar González Lorenzo, Andrea Kallmeyer	University master's degree in emergency medicine, Emergencies and Disaster Management	CEU San Pablo University
Pablo Mínguez	Master's degree in bioinformatics	Alfonso X el Sabio University
Pablo Mínguez	Master's degree in bioinformatics	University of Valencia

IIS-FJD Training Plan 10

TEACHER	MASTER'S DEGREE PROGRAMME	UNIVERSITY / INSTITUTION
Paula Río Galdo	University master's degree in clinical Genetics	University of Alcalá
Raquel González López	Expert Diploma in the Management of the Female Urinary Tract	Alfonso X el Sabio University
Raquel González López	Master's Degree in Andrology and Reconstructive Surgery	University of Salamanca
Raquel González López	Master's Degree in Functional Urology, Female Urology and Pelvic Floor Disorders	University of Salamanca
Raquel González López; Carmen González Enguita	University Expert Diploma in Minimally Invasive Diagnosis and Treatment of Prostatic Disease	Francisco de Vitoria University
Raúl Torres Ruiz	University master's degree in research in Immunology	Complutense University of Madrid
Vanesa Esteban, Marina I. Garín Ferreira	University master's degree in health biology	Complutense University of Madrid
Yuri Bellido Reyes, Ignacio Muguruza Trueba, David Rincón García, Sara Vicente Antunes	Online master's degree in Thoracic Oncology	CEU Cardenal Herrera University/ TECH School of Medicine Spain
Laura Prieto Pérez	Master's degree in microbiology and Parasitology	Complutense University of Madrid
Irene Carrillo Acosta	Master's degree in clinical Trial Monitoring	Villanueva University
Alfonso Cabello Úbeda	Master's degree in human Immunodeficiency Virus Infection	Rey Juan Carlos University
Laura Prieto Pérez	University Master's Degree in Infectious Diseases and International Health	Miguel Hernández University
Carmen Ayuso	Specialisation Diploma in Genetic Counselling and Clinical Genomics	University-Business Foundation of the University of Valencia
Pablo Mínguez	Master's degree in bioinformatics and data science in Precision Personalised Medicine and Health	National School of Public Health, Carlos III Health Institute
Paula Río Galdo	CECIC master's degree in study Coordination for Clinical Trials	ESAME Pharmaceutical Business School, Madrid
Raquel González López	Master's Degree in Rehabilitation Management of Pelvic Floor Disorders	Postgraduate Institute of the San Pablo Andalucía CEU Foundation
Elizabet Petkova	Master's degree in emergency medicine	QuirónSalud

At IIS-FJD, students undertake the practical component of Master's final projects associated with master's programmes at UAM and other universities. These placements consist of training stays in different laboratories within the institution and are carried out in coordination with the corresponding universities. The students who completed placements in one of the research groups of our Institute during 2025, under the supervision of IIS-FJD researchers, are listed below

Student	Supervisor/s	Group	Master's Degree Programme	University
Álvaro Arranz Fragua	Victoria del Pozo	Allergy and Immunology	Master's Degree in Translational Medicine Research	Complutense University of Madrid
Natalia Antón Sánchez	Federico Rojo Todo, uan Madoz Gúrpide	Anatomical Pathology	Master's degree in biotechnology	Autonomous University of Madrid
Carlos Prados Hidalgo	Borja Ibáñez, Ismael Ortuño Soriano	Cardiology	University master's degree in health care research	Complutense University of Madrid
Silvana J. Villacorta Chiotti	Meritxell de Jesús García Quintanilla	Microbiology	Master's degree in health biology	Complutense University of Madrid
Maria Trinidad Luna Sevilla	Laura González	Neurology	Master's degree in clinical Trial Monitoring and Pharmaceutical Development	INESEM
Paula Díaz Serna	María García Bravo, Andrea Molinos Vicente	Advanced Therapies (CIEMAT)	Master's Degree in Regenerative Medicine and Advanced Therapies	San Pablo CEU University
Bárbara Anais Villalonga Chico	Guillermo Güenechea Amurrio/Néstor W. Meza	Advanced Therapies (CIEMAT)	Master's Degree in Virology	Complutense University of Madrid
Ana Martínez García	Marina I. Garin Ferreira	Advanced Therapies (CIEMAT)	Health Biology	Complutense University of Madrid
Esther Díaz-Maroto Cicuéndez	Jordi Minguillón Pedreño	Advanced Therapies (CIEMAT)	Master's degree in health biology	Complutense University of Madrid
Sara Fernández Hernández	Jordi Minguillón Pedreño	Advanced Therapies (CIEMAT)	Master's Degree in Biochemistry, Molecular Biology and Biomedicine	Complutense University of Madrid
Beatriz García Benítez	Jordi Minguillón Pedreño	Advanced Therapies (CIEMAT)	Master's degree in health biology	Complutense University of Madrid

The students who completed their master's final project within one of the research groups of our Institute during 2025, under the supervision of IIS-FJD researchers, are detailed below:

Student	Supervisor/s	Research Group	Master's Degree Programme	University
Robinson Fabián Trujillo Cabanilla,	Javier Martínez Useros	Medical Oncology	Master's degree in molecular Oncology	Rey Juan Carlos University
Noel Blaya Boluda	Javier Martínez Useros	Medical Oncology	Master's degree in molecular Oncology	Rey Juan Carlos University
Ana Isabel Martín Quesada	Javier Martínez Useros	Medical Oncology	Master's degree in molecular Oncology	Rey Juan Carlos University
Brenda Paola Rodríguez Arroyo	Javier Martínez Useros	Medical Oncology	Master's degree in molecular Oncology	Rey Juan Carlos University

Student	Supervisor/s	Research Group	Master's Degree Programme	University
Lucía Bernal Guerrero	Lorenzo González, Oscar; Lumpuy Castillo, Jairo	Nephrology, Hypertension, Vascular Pathology and Diabetes	University Master's Degree in Therapeutic Targets in Cell Signalling: Research and Development	University of Alcala
Yingyue Deng	Carmen Gómez Guerrero	Nephrology, Hypertension, Vascular Pathology and Diabetes	Master's Degree in Pharmacological Research	Autonomous University of Madrid
Irene de María Camacho	Nerea Méndez, Vanesa Esteban	Nephrology, Hypertension, Vascular Pathology and Diabetes / Allergy and Immunology	Master's degree in health biology	Complutense University of Madrid
Gema Guillén	Victoria del Pozo Abejón	Allergy and Immunology	Master's Degree in Regenerative Medicine and Advanced Therapies	San Pablo CEU University
Antonio Serrano Santiago	Victoria del Pozo Abejón y José Antonio Cañas Mañas	Allergy and Immunology	Master's degree in research in Immunology	Complutense University of Madrid
Johanna Vanessa Villamarín Silva	Alfonso Cabello Úbeda	Infectious Diseases and Tropical Medicine	Institution-Specific Master's Degree in Tropical Medicine and International Health	Autonomous University of Madrid
Roberto Vates Gómez	Alfonso Cabello Úbeda	Infectious Diseases and Tropical Medicine	Institution-Specific Master's Degree in Tropical Medicine and International Health	Autonomous University of Madrid
Wendy Geraldine Quiroz Jarquin	Alfonso Cabello Úbeda	Infectious Diseases and Tropical Medicine	Institution-Specific Master's Degree in Tropical Medicine and International Health	Autonomous University of Madrid
Scott Garett Hudgson Rodríguez.	Alfonso Cabello Úbeda	Infectious Diseases and Tropical Medicine	Institution-Specific Master's Degree in Tropical Medicine and International Health	Autonomous University of Madrid
Daniela Martínez Olsen	Laura Prieto Pérez	Infectious Diseases and Tropical Medicine	Institution-Specific Master's Degree in Tropical Medicine and International Health	Autonomous University of Madrid
Mercedes Cantalapiedra	Laura Prieto Pérez	Infectious Diseases and Tropical Medicine	Institution-Specific Master's Degree in Tropical Medicine and International Health	Autonomous University of Madrid
Eva Gutiérrez Adrián	Laura Prieto Pérez	Infectious Diseases and Tropical Medicine	Institution-Specific Master's Degree in Tropical Medicine and International Health	Autonomous University of Madrid

Student	Supervisor/s	Research Group	Master's Degree Programme	University
Joana de Miguel de Landiríbar	Laura Prieto Pérez	Infectious Diseases and Tropical Medicine	Institution-Specific Master's Degree in Tropical Medicine and International Health	Autonomous University of Madrid
Ignacio Fernández Huerta	Laura Prieto Pérez	Infectious Diseases and Tropical Medicine	Institution-Specific Master's Degree in Tropical Medicine and International Health	Autonomous University of Madrid
Miguel Morante Ruiz	Alfonso Cabello Úbeda	Infectious Diseases and Tropical Medicine	Institution-Specific Master's Degree in Tropical Medicine and International Health	Autonomous University of Madrid
Silvana J. Villacorta Chiotti	Meritxell de Jesús García Quintanilla	Microbiology	Master's degree in health biology	Complutense University of Madrid
Ana Amil Manjón	Pablo Mínguez, Ana Osorio y Graciela Uría Regojo	Genetics and Genomics of Rare and Complex Diseases / Bioinformatics Unit	Master's degree in bioinformatics and data science in Precision Personalised Medicine and Health	National School of Public Health, Carlos III Health Institute (ISCIII)
Diego Sánchez González	Pablo Mínguez, Ana Osorio y Graciela Uría Regojo	Genetics and Genomics of Rare and Complex Diseases / Bioinformatics Unit	Master's degree in bioinformatics and computational biology	Autonomous University of Madrid (UAM)
Camila Reeb	Ana Osorio	Genetics and Genomics of Rare and Complex Diseases	Master's in Translational Medicine	Complutense University of Madrid
Jesús González González	Ana Osorio	Genetics and Genomics of Rare and Complex Diseases	Master's Degree in Biomedicine	Complutense University of Madrid
Lidia Inmaculada Alejo Liriano	María Dolores Martín Ríos, Marta Blanco Fernández, Helena Burggraaf Sánchez de las Matas	Preventive Medicine	Master's degree in public health	National School of Public Health
Yolanda Lilia Aguirrezabala Campano	María Dolores Martín Ríos, Marta Blanco Fernández	Preventive Medicine	Master's degree in public health	National School of Public Health
Raúl García Martínez	Araceli del Arco, Luis González Moreno	Mitochondrial Calcium Signalling	Molecular Biomedicine	Autonomous University of Madrid (UAM)
Sara Rosa Cortiñas Llarena	Marina Sánchez García, Luis Zafra Puerta	Neurology	Master's degree in Neuroscience	Autonomous University of Madrid (UAM)
Marco David Gutiérrez González	Marina Sánchez García	Neurology	Master's degree in Neurotechnology	Technical University of Madrid

Student	Supervisor/s	Research Group	Master's Degree Programme	University
Julieta González Marchesano	Esteban Chacón Solano y José A. Horcajadas	Regenerative Medicine and Tissue Bioengineering (CIEMAT-UC3M)	Master's degree in management and development of biomedical technologies	Carlos III University of Madrid
Jesús Gascón Murugarren	Lucía Martínez Santamaría y Ángela Llaneza	Regenerative Medicine and Tissue Bioengineering (CIEMAT-UC3M)	Master's degree in management and development of biomedical technologies	Carlos III University of Madrid
Evelin Paola Lalvay Caiza	Lucía Martínez Santamaría y Marina Diaz Perdigon	Regenerative Medicine and Tissue Bioengineering (CIEMAT-UC3M)	Master's degree in management and development of biomedical technologies	Carlos III University of Madrid
Jaime Navarro Navarro	Lucía Martínez Santamaría y Ángela Llaneza	Regenerative Medicine and Tissue Bioengineering (CIEMAT-UC3M)	Master's degree in management and development of biomedical technologies	Carlos III University of Madrid
Jaime Bachiller Hernández	Carlos León Canseco	Regenerative Medicine and Tissue Bioengineering (CIEMAT-UC3M)	Master's degree in management and development of biomedical technologies	Carlos III University of Madrid
Pau Bataller i Batllori	Carlos León Canseco	Regenerative Medicine and Tissue Bioengineering (CIEMAT-UC3M)	Master's degree in management and development of biomedical technologies	Carlos III University of Madrid
Alejandro Franklin Méndez Mateo	Marta García y Rodolfo Murillas	Regenerative Medicine and Tissue Bioengineering (CIEMAT-UC3M)	Master's degree in management and development of biomedical technologies	Carlos III University of Madrid
Adrián Egosa Guillén Ehidiaduwa	Marta García Diez y Javier González Peñas	Regenerative Medicine and Tissue Bioengineering (CIEMAT-UC3M)	Master's degree in management and development of biomedical technologies	Carlos III University of Madrid
Irene García Lara	Marta García Diez y Mónica Domínguez Merchán	Regenerative Medicine and Tissue Bioengineering (CIEMAT-UC3M)	Master's degree in management and development of biomedical technologies	Carlos III University of Madrid
Helena Oubiña Barbolla	Sara Guerrero Aspizua	Regenerative Medicine and Tissue Bioengineering (CIEMAT-UC3M)	Master's degree in management and development of biomedical technologies	Carlos III University of Madrid
Irene Bravo Blanco	Cristina Quílez López	Regenerative Medicine and Tissue Bioengineering (CIEMAT-UC3M)	Master's degree in management and development of biomedical technologies	Carlos III University of Madrid

Student	Supervisor/s	Research Group	Master's Degree Programme	University
Inés Fernández Arraiza	Cristina Quílez López	Regenerative Medicine and Tissue Bioengineering (CIEMAT-UC3M)	Master's degree in management and development of biomedical technologies	Carlos III University of Madrid
Jorge Miralles Peñalva	Cristina Quílez López	Regenerative Medicine and Tissue Bioengineering (CIEMAT-UC3M)	Master's degree in management and development of biomedical technologies	Carlos III University of Madrid
Sandy Gabriela Orellana Álvarez	Cristina Quílez López	Regenerative Medicine and Tissue Bioengineering (CIEMAT-UC3M)	Master's degree in management and development of biomedical technologies	Carlos III University of Madrid
Ana Ruiz Medina	Leticia Suárez Cabrera	Regenerative Medicine and Tissue Bioengineering (CIEMAT-UC3M)	Master's degree in management and development of biomedical technologies	Carlos III University of Madrid
Ángela Cayado Vega	Leticia Suárez Cabrera	Regenerative Medicine and Tissue Bioengineering (CIEMAT-UC3M)	Master's degree in management and development of biomedical technologies	Carlos III University of Madrid
Desiree Rivera Rodríguez	Leticia Suárez Cabrera	Regenerative Medicine and Tissue Bioengineering (CIEMAT-UC3M)	Master's degree in management and development of biomedical technologies	Carlos III University of Madrid
Alejandro Bullido Martin	Diego Velasco Bayón	Regenerative Medicine and Tissue Bioengineering (CIEMAT-UC3M)	Master's degree in management and development of biomedical technologies	Carlos III University of Madrid
Ana López Ruiz	Diego Velasco Bayón	Regenerative Medicine and Tissue Bioengineering (CIEMAT-UC3M)	Master's degree in management and development of biomedical technologies	Carlos III University of Madrid
Adriana Ritcher Lozada	Diego Velasco Bayón	Regenerative Medicine and Tissue Bioengineering (CIEMAT-UC3M)	Master's degree in management and development of biomedical technologies	Carlos III University of Madrid
Malen Villaescusa Azcarate	Diego Velasco Bayón	Regenerative Medicine and Tissue Bioengineering (CIEMAT-UC3M)	Master's degree in management and development of biomedical technologies	Carlos III University of Madrid
Álvaro Lagaron Cáceres	Leticia Valencia Blanco	Regenerative Medicine and Tissue Bioengineering (CIEMAT-UC3M)	Master's degree in management and development of biomedical technologies	Carlos III University of Madrid

Student	Supervisor/s	Research Group	Master's Degree Programme	University
Belén López Hernández	Leticia Valencia Blanco	Regenerative Medicine and Tissue Bioengineering (CIEMAT-UC3M)	Master's degree in management and development of biomedical technologies	Carlos III University of Madrid
María Pilar Urbano Calero	Leticia Valencia Blanco	Regenerative Medicine and Tissue Bioengineering (CIEMAT-UC3M)	Master's degree in management and development of biomedical technologies	Carlos III University of Madrid
Beatriz Rodríguez Rojo	Leticia Valencia Blanco	Regenerative Medicine and Tissue Bioengineering (CIEMAT-UC3M)	Interuniversity master's degree in Analytical and Bioanalytical Sciences and Technologies	Carlos III University of Madrid
Paula Díaz Serna	María García Bravo, Andrea Molinos Vicente	Advanced Therapies (CIEMAT)	Master's Degree in Regenerative Medicine and Advanced Therapies	CEU San Pablo University
Bárbara Anais Villalonga Chico	Guillermo Güenechea Amurrio/Néstor W. Meza	Advanced Therapies (CIEMAT)	Master's Degree in Virology	Complutense University of Madrid
Ana Martínez García	Marina I. Garin Ferreira	Advanced Therapies (CIEMAT)	Health Biology	Complutense University of Madrid
Esther Díaz-Maroto Cicuéndez	Jordi Minguillón Pedreño	Advanced Therapies (CIEMAT)	Master's degree in health biology	Complutense University of Madrid
Sara Fernández Hernández	Jordi Minguillón Pedreño	Advanced Therapies (CIEMAT)	Master's Degree in Biochemistry, Molecular Biology and Biomedicine	Complutense University of Madrid
Ana María Arévalo Gordo	Javier Gutiérrez Adame	Research in New Therapies	Nursing	Autonomous University of Madrid, FJD School of Nursing
Inés Mª Arós Marquina	Belén González Tejerina	Research in New Therapies	Nursing	Autonomous University of Madrid, FJD School of Nursing
Jesica Caicedo Caicedo	José Abad Valle	Research in New Therapies	Nursing	Autonomous University of Madrid, FJD School of Nursing
Constanza Contreras Valdebenito	José Abad Valle	Research in New Therapies	Nursing	Autonomous University of Madrid, FJD School of Nursing
Cristina de Miguel Barroso	Estela Álvarez Gómez	Research in New Therapies	Nursing	Autonomous University of Madrid, FJD School of Nursing
Alicia Denche Gutiérrez	Óscar Lorenzo González	Nephrology, Hypertension, Vascular Pathology and Diabetes	Nursing	Autonomous University of Madrid, FJD School of Nursing
María Fernández Quejigo	Elena Arroyo Bello	Research in New Therapies	Nursing	Autonomous University of Madrid, FJD School of Nursing

Student	Supervisor/s	Research Group	Master's Degree Programme	University
Daniel Gómez Balbás	Elisa Cortés Zamora	Research in New Therapies	Nursing	Autonomous University of Madrid, FJD School of Nursing
María Juarranz Baños	Cristina Gómez Moreno	Research in New Therapies	Nursing	Autonomous University of Madrid, FJD School of Nursing
Diana Llumiquinga Marcillo	José Abad	Research in New Therapies	Nursing	Autonomous University of Madrid, FJD School of Nursing
Elena Ojeda Pérez	Óscar Lorenzo	Research in New Therapies	Nursing	Autonomous University of Madrid, FJD School of Nursing
Ana Pérez Calle	Cristina Gómez Moreno	Research in New Therapies	Nursing	Autonomous University of Madrid, FJD School of Nursing
Coloma Pinilla Montero	Estela Álvarez Gómez	Research in New Therapies	Nursing	Autonomous University of Madrid, FJD School of Nursing
Marta Piñeiro Ferreiro	Estela Álvarez Gómez	Research in New Therapies	Nursing	Autonomous University of Madrid, FJD School of Nursing
Irene Rodríguez García	Javier Gutiérrez Adame	Research in New Therapies	Nursing	Autonomous University of Madrid, FJD School of Nursing
Cristina Sánchez Fernández	Rubén Casans Francés	Medical and Surgical Innovation	Nursing	Autonomous University of Madrid, FJD School of Nursing
Mª Rocío Urbano Cámara	Javier Gutiérrez	Research in New Therapies	Nursing	Autonomous University of Madrid, FJD School of Nursing
Beatriz García Benítez	Jordi Minguillón Pedreño	Advanced Therapies (CIEMAT)	Master's degree in health biology	Complutense University of Madrid

10.5.2 Supervision of Doctoral Theses

During 2025, a total of 25 doctoral theses were defended, six of which received the International Doctorate Mention. The research work on which these theses were based was carried out at the IIS-FJD under the supervision of researchers from this institution.

Student	Supervisor/s	Research Group/ Department	Thesis Title	Grade	University
Ariadna Martín Blázquez	Gloria Álvarez Llamas, Marta Martín Lorenzo	Allergy and Immunology	Claves moleculares del aneurisma aórtico torácico: del desarrollo silente a la identificación de marcadores diagnósticos	Excellent (Cum Laude)	UCM

Student	Supervisor/s	Research Group/ Department	Thesis Title	Grade	University
Marta Sanz Álvarez	Federico Rojo Todo, Juan Madoz Gúrpide	Anatomical Pathology	Papel de la proteína MDK en la respuesta a terapias dirigidas contra HER2 en cáncer de mama HER2 positivo	Excellent (Cum Laude)	UAM
Andrea Camblor Blasco	Álvaro Aceña, Borja Ibáñez	Cardiology	Caracterización y pronóstico de la amiloidosis cardíaca por transtiretina: correlación entre biomarcadores, evaluación funcional e imagen cardiaca avanzada. Ensayo clínico prospectivo con diflunisal como ventana de oportunidad terapéutica	Excellent (Cum Laude)	UAM
Óscar González Lorenzo	Franco Peláez, José Tuñón	Cardiology	La enfermedad arterial periférica: un marcador de mal pronóstico en pacientes sometidos a cirugía de revascularización coronaria	Excellent (Cum Laude)	UAM
Alejandra Tamayo Durán	Marta Cortón Pérez	Genetics and Genomics of Rare and Complex Diseases	Mejora del diagnóstico genético de la aniridia mediante secuenciación masiva y desarrollo de modelos experimentales	Excellent (Cum Laude)	UAH
Daniel Láinez González	Juan Manuel Alonso Domínguez, Juana Serrano López	Haematology	Nuevas terapias contra la leucemia mieloide aguda: inhibición de la quiescencia en células madre leucémicas	Excellent (Cum Laude)	UAM
Sergio Farrais Villalba	Juan Carlos Porres Cubero, María Concepción Núñez Pardo de Vera (No IIS-FJD)	Medical and Surgical Innovation	Caracterización de la enfermedad celíaca en la edad adulta: análisis de casos retrospectivo	Excellent (Cum Laude)	UAM
Lucas Madrid Vázquez	Luis Enrique Muñoz Alameda, Rubén Casans Francés	Medical and Surgical Innovation / General Surgery, Thoracic Surgery, Neurosurgery and Other Surgical Specialties	Modelos de aprendizaje automático basado en ecografía y exploración física para la evaluación de la vía aérea	Excellent (Cum Laude)	UAM
Bernadette Genevieve Pfang	Joaquín García Cañete, Jaime Esteban Moreno	Research in New Therapies / Microbiology	Osteosynthesis-associated infection of the hip: risk factors for therapeutic failure	Excellent (Cum Laude)	UAM
Ignacio Risueño Rojo	Leticia Valencia Blanco, Diego Velasco Bayón	Regenerative Medicine and Tissue Bioengineering (CIEMAT-UC3M)	Generation of a three-dimensional skin model based on a fibrin gel in a dynamic skin-on-a-chip platform	Excellent (Cum Laude)	UC3M
Manuel Mataix Rodríguez	Marta Carretero, Fernando Larcher	Regenerative Medicine and Tissue Bioengineering (CIEMAT-UC3M)	Terapia dirigida basada en aptámeros para la cicatrización de heridas y el crecimiento del cabello	Excellent (Cum Laude)	UC3M
Marta Martín García	Jaime Esteban Moreno, John Jairo Aguilera Correa	Microbiology	Evaluación microbiológica de la aleación de CoCrMo anodizada y de las estructuras biomiméticas porosas de Ti6Al2V	Excellent (Cum Laude)	UAM

Student	Supervisor/s	Research Group/ Department	Thesis Title	Grade	University
Beatriz María González Toledo	Alberto Ortiz Arduán, Maria Vanessa Pérez Gómez, Sergio Luis Lima	Nephrology, Hypertension, Vascular Pathology and Diabetes	Identificación de pacientes con Poliquistosis Renal Autosómica Dominante con rápida progresión de la Enfermedad Renal Crónica: papel de la tasa de filtración glomerular medida	Excellent (Cum Laude)	UAM
Jairo Lumpuy Castillo	Lorenzo González, Oscar	Nephrology, Hypertension, Vascular Pathology and Diabetes	Papel del eje AMPK/PGC-1α/SIRT3 en la respuesta adaptativa del corazón diabético	Excellent (Cum Laude)	UAM
Juan Guerrero Mauvecin	Ana Belén Sanz Bartolomé, Alberto Ortíz Arduán	Nephrology, Hypertension, Vascular Pathology and Diabetes	Nuevas dianas moleculares y estrategias terapéuticas para la monitorización y prevención de la necroinflamación en la lesión renal aguda	Excellent (Cum Laude)	UAM
Manuel Soto Catalán	Sebastián Más, Lucas Opazo Ríos	Nephrology, Hypertension, Vascular Pathology and Diabetes	Enfermedad hepática esteatósica asociada a disfunción metabólica: Mecanismos de progresión y evaluación de nuevas estrategias terapéuticas	Excellent (Cum Laude)	UAM
Raúl Fernández Prado	Alberto Ortiz Arduán, María Dolores Sánchez Niño	Nephrology, Hypertension, Vascular Pathology and Diabetes	PEPT2, una diana accionable en la nefrotoxicidad por colistina	Excellent (Cum Laude)	UAM
Sol María Carriazo Julio	María Dolores Sanchez Niño, Maria Vanessa Pérez Gómez	Nephrology, Hypertension, Vascular Pathology and Diabetes	Comprendiendo el alto riesgo de COVID-19 severo en personas con enfermedad renal crónica grave	Excellent (Cum Laude)	UAM
José Lucinio Mondaza Hernández	Javier Martín Broto	Medical Oncology	Advancing Treatment Strategies for Solitary Fibrous Tumor: Novel Biomarkers and Targeted Therapies	Excellent (Cum Laude)	UAM
Laura Jiménez Muñoz	Enrique Baca García	Psychiatry and Mental Health	Uso de las nuevas tecnologías para la mejora de la salud física y mental	Excellent (Cum Laude)	UAM
Pablo del Pozo Herce	Enrique Baca García, Raúl Juárez Vela (No IIS-FJD)	Psychiatry and Mental Health / Research in New Therapies	Evaluación de conductas de riesgo asociadas a la práctica de Chemsex	Excellent (Cum Laude)	UAM
Luis González Moreno	Araceli del Arco y Beatriz Pardo Merino	Mitochondrial Calcium Signalling	Regulación del calcio en la función mitocondrial de las células proliferantes: funciones de los transportadores mitocondriales regulados por calcio	Excellent (Cum Laude)	UAM
Sara Ruiz García	Javier Santos Hernández, Pilar López Nieva	Genetic Susceptibility to Rare and Complex Diseases	El papel del ARN largo no codificante MALAT1 en las neoplasias de células T precursoras	Excellent (Cum Laude)	UAM

Student	Supervisor/s	Research Group/ Department	Thesis Title	Grade	University
Andrea López Arranz	José Antonio Casado Olea, Juan Antonio Bueren Roncero	Advanced Therapies (CIEMAT)	Generation of CAR-T cells for the treatment of HNSCC in Fanconi Anemia patients / Desarrollo de una terapia CAR-T dirigida a receptores ErbB para el tratamiento de carcinomas escamosos de cabeza y cu	Excellent (Cum Laude)	UAM
Ismael Coifman Lucena	Emilio Calvo Crespo, María Valencia Mora	Traumatology	Estudio sobre la inervación del músculo subescapular y la cirugía de Latarjet	Excellent (Cum Laude)	UAM

10.5.3 Promotion of Research Training: Clinical and Experimental Research Awards.

In 2025, the 22nd edition of these awards was announced for doctoral theses defended during 2025. The awards were presented in 2026. The award-winning theses in the different categories are detailed below.

Clinical Research Doctoral Theses

1st Award

Dr Sol María Carriazo Julio

Title: **"Comprendiendo el alto riesgo de COVID-19 severo en personas con enfermedad renal crónica grave"**

Runner-up Award (ex aequo)

Dr Sergio Farrais Villalba

Title: **"Caracterización de la enfermedad celíaca en la edad adulta: análisis de casos retrospectivo"**

• Runner-up Award (ex aequo)

Dr Alejandra Tamayo Durán

Título: **"Mejora del diagnóstico genético de la aniridia mediante secuenciación masiva y desarrollo de modelos experimentales""**

• Runner-up Award (ex aequo)

Dr Raúl Fernández Prado

Title: **"PEPT2, una diana accionable en la nefrotoxicidad por colistina"**

Experimental Research Doctoral Theses

1st Award (ex aequo)

Dr Marta Sanz Álvarez

Title: **"Papel de la proteína MDK en la respuesta a terapias dirigidas contra HER2 en cáncer de mama HER2 positivo"**

1st Award (ex aequo)

Dr José Lucinio Mondaza Hernández

Title: **"Advancing Treatment Strategies for Solitary Fibrous Tumor: Novel Biomarkers and Targeted Therapies"**

Runner-up Award (ex aequo)

Dr Juan Guerrero Mauvecin

Title: **"Novel molecular targets and therapeutic strategies for monitoring and preventing necroinflammation in acute kidney injury"**

Runner-up Award (ex aequo)

Dr Daniel Láinez González

Title: **"Nuevas terapias contra la leucemia mieloide aguda: inhibición de la quiescencia en células madre leucémicas"**

Runner-up Award

Dr Ariadna Martín Blázquez

Title: **"Claves moleculares del aneurisma aórtico torácico: del desarrollo silente a la identificación de marcadores diagnósticos"**

10.6 Human Resources Programmes and Research Fellowships

(Awards granted in 2025)

The IIS-FJD has a workforce of research staff and research fellows, the majority of whom come from the two institutions that form an integral part of the IIS-FJD.

Within the framework of funding provided through the National R&D&I Plan, the IIS-FJD hosts and co-funds personnel supported by various programmes managed primarily by the Ministry of Science, Innovation and Universities, the Carlos III Health Institute (ISCIII), as well as the Ministry of Education, Vocational Training and Sports, the Regional Ministry of Science, Universities and Innovation of the Community of Madrid, and the European Union (see Section 5.1).

In addition, other researchers in training at the IIS-FJD receive funding from various foundations and institutions.

Conchita Rábago Foundation (FCR). "Jiménez Díaz" Research Fellowships:

(See the FCR Annual Report).

10.7 Training of IIS-FJD research staff

10.7.1 Specific Research Training Courses 2025

MANDATORY COURSES

- For research staff in training and open to medical staff, including residents.

ELECTIVE COURSES

- **Course on Good clinical practice guidelines and clinical trial development.**
  Held on the 7th, 14th and 21st of May 2025 in the Eloy López Lecture Hall, Fundación Jiménez Díaz University Hospital, with online access via Microsoft Teams.
  Course Directors: Dr Lucía Llanos Jiménez, Clinical Research and Clinical Trials Unit and Technical Secretariat of the Fundación Jiménez Díaz Research Ethics Committee for Medicinal Products (CEIm-FJD). Dr Rafael Dal-Ré Saavedra, Emeritus Researcher, Biostatistics and Epidemiology Unit, IIS-FJD.

- **Course: Fundamentals of Biostatistics.**
  Held on the 20th, 22nd, 26th and 28th of May 2025 in the Eloy López Lecture Hall, Fundación Jiménez Díaz University Hospital, with online access via Microsoft Teams.
  Course Director: Dr Ignacio Mahillo, Head of the IIS-FJD Biostatistics and Epidemiology Unit.

- **Good practices for the design of flow cytometry experiments.**
  On November 7th, 2025, Severo Ochoa Lecture Hall, Fundación Jiménez Díaz University Hospital.
  Delivered by: Becton Dickinson.

- **Course: Introduction to omics data analysis, 2025.**
  Held on the 24th, 25th and 26th of November 2025 at the Eloy López Lecture Hall, Fundación Jiménez Díaz University Hospital.
  Delivered by: Pablo Mínguez (head of unit), Graciela Uría Regojo and Yolanda Benítez Quesada. Bioinformatics Unit, IIS-FJD.

- **Multi-Omics Seminar: Unlock High-Dimensional Biology with 5D Multiomics.**
  On November 25th, 2025, Severo Ochoa Lecture Hall, Fundación Jiménez Díaz University Hospital.
  Speaker: Agnieszka Ciesielska, PhD. Sr Technical Sales Specialist, Element Biosciences.

10.7.2 Other training courses 2025

MANDATORY COURSES

- Whistleblowing channel.
- General cybersecurity training 2025.
- Integrity at Fresenius: doing the right thing when no one is watching.
- Phishing in your inbox.
- Occupational risk prevention (ORP) specific to your job position.
- Data protection awareness: security measures.

ELECTIVE COURSES

Cross-Functional Online Training and Soft Skills

- Emotional intelligence training for everyday life (I): Emotional intelligence I: self-care and healthy relationships.

- Emotional intelligence training for everyday life (II): Emotional intelligence II: Resilience and a positive constructive mindset.
- Emotional intelligence III: managing difficult emotions.
- Artificial intelligence in healthcare (From the 17th of November 2025 to the 5th of December 2025).

Online training in software tools

- Basic Excel
- Excel for data management and analysis at Quirónsalud (AF 614): first edition.
- Excel for data management and analysis at Quirónsalud: second edition (November).

10.7.3 Specific training activities organised by each research area: laboratory and journal club seminars

Each research group internally organises regular seminars on laboratory findings, journal club discussions, and other scientific topics, which are coordinated within the respective groups.



10.7.4 Training activities in the field in animal experimentation

The Experimental Medicine and Surgery Area participates in the organisation of several annual courses aimed at researchers and specialists from different fields, whose practical component requires the involvement of this unit. The courses held in 2025 are detailed below:

Course on endoscopy and anatomical-surgical dissection of the nasal cavities and paranasal sinuses, and temporal bone dissection

This training activity is aimed at specialists in Otorhinolaryngology (ENT) who seek to refine and develop new surgical approaches using anatomical specimens. These courses are promoted both nationally and internationally. Several editions were held in 2025:

Course Date	Course Duration	Number Of Participants	Title	Course Director
14-15 February	24 hours	12	Temporal bone dissection	Carlos Cenjor Español
20-21 June	24 hours	12	Temporal bone dissection	Carlos Cenjor Español

Longitudinal vascular surgery training course

A thorough understanding of the vascular anatomy of the lower limb is fundamental for performing surgical procedures appropriately. Dissection on a fresh cadaver provides a realistic view that facilitates the identification of these structures and improves the surgical approach in both emergency and elective procedures.

Course Date	Course Duration	Number Of Participants	Title	Course Director
26 June	12 hours	7	Longitudinal vascular surgery training course	Ciro Baeza Bermejillo, Carlos Castilla and Carlos Carnero

Workshop on preparation for clinical surgical practice (OSCE; Objective structured clinical examination, known in Spain as ECOE)

This activity is carried out in collaboration with the Faculty of Medicine of the Autonomous University of Madrid (UAM) and is intended for sixth-year medical students at UAM. Two editions were held:

Course Date	Course Duration	Number Of Participants	Title	Course Director
13 March	6 hours	35	ECOE	Héctor Guadalajara and Carlos Carnero
20 March	6 hours	35	ECOE	Héctor Guadalajara and Carlos Carnero

Surgical Training for Urology Residents.

This course forms part of the training programme for residents in the specialty of Urology. It focuses on the acquisition of new minimally invasive surgical techniques using in vivo models.

Course Date	Course Duration	Number Of Participants	Title	Course Director
29 January	6 hours	5	Surgical training for urology residents	Ramiro Cabello and Carlos Carnero
19 February	6 hours	5	Surgical training for urology residents	Ramiro Cabello and Carlos Carnero
26 February	5 hours	5	Surgical training for urology residents	Ramiro Cabello and Carlos Carnero

Surgical Training for Otorhinolaryngology Residents.

This course forms part of the training programme for residents in the specialty of Otorhinolaryngology. It focuses on the acquisition of new minimally invasive surgical techniques using in vivo models.

Course Date	Course Duration	Number Of Participants	Title	Course Director
29 January	7 hours	5	Surgical Training for Otorhinolaryngology Residents.	José Miguel Villacampa and Carlos Castilla
19 February	7 hours	6	Surgical Training for Otorhinolaryngology Residents.	José Miguel Villacampa and Carlos Castilla
26 February	7 hours	5	Surgical Training for Otorhinolaryngology Residents.	José Miguel Villacampa and Carlos Castilla

Workshop on new cardiovascular disease treatments for fourth-year UAX biomedicine students.

This workshop introduces cardiovascular anatomy, sample collection procedures, and preclinical imaging techniques using experimental models.

Course Date	Course Duration	Number Of Participants	Title	Course Director
17 October	8 hours	60	Introduction to research practice	Jorge Oller, Nerea Mendez and Carlos Carnero

Basic principles of laparoscopic surgery using a pelvic trainer.

During 2025, 10 sixth-year UAM medical students received training in the basic principles of laparoscopic surgery, including ergonomics, equipment handling, instrumentation, and basic suturing techniques.

These training sessions were conducted two days per week, with a maximum of two students per day and a duration of 5 hours per session.

Practical sessions within the second-year immunopathology course of the UAX biomedicine degree programme.

The learning objectives included basic mouse biology (anatomy, physiology, etc.), animal care, health and handling, and the fundamental principles of surgery.

Course Date	Course Duration	Number Of Participants	Title	Course Director
7 April	6 hours	30	Immunopathology (second year, biomedicine degree programme, UAX)	Vanesa Esteban and Carlos Castilla
22 April	6 hours	30	Immunopathology (second year, biomedicine degree programme, UAX)	Vanesa Esteban and Carlos Castilla

III Minor Surgery Course in Primary Care.

The aim of this course is to provide primary care physicians with the skills and knowledge required to perform minor surgical procedures, including instrumentation, local anaesthesia, surgical field preparation, and related techniques.

Course Date	Course Duration	Number Of Participants	Title	Course Director
19 June	7 hours	20	I Course in Primary Care	Enriqueta Bernal, Héctor Guadalajara, Óscar Gómez and Carlos Carnero

Resident induction course.

This annual course is designed to welcome newly appointed medical residents and aims to provide them with foundational competencies in suturing techniques, surgical field preparation, aseptic procedures...

Course Date	Course Duration	Number Of Participants	Title	Course Director
11 June	4 hours	20	Resident induction course	Carlos Castilla, Leandro Soriano, Carlos Carnero and Carlos Villalobos
10 July	4 hours	20	Resident induction course	Carlos Castilla, Leandro Soriano, Carlos Carnero and Carlos Villalobos
21 June	4 hours	20	Resident induction course	Carlos Castilla, Leandro Soriano, Carlos Carnero and Carlos Villalobos

II Course on Simulation in Laparoscopic Surgery.

This course was jointly developed by the department of general and digestive surgery and the department of experimental medicine and surgery, with the endorsement of the Madrid Society of Surgeons.

Course Date	Course Duration	Number Of Participants	Title	Course Director
19 June	7 hours	12	II Course on Simulation in Laparoscopic Surgery	Hector Guadalajara, Miguel León, Carlos Castilla y Carlos Carnero

Training for certification in the handling of laboratory animals

Two years ago, the IIS-FJD established a collaboration agreement with the Centre for Biomedical Studies (CEB) under which students external to the IIS-FJD, enrolled at the CEB to obtain an official certification in the handling of laboratory animals, carry out their practical training at the IIS-FJD Animal Experimentation Facility. These placements are supervised by IIS-FJD researchers involved in research projects using laboratory animals that have been approved by the Community of Madrid. Through this initiative, the Institute hosted 12 students enrolled at the CEB, external to the IIS-FJD, during 2025.

10.7.5 Training activities in scientific integrity

In 2018, the IIS-FJD Research Committee launched a series of specific training activities in the field of research integrity through a workshop introducing the newly established Research Integrity Committee, which had been created that same year.

During 2025, the IIS-FJD Research Integrity Committee continued its role in promoting compliance with the principles of Good Research Practices and in responding to enquiries submitted by IIS-FJD researchers:

The new version of the IIS-FJD Code of Good Research Practice was reviewed, disseminated and published (new version, in March 2025, available at (https://www.fjd.es/iis-fjd/es/estructura-organizativa/comite-integridad-cientifica/documentacion-interes).

- A self-assessment questionnaire on the new Code was distributed among IIS-FJD researchers.
- Research Integrity sessions by clinical department were conducted on the topics of Plagiarism, Generative Artificial Intelligence and Research Integrity. In January 2025: Department of Nephrology. In June 2025: FJD-UAM School of Nursing.
- A training session delivered by iThenticate (via Microsoft Teams) was organised, attended by 31 participants (November 20th, 2025).

10.8 Specialised healthcare training, primary care training and continuing education

10.8.1 Specialised healthcare training (in coordination with the Education Directorate)

Specialist training at HUFJD is delivered in accordance with the Fourth Strategic Plan for Resident Training and the Second Teaching Quality Management Plan. Both documents, approved by the Teaching Committee and the governing bodies of HUFJD, define the institution's commitment to excellence in the training of health sciences specialists. This commitment to excellence was recognised during the audit conducted by the Ministry of Health in July 2014, which once again accredited all our teaching units for a period of four years, the maximum reaccreditation interval permitted.

At present, 400 residents are undergoing training across 44 specialties. In May 2025, 108 new first-year residents joined the institution, eight of whom were nursing graduates. Prior to joining their respective training units, all new residents attended the 20th New Residents Induction Course in person.

The training programme encompasses a range of educational initiative:

- Cross-cutting training programme or generic core competencies programme for residents undertaking specialist training. This programme is offered not only to Quirónsalud residents but also to residents from other hospitals in the Community of Madrid, subject to the availability of places.
- Continuing professional development programme for healthcare professionals at HUFJD (continuing education).
- Continuing professional development programme for Primary Care physicians within the HUFJD catchment area.

These face-to-face courses are complemented by additional online courses available through the Aula Jiménez Díaz educational platform (www.aulajd.com).

In 2025, a total of 1,271 training activities were managed by the People and Organisation Department, through the Training Area. Of these, 354 were delivered face-to-face and 917 online, involving a total of 1,559 participants and 95,021 training hours (25,748 face-to-face hours and 69,273.42 online hours).

As in previous years, the sources of funding were the State Foundation for Training in Employment (FUNDAE) and Quirónsalud's own resources.

Among the most noteworthy training activities carried out were the following:

- **41 courses or workshops** aimed at both residents and the rest of the medical staff of the institution, of which:
  - **30** were cross-cutting training activities.
  - **6** were longitudinal training activities.
  - **5** were complementary training activities.
- **124 basic life support (BLS) courses,** accredited by the American Heart Association, for physicians, residents, and nurses at HUFJD.
- **2 Basic life support (BLS) refresher courses,** accredited by the American Heart Association, for physicians, residents, and nurses at HUFJD.
- **25 Advanced cardiovascular life support (ACLS) courses,** accredited by the American Heart Association, for physicians, residents, and nurses at HUFJD.
- **10 Paediatric emergency assessment, recognition and stabilization (PEARS) courses,** accredited by the American Heart Association, for physicians, residents, and nurses at HUFJD.
- **7 Paediatric advanced life support (PALS) courses,** accredited by the American Heart Association, for physicians, residents, and nurses at HUFJD.
- **1 fellowship competition (Astrolabio-Prof. Farré)** for resident training placements at centres of excellence abroad, covering travel and living expenses while maintaining participants' resident salaries at the Hospital.
- **1 clinical case competition (Prof. Jiménez Díaz)** aimed at promoting collaboration among healthcare professionals, improving communication skills, and fostering innovation.
- **1 fellowship competition (Areté),** providing educational grants to support professional specialty training placements at centres of excellence abroad for attending physicians ≤ 40 years.
- **1 fellowship competition (Hegémone),** providing educational grants to support professional specialty training placements at centres of excellence abroad for attending physicians aged 41 years or older ≥ 41 years.
- **Open Day for prospective residency applicants.** In March 2025, the event was held in person on 19th of March 2025, providing visibility to all specialties accredited at our institution.
- **New Residents Induction Course,** delivered in person over a period of six days at the beginning of June.
- **22 training activities** submitted for accreditation to the Continuing Education Commission for Health Professions of the Community of Madrid.
- **Opening of the advanced clinical simulation centre,** comprising a Scientific Director (Dr Luis Muñoz), Associate Scientific Directors (Dr Sara Heili and Dr José Miguel Villacampa), a Technical Director (Mr Carlos Carnero), a Board Member (Dr Carlos Villalobos), and an Administrative Officer (Mr Carlos Bersabé). More than 40 simulation-based training courses are organised each year.

In addition, as part of the cross-cutting training programme for residents, the following courses were also offered to specialists as part of the continuing professional development programme, as well as to IIS-FJD researchers, including both permanent research staff and researchers in training:

- Workshop on health sciences library services (on January 28th, 2025).
- Zotero bibliographic reference manager (on February 13th, 2025).

- First face-to-face course on the use of excel (on February 19th, 2025).
- Literature searches in PubMed and using artificial intelligence tools (on February 24th, 2025).
- Introduction to research methodology (on March 12th, 2025).
- UpToDate y UpToDate Advanced for your clinical practice (on March 18th, 2025).
- Critical appraisal: basic level (on April 2nd, 2025)
- Basic workshop on scientific writing and manuscript submission to journals (on April 8th, 2025).
- Introductory workshop on Artificial Intelligence (on June 3rd, 2025).
- First career development workshop (on 5th of June 2025).
- Second workshop on biostatistics I (on 10th of June 2025).
- CINHAL (on June 10th, 2025).
- Second workshop on conflict management and communicating bad news (on September 18th, 2025).
- Systematic reviews and meta-analysis (on September 30th, 2025).
- AI tools for research (on October 9th, 2025).
- CINAHL: Answers for nursing and allied health professions (on November 5th, 2025).
- Advanced PowerPoint course (on November 5th, 2025).

Among these courses, several are specifically focused on research training and are also open to non-medical researchers in training at the IIS-FJD:

- Workshop on health sciences library services (on January 28th, 2025).
- Zotero bibliographic reference manager (on February 13th, 2025).
- Literature searches in PubMed and using artificial intelligence tools (on February 24th, 2025).
- Introduction to research methodology (on March 12th, 2025).
- UpToDate y UpToDate Advanced for your clinical practice (on March 18th, 2025)
- Critical appraisal: basic level (April 2nd, 2025).
- Basic workshop on scientific writing and manuscript submission to journals (April 8th, 2025).
- Introductory workshop on artificial intelligence (3rd of June 2025).
- CINHAL (June 10th, 2026).
- Systematic reviews and meta-analysis (September 30th, 2025).
- AI tools for research (October 9th, 2026).
- CINAHL: All the answers for nursing and allied health disciplines (November 5th, 2025).
- Expansion of online content on the "Aula Jiménez Díaz" Educational Platform (www.aulajd.com).

10.8.2 Primary care professional portal (http://apfjd/default.aspx)

At present, the IIS-FJD participates in Primary Care (PC) training and research through the collaboration established between HUFJD and the 23 Primary Care Health Centres within its catchment area, belonging to the Dirección Asistencial Noroeste (with one centre belonging to the Central Healthcare Directorate) of the Primary Care Management Division of the Madrid Health Service (SERMAS).

These 23 health centres provide care to the HUFJD reference population of 433,000 people and are in the districts of Centro, Arganzuela and Moncloa-Aravaca.

As part of initiatives aimed at strengthening Primary Care services, HUFJD, together with the IIS-FJD, has developed shared electronic information-transfer tools, including the establishment of the PRIMARY CARE PROFESSIONAL PORTAL and the implementation of access to this portal from all Primary Care centres.

This tool facilitates communication between the IIS-FJD and Primary Care professionals, as the wide geographical distribution of the centres creates logistical challenges regarding access to information and participation by Primary Care teams in IIS-FJD training activities.

The PRIMARY CARE PROFESSIONAL PORTAL has been designed to address this challenge by facilitating the development of joint clinical, educational and research projects between the IIS-FJD and Primary Care services. The portal supports the creation and management of joint IIS-FJD and Primary Care working groups focused on specific clinical, research and educational topics, including distribution lists to facilitate communication:

1. Contact and communication with Primary Care professionals interested in participating in research initiatives.

2. Dissemination of IIS-FJD research findings and their translational application to Primary Care.

a. Most relevant news regarding published research results.

b. Summaries of IIS-FJD publications: distribution lists will be created for Primary Care professionals interested in following the research activities of the different IIS-FJD research areas.

3. Identification of training needs.

a. Through working groups.

b. Through discussions.

c. Through feedback collected following the training activities.

4. Training provision.

a. General:

I. Dissemination of the seminars, conferences and courses organised by the IIS-FJD described in the previous sections.

II. Availability on the website of the presentations delivered during IIS-FJD seminars, conferences and courses, subject to prior authorisation from the Primary Care Centres.

b. Specific:

I. Provision of informational sessions and courses specifically designed for Primary Care professionals, based on identified training needs, with appropriate accreditation and preferably delivered in a digital format.

II. Evaluation of both faculty members and the training course.

This training framework with Primary Care has already led to the implementation of four collaborative research projects involving these groups:

- Genetics and Pharmacogenetics of Attention Deficit Hyperactivity Disorder (ADHD) in children in the Spanish population. PI: Carmen Ayuso García.
- Psychiatry Research Project: International Latino Research Partnership (ILRP). PI: Enrique Baca García.
- Ortho Clinical Diagnostics Primary Care Multicentre Study.
- MAIC Continuum Project.

10.8.3 Continuing education programme and other training opportunities

Among the continuing professional development offerings, particular emphasis is placed on those courses specifically aimed at the training of researchers or at strengthening the scientific knowledge and skills of other staff members. The main sources of funding are the National Institute of Medical Education, the State Foundation for Training in Employment (FUNDAE), the Regional Ministry of Health of the Community of Madrid, and Quirónsalud's own funding programmes.

Some of the training activities carried out in 2025 that were focused on research and/or researchers have already been described in Section 10.8.

10.9 Seminars and Conferences

10.9.1 Regular General Seminars at IIS-FJD

Two main types of seminars stand out:

Generals:

These seminars are open to all IIS-FJD staff. Speakers are usually researchers from the Institute or invited researchers from other institutions. The aim of these sessions is to showcase the knowledge generated within the IIS-FJD while broadening participants' expertise through the experience and contributions of external researchers.

The following seminars were held during 2025:

- **Seminar: Obesity and Cancer: the link through the mitochondrial modulation.** Speaker: Mabel Catalán Díaz, researcher at the Faculty of Medicine, University of Chile. On March 21st, 2025, José Perianes Lecture Hall, Fundación Jiménez Díaz University Hospital.
- **Endocrinology Research Seminar: Identificación de fenotipos clínicos en sujetos prediabéticos con riesgo cardiometabólico.** Speaker: Juan Carlos Lizarzaburu. Endocrinology Unit, Central Air Force Hospital of Peru (HCFAP), Lima; PhD student at UAM. June 20th, 2025, Francisco Grande Lecture Hall, Fundación Jiménez Díaz .
- **10x Genomics Day.** September 22nd, 2025, Severo Ochoa Lecture Hall, Fundación Jiménez Díaz University Hospital. Event organised in collaboration with 10x Genomics and Bonsai Lab.

Laboratory-specific seminars:

These seminars are organised and delivered by members and researchers of the various laboratories and clinical departments. Each laboratory develops and maintains its own seminar schedule.

10.9.2 10th Margarita Salas Predoctoral Research Seminar Series at IIS-FJD

In 2025, the IIS-FJD Research Committee organised the **10th "Margarita Salas" Predoctoral Research Seminar Series** at the IIS-FJD. This event consisted of several seminars presented by predoctoral researchers from our Institute. The aim of this initiative was to contribute to the training of our early-career researchers while fostering the exchange of knowledge on ongoing research lines and doctoral thesis projects with the wider research community. Presentations were divided into two categories: clinical research and basic research. Each presentation lasted 10 minutes, during which the researcher presented an original study that will form part of their doctoral thesis, with thesis defence expected during the following year. Presentations in both the clinical and basic research categories were evaluated, and an award was presented to the best presentation in each category. This initiative received the support of the Scientific Directorate of the IIS-FJD, the Chair of its Board of Trustees, and the IIS-FJD External Scientific Committee.

These seminars were held the on November 21st, 2025, from 9:00 a.m. to 2:00 p.m., in the Main Auditorium of Fundación Jiménez Díaz University Hospital (HUFJD).

The **programme** was as follows:

Moderators: Nerea Mendez and Carmen Garcés.

9:15 **Opening sessions.** IIS-FJD Scientific Directorate.

9:30 **"Optimización del Prime editing como estrategia de terapia génica de precisión en células madre hematopoyéticas de pacientes con anemia de Fanconiqu".**
Beatriz Olalla Sastre. Research group: Advanced Therapies (CIEMAT). Category: basic research.

9:45 **"Anexina A8 como diana terapéutica en el desarrollo de aneurismas aórticos".**
Irene Mª de San Sebastián Jaraba. Research group: Nephrology, Hypertension, Vascular Pathology and Diabetes. Category: basic research.

10:00 **"El metabolismo del colesterol en la anafilaxia"**
Sergio Fernández Bravo. Research group: Allergy and Immunology. Category: basic research.

10:15 **"Claves moleculares del aneurisma aórtico torácico: del desarrollo silente a la identificación de marcadores diagnósticos".**
Ariadna Martín Blázquez. Research group: Allergy and Immunology. Category: basic research.

10:30 **"Terapia génica intracerebral con vectores adeno-asociados para la enfermedad de Lafora."**
Nerea Iglesias-Cabeza. Research group: Neurology. Category: basic research.

10:45 **"Alirocumab atenúa la inflamación de la placa inducida por PCSK9 en macrófagos M1 de manera independiente del efecto hipolipemiante".**
Cristina Espadas Ñíguez. Research group: Cardiology. Category: basic research.

11:00 **"Aspartate Glutamate Carrier 1 (Aralar) links aspartate availability to oligodendrocyte lineage expansion and postnatal myelination".**
Eduardo Herrada Soler. Research group: Calcium Signalling. Category: basic research.

11:15 **"Selección de mutantes resistentes a ceftazidima-avibactam a partir de biofilm de enterobacterias hiperproductoras de AMPc".**
Cristina Ortega Portas. Research group: Microbiology Category: basic research.

11:30 **"Identificación de fenotipos clínicos en pacientes prediabéticos con riesgo Cardiometabólico"**
Juan Carlos Lizarzaburu Robles. Research group: Nephrology, Hypertension, Vascular Pathology and Diabetes.

12:00 **"Evaluación de la calidad de vida en pacientes pediátricos con cardiopatías congénitas".**
María de la Parte Cancho. Research group: Cardiology. Category: clinical research.

12:15 **"Mycobacterium abscessus: un desafío emergente en pacientes con fibrosis quística."**
María Cano Fernández. Research group: Microbiology. Category: basic research.

12:30 **"Exosomal PSMD7 Promotes an Aggressive Phenotype in Pancreatic Cancer via PTEN/PI3K/AKT Signaling Pathway".**
Michael Ochieng´ Otieno. Research Group: Medical oncology. Category: basic research.

12:45 **"Potencial terapéutico del fago FT5P frente a infecciones por Enterococcus faecium resistente a vancomicina".**
Laura Ribes Martínez. Research Group: Microbiology. Category: basic research.

13:00 **"Edición génica mediante sistemas no-virales para el tratamiento de anemias hemolíticas hereditarias".**
Miruna Giurgiu. Research Group: Advanced Therapies (CIEMAT). Category: basic research.

13:15 **"El papel del factor de transcripción Fosl2 en la enfermedad renal crónica".**
Marta Ribagorda Bermejo. Research group: Nephrology, Hypertension, Vascular Pathology and Diabetes). Category: basic research.

13:30 **"Caracterización clínica y molecular de la alergia a nuez de nogal en un área del Mediterráneo Occidental".**
Laura Ortega Martín. Research group: Allergy and Immunology. Category: basic research.

14:00 Closing remarks.

10.9.3. 2nd early career researcher talks series

In 2025, the **"2nd Young Researchers Talk Series"** continued as an established forum and meeting point for scientific exchange among IIS-FJD predoctoral researchers. This initiative aims to encourage early-career researchers to share their research and knowledge in a collaborative and informal environment, promoting interdisciplinary dialogue, creating opportunities for collaboration, and facilitating the exchange of questions and experiences. The series was supported by the IIS-FJD Research Committee.

The talks were held in the Eloy López Lecture Hall of Fundación Jiménez Díaz University Hospital, from 3:00 p.m. to 4:00 p.m., with the participation of young researchers from different scientific areas of the Institute.

The programme included the following presentations:

- **On January 30th, 2025.**
  Speaker: Yolanda Benítez Quesada.
  Scientific area: Genetics and Epidemiology.
  Research Group: Genetics and Genomics of Rare and Complex Diseases.
  Support Unit: Bioinformatics.
  Talk: *Métodos de predicción de nuevas asociaciones gen-fenotipo.*

- **On February 27th, 2025.**
  Speaker: Jairo Lumpuy Castillo.
  Scientific Area: CRM (Cardiovascular, Renal and Metabolic Diseases).
  Research Group: Nephrology, Hypertension, Vascular Pathology and Diabetes.
  Talk: *Alteraciones en la homeostasis mitocondrial cardíaca en condiciones de hiperglucemia: papel del eje AMPK/PGC-1α/SIRT3.*

- **On March 18th, 2025.**
  Speaker: Jesús Frutos Diaz Alejo.
  Scientific Area: Cancer.
  Research Group: Anatomical Pathology.
  Talk: *Differences in Gene-Expression Profiling of Primary Cutaneous CD4+ Small/Medium T-Cell Lymphoproliferative Disorder and Angioimmunoblastic T-Cell Lymphom.*

- **On April 30th, 2025.**
  Speaker: Juan Guerrero Mauvecin.
  Scientific Area: CRM (Cardiovascular, Renal and Metabolic Diseases).
  Research Group: Nephrology, Hypertension, Vascular Pathology and Diabetes.
  Talk: *Novel molecular targets and therapeutic strategies for monitoring and preventing necroinflammation in acute kidney injury.*

- **On May 29th, 2025**
  Speaker: Ana García Bautista.
  Sientific Area: Cancer.
  Research Group: Medical Oncology
  Talk: *Molecular Characterizaton of ACLY-MDR1 axis in colorectal cancer and its modulation by Vitamin C.*

- **On October 1st, 2025**
  Speaker: Miguel Marco Bonilla.
  Scientific Area: Infectious, Inflammatory and Chronic Diseases.
  Research Group: Rheumatology and Bone Metabolism.
  Talk: *Dipiridamol y la modulación del sistema purinérgico: una estrategia farmacológica contra la sarcopenia reumatoide.*

- **On November 12th, 2025**
  Speaker: Cristina Espadas Niguez.
  Scientific Area: CRM (Cardiovascular, Renal and Metabolic Diseases).
  Research Group: Cardiology.
  Talk: *Alirocumab modula la activación inflamatoria de macrófagos M1 inducida por PCSK9 en la aterosclerosis, independientemente del colesterol.*

- **On December 3rd, 2025**
  Speaker: Ariadna Martín Blázquez.
  Scientific Area: Infectious, Inflammatory and Chronic Diseases.
  Research Group: Allergy and Immunology.
  Talk: *Claves Moleculares del Aneurisma Aórtico Torácico: del desarrollo silente a la identificación de marcadores diagnósticos.*

The series continues to establish itself as a key instrument for the training and scientific integration of IIS-FJD early-career researchers, promoting the internal dissemination of knowledge and strengthening the Institute's research community.

10.9.4 8th Fundación Jiménez Díaz research chair seminar series on regenerative medicine and tissue bioengineering (IIS-FJD-UC3M-CIEMAT).

During 2025, *the eighth Scientific Seminar Series, "Clinical and Translational Science Seminar Series"*, was held under the framework of the Fundación Jiménez Díaz Chair in Regenerative Medicine and Tissue Bioengineering. This annual series aims to bring the most relevant advances in advanced therapies, regenerative medicine and tissue bioengineering closer to the IIS-FJD research community.

The seminars, each lasting approximately one hour, were delivered online and featured nationally and internationally renowned speakers in their respective fields. The programme for the 2025 edition is detailed below:

- **On October 9th, 2025.**

  Speaker: Alejandra Leivas. PhD, Project Manager & Senior Regulatory Consultant ATMPs. Gradocell Advanth Clinical Services / Advanthera Regulatory Pathways.

  Seminar title: Types of ATMP Production: Manual and Automated Manufacturing.

  Moderated by: Dr María José Escámez. IIS-FJD-UC3M Research Chair, CIBERER (Centre for Biomedical Network Research on Rare Diseases).

- **On November 6th, 2025.**

  Speaker: Dr Gustavo Melen. Scientific Director of Advanthera Regulatory Pathways, Madrid.

  Seminar title: Visión general de Productos ATMPs.

  Moderated by: Dr Fernando Larcher. Regenerative Medicine and Tissue Bioengineering Research Group, IIS-FJD-CIEMAT; Carlos III University of Madrid (UC3M); CIBERER.

- **On November 13th, 2025.**

  Speaker: Javier Rodríguez. Full Professor. Thermal and Fluids Engineering Department. Fluid Mechanics Group at Carlos III University of Madrid.

  Seminar title: Transport of viral particles in evaporating respiratory droplets.

  Moderated by: Dr Leticia Valencia Blanco. Tissue Engineering and Regenerative Medicine (TERMeG), Regenerative Medicine and Tissue Bioengineering Research Group, IIS-FJD-CIEMAT; Carlos III University of Madrid (UC3M).

- **On November 20th, 2025.**

  Speaker: Víctor M. González. Deputy Director of the Ramón y Cajal Institute for Biomedical Research (IRYCIS). Head of the Aptamers Research Group and the Central Aptamer Support Unit, Health Institute Research Ramón y Cajal (IRYCIS).

  Seminar title: Development of Aptamers for Therapeutic Applications.

  Moderated by: Dr Marta Carretero. Regenerative Medicine and Tissue Bioengineering Research Group, IIS-FJD-CIEMAT; Carlos III University of Madrid (UC3M); CIBERER.

The eighth Seminar Series remains a key activity for scientific updating and knowledge transfer in strategic areas such as advanced therapies, tissue engineering and translational research, strengthening collaboration among institutions and supporting the continuous professional development of IIS-FJD researchers.

10.9.5 7th annual meeting of IIS-FJD research areas and groups

The overall objective of these meetings is to ensure that all researchers are aware of the research being conducted at the IIS-FJD and, in doing so, to promote interaction among the different research areas and groups within the Institute. Accordingly, in this edition, the scientific presentations provided an overview of the work carried out by each research group. In addition, at the end of each presentation, speakers shared with fellow researchers the skills and activities in which they have expertise, as well as the areas in which they would like to further develop their knowledge and capabilities. The sessions organised in 2025 by each of the research areas of our Institute, held in the Severo Ochoa Lecture Hall of Fundación Jiménez Díaz University Hospital, are detailed below:

- **On April 9th, 2025. VII Annual Meeting of the IIS-FJD Infectious, Inflammatory and Chronic Diseases Research Area.**

  Programme

  10:00-10:15: Opening remarks by the scientific directorate. Dr Carmen Ayuso, scientific director of the IIS-FJD.

  10:15-10:25: Presentation of the research area. Dr Raquel Largo, area coordinator.

  10:25-10:30: Moderation and introduction of the speakers. Dr Victoria del Pozo, area coordinator and deputy scientific director of IIS-FJD.

  10:30-10:45: Title: "El metabolismo del colesterol en la anafilaxia" Speaker: Dr Vanesa Esteban Vázquez. Group: Allergy and Immunology.

  10:45-11:00: Title: "Tratamiento de la infección cutánea causadas por Mycobacterium marinum usando nanopartículas de sílice mesoporoso funcionalizadas". Speaker: Dr John J. Aguilera Correa. Group: Microbiology.

  11:00-11:15: Title: "Coinfección por el VIH/VHC en la Era de los Antivirales de Acción Directa (AADs)". Speaker: Dr Beatriz Álvarez Álvarez. Group: Infectious Diseases and Tropical Medicine.

  11:15-11:30: Title: "Inestabilidad de hombro: La importancia del seguimiento a largo plazo en estudios clínicos". Speaker: Dr Emilio Calvo. Group: Traumatology Associated Group.

  11:30-12:00: Discussion and closing remarks.

- **On June 18th, 2025. VII Annual Meeting of the IIS-FJD Cancer Research Area.**

  Programme:

  10:00-10:15: Opening remarks. Dr Federico Rojo, head of the Cancer research area.

  10:15-10:25: Presentation of the research area and moderation. Dr Mª Rodriguez Pinilla, head of the Pathology research group.

  10:25-10:40: Title: "Explorando los mecanismos moleculares y funcionales de la leucemia mieloide aguda esporádica y familiar". Speaker: Dr Ana del Rio Machin. Group: Haematology.

  10:40-10:55: Title: "Células del estroma de la médula ósea como biomarcador temprano de leucemia mieloide aguda en el síndrome mielodisplásico". Speaker: Dr Juana Serrano López. Group: Haematology.

  10:55-11:10: Title: "Panel de la proteína MDK en respuesta a terapias dirigidas contra HER2 en cáncer de mama HER2 positivo". Speaker: Dr Marta Sanz Álvarez. Group: Anatomical Pathology.

11:10-11:30: Title: "Relevancia de las determinaciones moleculares de FGFR en carcinoma Urotelial". Speaker: Drs Beatrice Popescu and Elena Buendía González. Groups: Anatomical Pathology and Department of Urology.

11:30-12:00: Discussion and questions.

- **On July 4th, 2025. VII Annual Meeting of the IIS-FJD Renal, Metabolic and Cardiovascular Diseases Research Area.**

  Programme:

  10:00-10:15: Opening remarks by the scientific directorate. Dr Carmen Ayuso, scientific director of the IIS-FJD.

  10:15-10:30: Presentation of the research area and moderation. Dr Alberto Ortiz, area coordinator.

  10:30-10:50: Title: "Adrenarquia prematura como marcador de riesgo cardiovascular y desarrollo de síndrome de ovario poliquístico". Speaker: Dr Javier Mejorado Molano. Group: Lipid Disorders: Clinical and Experimental (adults and children).

  10:50-11:10: Title:"Descifrando nuevos mediadores del remodelado patológico de la pared vascular: desde el co-cultivo 3D a los modelos animales". Speaker: Dr Nerea Méndez Barbero. Group: Nephrology, Hypertension, Vascular Pathology and Diabetes.

  11:10-11:30: Title: "Atención sanitaria y sostenibilidad: una nueva perspectiva.". Speaker: Rodrigo Martínez Cadenas. Group: Nephrology, Hypertension, Vascular Pathology and Diabetes.

  11:30-12:00: Discussion and closing remarks.

- **On September 12th, 2025. VII Annual Platforms Meeting.**

  Programme:

  10:30-10:40. Opening remarks by the scientific directorate. Dr Carmen Ayuso, scientific director of the IIS-FJD.

  10:40-10:50. Presentation of the area and moderation. Dr Sandra Zazo.

  10:50-11:15. Bioinformatics unit. Speakers: Arancha Cebrián and Pablo Mínguez.

  11:15-11:40. Biobank. Speakers: Ángela Lamarca and Carolina Domínguez.

  11:40-12:05. Cell biology unit: Microscopy and Flow Cytometry. Speaker: José Antonio Cañas Mañas.

  12:05-12:30: Discussion and questions.

- **On October 2nd, 2025. VII Annual Meeting of the IIS-FJD Genetics and Genomics Research Area.**

  Programme:

  10:00-10:20: Opening remarks, presentation of the research area and moderation. Dr Carmen Ayuso García, scientific director of the IIS-FJD and head of the Research Area.

  10:20-10:30: Title: "Secuenciación de lecturas largas. Aplicaciones en el análisis de metilación y de enfermedades neurológicas por expansión". Speakers: Carolina Ruiz, Beatriz Isidoro. Group: Genetics and Genomics of Rare and Complex Diseases.

10:30-10:45: Title: "Enfermedades asociadas a RNA no codificantes: de la investigacion a la práctica clínica". Speaker: Berta Almoguera, Lidia Fernández-Caballero. Group: Genetics and Genomics of Rare and Complex Diseases.

10:45-10:55: Title: "Priorización de variantes, genes y funciones para guiar el diagnóstico de pacientes de enfermedades raras mediante consultas a una base de datos genómicos." Speaker: Pablo Mínguez. Group: Genetics and Genomics of Rare and Complex Diseases.

10:55-11:05 Title: "Herencia genética y riesgo de cáncer de próstata: análisis genético-clínico en población española". Speaker: Camila Reeb, Ana Osorio. Group: Genetics and Genomics of Rare and Complex Diseases.

11:05-11:20 Title: "Unidad de investigación y ensayos clínicos inmunización Fundación Jiménez Díaz. 3 años de recorrido. Investigaciones realizadas, resultados y proyectos en marcha". La inmunización como oportunidad de crecimiento". Speaker: Helena Moza Morinigo. Group: Preventive Medicine, Public Health and Primary Care.

11:20-12:00. Discussion and questions.

- **On November 26th, 2025. VII Annual Meeting of the IIS-FJD Neurosciences Research Area**

Programme:

13:30 – 13:40: Opening remarks by the scientific directorate.

13:40– 13:50: Presentation of the research area. Drs. Enrique Baca García and José María Serratosa Fernández.

13:50 – 14:20: Neurology research group.

13:50-14:00: Title: "Esclerosis múltiple". Speaker: Ms Irene Moreno.

14:00-14:10: Title: "Cefaleas". Speaker: Mr Alex Jaimes.

14:10-14:25: Title: "Epilepsia". Speaker: Mr Luis Zafra and Mr Jose Serratosa.

14:25– 14:40: Title: "Patología cortical". Speaker: Ms Estrella Gómez Tortosa.

14:40– 14:55: Title: "Trastornos del movimiento". Speaker: Mr Pedro Garcia Ruiz-Espiga.

14:55– 15:05: Title: "Ictus". Speaker: Ms Araceli Garcia Torres and Ms Inmaculada Navas.

15:05 – 15:20: Mitochondrial Calcium Signalling Research Group. Title: "Conducta social y metabolismo mitocondrial". Speaker: Mr Eduardo Herrada.

15:20: Discussion and questions.

- **On December 10th, 2025. VII Annual Meeting of the IIS-FJD Healthcare Technology and Innovation Research Area.**

Programme:

10:00-10:10: Opening remarks by the scientific directorate. Dr Carmen Ayuso.

10:10-10:20: Presentation of the research area and moderation. Dr Damian Garcia Olmo.

10:20-10:40: Title: "Avances en imagen mesoscópica optoacústica". Speaker: Dr Juan Aguirre Bueno. Group: Development and Innovation in Medical Engineering (UAM).

10:40-11:00: Title: "El papel de las células CAR-T en la Carcinomatosis peritoneal". Speaker: Dr Siyuan Qian Zhang. Research group: Research in New Therapies.

11:00-11:20: Title: "Máster de Práctica Avanzada en Circulación extracorpórea y Perfusión UAM" Speaker: Dr Eva García Perea and Lorena Carballo Rodríguez. Group: UAM Nursing: Extracorporeal Circulation and Perfusion.

11:20-11:40: Title: "Edición génica mediada por reparación homóloga dirigida para el tratamiento de anemias hereditarias". Speaker: Dr José Carlos Segovia. Group: Advanced Therapies Joint Unit (CIEMAT).

11:40-12:00: Advanced Therapies Joint Unit (CIEMAT).

10.9.6 Welcome day for new IIS-FJD researchers

The IIS-FJD Welcome Day for New Researchers, held annually, aims to facilitate the integration of researchers and newly appointed support, management and administrative staff who have joined the Institute during the year.

The session provides an overview of the Institute's organisational structure, available resources, the main research support services, and the IIS-FJD management procedures.

This activity facilitates their integration into the Institute and provides a general overview of the services, institutional resources and support channels available for research activities

The 2025 edition was held the on May 19th, 2025, and included the following presentations:

- Overview of the IIS-FJD. Speaker: Dr Carmen Ayuso, scientific director of the IIS-FJD.
- Welcome Pack. Speaker: Dr Victoria del Pozo, deputy scientific director of the IIS-FJD.
- Good Research Practices. Speaker: Dr Lucía Llanos, secretary of the research integrity committee and the Research Ethics Committee for Medicinal Products (CEIm).
- Training Programme. Speaker: Dr Raquel Largo, IIS-FJD Training Area.
- Organisational Aspects. Speaker: Mr Alberto Montero, Managing Director of the IIS-FJD.

10.9.7. Research open days at IIS-FJD affiliated hospitals

In 2025, one edition of the Research Open Days was held at the hospitals affiliated with the IIS-FJD, with the following objectives:

- To provide information about the Fundación Jiménez Díaz Health Institute Research Institute (IIS-FJD), its structure, operations and the resources it offers.
- To provide information about the Fundación Jiménez Díaz Health Research Institute (IIS-FJD), its structure, operations and the resources it offers.
- To increase the visibility of the research activities carried out within the hospitals.
- To increase the visibility of the research activities carried out within the hospitals.

Research day at General University Hospital of Villalba (HUGV)

On March 18th, 2025. General University Hospital of Villalba. Second Edition.

Programme:

- **The Fundación Jiménez Díaz Health Research Institute (IIS-FJD) and HUGV**
  Speaker: Dr Victoria del Pozo, Deputy Scientific Director of IIS-FJD.
- **Update and Practical Aspects of Submitting Studies to the FJD Research Ethics Committee (CEIm-FJD): What Do I Need to Know?**
  Speaker: Dr Lucía Llanos, Secretary of the Research Integrity Committee and the Research Ethics Committee for Medicinal Products (CEIm).
- **Support for Researchers: IIS-FJD Management Area**
  Speaker: Mr Alberto Montero, Managing Director of IIS-FJD.

10.9.8. 1st meeting with primary care researchers

The first Meeting with Primary Care Researchers was held online on October 6th, 2025.

The meeting was attended by Dr Carmen Ayuso, Scientific Director; Dr Victoria del Pozo, Deputy Scientific Director; Dr Lucía Llanos, Secretary of the Research Integrity Committee and the Research Ethics Committee for Medicinal Products (CEIm), and Head of the Preventive Medicine, Public Health and Primary Care Research Group; Mr Alberto Montero, Managing Director; and Dr Óscar Gómez, Director of Care Continuity for the four affiliated hospitals (4H).

10.9.9. Anniversary of the IIS-FJD Accreditation

On December 16th, 2025, the fifteenth anniversary of the first accreditation of the Fundación Jiménez Díaz Health Research Institute (IIS-FJD) was celebrated in the Main Auditorium of Fundación Jiménez Díaz University Hospital.

The event featured contributions from Dr Javier Arcos, Chair of the IIS-FJD Governing Board, and Dr Manuel Cuenca, Deputy Director-General for Research Evaluation and Promotion at the Carlos III Health Institute (ISCIII), who highlighted the Institute's trajectory, growth and scientific contribution throughout these years.

The ceremony continued with the presentation of the "Margarita Salas" Predoctoral Research Seminar Awards, recognising the quality and excellence of the presentations delivered by the Institute's predoctoral researchers.

10.10 Other outreach activities and scientific meetings

20th INTERNATIONAL CONFERENCE ON TRANSLATIONAL RESEARCH AND PRECISION MEDICINE: INTEGRATION OF GENETIC TESTING INCLUDED IN THE COMMON PORTFOLIO OF SERVICES INTO CLINICAL PRACTICE

On February 6th, 2025, Main Auditorium, Fundación Jiménez Díaz University Hospital.

Programme

09:30 h. Opening session

Ms Cristina González del Yerro. Deputy Director-General for the National Health System (NHS) Service Portfolio and Compensation Funds.

Dr Marta Cremades. Medical Director, Fundación Jiménez Díaz University Hospital.

Dr Carmen Ayuso. Head of the Department of Genetics, Fundación Jiménez Díaz University Hospital; Scientific Director of the IIS-FJD-UAM; Principal Investigator, CIBERER-ISCIII Research Group (CB06/07/0036).

Mr Federico Plaza. Vice-President of the Roche Institute Foundation.

10:00 - 10:15 h. Introduction to the Common Catalogue of Genetic Tests. Ms Marisa Vicente Saiz. Head of the Programme Costs Unit, Deputy Directorate-General for the National Health System (NHS) Service Portfolio and Compensation Funds, Directorate-General for the Common Portfolio of NHS Services and Pharmacy.

10:15h - 11:30h. Round Table: Implementation of the Catalogue of Genetic Tests in the Autonomous Communities

Dr Federico Rojo. Head of the Department of Pathology, Fundación Jiménez Díaz University Hospital.

Prof. Belén Pérez. Professor of Biochemistry and Molecular Biology, Autonomous University of Madrid. CIBERER-ISCIII (CB06/07/0004).

Andalusia: Dr Antonio Martínez Peinado Consultant in Molecular Genetics, Reina Sofía University Hospital, Córdoba.

Catalonia: Dr Ignacio Blanco Coordinator of the Clinical Genetics Counselling Programme, Germans Trias i Pujol University Hospital, Barcelona.

Community of Madrid: Dr Pilar Sánchez-Pobre. Deputy Director for Healthcare Planning and Organisational Innovation, Madrid Health Service (SERMAS).

Extremadura: Dr Adrián Llerena Professor of Pharmacology at the University of Extremadura; Director of the Extremadura University Institute for Biomedical Research (INUBE); CIBERER-ISCIII Research Group (GCV23/ER/2).

Galicia: Dr Ángel Carracedo Director of the Galician Public Foundation for Genomic Medicine (Galician Health Service); Coordinator of the Genomic Medicine Research Group, University of Santiago de Compostela (CIBERER-ISCIII, CB06/07/0088).

12:00 - 12:45 h. **Discussion: Challenges and opportunities in the implementation of the catalogue of genetic tests.**

Dr Federico Rojo.

Prof. Belén Pérez.

Participants:

Ms Marisa Vicente Saiz.

Dr Antonio Martínez Peinado.

Dr Ignacio Blanco.

Dr Pilar Sánchez-Pobre.

Dr Adrián Llerena.

Dr Ángel Carracedo.

12:45 - 13:15 h. Final reflections.

Dr Encarna Guillén. President of the Spanish Association of Human Genetics; Strategic Director of the ÚNICAS National Network, HSJD-Barcelona; Principal Investigator of the CIBERER-ISCIII Research Group (GCV14/ER/1).

13:15h- 13:30 h. Closing remarks.

Dr Carmen Ayuso Head of the Department of Genetics, Fundación Jiménez Díaz University Hospital; Scientific Director of IIS-FJD-UAM; Principal Investigator of the CIBERER-ISCIII Research Group (CB06/07/0036).

Ms Consuelo Martín de Dios Managing Director of the Roche Institute Foundation. D. Federico Rojo Head of the Department of Pathology, Fundación Jiménez Díaz University Hospital.

90th ANNIVERSARY FOUNDATION JIMÉNEZ DÍAZ LECTURE. CARLOS LOPEZ OTÍN.

On February 27th, 2025, Main Auditorium, Fundación Jiménez Díaz University Hospital

This inaugural session featured Carlos López-Otín, Professor of Biochemistry and Molecular Biology, writer and science communicator, who presented his book La levedad de las libélulas (The Lightness of Dragonflies).

SUSTAINABILITY SYMPOSIUM IN THE HEALTHCARE SECTOR. THURSDAY, the 27th OF MARCH 2025

On March 27th, 2025, Main Auditorium, Fundación Jiménez Díaz University Hospital

15:30 h. Opening and introduction to the symposium. Dr Javier Arcos. Chief Executive Officer, Fundación Jiménez Díaz. Leticia Moral - Director of Infrastructure, Equipment and ESG, Quirónsalud.

15:45 h. First panel session:

Aurora Hérraiz - Director of Corporate Social Responsibility, FJD

María José Checa - Deputy Director of Nursing, FJD.

Presentations: Awareness, what is climate change and how does it affect health? (Dr Felipe Villar - Department of Pneumology, FJD).

Sustainability in the healthcare system (Dr María del Pino Henríquez - ESG/Sustainability Director, Quirónsalud)

16:30 h. Second panel session:

Bibiana Navarro - Director of Quality, FJD.

Dr Javier Bécares - Corporate Head of Hospital Pharmacy, 4H Network.

Presentations:

Sustainable hospital pharmacy: elimination of desflurane from anaesthesia services (Dr Maruxa Hernández Corporate Pharmacy Director, Quirónsalud Group).

Sustainable and healthy nutrition (Dr Álvaro Flores - Department of Preventive Medicine, FJD).

Facilities, maintenance and infrastructure (David Romera - Head of Maintenance and Hospital Engineering, FJD).

17:45 h. Third panel session:

Manuel de Diego - Quality Department, FJD.

Dr Óscar Gómez - Director of Care Continuity, FJD.

Presentations:

SERGAS. A sustainable management model. (Beatriz Piñeiro — Coordinator of the SERGAS Circular Economy Strategy).

Sustainability in Primary Care. (Emilio Lozano - SIGAE GAAP Coordinator) Research in sustainability (Dr Mar Fernández — Allergy Department FJD).

Sustainable transport (Julián Checa - Information Systems and Technologies Department FJD).

MAS+ Programme (Dr Felipe Villar - Pneumology Department FJD).

UPDATE ON CUTANEOUS LYMPHOMAS. V EDITION

Aula Magna (Main Auditorium), Fundación Jiménez Díaz University Hospital.

Scientific Programme

- **Friday, the 4th of April 2025**

08:50 - 09:00 h. Introduction.
Dr Federico Rojo and Dr Carmen Ayuso.

09:00 - 09:30 h. Unusual cutaneous T- and B-cell lymphomas I.
Dr L. Cerroni.

09:30 - 10:00 h. Folliculotropic MF: Interest of clinicopathological grading.
Dr M. Battistella.

10:00 - 10:30 h. Clinicopathological case presentations.
Dr J. Torre-Castro and Dr I. Torres Navarro.

10:30 - 11:00 h. Adult T-cell lymphoma/leukemia.
Dr A. Gru.

11:00 - 11:30 h. Cutaneous involvement in angioimmunoblastic T-cell lymphoma.
Dr J. Díaz de la Pinta.

12:00 - 12:30 h. Spectrum of CD30+ cutaneous lymphoid proliferations.
Dr R. Pujol.

12:30 - 13:30 h. Clinicopathological case presentations.
Dr Falkenhain and Dr Nieto.

13:30 - 14:30 h. Poster presentations

15:30 - 16:00 h. Advances in Sézary syndrome
Dr F. Gallardo

16:00 - 16:30 h. Clinicopathological case presentations
Dr J. L. Rodríguez-Peralto

16:30 - 17:00 h. Allogeneic haematopoietic stem cell transplantation in patients with primary cutaneous lymphoma

Dr R. F. Duarte

17:00 - 17:30 h. New diagnostic tools in pathology: ultrasensitive dual mRNA ISH assay for kappa and lambda

Dr Lluís Colomo Saperas

17:30 - 18:00 h. Liquid biopsy in CTCL

Dr A. Chalid

- **Saturday, the 5th of April 2025**

09:00 - 09:30 h. Unusual cutaneous T- and B-cell lymphomas II.

Dr L. Cerroni.

09:30 - 10:00 h. EBV-related cutaneous proliferations/lymphoma.

Dr A. Gru.

10:00 - 10:30 h. Clinicopathological case presentations.

Dr M. García.

10:30 - 11:00 h. Molecular approach to cutaneous lymphoma.

Dr J. Vaqué.

11:30 - 12:00 h. B-cell lymphoma in skin: primary or secondary.

Dr M. Battistella.

12:00 - 12:30 h. The role of radiotherapy in cutaneous lymphomas.

Dr W. A. Vázquez-Rivas.

12:30 - 13:00 h. Clinicopathological case presentations.

Dr C. Póstigo and Dr L. Prieto.

13:00 - 13:30 h. Differential diagnosis: mycosis fungoides, atopic dermatitis, psoriasis, eczema, and other conditions.

Dr M. Llamas.

13:30 - 14:00 h. Multidisciplinary management of patients with cutaneous lymphoma.

Dr R. Córdoba and Dr J. Torre-Castro.

14:00 - 14:15 h. Award ceremony.

QUIRÓNSALUD ANNUAL RESEARCH MEETING

On June 12th, 2025. Main Auditorium, Fundación Jiménez Díaz University Hospital.

Programme

12:00 - 12:15 h. Welcome and opening remarks.

Dr Carmen Ayuso, Scientific Director of IIS-FJD.

12:15 - 12:30 h. First presentation:

Our contribution to gene therapy for patients with disorders of the haematopoietic system.

Speaker: Dr Juan Antonio Bueren, Director of Biomedical Innovation (CIEMAT; IIS-FJD).

12:30 – 12:45 h. Second lecture:

Impact of the AI-based real-time infection surveillance centre (ARGOS)

Speaker: Dr María Dolores Martín Ríos, Head of the Department of Preventive Medicine, Fundación Jiménez Díaz University Hospital.

12:45 – 13:00 h. Third presentation:

Innovations in the management of rectal cancer: impact on health outcomes, patient experience and efficiency.

Speakers: Multidisciplinary FOREST Programme Team.

13:00 – 13:50 h. Quirónsalud Research Awards Ceremony.

Organised by:

D Víctor Madera Núñez, Chairman and CEO, Quirónsalud Group.

D Juan Antonio Álvaro de la Parra, Chief Operating Officer.

Dr Carmen Ayuso, Scientific Director of IIS-FJD.

Dr Cristina Caramés, Director of Healthcare and Corporate Research.

13:50 – 14:00 h. Closing remarks.

Research and Innovation as Hallmarks of Quirónsalud.

Dr Cristina Caramés, Director of Healthcare and Corporate Research.

IX LYMPHOMA/LEUKAEMIA MEETING: DIAGNOSIS FOR TARGETED THERAPY 2025

Organised by the Scientific Committee composed of Pilar Llamas Sillero, Rocío Salgado Sánchez and María Socorro Rodríguez Pinilla.

On November 13th, 2025, Main Auditorium, Fundación Jiménez Díaz University Hospital.

Programme

10:00 - 10:10 h. Welcome

Dr Pilar Llamas, Dr María Rodríguez Pinilla, Dr Rocío Salgado, Dr Federico Rojo. Fundación Jiménez Díaz University Hospital, Madrid.

10:10- 10:40 h. Targeted therapy in lymphoid neoplasms: challenges. Dr Miguel Ángel Piris. Emeritus Researcher in Pathology. Fundación Jiménez Díaz University Hospital, Madrid.

10:40 - 10:55 h. Clinical case 1. Dr Francisca Ferrer. Fundación Jiménez Díaz University Hospital.

10:55 - 11:10 h. Clinical case 2. Dr Francisca Inmaculada Camacho Castañeda. University Hospital of Getafe.

11:10 - 11:40 h. Impact of new technologies on the diagnosis of mantle cell lymphoma mpacto de las nuevas tecnologías en el diagnóstico del linfoma de células del manto. Dr Cristina López. Department of Pathology, Oncohaematological Cytogenetics Laboratory, Hospital Clínic, Barcelona. IDIBAPS.

11:40 - 11.55 h. Clinical case 3. Dr Laura Astilleros. 12 de Octubre University Hospital.

11:55 - 12:10 h. Clinical case 4 Dr María Requero. General University Hospital of Toledo.

12:40 - 13:10 h. Liquid biopsy: an ally for personalising and monitoring lymphoma treatments. Dr Margarita Sánchez Beato. Lymphoma Research Group, Puerta de Hierro-Majadahonda University Hospital, Madrid.

13:10 - 13:25 h. Clinical case 5. Dr Fina Climent. Bellvitge University Hospital, Barcelona.

13:25 - 13:40 h. Clinical case 6. Dr María Eugenia García Fernández, La Paz University Hospital, Madrid.

13:40 - 14:10 h. NLRP3 inflammasome activation and the symptom burden of patients with KRAS-mutated CMML are reversed by anti-IL-1 therapy. Dr Francisca Ferrer. Department of Haematology, Fundación Jiménez Díaz University Hospital, Madrid.

15:00 - 15:30 h. Germline predisposition in haematological malignancies: from genetic diagnosis to clinical management. Dr Ana Río-Machín Miguel Servet Researcher, Haematology, Fundación Jiménez Díaz Health Research Institute (IIS-FJD).

15:30 - 15:45 h. Clinical case 7. Dr (Pathology), Dr Jorge Ortega Carriedo (Haematology), Dr Tamara Castaño (Flow Cytometry), Dr Ana Río-Machín (Miguel Servet Researcher, Haematology, IIS-FJD).

15:45 - 16:00 h. Clinical case 8. Dr Elena Vega (Flow Cytometry), Dr María Bernarda Álvarez Álvarez (Pathology).

16:00 - 16:30 h. Mantle cell lymphoma: first-line treatment. Dr Tycho Baumann 12 de Octubre University Hospital. Madrid.

16:30 - 16:45 h. Clinical case 9. Dr Cristina Serrano del Castillo (Cytometry).

16:45 - 17:00 h. Clinical case 9. Dr Jorge Ortega Carriedo (Haematology), Ana López Prieto (Anatomical Pathology), Dr Juan Torre (Dermatology) Fundación Jiménez Díaz University Hospital, Madrid.

17:00 h. Closing remarks. Dr Pilar Llamas Scientific Committee: Dr Pilar Llamas Sillero, Dr Rocío Salgado Sánchez, Dr María Socorro Rodríguez Pinilla. Fundación Jiménez Díaz University Hospital, Madrid.

ACTIVITIES TARGETING THE GENERAL PUBLIC

During 2025, the IIS-FJD carried out an extensive programme of science communication, public engagement and knowledge transfer activities, aimed both at the public and at specific groups, including patients, patient associations, and students at different educational levels. These initiatives benefited from the active participation of IIS-FJD researchers.

4th ESO + Enterprise Programme

Within the framework of the 4º ESO + Enterprise Programme of the Community of Madrid, the IIS-FJD hosted a total of 20 students from different secondary schools in 2025. These students undertook observational placements during March and April, receiving career guidance within various research groups based in the laboratories of Fundación Jiménez Díaz University Hospital (HUFJD).

List of participating students:

Student	Supervisor/s	Research Group	Educational Level	Educational Institution
Gabriel Martínez García María de Valvanera Galindo Palacios, Carmen Rojo Nájera, Alejandra Ruiz Fraile	Federico Rojo	Anatomical Pathology	4th year of Compulsory Secondary Education (ESO)	Fuentelarreyna School
Nicolás Sturzu Pinedo	Daniel Lainez y Rocio Olivera	Haematology	4th year of Compulsory Secondary Education (ESO)	Santa Teresa School (Getafe)

Student	Supervisor/s	Research Group	Educational Level	Educational Institution
Emma Andreea Balc Sbarnau, Elena Marugán Jiménez, Jimena Ortega Sequera	Juana Serrano	Haematology	4th year of Compulsory Secondary Education (ESO)	Blas Otero Secondary School
María Martín Antoranz	Ana del Río	Haematology	4th year of Compulsory Secondary Education (ESO)	Joaquín de Araujo Secondary School
Blai Liceaga Carrillo	Arancha Cebrián	Medical Oncology	4th year of Compulsory Secondary Education (ESO)	VegaSur School (San Martín de la Vega
Daniel Díaz Molina	Arancha Cebrián	Medical Oncology	4th year of Compulsory Secondary Education (ESO)	San Jaime Secondary School
Almudena Más Aceña	Oscar Lorenzo	Nephrology, Hypertension, Vascular Pathology and Diabetes	4th year of Compulsory Secondary Education (ESO)	Siglo XXI School
Amaya Barrera, Kiara Piergiacomi, Isabel Saez	Luis Blanco Colio	Nephrology, Hypertension, Vascular Pathology and Diabetes	4th year of Compulsory Secondary Education (ESO)	Vallmont School
Lucía Jiménez Hernández	Adrián Ramos y Ana Belén Sanz Bartolomé	Nephrology, Hypertension, Vascular Pathology and Diabetes	4th year of Compulsory Secondary Education (ESO)	Cristo Rey School (Las Rozas)
Carla Martín Tercero	Nerea Méndez y María José Fernández	Nephrology, Hypertension, Vascular Pathology and Diabetes	4th year of Compulsory Secondary Education (ESO)	José Hierro Secondary School
Alejandro de Lucas Fernández-Bravo	Meritxell de Jesús García Quintanilla	Microbiology	4th year of Compulsory Secondary Education (ESO)	San Jaime Secondary School
Carmen Monge de Andrés	Aranzazu Mediero y Raquel Largo	Rheumatology and Bone Metabolism	4th year r of Compulsory Secondary Education (ESO)	María Virgen School
Noemí Cerezo Herrera, Cristina Jiménez Hortelano	Carlos Carnero	Platform for Animal Experimentation and Experimental Surgery	4th year of Compulsory Secondary Education (ESO)	María Moliner Secondary School

Most of these placements took place during March and April, including activities involving affiliated institutions such as CIEMAT. In this context, the **Advanced Therapies Research Group (CIEMAT)** conducted training activities from the **1st to the 4th of April 2025,** with the participation of researchers Mercedes López Santalla, Marta Covadonga Ordóñez Velasco, Jesús Martínez Palacio, and María Isabel Carbonell Simón. In addition, **April 7th, 2025,** a further activity was carried out at IES Villa de Móstoles, with the participation of Mercedes López Santalla

Furthermore, Sara Guerrero Aspizua, member of the Regenerative Medicine and Tissue Engineering Research Group at IIS-FJD, participated as a speaker in programme talks held at Carlos III University of Madrid.

Overall, this initiative reinforces the IIS-FJD's commitment to early-stage training, career guidance, and the promotion of scientific vocations among secondary school students.

International Day of Women and Girls in Science (On February 11th, 2025)

On the International Day of Women and Girls in Science, the IIS-FJD organised and participated in several activities aimed at promoting scientific careers and bringing biomedical research closer to society.

Among the main initiatives were the following:

- **Second Open Day: What does it mean to be a scientist? Bringing science to schools.** On February 11th, 2025, Aula Magna (Main Auditorium) of Fundación Jiménez Díaz University Hospital and IIS-FJD laboratories. Activity organised by the IIS-FJD and aimed at sixth grade primary school students from Montpellier School.

Science outreach talks: What does it mean to be a scientist? Bringing science to schools, delivered to primary schools:

- **Lucía Palacio García and María José Fernández Gómez,** predoctoral researchers at IIS-FJD. ADDIS School (Villaverde). On February 10th, 2025.
- **Ana del Río Machín,** Miguel Servet Researcher, and Juana Serrano, Senior Postdoctoral Researcher in the IIS-FJD Haematology research group. Emilia Pardo Bazán and San Eugenio y San Isidro Primary School. On February 13th, 2025.
- **Lucía Palacio García and Irene de María Camacho,** predoctoral researchers in the IIS-FJD Allergy and Immunology research group. On February 14th, 2025.

Science outreach talks and workshops for secondary schools:

- **Research, discover, inspire: The future of science belongs to everyone.** Arancha Cebrián, Principal Investigator of the Medical Oncology research group, IIS-FJD (UAM). Marqués de Santillana Secondary School (IES Marqués de Santillana). On February 7th, 2025.
- **Researcher for a day at Madres Mercedarias School.** FJD-UAM School of Nursing. Madres Mercedarias de Don Juan de Alarcón School. On February 11th, 2025.
- **Women made science: we do it and you will do science.** Victoria del Pozo, head of research group and principal investigator at IIS-FJD. Blanca Fernández Secondary School (IES Blanca Fernández). On February 12th, 2025. Activity aimed at secondary school students.
- **Women in science: STEM careers. Science outreach talks and workshops for secondary and upper secondary schools.** Dr Gloria Álvarez Llamas, head of research group and principal investigator in the Allergy and Immunology research group, IIS-FJD. Montpellier School. On February 13th, 2025.
- **Science outreach workshop: What is bioinformatics? Discover how programming helps us study and diagnose diseases!** Graciela Uría, Yolanda Benítez and Lucía López, predoctoral researchers in the Genetics and Genomics of Rare and Complex Diseases research group, IIS-FJD. San Isidro Secondary School (IES San Isidro). On February 13th, 2025. Activity aimed at secondary and upper secondary school students.
- **The cancer detectives: meet them (ASEICA).** Ana del Río Machín, Miguel Servet researcher in the Haematology research group, IIS-FJD. Europa Secondary School (IES Europa, Rivas-Vaciamadrid). On February 14th, 2025.
- **What does it mean to be a scientist? Bringing science to schools.** Marta Martín Lorenzo, researcher and principal investigator in the Allergy and Immunology research group, IIS-FJD. San Isidro Secondary School (IES San Isidro). On February 14th, 2025.

These activities enabled the Institute to reach students at different educational levels, promoting gender equality in science and increasing the visibility of the role of women in research.

Science outreach activities aimed at educational institutions

Throughout the year, IIS-FJD researchers participated in several outreach initiatives aimed at students

- **Science outreach activity for upper secondary school students.** Jimena Pérez Maroto, Advanced Therapies research group (CIEMAT). José Saramago School (Arganda del Rey, Madrid). On March 11th, 2025. Activity aimed at upper secondary school students.
- **UniStem Day 2025: The never-ending journey of stem cell research.** Mariano García Arranz and José Carlos Segovia, IIS-FJD researchers. Santiago Ramón y Cajal Amphitheatre, Faculty of Medicine (UCM). On March 14th, 2025. Activity aimed at upper secondary school students.
- **Science outreach activity in a scientific environment.** Óscar Quintana Bustamante, Advanced Therapies research group (CIEMAT). CIEMAT. On March 17th, 2025. Public engagement activity.
- **Science outreach activity at a public exhibition event.** Óscar Quintana Bustamante Advanced Therapies research group (CIEMAT). IES Malala Yousafzai (Madrid). On March 21st, 2025. Activity aimed at secondary school students.
- **Science outreach activity at a public exhibition event.** María Isabel Carbonell Simón, Advanced Therapies research group (CIEMAT). IFEMA Madrid. On March 27th, 2025. Public engagement activity.
- **Talk from the "CIEMAT at your school" programme.** Advanced Therapies research group, CIEMAT (Mercedes López Santalla). Villa de Móstoles Primary School (Móstoles, Madrid). On April 7th, 2025. Activity aimed at secondary school students.
- **Online science outreach activity.** Óscar Quintana Bustamante, Advanced Therapies research group (CIEMAT). Online format. On July 3rd, 2025. Public engagement activity.
- **Upper secondary school student placements: Bioprinting hearts: advances, challenges and the future of regenerative medicine.** Advanced Therapies research group (CIEMAT), IIS-FJD (Marta Covadonga Ordóñez Velasco). CIEMAT. From the 18th to 24th of July 2025.
- **Science outreach lectures: Biotechnology and regenerative medicine: new ideas for old problems.** Regenerative Medicine and Tissue Engineering research group (UC3M-IIS-FJD In-person and online formats. From the 9th of October 2025 to the 28th of March 2026. Activity aimed at secondary and upper secondary school students.
- **Science outreach lectures: Bioengineering for the humanity of the future: advances in molecular and cellular biology.** Regenerative Medicine and Tissue Engineering research group (UC3M-IIS-FJD). In-person and online formats. From the 9th of October 2025 to the 28th of February 2026. Activity aimed at secondary and upper secondary school students.
- **Tenth edition of the programme "Bringing science to schools"** which involves nearly 250 secondary and upper secondary school students from five educational institutions: IES El Espinillo, IES Diego Velázquez, IES Cervantes, IES Santa Teresa de Jesús, Sagrado Corazón Chamartín School, and Arturo Soria School. Speaker: Lucía Llanos, head of the IIS-FJD clinical research unit. On December 10th, 2025. Aula Magna (Main Auditorium), HUFJD. Activity organised in collaboration with Farmaindustria.
- **Science outreach activity for secondary school students.** Óscar Quintana Bustamante. Advanced Therapies research group (CIEMAT). Gloria Fuertes Primary School (Alcobendas, Madrid). On December 12th, 2025. Activity aimed at secondary school students.

Madrid Science and Innovation Week 2025

The IIS-FJD participated in the Madrid Science and Innovation Week with activities aimed at upper secondary school students, designed to promote scientific vocations and increase awareness of biomedical research among young people:

- **Science outreach activity for upper secondary school students the Madrid Science and Innovation Week.** Jimena Pérez Maroto and Miriam Sánchez Calvo, Advanced Therapies research group (CIEMAT). CIEMAT. On November 6th, 2025.
- **Workshop: What is bioinformatics? Discover how programming helps us study and diagnose diseases!** On November 14th, 2025. Aula Eloy López Fundación Jiménez Díaz University Hospital. Yolanda Benítez, Graciela Uría and Pablo Mínguez, researchers from the Genetics and Genomics of Rare and Complex Diseases research group. Activity aimed at third and fourth year of compulsory secondary education (ESO) students and upper secondary school students.

Science outreach activities aimed at society, patient associations and patients' families

The IIS-FJD also promoted activities aimed at society, patients and patient associations:

- **European Kidney Forum 2025: Early Detection, Better Outcomes: Advancing Kidney Disease Screening in the EU.** Alberto Ortiz, head of research group and principal investigator of the Nephrology, Hypertension, Vascular Pathology and Diabetes research group. European Parliament (Brussels). On January 28th, 2025.
- **Discussion forum between researchers and patients from the Spanish Association of People with Food and Latex Allergies (AEPNAA).** Organised by: Vanesa Esteban, head of research group and principal investigator of the Allergy and Immunology research group at IIS-FJD, in collaboration with AEPNAA. Fomat: online. On February 12th, 2025.
- **I outreach conference about biobanks in cancer research.** IIS-FJD and Anatomical Pathology department of the HUFJD. Aula Magna of Fundación Jiménez Díaz University Hospital. Format: hybrid. On February 27th, 2025.
- **Patient meeting: II Asthma and Women Conference.** Organised by the departments of Allergy and Pneumology of Fundación Jiménez Díaz University Hospital. Severo Ochoa lecture hall, Fundación Jiménez Díaz University Hospital. Hybrid format. On March 7th, 2025. With the participation of ASMABI Euskadi, RESPIRA, and the National Association of Patients with Nasal Polyposisl.
- **Pancreatic cancer conference for patients.** Organised by the Department of Urology. Aula Magna (Main Auditorium) of the Fundación Jiménez Díaz University Hospital. On April 24th, 2025. With the participation of the Spanish Association Against Cancer.
- **Discussion forum: "Diabetes, nephropathy and research: 2025 update".** Beatriz Fernández Fernández, Carmen Gómez Guerrero, Marta Ruiz Ortega and Vanesa Marchant, researchers from the Nephrology, Hypertension, Vascular Pathology and Diabetes research group. Organised by the IIS-FJD in collaboration with Diabetes Madrid Association. Online format. On May 14th, 2025.
- **X Edition Pint of Science Madrid.** Alberto Ortiz, head of research group and principal investigator of the Nephrology, Hypertension, Vascular Pathology and Diabetes research group.

- **Seminar "Extended mind: To infinity and beyond?". 12th Seminar Series on Philosophy, Evolution and Health.** Coordinated by Dr María José Trujillo Tiebas, researcher in the Genetics and Genomics of Rare and Complex Diseases research group. Severo Ochoa Lecture Hall, Fundación Jiménez Díaz University Hospital. On May 27th, 2025.

- **Inherited retinal diseases: knowing them, understanding them, coping with them.** Organised by the Department of Genetics, Carmen Ayuso, Scientific director of the IIS-FJD and head and principal investigator of the Genetics and Genomics of Rare and Complex Diseases research group, and the Corporate Social Responsibility department of the Fundación Jiménez Díaz University Hospital, with the support of the IIS-FJD. Online. On June 26th, 2025.

- **Science outreach activity for patients.** Óscar Quintana Bustamante, Advanced Therapies research group (CIEMAT). Online format. On September 15th, 2025. Public engagement activity and aimed at patients.

- **National Sarcoma Day. Open day for patients.** Organised by the Sarcoma unit of the IIS-FJD and the Fundación Jiménez Díaz University Hospital. On September 19th, 2025. With the participation of the Mari Paz Jiménez Casado Foundation.

- **II Conference for Patients with Congenital Platelet Disorders.** Organised by the IIS-FJD and the Department of Haematology, Fundación Jiménez Díaz University Hospital. Severo Ochoa Lecture Hall, Fundación Jiménez Díaz University Hospital. On October 3rd, 2025. With the participation of D'Genes, the Rare Diseases Association of Murcia.

- **End of life: changing the way we see it.** María Herrera Abián, Corporate Social Responsibility department, Fundación Jiménez Díaz University Hospital. Aula Magna (Main Auditorium) of the Fundación Jiménez Díaz University Hospital. Hybrid format.

- **Madrid Headache Forum.** Organised by the Department of Neurology, with the support of the IIS-FJD. Main Auditorium and Eloy López Lecture Hall, Fundación Jiménez Díaz University Hospital. From the 20th to the 24th of October 2025.

- **I Conference for Patients with Multiple Sclerosis.** Organised by the department of Neurology, with the support of the IIS-FJD. Aula Magna (Main Auditorium) of the Fundación Jiménez Díaz University Hospital. On November 17th, 2025.

- **Movember FJD: Prostate cancer awareness day.** Organised by the department of Urology, with the support of the IIS-FJD. Aula Magna (Main Auditorium) of the Fundación Jiménez Díaz University Hospital. On November 18th, 2025. With the participation of The Move Men and the National Prostate Cancer Association (ANCAP).

Overall, these initiatives reflect the IIS-FJD's strong commitment to science communication, the education of future generations, patient involvement in research, and the effective transfer of knowledge to society, further consolidating its role as a leading institution in biomedical research and social responsibility.


FUNDACION JIMENEZ DIAZ



11

Conchita Rábago **Foundation**

GOVERNING BODIES

Board of trustees

Chair: Gregorio de Rábago Juan-Aracil

Secretary: Luis Jiménez-Díaz Egoscozábal

Members: Carmen Ayuso García
Rosa de Rábago Sociats

Managing director: Isabel Ferreiro Carrobles

Economic advisor: José María Pinedo y de Noriega

Executive Committee of the Commemorative Lecture

Chair: Joaquín Sastre Domínguez
HUFJD/UAM

Vice-Chair: Borja Ibáñez Cabeza
CNIC/HUFJD

Secretary: Luis Jiménez-Díaz Egoscozábal
Partner of Jones Day

11 Conchita Rábago Foundation

Instituto de Investigación Sanitaria
Fundación Jiménez Díaz

Members:

Fernando Alfonso Manterola
La Princesa University Hospital, Autonomous University of Madrid

Juan Luis Arsuaga Ferreras
Complutense University of Madrid. UCM-ISCIII Centre for Human Evolution and Behaviour

Carmen Ayuso García
HUFJD/IIS-FJD/UAM/ Conchita Rábago de Jiménez Díaz Foundation

Lina Badimón Maestro
CSIC-ICCC Cardiovascular Research Centre / Hospital de la Santa Creu i Sant Pau

José Luis Calleja Panero
Puerta de Hierro University Hospita, Autonomous University of Madrid

Ana María Cuervo
Einstein Institute for Aging Research, Albert Einstein College of Medicine, New York

Damián García Olmo
Fundación Jiménez Díaz University Hospital, Autonomous University of Madrid

Pedro Guillén García
CEMTRO Clinics
Royal National Academy of Medicine of Spain

Juan Carlos Izpisua Belmonte
San Diego Institute of Science, Altos Labs University of California, San Diego

Katalin Karikó
University of Pensilvania- USA. Universidad Szeged- Hungary

Dennis Lo
Li Ka Shing Professor of Medicine, The Chinese University of Hong Kong

Silvia G. Priori
University of Pavia
ICS Maugeri (Maugeri Scientific Clinical Institutes)

Domingo A. Pascual Figal
Fundación Jiménez Díaz University Hospital, Autonomous University of Madrid

Pedro de Rábago González
Conchita Rábago de Jiménez Díaz Foundation

Gregorio de Rábago Juan-Aracil
Clinic University of Navarra
Conchita Rábago de Jiménez Díaz Foundation

Isaura de Rábago Juan-Aracil
Centre for Energy, Environmental and Technological Research (CIEMAT)

Rosa de Rábago Sociats
Fundación Jiménez Díaz University Hospital,
Conchita Rábago de Jiménez Díaz Foundation

Olga Sánchez Pernaute
Clinic University of Navarra

56th JIMÉNEZ DÍAZ COMMERATIVE LECTURE

Professor Ana María Cuervo was awarded the 56th Jiménez Díaz Commemorative Lecture 2025, held on May 27th, 2025, in the Aula Magna (Main Auditorium) of the Fundación Jiménez Díaz University Hospital.

The event was chaired by Mr Juan Cruz Cigudosa García, Secretary of State for Science, Innovation and Universities.

The 56th Jiménez Díaz Commemorative Lecture included the following programme:

- **Symposium**

  "Therapeutic targets against ageing"

- **Introduction and moderation:**

  Gregorio de Rábago Juan-Aracil

  Deputy Director of the Department of Cardiology and Cardiac Surgery, Clinic University of Navarra. Chair of the Board of Trustees of the Conchita Rábago de Jiménez Díaz Foundation.

  Borja Ibáñez Cabeza

  Cardiologist, Fundación Jiménez Díaz University Hospital (IIS-FJD, UAM). Director, National Centre for Cardiovascular Research (CNIC), Madrid.

- **How to become a long-lived species**

  Juan Luis Arsuaga Ferreras

  Professor of Palaeontology, Faculty of Geological Sciences, Complutense University of Madrid. Scientific Director, Museum of Human Evolution, Burgos.

- **Cellular reprogramming and ageing**

  Juan Carlos Izpisua Belmonte

  Founding Scientist and Director, San Diego Institute for Science, Altos Labs. Professor, University of California San Diego, USA.

- **Mitochondrial dysfunction, immunosenescence and ageing**

  María Mittelbrunn Herrero

  Senior Scientist, Spanish National Research Council (CSIC). Laboratory of Immunometabolism and Inflammation, Severo Ochoa Centre for Molecular Biology (CSIC-UAM), Madrid.

- **Microbiota and nutrition: innovation and new frontiers for health**

  María Carmen Collado Amores

  Research Professor, Institute of Agrochemistry and Food Technology (IATA-CSIC), Valencia.

- **Precision nutrition and the epigenetics of ageing**

  Dolores Corella Piquer

  Professor of Preventive Medicine and Public Health, Faculty of Medicine, University of Valencia. Group Leader at the CIBER Research Centre for the Physiopathology of Obesity and Nutrition (CIBEROBN), Carlos III Health Institute (ISCIII), Madrid.

11 Conchita Rábago Foundation

Instituto de Investigación Sanitaria
Fundación Jiménez Díaz

56th JIMÉNEZ DÍAZ COMMEMORATIVE LECTURE

- **Selective autophagy as a therapeutic target in ageing and age-related diseases**

Ana María Cuervo

Distinguished Professor and holder of the Robert and Renée Belfer Chair for the Study of Neurodegenerative Diseases. Co-Director of the Einstein Institute for Aging Research, Albert Einstein College of Medicine, New York, USA.

2025 JIMÉNEZ DÍAZ FELLOWSHIPS: PREDOCTORAL RESEARCH FELLOWSHIPS

During 2025, the Conchita Rábago Foundation continued its fellowship programme.

Research: Research fellowships are awarded to postgraduate graduates to carry out a research project at Fundación Jiménez Díaz. These fellowships are granted for an initial period of one year, renewable up to three years, and exceptionally for a fourth year, after which recipients are expected to submit their doctoral thesis.

A total of five second-year fellowships and six first-year fellowships were awarded.

De la Riva Bueno, Macarena	Rheumatology / Dr Mediero	2nd year
López López, Lucía	Genetics / Dr Almoguera	2nd year
Rochano Ortiz, Antonio	Nephrology / Dr Oller	2nd year
Frutos Díaz-Alejo, Jesús	Oncology /Dr Rodríguez Pinilla	2nd year
Romero Cote, María	Nephrology / Dr González Parra	2nd year
López Alcojor, Aroa	Genetics/ Drs Ayuso and Cortón	1st year
Hidalgo León, Miguel Ángel	Oncology/ Dr Martínez Useros	1st year
Miño Izquierdo, Lucía	Nephrology / Dr Sanz Bartolomé	1st year
Serrano Santiago, Antonio	Allergy and Immunology / Dr Cañas and Dr del Pozo	1st year
González González, Jesús	Genetics/ Dr Osorio	1st year
Selva Giménez, Marta	Oncology/ Dr Lamarca	1st year (A)

(A) Fellowship relinquished on September 15th, 2025.

Training placements abroad grants

- A grant was awarded to Dr Walter Vásquez Rivas (Radiation Oncology, HUFJD) to undertake a one-month training placement in Verona, Italy, focusing on the use of the new MR Linac system.
- A grant was awarded to Dr Miguel Durán Aparicio (Anaesthesiology and Critical Care, HUFJD) to undertake an 18-month training programme in Cardiovascular Anaesthesiology at the General Hospital of Toronto, Canada.





12

Public Funding Bodies

Comunidad de Madrid
Dirección General de Investigación e Innovación Tecnológica
CONSEJERÍA DE EDUCACIÓN, CIENCIA Y UNIVERSIDADES

GOBIERNO DE ESPAÑA
MINISTERIO DE CIENCIA, INNOVACIÓN Y UNIVERSIDADES
Instituto de Salud Carlos III

GOBIERNO DE ESPAÑA
MINISTERIO DE CIENCIA, INNOVACIÓN Y UNIVERSIDADES
AGENCIA ESTATAL DE INVESTIGACIÓN

GOBIERNO DE ESPAÑA
MINISTERIO DE CIENCIA, INNOVACIÓN Y UNIVERSIDADES
AGENDA 2030
AGENCIA ESTATAL DE INVESTIGACIÓN

GOBIERNO DE ESPAÑA
MINISTERIO DE EDUCACIÓN, FORMACIÓN PROFESIONAL Y DEPORTES

GOBIERNO DE ESPAÑA
MINISTERIO DE SANIDAD

NIH National Institutes of Health
Turning Discovery Into Health

Cofinanciado por la Unión Europea

Cofinanciado por la Unión Europea

Financiado por la Unión Europea
NextGenerationEU

Plan de Recuperación, Transformación y Resiliencia

Fondos Europeos



Instituto de Investigación Sanitaria
Fundación Jiménez Díaz

UAM
Universidad Autónoma de Madrid

Hospital Universitario Fundación Jiménez Díaz
Grupo Quirónsalud

https://www.fjd.es/iis-fjd